**AMERICAN TRANSPLANT CONGRESS**

**Day-at-a-Glance, Saturday, June 11, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
</table>
| 1:00 pm — 5:30 pm | Pre-Meeting Symposia  

**Page 6**

- Theoretical and Practical Aspects of HLA Antibodies as a Basis for Clinical Decision Making  
  Room 302

**Page 6**

- Advanced Immunology Updates for Basic and Clinical Scientists  
  Ballroom A

**Page 7**

- Basic Immunology and Transplant Immunology for the Clinician  
  Ballroom C

**Page 7**

- Best Practices in the Peri-Operative Care of the Liver Transplant Patient  
  Room 304

**Page 8**

- Kidney  
  Ballroom B

**Page 8**

- Transplant Program Leadership  
  Room 310

**Page 9**

- Exciting Updates in Transplant ID: Case-based Learning  
  Room 311

**Page 10**

- Collaboration At Its Finest: A Case-Based Approach Highlighting The Significance Of The Multi-Disciplinary Team  
  Room 306

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 pm — 7:30 pm</td>
<td>Opening Reception, Exhibits and Poster Session A</td>
</tr>
</tbody>
</table>

**Presenters in Attendance**

**Halls C&D**

<table>
<thead>
<tr>
<th>Page 105</th>
<th>B cells &amp; AMR, Alloreactivity, Immune Regulation &amp; Regulatory T Cells, T Cell Biology and Alloreactivity, Immunesuppression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page 108</td>
<td>Clinical Pancreas Transplantation and All Islet Cell Transplantation Topics</td>
</tr>
</tbody>
</table>
AMERICAN TRANSPLANT CONGRESS
Program, Saturday, June 11, 2016

Pre-Meeting Symposia
1:00 pm — 5:30 pm

Theoretical and Practical Aspects of HLA Antibodies as a Basis for Clinical Decision Making
Room 302

Laying the Foundation
Moderators: Peter Nickerson, MD, University of Manitoba, Winnipeg, MB, Canada and Anat Tambur, DMB, PhD, Northwestern University, Chicago, IL, USA

1:00 pm Basic Genetics of HLA
Annette Jackson, MD
Johns Hopkins University
Baltimore, MD, USA

1:30 pm Generation of HLA Antibodies
Medhat Askar, MD, PhD
Baylor University Medical Center
Dallas, TX, USA

2:00 pm The ABC’s of HLA Antibodies
Elaine Reed,
University of California Los Angeles
Los Angeles, CA, USA

2:30 pm Getting It to Transplant
Howard Gebel, PhD
Emory University Hospital
Atlanta, GA, USA

3:00 pm Coffee Break

Bringing the Lab to the Clinic
Moderators: Parmjeet Randhawa, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA and Michael Mengel, MD, University of Alberta, Edmonton, AB, Canada

3:30 pm Antibody Mediated Rejection in the Transplanted Kidney
Parmjeet Randhawa, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

4:00 pm Antibody Mediated Rejection in the Transplanted Heart
Rene Rodriguez, MD
Cleveland Clinic
Cleveland, OH, USA

4:30 pm Monitoring for Anti-HLA Antibodies Following Transplantation
Chris Wiebe, PhD
University of Manitoba
Winnipeg, MB, Canada

5:00 pm Putting It All Together
John Friedewald, MD
Northwestern University
Chicago, IL, USA

Advanced Immunology Updates for Basic and Clinical Scientists
Ballroom A
Moderators: Marisa Alegre, MD, PhD, University of Chicago, Chicago, IL, USA and Jonathan Maltzman, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

1:00 pm Update on Innate Immunity
Paolo Cravedi, MD
Icahn School of Medicine at Mt. Sinai
New York, NY, USA

1:30 pm Update on NK cells and Rejection
Shari Krams, PhD
Stanford University School of Medicine
Stanford, CA, USA

2:00 pm Update on Th Subsets and T Cell Alloimmunity
Leonardo Riella, MD, PhD
Brigham and Women’s Hospital Harvard University
Boston, MA, USA

2:30 pm Update on B Cell Subsets and B Cell Alloimmunity
Anita Chong, MD, PhD
University of Chicago
Chicago, IL, USA

3:00 pm Coffee Break

3:15 pm Update on Molecular Mechanisms of Regulatory Cells
Andrew Wells, PhD
University of Pennsylvania
Philadelphia, PA

3:45 pm Update on Memory Cells
Mandy Ford, MD, PhD
Emory University
Atlanta, GA, USA
4:15 pm  Top 10 Immunology Papers of the Year
Jonathan Bromberg, MD, PhD
University of Maryland School of Medicine
Baltimore, MD, USA

4:45 pm  Understanding and Interpreting Genomic Studies in Transplantation
Madhav Menon, MD
Icahn School of Medicine at Mount Sinai
NY, NY, USA

**Basic Immunology and Transplant Immunology for the Clinician**
**Ballroom C**
Moderators: Robert Gaston, MD, University of Alabama at Birmingham, Birmingham, AL, USA and Stefan Tullius, MD, PhD, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA

1:00 pm  Overview – What Does an Immune Response Look Like, Start to Finish
Robert Fairchild, PhD
Cleveland Clinic Foundation
Cleveland, OH, USA

1:30 pm  Inflammation and Innate Immunity and Their Role in Graft Rejection
Andrew Gelman, PhD
Washington University School of Medicine
St. Louis, MO, USA

2:00 pm  Development and Detection of Donor-Reactive T Cell Responses
Melissa Yeung, MD, FRCPC
Brigham & Women’s Hospital/Harvard Medical School
Boston, MA, USA

2:30 pm  Cell Mediated Rejection: Effector Mechanisms in Graft Injury
Ronald Gill, PhD
University of Colorado
Denver CO, USA

3:00 pm  Coffee Break

3:15 pm  B Cells and Antibody Mediated Effector Mechanisms in Graft Injury
Marilia Cascalho, MD, PhD
University of Michigan
Ann Arbor, MI, USA

3:45 pm  T Cell and B Cell Targeted Immunosuppression in Transplantation
Roslyn Mannion, MD
University of Alabama at Birmingham
Birmingham, AL, USA

4:15 pm  Impact of Immunological Memory on Graft Outcome
Andrew Adams, MD, PhD
Emory University School of Medicine
Atlanta, GA, USA

**Best Practices in the Peri-Operative Care of the Liver Transplant Patient**
**Room 304**

Pre-Transplant: Optimizing Survival on the Liver Transplant Wait-list
Moderators:  Jennifer Lai, MD, MBA, University of California San Francisco, San Francisco, CA, USA and David Foley, MD, FACS, University of Wisconsin, Madison, WI, USA

1:00 pm  Key Life-Saving Interventions in Acute on Chronic Liver Failure
Rajiv Jalan, RJ
UCL Medical School
London, United Kingdom

1:30 pm  Pearls of the Pre-operative Cardio-Hemodynamic Assessment
Geraldine Diaz, DO
University of Chicago
Chicago, IL, USA

2:00 pm  Unique Aspects of Liver Intensive Care: What Makes these Patients Different?
Jody Olson, MD
University of Kansas Medical Center
Kansas City, KS, USA

2:30 pm  When to Say Enough is Enough: The Validity of Pre-Operative Futility Assessments
Dean Karvellas, MD, SM, FRCPC
University of Alberta
Edmonton, AB, Canada

3:00 pm  Coffee Break

Post-Transplant: Optimizing Early Patient and Liver Graft Survival
Moderators:  Anton Skaro, MD, PhD, Northwestern University, Chicago, IL, USA and Michael Curry, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA

3:15 pm  Intra-operative Care: What Goes In Must Come Out
Michael Ramsay, MD
Baylor University Medical Center
Dallas, TX, USA
3:45 pm  Holding Killer Microbes at Bay  
Deepali Kumar, MD  
University Health Network  
Toronto, ON, Canada

4:15 pm  Early Graft Dysfunction: Donor Issues and Surgical Complications  
Mark Ghobrial, MD, PhD  
Methodist Hospital  
Houston, TX, USA

4:45 pm  Optimizing Nutrition and Physical Functioning: Recovering From Frailty  
Jennifer Lai, MD, MBA  
University of California San Francisco  
San Francisco, CA, USA

Kidney

Ballroom B  
Moderators: Lisa Florence, MD, Swedish Organ Transplant Program, Seattle, WA, USA and Michael Davis, MD, University of New Mexico, Albuquerque, NM, USA

1:00 pm  Immunobiology of Rejection for the Nephrologist  
Daniel Salomon, MD  
The Scripps Research Institute  
La Jolla, CA, USA

1:20 pm  Immunosuppression Current Approaches and Future Strategies  
Allan Kirk, MD, PhD  
Duke University  
Durham, NC, USA

1:40 pm  Immunological Assessment of The Transplant Recipient  
Kathryn Tinckam, MD  
University of Health Network  
Toronto, ON, Canada

2:00 pm  The Pathology of Rejection  
Robert Colvin, MD  
Massachusetts General Hospital  
Boston, MA, USA

2:20 pm  Q/A Discussion  

Issues in Candidate Evaluation  
Moderators: Lisa Florence, MD, Swedish Organ Transplant Program, Seattle, WA, USA and Michael Davis, MD, University of New Mexico, Albuquerque, NM, USA

2:40 pm  Evaluation of the Combined Organ Transplant Candidate  
Richard Formica, MD  
Yale University School of Medicine  
New Haven, CT, USA

3:00 pm  Evaluation of the Living Kidney Donor  
Peter Reese, MD  
The University of Pennsylvania  
Philadelphia, PA, USA

3:20 pm  Q/A – Panel Discussion

3:30 pm  Break

Expect the Unexpected: Complications  
Moderators: Stuart Flechner, MD, Cleveland Clinic, Cleveland, OH, USA and Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA

4:00 pm  Surgical Complications After Kidney Transplantation for the Non-surgeon  
Kenneth Newell, MD, PhD  
Emory University  
Atlanta, GA, USA

4:20 pm  Recurrent Disease Management  
Alexander Wiseman, MD  
University of Colorado Denver  
Aurora, CO, USA

4:40 pm  Q/A Discussion

Transplant Infections  
Moderators: Stuart Flechner, MD, Cleveland Clinic, Cleveland, OH, USA and Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA

4:50 pm  The Pre-Transplant Infectious Disease Evaluation  
Aruna Subramanian, MD  
Stanford University  
Los Altos, CA, USA

5:10 pm  BK Virus – Prevention and Treatment  
Michael Ison, MD, MS  
Northwestern University  
Chicago, IL, USA

5:30 pm  Q/A Discussion

Transplant Program Leadership  
Room 310

For Novices and Advanced Professionals  
Moderators: Gwen McNatt, MS, CNN, Northwestern Memorial Hospital, Chicago, IL, USA and Angela Marquez, MPH, Massachusetts General Hospital, Boston, MA, USA

1:00 pm  Ensuring the Overall Financial Health of your Transplant Program  
Michael Abecassis, MD, MBA  
Northwestern University  
Chicago, IL, USA
Exciting Updates in Transplant ID: Case-based Learning

Room 311

A Little Help From Our Friends – Featuring Boston Specialists
Moderators: Jay Fishman, MD, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA and Michael Green, MD, MPH, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

1:00 pm  PTLD For The Transplant Specialist - Risk Factors, Diagnosis, Initial Treatment Strategies
Jeffrey Barnes
Massachusetts General Hospital
Boston, MA, USA

1:20 pm  Dermatology: Infection and Mimics for the Transplant Specialist
Adam Lipworth
Brigham and Women’s Hospital
Boston, MA, USA

1:40 pm  Radiology Imaging, Infection, and Mimics for the Transplant Specialist
Subba Digumarthy, MD
Massachusetts General Hospital
Boston, MA, USA

2:00 pm  Clinical Microbiology for the Transplant Specialist
Eric Rosenberg, MD
Massachusetts General Hospital
Boston, MA, USA

An Ounce of Prevention is Worth a Pound of Cure
Moderators: Emily Blumberg, MD, University Hospital of Pennsylvania, Philadelphia, PA, USA and Marian Michaels, MD, MPH, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

2:20 pm  Avoidance is Not Always the Answer: Transplant Perioperative Prophylaxis and Surgical Site Infections
Ricardo LaHoz, MD, FRCP
UT Southwestern Medical Center
Dallas, TX, USA

2:40 pm  O Candida! Transplant Fungal Prophylaxis, including a Pre-Emptive Therapy Approach and Endemic Fungi
Shahid Husain, MD, MS
University Health Network
Toronto, ON, Canada

3:00 pm  Latent TB (Diagnosis and Treatment): Don’t Let the Red Snappers Escape!
Deepali Kumar, MD
University Health Network
Toronto, ON, Canada
3:20 pm  Travel after Transplant: The Icing on the Cake
Camille Kotton, MD
Massachusetts General Hospital
Boston, MA, USA

3:40 pm  Coffee Break

Treatment: Keeping the Wolves at Bay
Moderators: Michael Green, MD, MPH, Children’s Hospital of Pittsburgh, Pittsburgh, PA and David van Duin, MD, University of North Carolina, Chapel Hill, NC, USA

4:00 pm  Stewardship and Infection Control: Who Let the Dogs Out?
Gopi Patel, MD
Mount Sinai School of Medicine
New York, NY, USA

4:20 pm  MDRO in Transplant: The Dark Side of the Force
Shirish Huprikar, MD
Icahn School of Medicine at Mt. Sinai
New York, NY, USA

4:40 pm  Diarrhea!! Some People Think Its Really Funny
Diana Florescu, MD
University of Nebraska Medical Center
Omaha, NE, USA

5:00 pm  On Your Toes: Rapid Fire Cases - “The 4am Phone Call” (with audience response)
Panelists: Camille Kotton, MD, Massachusetts General Hospital, Boston, MA, USA, Shirish Huprikar, MD, Icahn School of Medicine at Mt. Sinai, New York, NY, USA, Deepali Kumar, MD, University Health Network, Toronto, ON, Canada, Marilyn Levi, MD, University of Colorado Hospital, Aurora, CO, USA, David van Duin, MD, University of North Carolina, Chapel Hill, NC, USA, Sherif Mossad, MD, FACP, Cleveland Clinic Foundation, Cleveland, OH, USA and Sarah Longworth, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Collaboration At Its Finest: A Case-Based Approach Highlighting The Significance Of The Multi-Disciplinary Team
Room 306

Pre-transplant Phase
Moderators: Anne LaFleur, M.Ed, MSW, Massachusetts General Hospital, Boston, MA, USA and Jennifer Harris, BSN, RN, CCTC, University of Cincinnati Medical Center, Cincinnati, OH, USA

1:00 pm  Maximizing Efficiency of Living Donor Evaluations
Denise Morin, RN, MSN
Beth Israel Deaconess Medical Center
Boston, MA, USA

1:20 pm  Exploring Options for Sensitized Patients
Janet Hiller, RN, MSN
Johns Hopkins Hospital
Baltimore, MD, USA

1:40 pm  Managing Complex Psychosocial Situations
Noelle Dimitri, LICSW, CCTSW
Beth Israel Deaconess Medical Center
Boston, MA, USA

2:00 pm  Effective Pharmacologic Evaluation Of Transplant Candidates
Jennifer Trofe-Clark, PharmD, BCPS
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

Transplant Phase
Moderators: Winston Ally, PharmD, BCPS, University of Virginia Medical Center, Charlottesville, VA, USA and Christine Trotter, MSN, University of Chicago, Chicago, IL, USA

2:20 pm  Advanced Transplant Providers In The OR: Providing More Than First Assist
Georgeine Smith, MS, MHS, PA-C
Hospital of the University of Pennsylvania
Philadelphia, PA, USA
2:40 pm  Best Practice For A Multidisciplinary Approach To Discharge Planning: How We Do It
Ashley Seawright, DNP, ACNP
University of Mississippi Medical Center
Jackson, MS, USA

Nicole Alvey, PharmD, BCPS
Rush University Medical Center
Chicago, IL, USA

Kay Kendall, LISW
Cleveland Clinic Foundation
Cleveland, OH, USA

3:40 pm  Coffee Break

3:40 pm  Coffee Break

Post-Transplant Phase
Moderators: Katelyn Richards, PharmD, Beth Israel Deaconess Medical Center, Boston, MA, USA and Matt Sigafus, MSN, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

4:00 pm  Ensuring Adequate Living Donor Follow-Up In The Post-Donation Setting
Dianne LaPointe Rudow, ANP-BC, DNP
Mount Sinai Medical Center
New York, NY, USA

4:20 pm  Optimizing The Role Of The Pharmacist In The Ambulatory Clinic
Lindsey Bowman Anger, PharmD
Tampa General Hospital
Tampa, FL, USA

4:40 pm  Novel Outpatient Services to Improve Outcomes and Decrease Readmissions
Use Of Tele Health To Improve Communication In The Liver Transplant Population
Jennifer Harris, BSN, RN, CCTC
University of Cincinnati Medical Center
Cincinnati, OH, USA

4:55 pm  Use Of Specialty Pharmacy And Transplant Based Infusion Services To Generate Revenue
Lonnie Smith, PharmD
University of Utah Healthcare
Salt Lake City, UT, USA

5:10 pm  Post-discharge Hotel Follow-up to Decrease Length of Stay and Prevent Readmissions
Jordan Davenport, RN, BSN, BA, CMSRN
Inpatient Transplant Discharge Coordinator
Medical University of South Carolina, Charleston, SC

Opening Reception with Exhibits
5:30 pm — 7:30 pm
Halls C&D

Poster Session A
5:30 pm – 7:30 pm
Poster Viewing: 5:30 pm – 7:30 pm
Presenters in Attendance: 5:30 pm – 7:30 pm
Halls C&D
Poster Session A can be found on pages 105-129.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am — 8:15 am</td>
<td>Sunrise Symposia</td>
</tr>
<tr>
<td>Page 15</td>
<td>Controversies &amp; Strategies Surrounding Substance Use in Transplant Candidates</td>
</tr>
<tr>
<td>Room 311</td>
<td></td>
</tr>
<tr>
<td>Page 15</td>
<td>Clinical Transplant Tolerance – Molecular and Cellular Biomarkers</td>
</tr>
<tr>
<td>Ballroom B</td>
<td></td>
</tr>
<tr>
<td>Page 15</td>
<td>New Roles for Macrophages</td>
</tr>
<tr>
<td>Room 306</td>
<td></td>
</tr>
<tr>
<td>Page 15</td>
<td>Renal Controversies in Liver Transplantitation</td>
</tr>
<tr>
<td>Ballroom C</td>
<td></td>
</tr>
<tr>
<td>Page 16</td>
<td>Sex and Drugs in Transplantation</td>
</tr>
<tr>
<td>Room 312</td>
<td></td>
</tr>
<tr>
<td>Page 16</td>
<td>Reaching Consensus on AMR in Lung Transplantation</td>
</tr>
<tr>
<td>Room 310</td>
<td></td>
</tr>
<tr>
<td>Page 16</td>
<td>Top New Papers In Transplant Infectious Disease</td>
</tr>
<tr>
<td>Ballroom A</td>
<td></td>
</tr>
<tr>
<td>Page 16</td>
<td>Repairing Organs Ex-Vivo</td>
</tr>
<tr>
<td>Room 304</td>
<td></td>
</tr>
<tr>
<td>Page 17</td>
<td>Informed Decision Making in Living Organ Donation</td>
</tr>
<tr>
<td>Room 302</td>
<td></td>
</tr>
<tr>
<td>8:30 am — 9:45 am</td>
<td>Plenary</td>
</tr>
<tr>
<td>Page 17</td>
<td>Joint Plenary Session I</td>
</tr>
<tr>
<td>Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>Page 17</td>
<td>Special Announcements</td>
</tr>
<tr>
<td>Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>9:45 am — 10:00 am</td>
<td>AMR in Liver Transplantation</td>
</tr>
<tr>
<td>Room 302</td>
<td></td>
</tr>
<tr>
<td>10:00 am — 10:15 am</td>
<td>AST Lifetime Achievement Award</td>
</tr>
<tr>
<td>Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>10:15 am — 10:30 am</td>
<td>ASTS Pioneer Award</td>
</tr>
<tr>
<td>Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>10:30 am — 11:00 am</td>
<td>State-of-the-Art Presentation</td>
</tr>
<tr>
<td>Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>11:00 am — 11:30 am</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>Halls C&amp;D</td>
<td></td>
</tr>
<tr>
<td>11:30 am — 1:00 pm</td>
<td>Midday Symposia</td>
</tr>
<tr>
<td>Advances in Treg Biology</td>
<td>Room 304</td>
</tr>
<tr>
<td>Frontiers in Inflammation Relevant to Transplantation</td>
<td>Room 306</td>
</tr>
<tr>
<td>Rapid Fire State-of-the-Art in Xenotransplantation</td>
<td>Room 310</td>
</tr>
<tr>
<td>A Year Following the New Kidney Allocation System (KAS) – What’s Working, What’s Not!</td>
<td>Veterans Auditorium</td>
</tr>
<tr>
<td>AMR in Liver Transplantation</td>
<td>Room 302</td>
</tr>
<tr>
<td>Predictors of Survival after Lung Transplant</td>
<td>Room 309</td>
</tr>
<tr>
<td>Donor Derived Infections: New Insights on the Use of Infected Donors</td>
<td>Ballroom C</td>
</tr>
<tr>
<td>What’s New for the Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients?</td>
<td>Room 311</td>
</tr>
</tbody>
</table>
Liver Transplantation for Malignancy? State of the Art and Future Directions
Room 312

Developing New Therapy for Transplant Recipients: What are the Barriers?
Ballroom B

Kidney Transplantation – Technical Challenges
Ballroom C

1:00 pm — 2:15 pm Luncheon Workshops*

Ticketed Events

1:30 pm — 4:30 pm Transplantation in Depth

B Cells
Room 302

2:30 pm — 4:00 pm Concurrent Sessions

Concurrent Session: Cardiovascular Complications in Kidney Transplantation
Room 304

Concurrent Session: Challenges in Hearts and VADs - Striking Back
Room 309

Concurrent Session: Donor Management: All Organs
Room 306

Concurrent Session: Kidney Acute Cellular Rejection: Clinical Outcomes and Pathological Characteristics
Ballroom C

Concurrent Session: Kidney Transplant: CNI Minimization
Room 311

Concurrent Session: Kidney Transplantation: Outcomes, Matching and Marginal Donors
Ballroom B

Concurrent Session: Living Kidney Donation: Risk Factors for Adverse Long term Outcome
Veterans Auditorium

Concurrent Session: Novel Markers of Long Term Kidney Transplant Outcomes
Ballroom A

Concurrent Session: Policy and Practice: Implications for Long Term Outcomes
Room 312

Concurrent Session: SOT: HIV, HBV, & HCV
Room 313

Concurrent Session: The Kidney in Liver Transplantation
Room 302

2:30 pm — 5:30 pm Allied Health Symposium

Identifying Opportunities to Incorporate Quality Improvement and Research into your Day
Room 206

2:30 pm — 5:30 pm Pediatric Symposium

Improving Long-term Outcomes in Pediatric Transplantation
Room 310

2:30 pm — 5:30 pm Student Program

The Science, The Art and the Allure of Transplantation
Room 208

4:00 pm — 4:30 pm Coffee Break
Halls C&D

4:30 pm — 6:00 pm Concurrent Sessions

Concurrent Session: Allograft Tolerance 1: Animal Models
Room 306

Concurrent Session: Chronic Allograft Rejection: Animal Models
Room 309
Concurrent Session: Delayed Graft Function and Protocol Biopsy
Room 302

Concurrent Session: Hepatic Malignancies
Room 304

Concurrent Session: Impact of New Allocation Systems and Novel Tools for Performance Enhancement in Abdominal Transplantation
Room 210

Concurrent Session: Kidney Donor Surgery and Outcomes
Ballroom B

Concurrent Session: Kidney Immune Monitoring 1
Ballroom C

Concurrent Session: Liver: Immunosuppression and Rejection
Room 312

Concurrent Session: Lung Transplant: Moving the Field Forward
Room 313

Concurrent Session: Older and High Risk Kidney Transplant Recipients/Donors
Ballroom A

Concurrent Session: Organ Transplantation in the Era of Highly Resistant Pathogens
Room 311

6:00 pm — 7:00 pm Poster Session B

Presenters in Attendance
Halls C&D

Allograft Rejection, Tolerance, and Xenotransplantation

Disparities in Access and Outcomes
Sunrise Symposia  
7:00 am — 8:15 am

**Controversies & Strategies Surrounding Substance Use in Transplant Candidates**

*Room 311*

Moderators: Sheila Jowsey-Gregoire, MD, Mayo Clinic, Rochester, MN, USA and John Rice, MD, University of Wisconsin Health, Madison, WI, USA

7:00 am **Marijuana in the Transplant Patient? The University of Colorado/OSHU Experience**  
Susan Orloff, MD  
Oregon Health Sciences University  
Portland, OR, USA

7:25 am **Opioids and Methadone in Transplant Candidates**  
Shari Rogal, MD, MPH  
University of Pittsburgh  
Pittsburgh, PA, USA

7:50 am **Components of the Transplant Addictions Evaluation**  
Marian Fireman, MD  
Oregon Health Sciences University  
Portland, OR, USA

**Clinical Transplant Tolerance – Molecular and Cellular Biomarkers**

*Ballroom B*

Moderators: Daniel Salomon, MD, The Scripps Research Institute, La Jolla, CA and Alberto Sanchez-Fueyo, MD, PhD, King’s College, London, United Kingdom

7:00 am **B cells (biomarkers) of Spontaneous Transplant Tolerance**  
Sophie Brouard, PhD, DVM  
University of Nantes  
Nantes, France

7:25 am **Discovering and Validating Molecular Biomarkers in Induced Transplant Tolerance**  
Sunil Kurian, PhD  
The Scripps Research Institute  
La Jolla, CA, USA

7:50 am **Functional Assessment for Clinical Transplant Tolerance**  
James Mathew, PhD  
Northwestern University  
Chicago, IL, USA

**New Roles for Macrophages**

*Room 306*

Moderators: Mark Ghobrial, MD, PhD, Methodist Hospital, Houston, TX, USA and Heth Turnquist, PhD, University of Pittsburgh, Pittsburgh, PA, USA

7:00 am **Tissue Resident Macrophages in Islets and Hearts**  
Terry Strom, MD  
Beth Israel Deaconess Medical Center  
Boston, MA, USA

7:25 am **GMSCCR Promotes Macrophage Alternative Activation after Renal IR Injury**  
Lloyd Cantley, MD  
Yale New Haven Hospital  
New Haven, CT, USA

7:50 am **Sign and Regulatory Macrophages and Transplant Tolerance Immunity Online Now**  
Jordi Ochando, PhD  
Mount Sinai School of Medicine  
New York, NY, USA

**Renal Controversies in Liver Transplantation**

*Ballroom C*

Moderators: Mitra Nadim, MD, University of Southern California, Los Angeles, CA, USA and James Trotter, MD, Baylor University Medical Center, Dallas, TX, USA

7:00 am **Renal Transplant Alone in Patients with Liver Disease: What are the Limits**  
Sumeet Asrani, MD  
Liver Consultants of Texas  
Dallas, TX, USA

7:25 am **Debate on the Approaches to Renal Allocation in the Liver Transplant Candidate/Recipient: SLKT vs. Liver Only with Safety Net**  
Josh Levitsky, MD, MS  
Northwestern University Feinberg School of Medicine  
Chicago, IL, USA
7:50 am  Pro Liver Only with Safety Net
Alexander Wiseman, MD
University of Colorado at Denver
Aurora, CO, USA

**Sex and Drugs in Transplantation**

**Room 312**
Moderators: Deirdre Sawinski, MD, University of Pennsylvania, Philadelphia, PA, USA and Dianne McKay, MD, University of California San Diego, La Jolla, CA, USA

7:00 am  Sexual Function and Dysfunction in the Transplant Recipient
Martha Pavlakis, MD
Beth Israel Deaconess Medical Center/
Harvard Medical School
Boston, MA, USA

7:25 am  Family Planning and Contraception for Donors and Recipients
Serban Constantnescu, MD, PhD
Temple University
Philadelphia, PA, USA

7:50 am  Peri And Post Menopausal Health In Transplant Recipients
Karin True, MD
University of North Carolina
Chapel Hill, NC, USA

**Reaching Consensus on AMR in Lung Transplantation**

**Room 310**
Moderators: Allan Glanville, MBBS, MD, St. Vincent’s Hospital, Darlinghurst, NSW, Australia and Nancy Reinsmoen, PhD, Cedars Sinai Medical Center, Los Angeles, CA, USA

7:00 am  The Pathology of Lung AMR
Desley Neil, MD, PhD
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom

7:25 am  The Immunology of Lung AMR
Adrianna Zeevi, PhD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

7:50 am  Putting it All Together – How Does the Clinician Define and Treat Lung AMR?
Deborah Levine, MD
University of Texas Health Sciences Center
San Antonio, TX, USA

**Top New Papers In Transplant Infectious Disease**

**Ballroom A**
Moderators: Michele Morris, MD, FACP, University of Miami, Miami Beach, FL, USA and Marian Michaels, MD, MPH, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

7:00 am  Viruses - Top New Papers In Transplant Infectious Disease
Atul Humar, MD, MSC
Toronto General Hospital
Toronto, ON, Canada

7:25 am  Bacteria - Top New Papers In Transplant Infectious Disease
Emily Blumberg, MD
Hospital of the University of Pennsylvania
Philadelphia, PA, USA

7:50 am  Fungi - Top New Papers In Transplant Infectious Disease
Jay Fishman, MD
Harvard Medical School
Boston, MA, USA

**Repairing Organs Ex-Vivo**

**Room 304**
Moderators: Hamid Rabb, MD, FACP, Johns Hopkins University Hospital, Baltimore, MD, USA and Rutger Ploeg, MD, PhD, Churchill Hospital, Oxford, United Kingdom

7:00 am  Running An Organ Repair Center
Marcelo Cypel, MD, MSc
University of Toronto
Toronto, ON, Canada

7:25 am  The Potential Of Normothermic Preservation
Peter Friend, MD
University of Oxford
Oxford, United Kingdom

7:50 am  The Significance Of Pulsatility For Endothelial Protection
Stefan Tullius, MD, PhD
Brigham & Women’s Hospital/Harvard Medical Center
Boston, MA, USA
Informed Decision Making in Living Organ Donation

Room 302
Moderators: Mary Amanda Dew, PhD, University of Pittsburgh, Pittsburgh, PA, USA and James Rodrigue, PhD, Beth Israel Deaconess Medical Center, Boston, MA, USA

7:00 am Ethical and Legal Aspects of Informed Consent
I. Glenn Cohen, Esq.
Harvard University
Boston, MA, USA

7:25 am What Do Patients and Donors Want to Know About the Risks of Living Donation and How Do They Make Decisions?
Allison Tong, BMedSc, MPH, MM, PhD
University of Sydney
Westmead, Sydney, Australia

7:50 am Innovative Approaches to Improve Informed Consent for Living Donation
Elisa Gordon, PhD, MPH
Northwestern University Feinberg School of Medicine
Chicago, IL, USA

Joint Plenary Session I
8:30 am — 9:45 am
Veterans Auditorium

Chairs: Charles Miller, MD, Cleveland Clinic Foundation, Cleveland, OH, USA and James Allan, MD, MBA, Massachusetts General Hospital, Boston, MA, USA

8:30 am Three-Year Graft Loss Risk in Kidney Transplants: Dynamic Patient Level Data Improve Predictive Efficacy. (Abstract #1)

8:45 am Non-Human Primate Lung Allograft Survival Is Prolonged by IL-6 Inhibition and ATG Treatment Possibly Through Expansion of Peripheral Regulatory T Cells. (Abstract #2)
Akihiro Aoyama, Makoto Tonsho, Rex-Neal Smith, Robert B. Colvin, Abbas Dehnadi, Joren C. Madsen, A. Benedict Cosimi, Gilles Benichou, Tatsuo Kawai, James S. Allan. Boston, MA.

9:00 am Acute Rejection in Non-Human Primates Treated with Belatacept Is Mediated by a Unique CD8 Memory Subset. (Abstract #3)

9:15 am Thoracic Simulation Allocation Modeling (TSAM) of a 6-Tier Allocation Strategy. (Abstract #4)
Monica Colvin, M. Skeans, L. Robbins Callahan, L. Edwards, J. Zeglin, S. Silvestry, R. Davies, M. Farr, A. Israni, J. Rogers. Minneapolis; Richmond; Orlando; Wilmington; New York; Durham.

9:30 am A 5-Year Multicenter Evaluation of Seasonal Influenza Infection in Transplant Recipients. (Abstract #5)
D. Kumar, E. Cordero, E. Blumberg, A. P. Limaye, M. Levi, L. Danziger-Isakov, J. Englund, S. Husain, F. Silveira, G. Reid, T. Sharma, Atul Humar. Toronto, Canada; Philadelphia; Boston; Seville, Spain; Seattle; ChicagoDenver; Cincinnati; Pittsburgh.

Special Announcements
9:45 am — 10:00 am
Veterans Auditorium

AST Lifetime Achievement Award
10:00 am — 10:15 am
Veterans Auditorium

ASTS Pioneer Award
10:15 am — 10:30 am
Veterans Auditorium

State of the Art Presentation
10:30 am — 11:00 am
Veterans Auditorium

Thymus Transplantation: An Approach to Tolerance Induction
M. Louise Markert, MD, PhD
Professor of Pediatrics and Immunology
Duke University Medical Center
Durham, NC, USA
Coffee Break – with Exhibits  
11:00 am — 11:30 am  
**Halls C&D**

Midday Symposia  
11:30 am — 1:00 pm  

**Advances in Treg Biology**

*Room 304*  
Moderators: Qizhi Tang, PhD, University of California San Francisco, San Francisco, CA, USA and Jordi Ochando, PhD, Mount Sinai Medical Center, New York, NY, USA

11:30 am  
**Treg Function and Stability**  
Wayne Hancock, MD, PhD  
Children’s Hospital of Philadelphia  
Philadelphia, PA, USA

12:00 pm  
**Redirecting Tregs with CAR Technology**  
Megan Levings, PhD  
Child & Family Research Institute  
Vancouver, BC, Canada

12:30 pm  
**A Wave of Regulatory T Cells into Neonatal Skin Mediates Tolerance to Commensal Microbes**  
Michael Rosenblum, MD, PhD  
University of California San Francisco  
San Francisco, CA, USA

**Frontiers in Inflammation Relevant to Transplantation**

*Room 306*  
Moderators: Jessamyn Bagley, Tufts University, Boston, MA, USA and Leonardo Riella, MD, PhD, Brigham and Women’s Hospital, Boston, MA, USA

11:30 am  
**Mitochondrial DAMPS and Inflammation**  
Carl Hauser, MD  
Beth Israel Deaconess Medical Center  
Boston, MA, USA

12:00 pm  
**Inflammasome-Independent Regulation of IL-1-Family Cytokines**  
Leo Joosten, PhD  
Radboud University Medical Center  
Nijmegen, The Netherlands

12:30 pm  
**TLRs and Inflammasome Activation**  
Julie Blander, PhD  
Icahn School of Medicine at Mount Sinai Hospital  
New York, NY, USA

**Rapid Fire State-of-the-Art in Xenotransplantation**

*Room 310*  
Moderators: David Cooper, MD, PhD, University of Pittsburgh, Pittsburgh, PA, USA and Richard Pierson, MD, University of Maryland at Baltimore, Baltimore, MD, USA

11:30 am  
**Heart**  
Bruno Reichart  
Klinikum der Universität München  
Munich, Germany

11:45 am  
**Kidney**  
Peter Cowan, PhD  
St. Vincent’s Hospital Melbourne  
Melbourne, Australia

12:00 pm  
**Liver**  
Joseph Tector, MD, PhD  
University of Pittsburgh  
Pittsburgh, PA, USA

12:15 pm  
**Lung**  
Richard Pierson, MD  
University of Maryland  
Baltimore, MD, USA

12:30 pm  
**Islet**  
Bernhard Hering, MD  
University of Minnesota  
Minneapolis, MN, USA

12:45 pm  
**Panel Discussion – Which Residual Barriers are Common and Which are Unique?**

**A Year Following the New Kidney Allocation System (KAS) – What’s Working, What’s Not!**

*Veterans Auditorium*  
Moderators: Clifford Miles, MD, University of Nebraska Medical Center, Omaha, NE, USA and Richard Formica, MD, Yale University, New Haven CT, USA

11:30 am  
**Is it Achieving the Goals?**  
Alexander Gilbert, MD  
Medstar Georgetown Transplant Institute  
Washington, DC, USA

12:00 pm  
**Does it Help KAS Find a Home for High KDPI Kidneys?**  
Mark Aeder, MD  
University Hospital Case Western Medical Center  
Cleveland, OH, USA
12:30 pm  **HLA Challenges: Impact on Nationally Allocated Kidneys to the Extremely Sensitized Kidney Transplant Candidate**  
Howard Gebel, PhD  
Emory University  
Atlanta, GA, USA

**AMR in Liver Transplantation**

**Room 302**

Moderators: John O'Grady, MD, Kings College London, London, United Kingdom and Abraham Shaked, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

11:30 am  **Histopathologic Consequences of DSA in Liver**  
Anthony Jake Demetris, MD  
University of Pittsburgh Medical Center  
Pittsburgh, PA, USA

12:00 pm  **Acute AMR: Diagnosis and Treatment in Liver Transplant**  
Stuart Knechtle, MD –  
Duke University Medical Center  
Durham, NC, USA

12:30 pm  **Chronic AMR in Liver Transplant - The Next Frontier**  
Jacqueline O’Leary, MD, MPH  
Baylor Health Center  
Dallas, TX, USA

**Predictors of Survival after Lung Transplant**

**Room 309**

Moderators: Wayne Tsuang, MD, MHS, Cleveland Clinic, Cleveland, OH, USA and Joshua Mooney, MD, Stanford University, Stanford, CA, USA

11:30 am  **Effects of Declining Health Status on the Lung Transplant Waiting List on Wait List Mortality and Posttransplant Survival**  
Cynthia Gries, MD, MSc  
Florida Hospital  
Orlando, FL, USA

12:00 pm  **Obesity and Advanced Age in Lung Transplant**  
Edward Garrity, MD  
University of Chicago Medical Center  
Chicago, IL, USA

12:30 pm  **The Impact of Single vs. Bilateral Lung Transplant on Survival**  
Robert Duane Davis, MD, MBA  
Florida Hospital  
Orlando, FL, USA

**Donor Derived Infections: New Insights on the Use of Infected Donors**

**Ballroom C**

Moderators: Cameron Wolfe, MD, Duke University, Durham, NC, USA and Daniel Kaul, MD, University of Michigan, Ann Arbor, MI, USA

11:30 am  **Hindsight is 20/20**  
Shirish Huprikar, MD  
Icahn School of Medicine at Mt. Sinai  
New York, NY, USA

12:00 pm  **Risk of HIV Transmission Among Increased Risk Donors**  
Brian Gurbaxani, PhD  
CDC – Georgia Institute of Technology  
Atlanta, GA, USA

12:30 pm  **Communication Enhances Transplant Outcomes**  
Rachel Miller, MD  
University of Iowa  
Iowa City, IA, USA

**What's New for the Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients?**

**Room 311**

Moderators: Ryan Ehrensberger, PhD, United Network for Organ Sharing, Richmond, VA, USA and Bertram Kasiske, MD, Hennepin County Medical Center, Minneapolis, MN, USA

11:30 am  **Metrics to Assess Pre-Transplant Program Performance**  
David Axelrod, MD, MBA  
Dartmouth-Hitchcock Medical Center  
Lebanon, NH, USA

12:00 pm  **The Unmet Need: Who are the Potential Donors?**  
Darren Stewart, MS  
United Network for Organ Sharing  
Richmond, VA, USA

12:30 pm  **Measuring Deceased Donor: Progress and Promise**  
Jon Snyder, PhD  
Scientific Registry of Transplant Recipients  
Lakeville, MN, USA
Liver Transplantation for Malignancy? State of the Art and Future Directions

Room 312
Moderators: John Lake, MD, University of Minnesota Medical School, Minneapolis, MN, USA and Majella Doyle, MD, Washington University School of Medicine, St. Louis, MO, USA

11:30 am Hepatic Resection versus Transplantation for HCC in the Era of Hepatitis C Treatment
Paul Greig, MD, FRCSC
University of Toronto
Toronto, ON, Canada

11:50 am How Far Can We “Push It” with Hepatocellular Carcinoma – Can/Should We Change Our Indications?
William Chapman, MD
Washington University in St. Louis
St. Louis, MO, USA

12:10 pm Should We Be Using mTOR Inhibitors for All Patients with HCC?
Kymberly Watt, MD
Mayo Clinic
Rochester, MN, USA

12:30 pm Role of Liver Transplantation in Patients with Colorectal Hepatic Metastases
Morten Hagness, MD, PhD
Oslo University Hospital
Oslo, Norway

Kidney Transplantation – Technical Challenges

Ballroom C
Moderators: Robert Montgomery, MD, PhD, Johns Hopkins University, Baltimore, MD, USA and Lloyd Ratner, MD, Columbia University, New York, NY, USA

11:30 am Transplantation of Anatomically Complex Kidneys
H. Albin Gritsch, MD
University of California Los Angeles
Los Angeles, CA, USA

12:00 pm Treatment of Early and Late Ureteral Complications
Patrick Luke, MD
London Health Science Center
London, ON, Canada

12:30 pm Transplant Renal Artery Pseudoanerysm and Other Vascular Complications
Scott Ames, MD
Mount Sinai Hospital
New York, NY, USA

Luncheon Workshops - Ticketed Events
1:00 pm — 2:15 pm

1. Liver Pathology Workshop: Basic and Challenging Cases
Room 108
Moderators: Thomas Schiano, MD, Ichan School of Medicine at Mount Sinai, New York, NY, USA and Isabel Fiel, MD, Ichan School of Medicine at Mount Sinai, New York, NY, USA

2. What to Do with the Biopsy Findings? Potential Topics: BK Nephritis, AMR, Recurrence of GN
Room 102
Moderators: Cinthia Drachenberg, MD, University of Maryland, Baltimore, MD, USA and Fernando Cosio, MD, Mayo Clinic, Rochester, MN, USA

3. Biosimilars in Patient Care: What Are They and How Will They Impact Transplant Patient Management
Room 104
Moderators: Steven Gabardi, PharmD, Brigham and Women’s Hospital, Boston, MA, USA and Teun van Gelder, MD, Erasmus Medical Center, Rotterdam, The Netherlands

Developing New Therapy for Transplant Recipients: What are the Barriers?

Ballroom B
Moderators: Rita Alloway, PharmD, FCCP, University of Cincinnati College of Medicine, Cincinnati, OH, USA and Dixon Kaufman, MD, PhD, University of Wisconsin, Madison, WI, USA

11:30 am What Are The Unmet Needs In Transplantation—How Can We Move Forward?
Mark Stegall, MD
Mayo Clinic
Rochester, MN, USA

12:00 pm Regulatory Barriers to New Therapy
Roslyn Mannon, MD
University of Alabama at Birmingham
Birmingham, AL, USA

12:30 pm Barriers in Industry
Randall Morris, MD, FRCP
Stanford University, Emeritus
Carmel, CA, USA
4. Meet the Experts: Difficult Antibody Cases in Heart Transplantation

**Room 101**

Moderators: Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA and Adriana Zeevi, PhD, University of Pittsburgh, Pittsburgh, PA, USA

---

5. NIH Grant Writing From Multiple Perspectives - Panel Discussion

**Room 103**

Moderators: Kirsty Kraemer, PhD and Jin Huang, PhD, Transplantation Tolerance and Tumor Immunity Study Section at the CSR/NIH; David Briscoe, MD, MB, Children’s Hospital Boston, Boston, MA, USA, Mandy Ford, PhD, Emory University, Atlanta, GA, USA and Scott Palmer, MD, Duke University, Durham, NC, USA, Priti Mehrotra, NIAID, NIH, DHHS, Bethesda, MD, USA and Nancy Vasquez-Maldonado, NIAID, NIH, DHHS, Bethesda, MD, USA

---

**Transplantation in Depth**

1:30 pm — 4:30 pm

**B Cells**

**Room 302**

Moderators: Anita Chong, PhD, University of Chicago, Chicago, IL, USA

1:30 pm Basic Mechanisms of B cell Tolerance and Anergy

Andrew Getahun

University of Colorado

Denver, CO, USA

2:00 pm New Insights into Mucosal Antibody Responses

Andrea Cerutti, MD

Mount Sinai

New York, NY, USA

2:30 pm B cell Memory

Michael McHeyzer-Williams, PhD

Scripps Research Institute

La Jolla, CA, USA

3:00 pm B regs

David Rothstein, MD

Thomas E. Starzl Transplant Institute

Pittsburgh, PA, USA

3:30 pm Poly Reactive Antibodies, Markers and Mechanisms

Emanuel Zorn, PhD

Columbia University Medical Center

New York, NY, USA

4:00 pm Targeting B cells in Transplantation

Menna Clatworthy, BSc, MBCh, PhD, FRCP

Cambridge University

Cambridge, United Kingdom

---

**Concurrent Oral Abstract Sessions**

2:30 pm — 4:00 pm

**Cardiovascular Complications in Kidney Transplantation**

**Room 304**

Chairs: Krista Lentine, MD, PhD, Saint Louis University Medical Center, St. Louis, MO, United States and Bertram Kasiske, MD, Hennepin County Medical Center, Minneapolis, MN, United States

2:30 pm Validation of a Simplified Cost-Effective Clinical Risk Stratification That Predicts Myocardial Ischemic Events in Kidney Transplant Candidates. (Abstract #6)

T. Jiamjariyapon, N. Townamchai, N. Garg, M. Pavlakis, A. Chandraker. Bangkok, Thailand; Boston, MA.

2:42 pm Clinical and Subclinical Cardiac Events After Kidney Transplantation (KTX). (Abstract #7)

Fernando Cosio, Hatem Amer, Mira Keddis, Allan Jaffe. Rochester, MN; Phoenix, AZ.

2:54 pm Predicting Obstructive Coronary Artery Disease in Asymptomatic Patients Undergoing Renal Transplantation Using a Simple Risk Score. (Abstract #8)


3:06 pm Using Predictive Modeling to Manage Cardiovascular Risk and Improve Kidney Transplant Outcomes. (Abstract #9)

3:18 pm Sociodemographic and Comorbidity Differences Between Dialysis, Waitlisted and Transplant Patients in the UK: Findings from the ATTOM Study. (Abstract #10) Diana Wu, Matthew Robb, Chris Watson, Rommel Ravan, John Forsythe, Andrew Bradley, Gabriel Oniscu. Edinburgh, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom.

3:30 pm Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients. (Abstract #11) Shaifali Sandal, Sunjae Bae, Allan Massie, Marcelo Cantarovich, Dorry Segev. Montreal, Canada; Baltimore.


Challenges in Hearts and VADs - Striking Back
Room 309
Chairs: Howard Eisen, Drexel University, Philadelphia, PA, United States and Jignesh Patel, Cedars-Sinai Heart Institute, Los Angeles, CA, United States

2:30 pm Pregnancy Outcomes in 17 Female Heart Transplant Recipients with the Initial Diagnosis of Congenital Heart Defect. (Abstract #13) Lisa A. Coscia, Dawn P. Armenti, Serban Constantinescu, Michael J. Moritz. Philadelphia; Allentown.


2:54 pm Solid Phase Assay Demonstrates High Rates of Allosensitization in Pediatric Heart Recipients. (Abstract #15) Warren Zuckerman, Brian Feingold, Adriana Zeevi, Carol Bentlejewski, Linda Addonizio, Elizabeth Blume, Charles Canter, Anne Dipchand, Daphne Hsu, Robert Shaddy, William Mahle, Kristen Much, Brian Armstrong, David Ikle, Helena Diop, Jonah Odim, Steven Webber. NYC; Pittsburgh; Boston; St. Louis; Toronto, Canada; Philadelphia; Atlanta; Chapel Hill; Bethesda; Nashville.


3:18 pm The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation. (Abstract #17) Jignesh Patel, Michelle Kittleson, David Chang, Tamar Aintablian, Angela Velleca, Danny Ramzy, Lawrence Czer, Jon Kobashigawa. Los Angeles, CA.

3:30 pm Dilution of Patient Sera Improves MFI Correlation with Complement Fixation in Solid Phase Assay Assessment. (Abstract #18) Chesney D. Castleberry, Donna Phelan, Kathleen Simpson, Thalachallour Mohanakumar, Charles Canter. St. Louis, MO.

Donor Management: All Organs

Room 306
Chairs: David Foley, University of Wisconsin, Madison, WI, United States and Luis Fernandez, MD, University of Wisconsin, Madison, WI, United States

2:30 pm Activated Cytoprotective Mechanisms in DBD Kidneys Correlate with Kidney Function in Transplant Recipients: A Study Using Clinical Samples from the UK QUOD Biobank. (Abstract #20)

2:42 pm Normothermic Ex Vivo Liver Perfusion (NEVLP) Using Steen Solution as Preservation Technique for Liver Transplantation—First Clinical Results. (Abstract #21)

2:54 pm Deceased Organ Donor Management: Does Hospital Volume Matter? (Abstract #22)

3:06 pm The “PHS Increased Risk” Label Is Associated with Non-Utilization of Hundreds of Organs Per Year. (Abstract #23)
Michael L. Volk, Amber R. Wilk, Cameron Wolfe, Daniel Kaul. Loma Linda, CA; Richmond, VA; Durham, NC; Ann Arbor, MI.

3:18 pm Are We Refusing Good Organs? Outcomes of Ventilator Management of Sub-Optimal Lung Donors. (Abstract #24)
Brandi B. Scully, David Horne, Jeffrey S. Heinle, E. Dean McKenzie, Kathleen E. Hosek, Wei Zhang, George B. Mallory, Ernestina Melicoff. Houston, TX.

3:30 pm Pancreas Transplantation from Pediatric Donors: A UNOS Registry Analysis. (Abstract #25)
Mario Spaggiari, Ivo Tzvetanov, Hoobae Jeon, Enrico Benedetti, Jose Oberholzer. Chicago.

3:42 pm Comparison of Three Approaches for Laparoscopic Donor Nephrectomy: Transvaginal, Transumbilical Single Site and Retroperitoneal. (Abstract #26)
Masayoshi Miura, Hiroshi Higashiyama. Sapporo, Japan.

Kidney Acute Cellular Rejection: Clinical Outcomes and Pathological Characteristics

Ballroom C
Chairs: Christopher Blosser, MD, Univ of Washington, Seattle, WA, United States and Michelle Josephson, MD, University of Chicago Medicine, Chicago, IL, United States

2:30 pm Clinical Significance of Isolated v1 Arteritis in Renal Transplantation. (Abstract #27)

2:42 pm Molecular Assessment of Kidney Transplant Biopsies Performs Similarly in Medulla and Cortex. (Abstract #28)
K. S. Madill-Thomsen, J. Reeve, G. Bohmig, F. Eskandary, P. F. Halloran. Edmonton, AB, Canada; Vienna, Austria.

2:54 pm Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients. (Abstract #29)
Thomas Schachtner, Maik Stein, Petra Reinke. Berlin, Germany.

3:06 pm Post-Transplant T-Cell Alloreactive Perturbation Precedes the Advent of Humoral Immunity in Kidney Transplant Patients. (Abstract #30)
Elena Crespo, Sergi Luque, Josep M. Cruzado, Edoardo Melilli, Josep M. Grinyo, Marc Lucia, Oriol Bestard. Barcelona, Spain.
3:18 pm The Effect of Donor Age on Acute Rejection Age – The Clinical Impact of Donor Immuno-Senescence in the Modern Immunosuppressive Era. (Abstract #31)
Usman Khalid, Paola Donato, Lazlo Szabo, Rafael Chavez, Elijah Ablorsu, Argiris Asderakis. Cardiff, United Kingdom.

2:54 pm Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients. (Abstract #36)
F. Shihab, Y. Qazi, S. Mulgaonkar, K. McCague, D. Patel, V. R. Peddi, D. Shaffer. Salt Lake City, UT; Los Angeles, CA; West Orange, NJ; East Hanover, NJ; San Francisco, CA; Nashville, TN.

3:30 pm Reversibility of Acute Kidney Rejection According to the Banff 2013 Classification: A Retrospective Cohort Study. (Abstract #32)

3:06 pm Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients. (Abstract #37)
Y. Qazi, F. Shihab, S. Mulgaonkar, K. McCague, D. Patel. Los Angeles; Salt Lake City; West Orange; East Hanover.

3:18 pm Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant. (Abstract #38)
Aneesha Shetty, Traitanon Opas, James Mathew, Valeria Mas, Joseph Leventhal, Nedjema Sustento-Reodica, Lorenzo Gallon. Chicago, IL; Charlottesville, VA.

3:30 pm Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results. (Abstract #39)
Ronaldo M. Esmeraldo, Maria L. M. B. Oliveira, Petrucia M. A. Pinheiro, Celi M. Girao, Taina V. S. Freitas. Fortaleza, CE, Brazil.

3:42 pm Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus. (Abstract #40)
Gionata Spagnoletti, Maria Paola Salerno, Valentina Bianchi, Nicola Silvestrini, Francesca Apponi, Jacopo Romagnoli, Franco Citterio. Rome, Italy.
Kidney Transplantation: Outcomes, Matching and Marginal Donors

Ballroom B

Chairs: Ronald Pelletier, MD, Ohio State Univ Med Ctr, Columbus, OH, United States and Amy Evenson, Beth Israel Deaconess Medical Center, Boston, MA, United States

2:30 pm A Virtual Crossmatch Algorithm That Mimics the Sensitivity of Flow Cytometric Crossmatch. (Abstract #41)
Prakash Rao, Dayanand Deo, Cecil Rhodes, Donna King, Patricia Bowe, Julien Napoleon, Ijeoma Okere. New Providence, NJ.

2:42 pm U.S. Dialysis Facility Characteristics Associated with Racial Disparities in Access to the Kidney Deceased Donor Transplant Waiting List. (Abstract #42)

2:54 pm Evaluation of Scoring Systems Predicting Patient Survival at Time of Kidney Transplantation. (Abstract #43)
Oliver Staeck, Dmytro Khadzhynov, Anna Kleinstuber, Lukas Lehner, Michael Duer, Klemens Budde, Fabian Halleck. Berlin, Germany.

3:06 pm Does DCD Donor Time-to-Death After Withdrawal of Support Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United States. (Abstract #44)

3:18 pm Donor-Recipient Absolute Weight Mismatch and the Risk of Graft Loss in Renal Transplantation. (Abstract #45)

3:30 pm The Impact of Early Acute Rejection and Delayed Graft Function on Graft Outcomes at Six Months in Adult Deceased Donor Kidney Recipients. (Abstract #46)
Douglas Keith, Gayle Vranic, Angie Nishio Lucar. Charlottesville, VA.

3:42 pm Factors Associated with Acute Rejections in Kidney Transplant Recipients: Time for HLA-DR Matching in Elderly Recipients? (Abstract #47)
Dmytro Khadzhynov, Fabian Halleck, Lukas J. Lehner, Michael Duer, Anna Kleinstuber, Danilo Schmidt, Klemens Budde, Oliver Staeck. Berlin, Germany.

Living Kidney Donation: Risk Factors for Adverse Long term Outcome

Veterans Auditorium

Chairs: Christian Kuhr, MD, Virginia Mason Medical Center, Seattle, WA, United States and Kasi McCune, MD, Columbia, New york, NY, United States

2:30 pm Short-Term Post-Donation Renal Function in Living Kidney Donors. (Abstract #48)

2:42 pm Obesity Is Associated with Increased Risk of ESRD Among Living Kidney Donors. (Abstract #49)
Jayme E. Locke, Cora E. Lewis, Rhiannon D. Reed, Vineeta Kumar, Deirdre Sawinski, Allan B. Massie, Paul A. MacLennan, Roslyn B. Mannen, Robert Gaston, Dorry L. Segev. Birmingham, AL; Philadelphia, PA; Baltimore, MD.

2:54 pm Incidence and Renal Consequences of Type 2 Diabetes Mellitus in Kidney Donors. (Abstract #50)

3:06 pm Risk of ESRD in Potential HIV+ Live Kidney Donors. (Abstract #51)
Abimereki Muzaale, Lauren Kucirka, Allan Massie, Christine Durand, Jayme Locke, Gregory Lucas, Dorry Segev. Baltimore; Birmingham.

3:18 pm Risk Prediction of End-Stage Renal Disease in Living Kidney Donors. (Abstract #52)

3:30 pm Impact of Donor-Recipient Relationship on Development of CKD. (Abstract #53)
Arthur Matas, David Vock, Hassan Ibrahim. Mpls, MN.
3:42 pm  |  Are Prior Living Kidney Donors with ESRD Being Listed and Receiving Transplantation Priority in a Timely Manner? (Abstract #54)
J. Wainright, A. Kucheryavaya, D. Klassen, D. Stewart. Richmond, VA.

**Novel Markers of Long Term Kidney Transplant Outcomes**

*Ballroom A*

**Chairs:** Emilio Poggio, Cleveland Clinic, Cleveland, OH, United States and Brian Stephany, MD, The Cleveland Clinic Foundation, Cleveland, OH, United States

2:30 pm  |  Complement-Binding Donor-Specific Anti-HLA Antibodies Are Associated with Severe Kidney Allograft Arteriosclerosis. (Abstract #55)

2:42 pm  |  Molecular Significance of Microvascular Inflammation and C4d Negative Transplant Glomerulopathy. (Abstract #56)
M. Lubetzky, P. O Broin, Y. Bao, E. Akalin. Bronx; Galway, Ireland.

2:54 pm  |  Beyond the Bones – The Association Between Vitamin D, Graft Outcomes and Vascular Disease. (Abstract #61)

3:06 pm  |  Clinical Significance of Non-HLA Antibodies in the Development of Microcirculation Inflammation in Allograft Tissue After Kidney Transplantation. (Abstract #58)

3:18 pm  |  Complexity of Hylinosis in Renal Transplant Biopsies: Donor Age, Glomerular Disease, and Time. (Abstract #59)
G. Einecke, J. Reeve, P. F. Halloran. Hannover, Germany; Edmonton, Canada.

3:30 pm  |  Pulse Pressure and GFR Decay in Kidney Transplant Recipients. (Abstract #60)

3:42 pm  |  Impact of Pretransplant Non-Donor-Specific HLA Immunization: Mainly Class 1 Immunization Leads to Poor Immunologic Outcome and Graft Loss. (Abstract #57)
Oliver Staeck, Fabian Halleck, Anja Staeck, Lukas Lehner, Michael Duerr, Eva Schrezenmeier, Klemens Busde, Dmytro Khadzhynov. Berlin, Germany.

**Policy and Practice: Implications for Long Term Outcomes**

*Room 312*

**Chairs:** Raymond Heilman, Mayo Clinic Hospital, Phoenix, AZ, United States and Nagaraju Sarabu, University Hospitals Case Medical School, Cleveland, OH, United States

2:30 pm  |  Effect of mTOR Inhibitors on the Risk of Cancer Development After Kidney Transplantation in Chinese Population. (Abstract #62)
Chih-Chin Kao, Jia-Sin Liu, Ming-Huang Lin, Fan-Chi Chang, Yen-Chung Lin, Hsi-Hsien Chen, Tzen-Wen Chen, Chih-Cheng Hsu, Mai-Szu Wu. Taipei, Taiwan; Zhunan, Taiwan.

2:42 pm  |  Short UK Dialysis Does Not Significantly Impact on Live Donor Kidney Allograft Survival. (Abstract #63)
Andrew Bentall, Mark Jesky, Richard Borrows, Rachel Johnson, Simon Ball. Birmingham, United Kingdom; Bristol, United Kingdom.

2:54 pm  |  Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA). (Abstract #64)
Alexandra Brigido, Helio Tedesco, Claudia Felipe, Marina Cristelli, Marcello Franco, Jose Medina-Pestana. Sao Paulo, Brazil.

3:06 pm  |  Monitoring of De Novo DSA Post Alemtuzumab Induction in Renal Transplant Recipients: One Year Follow Up. (Abstract #65)
Yezina Nigatu, Chelsea Estrada, Frank Darras, Heesuck Suh, Mersema T. Abate, Edward P. Nord. Stony Brook, NY.
3:18 pm  Mycophenolic Acid Product Discontinuation Prior to Conception: Analysis of Pregnancies in Kidney Transplant Recipients. (Abstract #66)
Serban Constantinescu, Lisa A. Coscia, Dawn P. Armenti, Michael J. Moritz.
Philadelphia, PA; Allentown, PA.

3:30 pm  Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study. (Abstract #67)
Mario Carmellini, Paola Todeschini, Antonio Secchi, Silvio Sandrini, Enrico Minetti, Lucrezia Furiu, Gionata Spagnoletti, Francesco Pisani, Gian Benedetto Piredda, Gianni Cappelli, Giuseppe Tisone. Siena, Italy; Bologna, Italy; Milano, Italy; Brescia, Italy; Firenze, Italy; Padova, ItalyRoma, Italy; L'Aquila, Italy; Cagliari, Italy; Modena, Italy.

3:42 pm  Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States. (Abstract #68)
Alfonso Santos, Michael Casey, Xuerong Wen, Shehzad Rehman, Karl Womer.
Gainesville, FL.

SOT: HIV, HBV, & HCV

Room 313
Chairs: Shmuel Shoham, MD, Johns Hopkins University School of Medicine, Baltimore, MD, United States and Natalie Nierenberg, MD MPH, Tufts Medical Center, Boston, MA, United States

2:30 pm  Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges. (Abstract #72)

2:42 pm  Kidney Transplantation in HIV Patients: Effect of Race on the Choice of Anti-Thymocyte Globulin Induction Immunosuppression. (Abstract #70)

2:54 pm  Donors with Isolated Anti-HBc ("HBcAb Only") Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb. (Abstract #71)
Youngil Chang, Claudia Chinchilla-Reyes, Michael Koss, Marek J. Nowicki. Los Angeles, CA; Pomona, CA.

3:06 pm  Kidney Retransplantation Is Associated with Higher Mortality Risk Among HIV+ vs. HIV- Recipients. (Abstract #69)
Brittany Shelton, Shikha Mehta, Deirdre Sawinski, Rhiannon D. Reed, Paul A. MacLennan, Sally Gustafson, Christine Durand, Dorry L. Segev, Jayme E. Locke. Birmingham, AL; Philadelphia, PA; Minneapolis, MN; Baltimore, MD.

3:18 pm  The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection. (Abstract #73)

3:30 pm  Efficacy and Safety of Direct Antiviral Agents (DAA)-Based Therapies for Hepatitis C Virus (HCV) Infection in Kidney Transplant (KT) Recipients. (Abstract #74)

3:42 pm  Utilization of HCV-Positive Donors’ Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy. (Abstract #75)
Beth Amundsen, Meghan Sise, Ming Lin, Hany Deirawan, Elliot Heher, Brendan Kimball, James Markmann, Nahel Elias. Boston, MA.
The Kidney in Liver Transplantation

**Room 302**

**Chairs:** Goran Klintmalm, MD, PhD, Baylor University Medical Center, Dallas, TX, United States and W. Ray Kim, Div of Gastroenterology and Hepatology, Stanford University, Stanford, CA, United States

### 2:30 pm

**Combination of Delayed Kidney Transplant (KT) and Better Quality Kidneys Offers Excellent Patient Survival in Combined Liver-Kidney Transplantation (CLKT).** (Abstract #76)


### 2:42 pm

**The Effect of DRI and KDPI on Outcomes of High MELD Patients Undergoing Simultaneous Liver Kidney Transplant.** (Abstract #77)

Edie Y. Chan, Martin Hertl, James D. Perkins. Chicago, IL; Seattle, WA.

### 2:54 pm

**Utility in Treating Renal Failure in End-Stage Liver Disease with Simultaneous Liver-Kidney Transplantation.** (Abstract #78)


### 3:06 pm

**Acute Kidney Injury After Liver Transplantation Is Set in Motion Early After Reperfusion of the Liver Graft: A Prospective Cohort Study.** (Abstract #79)

Ina Jochmans, Nicolas Meurisse, Diethard Monbaliu, Jacques Pirenne. Leuven, Belgium; Liège, Belgium.

### 3:18 pm

**AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.** (Abstract #80)

Jacqueline G. O’Leary, Aurélie Philippe, Harald Heidecke, Robert Freeman, Linda W. Jennings, Rusan Catar, Goran B. Klintmalm, Duska Dragun. Dallas, TX; Berlin, Germany.

### 3:30 pm

**Acute Kidney Injury and Chronic Kidney Disease in Donation After Circulatory Death Liver Transplantation: UK Single Centre Study.** (Abstract #81)

Ilaria Umbro, Francesca Tinti, Felicity Evison, Adnan Sharif, Bridget Gunson, Anna Paola Mitterhofer, James W. Ferguson, Paolo Muiesan. Birmingham, United Kingdom; Rome, Italy.

### 3:42 pm

**Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.** (Abstract #82)

Peter Bernhardt, Gaohong Dong, Patricia Lopez, Gregory Hustache, Giovanni Bader. Basel, Switzerland; East Hanover.

---

### Allied Health Symposium 1

**2:30 pm — 5:30 pm**

**Identifying Opportunities to Incorporate Quality Improvement and Research into your Day**

**Room 206**

**The Electronics of Transplantation and Performance Improvement: Dashboards, Documentation, and Medication Errors**

Moderators: Demetra Tsapepas, PharmD, New York-Presbyterian Hospital, New York, NY, USA and Tiffany Kaiser, PharmD, University of Cincinnati, Cincinnati, OH, USA

### 2:30 pm

**Utilizing Electronic Dashboards to Create a Culture of Quality and Transparency**

Brigitte Sullivan, MBA

NYU Langone Transplant Institute

New York, NY, USA

### 2:55 pm

**Electronic Documentation Practices to Foster Multi-disciplinary Participation in the Quality and Compliance Process**

Marian O’Rourke, RN, CCTC

Jackson Memorial Hospital

Miami, FL, USA

### 3:20 pm

**Electronic Medication Error Reporting to Enhance Patient Safety**

Meredith Aull, PharmD

New York Presbyterian – Weill Cornell Kidney and Pancreas transplant Program

New York, NY, USA
3:45 pm  Coffee Break

Developing Pharmacists and Allied Health Professionals into Clinical/Translational Scientists
Moderators: James Fleming, Pharm D, Medical University of South Carolina, Charleston, SC, USA and Angela Maldonado, PharmD, Vidant Medical Center, Greenville, NC, USA

4:00 pm  Fitting Clinical Research into Your (Already Busy) Practice
Nicole Pilch, PharmD
Medical University of South Carolina
Charleston, SC, USA

4:30 pm  Making Clinical/Translational Research Your Career
Rita Alloway, PharmD
University of Cincinnati College of Medicine
Cincinnati, OH, USA

5:00 pm  The Importance of Pharmacists and Allied Health Providers in Multidisciplinary Transplant Research
A Osama Gaber, MD
Houston Methodist Hospital System
Houston, TX, USA

Pediatric Symposium 1
2:30 pm — 5:30 pm

Improving Long-term Outcomes in Pediatric Transplantation
Room 310

Pediatric Late Liver Graft Outcomes: Moving the Needle
Moderators: John Bucuvalas, MD Cincinnati Children’s Hospital, Cincinnati, OH, USA and George Mazariegos, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

2:30 pm  Clinical Manifestations of Late Allograft Injury in Children/Approach to Histologic Assessment in Long-Term Pediatric Liver Allograft
Anthony Jake Demetris, MD
UPMC – Montefiore
Pittsburgh, PA, USA

2:50 pm  Multicenter Collaboration: It takes a GIGOLO
Deirdre Kelly, MD
Birmingham Children’s Hospital
Birmingham, United Kingdom

3:10 pm  MALT Study: Methods, Implementation, Primary And Secondary Analysis Results
Eyal Shemesh, MD
Icahn School of Medicine at Mt. Sinai
New York, NY, USA

3:30 pm  Coffee Break

Tolerance After Pediatric Solid Organ Transplantation? How Close are We to Prime Time?
Moderators: Peter Heeger, MD, Mount Sinai School of Medicine, New York, NY, USA and Abraham Shaked, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

4:00 pm  Tolerance: Determinants, Definitions And Forms
Megan Sykes, MD
Harvard University
Boston, MA, USA

4:20 pm  Immune Monitoring: Current Assays And Clinical Application In Pediatric Solid Organ Transplantation
Alberto Sanchez-Fueyo, MD, PhD
Kings College
London, United Kingdom

4:40 pm  Taking Tolerance To The Bedside: Models Of Tolerance Induction, And When Immunosuppression Is Needed: Lessons From Iwith
Sandy Feng, MD, PhD
University of California San Francisco
San Francisco, CA, USA

Long-term follow up, Achilles Heel of Pediatric Transplantation?
Moderators: Nancy Halnon, MD, University of California Los Angeles, Los Angeles, CA, USA and Beverly Kosmach-Park, DNP, RN, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

5:00 pm  What Are They Thinking?
Developmental And Psychological Factors That Affect Adherence And Compliance In Pediatric Transplant Recipients
Rachel Annunziato, PhD
Fordham University
New York, NY, USA

5:20 pm  Q/A Discussion
Student Program – The Science, The Art and the Allure of Transplantation
2:30 pm — 5:30 pm

Fundamental Concepts of Transplantation
Room 208

Transplantation is a broad reaching field. In almost every medical specialty, you can pursue a transplant subspecialty. The transplant-specific areas of each specialty are unique, interesting and an elegant combination of science specific to the specialty and science common to transplantation.

Moderators: Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore MD, USA and Randall Sung, MD, University of Michigan, Ann Arbor, MI, USA

2:30 pm   Expanding Transplantation is More than Just Wishing: Practical Thoughts from the ASTS President
Charles Miller, MD
Cleveland Clinic Foundation
Cleveland, OH, USA

2:45 pm   Nephrology is More than Just Dialysis: Kidney Transplantation for the Win
Krista Lentine, MD
St. Louis University School of Medicine
St. Louis, MO, USA

3:00 pm   Liver Transplantation is More than Just Surgery: It’s Really Big Surgery
Mark Ghobrial, MD, PhD
Methodist Hospital
Houston, TX, USA

3:15 pm   Outcomes Research is More than Just Excel: Data, More Data, and Statistics
Dorry Segev, MD, PhD
Johns Hopkins University
Baltimore, MD, USA

3:30 pm   Transplantation is More than Just Solid Organs: Hands, Face, and other Vascularized Composite Allografts
Linda Cendales, MD
Duke University Medical Center
Durham, NC, USA

3:45 pm   ID is More than Just Bacteria: HCV and HIV in the Spotlight
Christine Durand, MD
Johns Hopkins University
Baltimore, MD, USA

4:00 pm   Coffee Break

4:30 pm   Rejection is More than Just Something that Happened in High School: The Immune System
Christin Rogers, PharmD, BCPS
Beth Israel Deaconess Medical Center
Boston, MA, USA

4:45 pm   The Heart is More than Just for Breaking: Thoracic Transplantation
Maryl Johnson, MD
University of Wisconsin-Madison
Madison, WI, USA

5:00 pm   Mice are More than Just Rodents: Advancing Transplantation Through Scientific Discovery
Peter Heeger, MD
Mt. Sinai School of Medicine
New York, NY, USA

5:15 pm   Q/A Discussion

Coffee Break in the Exhibit Hall
4:00 pm — 4:30 pm

Halls C&D

Concurrent Oral Abstract Sessions
4:30 pm — 6:00 pm

Allograft Tolerance 1: Animal Models
Room 306
Chairs: Xunrong Luo, Northwestern University, Chicago, IL, United States and Jonathan Bromberg, University of Maryland School of Medicine, Baltimore, MD, United States

4:30 pm   Erythropoietin (EPO) Mediates Spontaneous Kidney Transplant Tolerance in Mice. (Abstract #83)

4:42 pm   Designing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Longterm Heart Allograft Acceptance While Inducing Immune Cell Exhaustion, Treg Induction and Memory Cell Suppression. (Abstract #84)
4:54 pm Tracking of Endogenous Graft-Reactive Tregs Reveals Their Peripheral Enrichment During Transplantation Tolerance. (Abstract #85)
James S. Young, Jianjun Chen, Michelle Miller, Dengping Yin, James Moon, Marialuisa Alegre, Anita Chong. Chicago, IL; Boston, MA.

5:06 pm αLFA-1 Monotherapy Induced Tolerance Is Dependent on Indirect CD8 T-Cells and Augments a Population of CD8 Cells with a Suppressor Phenotype. (Abstract #86)

5:18 pm Role of Regulatory T Cells in Induction of Tolerance in Mouse Vascularized Osteomyocutaneous Allotransplantation Under Combined Costimulation Blockade. (Abstract #87)

5:30 pm Engineering a “Hybrid Thymus” to Promote Transplant Tolerance. (Abstract #88)
Sara AlFadil, Mi-Jeong Kim, Marcos Iglesias Lozano, Byoungchol Oh, W. P. Andrew Lee, Gerald Brandacher, Thomas Serworld, Giorgio Raimondi. Baltimore, MD; Boston, MA.

5:42 pm Mechanisms of Alloantigen-Specific Regulation After Donor Specific Transfusion and Costimulatory Blockade in YFP-Foxp3/TdTomRed-Ebi3 Marker Mice. (Abstract #89)

Chronic Allograft Rejection: Animal Models

Room 309
Chairs: Roslyn Mannon, MD, University of Alabama, Birmingham, Birmingham, AL, United States and Madhav Menon, MBBS, MD, Mount Sinai School of Medicine, New York, NY, United States

4:30 pm miR-21 in Chronic Allograft Vasculopathy. (Abstract #90)
Vera Usuelli, Moufida Ben Nasr, Francesca D’Addio, Liu Kaifeng, Laura Borgese, Luciano Potena, Anna Solini, Chiara Rossi, Antonio Secchi, Domenico Corradi, Nelson Chau, Paolo Fiorina. Milano, Italy; Boston; Bologna, Italy; Pisa, Italy; Parma, Italy; San Diego.

4:42 pm Ameliorating Progression of Allograft Vasculopathy by Targeting the T Follicular Helper Cell Subset. (Abstract #91)

4:54 pm Conditional Deletion of mTOR in Myeloid Cells Inhibits Chronic Allograft Rejection – A Novel Role for Macrophages in Transplant Vasculopathy. (Abstract #92)
Yue Zhao, Wenhao Chen, Peixiang Lan, Xiang Xiao, Wentao Liu, Malgosia Kloc, Yianzhu Liu, Rafik Ghobrial, Osama Gaber, Xian C. Li. Houston, TX.

5:06 pm BATF Deficiency in Tolerant Lung Allograft Recipients Are Resistant to Anti-MHC and Anti-Self-Antigen Mediated Pathogenesis of Obliterative Airway Disease. (Abstract #93)
Z. Xu, X. Lin, M. Gunasekaran, M. Sharma, A. Gelman, Thalachallour Mohanakumar. St. Louis, MO; Phoenix, AZ.

5:18 pm Obliterative Bronchiolitis Following Lung Transplantation Is Preceded by Depletion of Airway Submucosal Glands and Basal Stem Cells. (Abstract #94)
5:30 pm Intracellular OPN Is an Essential Protective Factor for Cardiac Endothelial Cell and the Long Term Heart Graft Survival. (Abstract #95) Ye Su, Zhu-Xu Zhang, Zi-Qin Yin, Xu-Yan Huang, Anthony M. Jevnikar. London, ON, Canada; London, ON, Canada.


Delayed Graft Function and Protocol Biopsy

Room 302
Chairs: Joshua Augustine, University Hospitals of Cleveland, Cleveland, OH, United States and Karin True, MD, FASN, University of North Carolina, Chapel Hill, NC, United States

4:30 pm Understanding the Drivers Behind an Early Post-KAS Rise in Delayed Graft Function (DGF) Rates. (Abstract #97) Darren Stewart, Anna Kucheryavaya, David Klassen. Richmond, VA.

4:42 pm The First Impressions: A Study in Pre and Post-Implantation Renal Grafts for Early Detection Markers of Delayed Graft Function and Recovery. (Abstract #98) Sai Vineela Bontha, Lacey Suh, Phil Dormish, Ricardo Gehrau, Erika Rhone, Lorenzo Gallon, Anne King, Catherine Dumur, Daniel Maluf, Valeria Mas. Charlottesville; Chicago.


5:06 pm Associations Between Deceased-Donor Urine MCP-1 and Kidney Transplant Outcomes. (Abstract #100) Sherry G. Mansour, Jeremy Puthumanan, Peter P. Reese, Isaac E. Hall, Mona D. Doshi, Francis L. Weng, Bernd Schröppel, Heather Thiessen-Philbrook, Milan Bimali, Chirag R. Parikh. New Haven, CT; Philadelphia, PA; Detroit, MI; Livingston, NJ; Ulm, Germany; London, ON, Canada.


Hepatic Malignancies

Room 304
Chairs: Gregory McKenna, M.D., Baylor University Medical Center, Dallas, TX, United States and Susan Orloff, Oregon Health & Science University, Portland, OR, United States


4:54 pm Traditionally Unacceptable Organs Promote Liver Transplantation in Patients with Long Waiting Times in the Share 35 Era. (Abstract #106) Eric Siskind, Tara MacDonald, Rolf Barth, John LaMattina, David A. Bruno, Steven I. Hanish. Baltimore, MD.
5:06 pm  Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era. (Abstract #107)
Stacey B. Prenner, Lisa B. VanWagner, Laura M. Kulik. Chicago, IL.

5:18 pm  Is Pretransplant Determination of Hepatocellular Carcinoma Tumor Grade Using Needle Biopsy Reliable for Transplant Candidate Selection? Analysis of 217 Liver Transplant Recipients. (Abstract #108)

5:30 pm  The Influence of Rising Lab MELD on Vascular Invasion in HCC. (Abstract #109)

5:42 pm  Visceral Adiposity Is Associated with Increased Recurrence of Hepatocellular Carcinoma Following Liver Transplantation. (Abstract #110)
Abhishek Mathur, Li Boyangzi, Martin Prince, James Guerrera, Benjamin Samstein, Adam Griesemer, Karim Halazun, Tomoaki Kato, Jean Emond. NY, NY.

Impact of New Allocation Systems and Novel Tools for Performance Enhancement in Abdominal Transplantation

Room 210
Chairs: Betty Crandall, MS, RN, Wake Forest Baptist Medical Center, Winston-Salem, NC, United States and Gwen McNatt, RN, PhD, Northwestern Memorial Hospital, Chicago, IL, United States

4:30 pm  Big Data Predictive Solution to Optimize Kidney Transplant Outcome and Resource Utilization. (Abstract #111)

4:42 pm  A Multidisciplinary Approach to Reviewing Patient Care in Abdominal Transplantation. (Abstract #112)

4:54 pm  Kidney Waitlist Management with Lean Six Sigma. (Abstract #113)

5:06 pm  Impact of the Kidney Allocation System with Deceased Donor Kidney Utilization at the DSA Level. (Abstract #114)
Winston Ally, Carl Saunders, Kenneth Brayman, Avinash Agarwal. Virginia Beach, VA; Charlottesville, VA.

5:18 pm  Impact of the Kidney Allocation System with Deceased Donor Kidney Transplantation: A Single Center Experience. (Abstract #115)
Avinash Agarwal, Winston Ally, Daniel Maluf, Shawn Pelletier, Kenneth Brayman. Charlottesville, VA.

5:30 pm  Assessing the Impact of the Share35 Liver Allocation Policy: Survival Outcomes Among Liver Re-Transplant Recipients. (Abstract #116)
Jorge Ortiz, Naoru Koizumi, Chang Kwon, Yanjia Zhang, Christopher Ortiz. Toledo, OH; Fairfax, VA; Lewisburg, PA.

5:42 pm  The Finances of Broader Sharing of Livers Following Share 35. (Abstract #117)
Ann Harper, Erick Edwards, Richard Gilroy, William Chapman, David Mulligan, Goran Klintmalm. Richmond, VA; Kansas City, KS; St Louis, MO; New Haven, CT; Houston, TX.
Kidney AMR: Making the Diagnosis

Veterans Auditorium
Chairs: Ashley Vo, PharmD, Cedars Sinai Medical Ctr, Los Angeles, CA, United States, Kathryn Tinckam, MD, MMSc, FRCP, University Health Network, Toronto, ON, Canada and Robert Montgomery, MD PhD FACS, Johns Hopkins University, Baltimore, MD, United States

4:30 pm Circulating Angiotensin II Receptor: Possible Marker for Antibody Mediated Tissue Injury? (Abstract #118)
   Pamela Kimball, Felecia McDougan, Guarav Gupta. Richmond, VA.

4:42 pm Mapping Heterogeneity in Antibody-Mediated Rejection Using Molecular Phenotypes and Archetype Analysis. (Abstract #119)
   Jeff Reeve, Philip F. Halloran. Edmonton, AB, Canada.

4:54 pm Positive Lymphocytes Flow Cytometry Crossmatch Due to AT1r Antibodies in Absence of HLA-DSA. (Abstract #120)
   Maria Ramirez, David Kershaw, Yihung Huang, John Magee, Milagros Samaniego, Timothy Williams, Debra Schauss, Thomas Franks, Yelena Kleyman, Daniel Ramon. Ann Arbor, MI; Ann Arbor.

5:06 pm Criteria for the Diagnosis of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx). (Abstract #121)
   Joseph P. Grande, Robert Leduc, The DeKAF Study Group. Rochester, MN; Minneapolis, MN.

5:18 pm Analysis of Intra-Graft Anti-HLA Antibodies Suggests That HLA Sensitization Occurs Long After an Allograft Nephrectomy and Is Not Due to a Release of Anti-HLA Antibodies from the Failed Kidney. (Abstract #122)

5:30 pm Comparison of C4d Deposition in Renal Biopsies with Luminex-Based C3d Single Antigen Bead (SAB) Detection. (Abstract #123)
   Ronald P. Pelletier, Ivan Balazs, Patrick Adams, Paula Steller, Nicholas DiPaola, Leslie Rankin, Alexandre Diez, Mitchell L. Henry. Columbus, OH; Stamford, CT; Houston, TX.

5:42 pm Urine Cell-Free Supernatant Metabolites Diagnostic of Antibody Mediated Rejection in Kidney Allografts. (Abstract #124)

Kidney Donor Surgery and Outcomes

Ballroom B
Chairs: Lloyd Ratner, MD MPH, Columbia University, New York, NY, United States and Jagbir Gill, University of British Columbia, West Vancouver, BC, Canada

4:30 pm Learning Curve of Laparoscopic Donor Nephrectomy for Abdominal Transplant Surgery Fellows. (Abstract #125)
   Oscar K. Serrano, Ananta Bangdiwala, David Vock, Varvara Kirchner, Ty B. Dunn, Erik B. Finger, Timothy L. Pruett, Arthur Matas, Raja Kandaswamy. Minneapolis, MN.

4:42 pm Acute Operative Complications and 1,5,& 10 Year Outcomes in Living Donors by Type of Live Donor Nephrectomy – UK Cohort Study. (Abstract #126)
   Nithya Santhanha Krishnan, Lisa Bradbury, Neil Raymond. Coventry, United Kingdom; Bristol, United Kingdom.

4:54 pm The Oldest and Coldest in Kidney Paired Donation: Experience of the National Kidney Registry. (Abstract #127)
   Nima Nassiri, Lorna Kwan, Joseph Sinacore, Jeffrey Veale. Los Angeles, CA; Babylon, NY.

5:06 pm Living Donor Kidney Transplant Outcomes Have Improved Over the Last Decade. (Abstract #128)
   Angie Nishio Lucar, Gayle Vranic, Douglas S. Keith. Charlottesville, VA.

5:30 pm Association of Neighborhood Poverty and Living Donor Kidney Transplant Rates by Donor Relationship to Recipient. (Abstract #130) Gayle Vranic, Angie Nishio Lucar, Douglas Keith. Charlottesville, VA.


Kidney Immune Monitoring 1

Ballroom C

Chairs: John Friedewald, Northwestern University, Chicago, IL, United States and David Axelrod, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States


4:42 pm Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10. (Abstract #133) Julie Ho, Atul Sharma, Rupasri Mandal, David Wishart, Chris Wiebe, Leroy Storsley, Martin Karpinski, Ian Gibson, Peter Nickerson, David Rush. Winnipeg, MB, Canada; Edmonton, AB, Canada.


5:30 pm Rapid Detection of Urinary CXCL9 as a Diagnostic and Prognostic Tool for Managing Acute Cellular Rejection (ACR) in Kidney Transplantation. (Abstract #137) Ilaria Gandolfini, Cynthia K. Harris, Carolina Purroy, Vinay Nair, Jessica Reid-Adam, Oriol Bestard, Peter S. Heeger. New York, NY; Barcelona, Spain.


Liver: Immunosuppression and Rejection

Room 312

Chairs: Sumeet Asrani, MD MSc, Baylor University Medical Center, Dallas, TX, United States and Thomas Schiano, MD, The Mount Sinai Medical Ctr, New York, NY, United States

4:42 pm Clinical Rejection-Risk Assessment with Allospecific CD154+T-Cytotoxic Memory Cells (CD154+TcM) After Pediatric Liver or Intestine Transplantation (LTx, ITx). (Abstract #140)
Kyle Soltys, Geoffrey Bond, George Mazariegos, Lindsay O’Toole, Christine Trautz, Lisa Remaley, Adriana Zeevi, Chethan Ashokkumar, Rakesh Sindi. Pittsburgh, PA.

4:54 pm Proteoforms: Novel Biomarkers for Acute Rejection in Liver Transplant Recipients. (Abstract #141)

5:06 pm Profiling Immunologic Risk for Acute Rejection in Liver Transplantation: Recipient Age Is a Robust Risk Factor. (Abstract #142)
Michael L. Kueht, Ronald T. Cotton, Christine O’Mahony, John Goss, Abbas Rana. Houston, TX.

5:18 pm A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation. (Abstract #143)

5:30 pm Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies. (Abstract #144)

Lung Transplant: Moving the Field Forward
Room 313
Chairs: Sangeeta Bhorade, Northwestern University, Chicago, IL and Deborah Levine, University of Texas Health Science Center, San Antonio, TX

4:30 pm Exosomes with Lung Associated Self-Antigens (Collagen V and K alpha 1 Tubulin): Role in Rejection Following Human Lung Transplantation. (Abstract #146)
Muthukumar Gunasekaran, Zhongping Xu, Deepak Nayak, Monal Sharma, Ramsey Hachem, Thalachallour Mohanakumar. St. Louis, MO; Phoenix, AZ.

4:42 pm Microarray Analysis of Transbronchial and Mucosal Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-Cell Mediated Inflammation. (Abstract #147)

4:54 pm High-Risk Age Window for Graft Loss in Pediatric Lung and Heart Transplant Recipients. (Abstract #148)

5:06 pm Resolution of Undefined Etiology of Respiratory Infections in Lung Transplant Patients with Unbiased Metagenomic Sequencing. (Abstract #149)

5:18 pm Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients. (Abstract #150)
Christopher Ensor, Katherine Harrigan, Raman Venkataramanan, Matthew Morrell, Cody Moore, J. Awori Hayanga, Maria Crespo, Jonathan D'Cunha, Adriana Zeevi, John McDyer. Pittsburgh, PA.
5:30 pm Utility of Six-Minute-Walk Distance in Predicting Lung Transplant Benefit in the Lung Allocation Score Era. (Abstract #151)

5:42 pm Successful Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. (Abstract #152)

Older and High Risk Kidney Transplant Recipients/Donors

Ballroom A
Chairs: David Leeser, MD MBA, University of Maryland, Baltimore, MD, United States and Bhavna Chopra, MD, Allegheny General Hospital, Pittsburgh, PA, United States

4:30 pm Frailty in KT Recipients of All Ages. (Abstract #153)
Mara McAdams-DeMarco, Hao Ying, Israel Olorundare, Elizabeth King, Dorry Segev. Baltimore.

4:42 pm Improved Health Related Quality of Life Also in Older Recipients Following Kidney Transplantation. (Abstract #154)
Kjersti Lønning, Kristian Heldal, Tomm Bernklev, Marit H. Andersen, Anders Hartmann, Nanna Von der Lippe, Anna V. Reisætter, Karsten Midtvedt. Oslo, Norway; Skien, Norway.

4:54 pm Short Term Changes in HRQOL Following Kidney Transplantation. (Abstract #155)

5:06 pm Association of Pre-Transplant Midodrine Use and Complications After Kidney Transplantation. (Abstract #156)

5:18 pm Cognitive Impairment in Kidney Transplant Recipients. (Abstract #157)
Aditi Gupta, David Johnson, Guoqing Chen, Dipti Subramaniam, Tyler Polshak, Tashra Thomas, Timothy Schmitt, Daniela Ladner, Alan Yu, Jeffrey Burns. Kansas City, KS; Chicago, IL.

5:30 pm Black Ethnicity as a Risk Factor for Poor Kidney Allograft Outcomes Post-Transplantation. (Abstract #158)
Sanna Tahir, Francesca Jackson-Spence, Holly Gillott, Felicity Everson, Jay Nath, Adnan Sharif. Birmingham, United Kingdom.

5:42 pm Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer. (Abstract #159)

Organ Transplantation in the Era of Highly Resistant Pathogens

Room 311
Chairs: Anoma Nellore, MD, University of Alabama at Birmingham, Birmingham, AL, United States and Stephanie Pouch, MD, MS, Ohio State University Medical Center, Columbus, OH, United States

4:30 pm Factors and Outcomes Associated with Daptomycin Non-Susceptible Enterococcal Infections in Solid Organ Transplant Recipients. (Abstract #160)

4:42 pm Prior Infection or Colonization with Carbapenem-Resistant Enterobacteriaceae Is Not an Absolute Contraindication for Solid Organ Transplantation. (Abstract #161)
Shirish Huprikar, L. Casner, S. Pouch, M. Pinheiro Freire, R. Madan, E. J. Kwak, M. Satlin, P. Hartman, L. Pisney, P. Henrique Mourão, R. La Hoz, G. Patel. New York; Columbus; Sao Paulo, Brazil; Bronx; Pittsburgh Detroit; Denver; Belo Horizonte, Brazil; Dallas.
4:54 pm Characteristics and Outcomes of Vancomycin Resistant Enterococcus Bacteremia After Liver Transplant. (Abstract #162)
Robert Odrobina, Christopher S. Kovacs, Robert Butler, Christine E. Koval.
Cleveland, OH.

5:06 pm Colonization and Risk of Bacteremia by Multi-Drug Resistant Organisms in Intestinal Transplant Recipients. (Abstract #163)
Jacques Simkins, Jose F. Camargo, Michele I. Morris, Rodrigo Vianna, Thiago Beduschi, Lilian M. Abbo. Miami, FL.

5:18 pm The Impact of Pre-Transplant Infections on Post-Liver Transplant Outcomes. (Abstract #164)
Stephen Ngo, Josh Levitsky, Michel G. Ison. Chicago, IL.

5:30 pm Clinical Impact of the Verigene® Blood Culture System on Rapid Diagnosis and Antibiotic Optimization in Bacteremic Solid Organ Transplant (SOT) Recipients. (Abstract #165)

5:42 pm Infectious Complication in Extremely Elderly Kidney Transplant (KT) Recipients: A Leading Cause of Death. (Abstract #166)

Poster Session B
6:00 pm – 7:00 pm
Poster Viewing: 9:30 am – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm

Halls C&D
Poster Session B can be found on pages 130-153.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am —</td>
<td>Sunrise Symposia</td>
<td>Page 42</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Practical Challenges in Intestinal Transplant – An Open Discussion</td>
<td>Room 310</td>
</tr>
<tr>
<td></td>
<td>with Major Centers – a Panel Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pregnancy Donors, Recipients, and a Link to Tolerance</td>
<td>Room 312</td>
</tr>
<tr>
<td></td>
<td>Obesity and NASH in Transplant</td>
<td>Room 311</td>
</tr>
<tr>
<td></td>
<td>Do High-Risk Transplant Recipients take Higher Risk when treated with</td>
<td>Ballroom C</td>
</tr>
<tr>
<td></td>
<td>Tacrolimus?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heart – Does My Patient Have AMR and How Do I Treat It?</td>
<td>Room 306</td>
</tr>
<tr>
<td></td>
<td>You Can’t Always Get What You Want: Multidrug Resistant Organisms</td>
<td>Room 304</td>
</tr>
<tr>
<td></td>
<td>Organ Donor Management: Maximizing Quality and Quantity of Donated</td>
<td>Ballroom A</td>
</tr>
<tr>
<td></td>
<td>Organs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cell Death Pathways and Transplant</td>
<td>Room 302</td>
</tr>
<tr>
<td></td>
<td>Management of Urologic Issues and Complications with Renal Transplant</td>
<td>Room 310</td>
</tr>
<tr>
<td>8:30 am —</td>
<td>Plenary</td>
<td>Page 43</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Joint Plenary Session II</td>
<td>Veterans Auditorium</td>
</tr>
<tr>
<td>9:45 am —</td>
<td>AST Presidential Address</td>
<td>Veterans Auditorium</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Coffee Break</td>
<td>Halls C&amp;D</td>
</tr>
<tr>
<td>10:45 am —</td>
<td>State-of-the-Art Presentation</td>
<td>Veterans Auditorium</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:30 am —</td>
<td>Midday Symposia</td>
<td>Page 45</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Immune Cell Trafficking In Vivo New Insights</td>
<td>Room 304</td>
</tr>
<tr>
<td></td>
<td>Innate Lymphoid Cells</td>
<td>Room 306</td>
</tr>
<tr>
<td></td>
<td>Pancreas Transplantation – How I Do It!</td>
<td>Room 310</td>
</tr>
<tr>
<td></td>
<td>Understanding and Minimizing the Costs of Living Kidney Donation</td>
<td>Ballroom A</td>
</tr>
<tr>
<td></td>
<td>Viral Hepatitis Pre-, Peri- and Post-Liver Transplantation</td>
<td>Room 311</td>
</tr>
<tr>
<td></td>
<td>Heart – Controversies in Immunosuppression</td>
<td>Room 309</td>
</tr>
<tr>
<td></td>
<td>Cutting Edge Topics in CMV and Transplant</td>
<td>Veterans Auditorium</td>
</tr>
<tr>
<td></td>
<td>Far from the Madding Crowd: Best Practices in OPO and Transplant</td>
<td>Room 313</td>
</tr>
</tbody>
</table>

Page 42

Page 43

Page 44

Page 45

Page 46

Page 47
<table>
<thead>
<tr>
<th>Page</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>Technical Challenges in Liver Transplantation – Audience Response Program</td>
<td>312</td>
</tr>
<tr>
<td>47</td>
<td>New Avenues for Developing Biomarkers</td>
<td>302</td>
</tr>
<tr>
<td>48</td>
<td>Impact of Belatacept in the Clinic</td>
<td>B</td>
</tr>
<tr>
<td>48</td>
<td>Detecting and Dealing with Non-adherence in Transplant Recipients</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>1:00 pm — 2:15 am Break</td>
<td></td>
</tr>
<tr>
<td>2:30 pm — 4:00 pm</td>
<td>Concurrent Sessions</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Concurrent Session: Novel Predictors of Outcome, Big Data and Technology</td>
<td>302</td>
</tr>
<tr>
<td>49</td>
<td>Concurrent Session: B Cells in Rejection and Tolerance: Animal Models</td>
<td>310</td>
</tr>
<tr>
<td>50</td>
<td>Concurrent Session: Clinical Science: Tolerance: Clinical Studies</td>
<td>304</td>
</tr>
<tr>
<td>50</td>
<td>Concurrent Session: Identifying Antibodies - Tools of the Trade</td>
<td>B</td>
</tr>
<tr>
<td>51</td>
<td>Concurrent Session: Innate Immunity in Rejection and Tolerance: Animal Models</td>
<td>313</td>
</tr>
<tr>
<td>52</td>
<td>Concurrent Session: Kidney Immune Monitoring 2</td>
<td>C</td>
</tr>
<tr>
<td>52</td>
<td>Concurrent Session: Kidney Transplantation: Allocation, Discard, and HCV</td>
<td>Veterans Auditorium</td>
</tr>
<tr>
<td>53</td>
<td>Concurrent Session: Kidney: Induction Therapy 1</td>
<td>312</td>
</tr>
<tr>
<td>53</td>
<td>Concurrent Session: Kidney: Induction Therapy 1</td>
<td>312</td>
</tr>
<tr>
<td>54</td>
<td>Concurrent Session: Living Donor Liver Transplantation</td>
<td>210</td>
</tr>
<tr>
<td>55</td>
<td>Concurrent Session: Molecular and Bio-Markers in Hearts and VADs - A New Hope</td>
<td>102</td>
</tr>
<tr>
<td>56</td>
<td>Concurrent Session: Regulatory T Cells: Animal Models</td>
<td>309</td>
</tr>
<tr>
<td>56</td>
<td>Concurrent Session: Various Viruses, Vaccines, and SOT</td>
<td>306</td>
</tr>
<tr>
<td>57</td>
<td>Concurrent Session: Viral Hepatitis</td>
<td>A</td>
</tr>
<tr>
<td>58</td>
<td>2:30 pm — 5:30 pm</td>
<td>Pediatric/Allied Health Symposium</td>
</tr>
<tr>
<td>58</td>
<td>Adherence in Transplantation: Applying Findings from the MALT and BRIGHT Studies</td>
<td>208</td>
</tr>
<tr>
<td>59</td>
<td>4:00 pm — 4:30 am Coffee Break</td>
<td>C&amp;D</td>
</tr>
<tr>
<td>60</td>
<td>4:30 pm — 6:00 pm</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>58</td>
<td>Concurrent Session: Acute Kidney Injury and Recovery after Transplantation</td>
<td>C</td>
</tr>
<tr>
<td>59</td>
<td>Concurrent Session: Antibody Mediated Rejection in Kidney Transplantation: De Novo DSA</td>
<td>B</td>
</tr>
<tr>
<td>60</td>
<td>Concurrent Session: Belatacept and Steroid Withdrawal in Kidney Transplantation</td>
<td>A</td>
</tr>
<tr>
<td>60</td>
<td>Concurrent Session: Challenges to Graft Survival and Tolerance: Animal Models</td>
<td>306</td>
</tr>
<tr>
<td>Page 61</td>
<td>Concurrent Session: Clinical Pancreas Transplantation 1 Room 309</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>6:00 pm — 7:00 pm</strong> Poster Session C</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Halls C&amp;D</strong></td>
<td></td>
</tr>
<tr>
<td>Page 61</td>
<td>Concurrent Session: CMV: Immune Monitoring &amp; MicroRNA Responses Room 306</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 154</strong> Antibody Mediated Rejection: Session #1</td>
<td></td>
</tr>
<tr>
<td>Page 62</td>
<td>Concurrent Session: Kidney Transplant Recipient: Long Term Outcomes Session I Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 157</strong> Clinical Science - Kidney Immunosuppression: Induction Therapy</td>
<td></td>
</tr>
<tr>
<td>Page 62</td>
<td>Concurrent Session: Kidney Transplant Recipient: Long Term Outcomes Session I Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 159</strong> Economics, Public Policy, Allocation, Ethics</td>
<td></td>
</tr>
<tr>
<td>Page 63</td>
<td>Concurrent Session: Kidney: Desensitization Room 304</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 161</strong> Ischemia Reperfusion Injury and Organ Preservation</td>
<td></td>
</tr>
<tr>
<td>Page 63</td>
<td>Concurrent Session: Liver Transplantation Peri-Operative Considerations Room 311</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 165</strong> Kidney Donor Evaluation and Donor Nephrectomy</td>
<td></td>
</tr>
<tr>
<td>Page 64</td>
<td>Concurrent Session: Medication Errors, Variability and Adherence Room 302</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 167</strong> Kidney Transplantation: AKI/Preservation/DCD</td>
<td></td>
</tr>
<tr>
<td>Page 65</td>
<td>Concurrent Session: Metabolic Complications in Kidney Transplantation Room 312</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 172</strong> Kidney Complications-Other I</td>
<td></td>
</tr>
<tr>
<td>Page 65</td>
<td>Concurrent Session: Pathways of Allograft Rejection: Animal Models Room 310</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Page 175</strong> Viruses and SOT</td>
<td></td>
</tr>
<tr>
<td>Page 66</td>
<td>Concurrent Session: Pediatric Liver Transplant Room 206</td>
<td></td>
</tr>
<tr>
<td>Page 66</td>
<td>Concurrent Session: Xenotransplantation: Animal Models Room 102</td>
<td></td>
</tr>
<tr>
<td>Page 67</td>
<td>Concurrent Session: Late Breaking Room 210</td>
<td></td>
</tr>
</tbody>
</table>

**5:45 pm — 7:00 pm** AST Town Hall & Reception

| Page 68 | Republic Ballroom, Sheraton Boston Hotel |

---

*Monday, June 13*
Sunrise Symposia
7:00 am — 8:15 am

Practical Challenges in Intestinal Transplant — An Open Discussion with Major Centers – a Panel Discussion

Room 310
Moderator: David Mercer, MD, PhD, University of Nebraska Medical Center, Omaha, NE, USA

Panelists: Rodrigo Vianna, MD, University of Miami, Miami, FL, USA, Kareem Abu-El Magd, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH, USA, Richard Shane Mangus, MD, MS, FACS, University of Indiana, Indianapolis, IN, USA and Cal Matsumoto, MD, Georgetown University Hospital, Washington, DC, USA

Pregnancy Donors, Recipients, and a Link to Tolerance

Room 312
Moderators: Deirdre Sawinski, University of Pennsylvania, Philadelphia, PA, USA and Lisa Coscia, RN, BSN, National Transplantation Pregnancy Registry, Philadelphia, PA, USA

7:00 am Living Donors and Pregnancy
Hassan Ibrahim, MD
University of Minnesota
Minneapolis, MN, USA

7:25 am National Transplant Pregnancy Registry: 2,500 Pregnancy Outcomes after Transplantation
Michael Moritz, MD
Gift of Life Institute, National Transplantation Pregnancy Registry
Philadelphia, PA, USA

7:50 am Pregnancy: A State of Immune Tolerance
Paige Porrett, MD, PhD
University of Pennsylvania
Philadelphia, PA, USA

Obesity and NASH in Transplant

Room 311
Moderators: Mary Rinella, MD, Northwestern University, Chicago, IL, USA and Michael Charlton, MD, Intermountain Medical Center, Salt Lake City, UT, USA

7:00 am Novel NASH Therapies in the Transplant Setting
Mary Rinella, MD
Northwestern University
Chicago, IL, USA

7:25 am Sarcopenic Obesity: Assessing Frailty and Risk in the face of Obesity
Jennifer Lai, MD, MBA
University of California San Francisco
San Francisco, CA, USA

7:50 am Timing and Results with Bariatric Surgery’s in Liver Transplantation
Julie Heimbach, MD
Mayo Clinic
Rochester, MN, USA

Do High-Risk Transplant Recipients take Higher Risk when treated with Generic Tacrolimus?

Ballroom C
Moderators: Teun van Gelder, MD, Erasmus Medical Center, Rotterdam, The Netherlands and Wenlei Jiang, PhD, Food & Drug Administration, Office of Generic Drugs, City, State, USA

7:00 am Retrospective Analysis of Tacrolimus Trough Level Variability and the Identification of the “High Risk” Transplant Recipient
Rita Alloway, Pharm D
University of Cincinnati
Cincinnati, OH, USA

7:25 am Pharmacokinetic Studies of Brand and Five Generic Tacrolimus Formulation in High Risk Transplant Recipients
Uwe Christians, MD, PhD
University of Colorado
Aurora, CO, USA
7:50 am Evaluating Transplant Donor and Recipients Pharmacogenetics and its Impact on Variability in Tacrolimus and Metabolites Pharmacokinetics
Alexander Vinks, PharmD
Cincinnati Children's Medical Center
Cincinnati, OH, USA

Heart – Does My Patient Have AMR and How Do I Treat It?
Room 306
Moderator: Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, USA

Panelists: Jignesh Patel, MD, PhD, Cedars Sinai Heart Institute, Los Angeles, CA, USA and Josef Stehlik, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

7:00 am Case # 1: Patient With Normal Graft Function, No Antibodies Crossed At The Time Of Transplant, No DSA But Persistent IHC Staining
Jared Herr, MD
Sutter Health – Palo Alto Medical Foundation
Palo Alto, CA, USA

7:25 am Case # 2: Patient With Low MFI DSA, IHC Staining, And Normal Graft Function
Brent Lampert, DO
Ohio State University Wexner Medical Center
Bexley, OH, USA

7:50 am Case # 3: Patient With IHC Staining, DSA And Abnormal Graft Function
Van Selby, MD
University of California San Francisco
San Francisco, CA, USA

You Can’t Always Get What You Want: Multidrug Resistant Organisms
Room 304
Moderators: Nicole Theodoropoulos, MD, Ohio State University, Columbus, OH, USA and David VanDuijn, MD, University of North Carolina, Chapel Hill, NC, USA

7:00 am Overview and Impact of Multidrug Resistant Organisms on Transplantation
Stephanie Pouch, MD, MS
Ohio State University Medical Center
Columbus, OH, USA

7:25 am On the Minus Side: Highly Resistant Gram negative Organisms and Transplantation
Christian Van Delden, MD
University Hospital Geneva
Geneva, Switzerland

7:50 am What Is New And What Is New In The Old Antimicrobial Agents For MDRO Infections
Tiffany Bias, PharmD
Hahneman University Hospital
Philadelphia, PA, USA

Organ Donor Management: Maximizing Quality and Quantity of Donated Organs
Ballroom A
Moderators: Anil Paramesh, MD, FACS, Tulane University Abdominal Transplant Institute, New Orleans, LA and Marlon Levy, MD, Baylor Medical Center, Dallas, TX, USA

7:00 am The Toxic Milieu: Hemodynamic Changes of Brain Death
Rajat Dhar, MD, MRCP(C)
Washington University School of Medicine
St. Louis, MO, USA

7:25 am I’m Feeling Hormonal! Review of Endocrine Therapies during Organ Donor Management
Michael Souter, MB, ChB
The University of Washington
Seattle, WA, USA

7:50 am Newer Technologies and the Use of Hypothermia in Organ Donor Management
Claus Niemann, MD
University of California San Francisco
San Francisco, CA, USA

Cell Death Pathways and Transplantation
Room 302
Moderators: Reza Abdi, MD, Brigham and Women’s Hospital, Boston, MA and Anthony Jevnikar, MD, London Health Sciences Center, London, ON, Canada

7:00 am Regulated Necrosis Kidney Injury and Transplantation
Andreas Linkeran, FASN
University Hospital Schleswig-Holstein
Kiel, Germany
7:25 am  Effects of Regulated Cell Death in in
the Kidney on the Lung
Heitham Hassoun, MD
Johns Hopkins University
Baltimore, MD, USA

7:50 am  Small Molecules Necrostatins to
Block Regulated Necrosis Parkinsons
Disease
Adrian Ting, PhD
Ichsan School of Medicine at Mt. Sinai
New York, NY, USA

Management of Urologic Issues and
Complications with Renal Transplant
Ballroom B
Moderators: Puneet Sindhwani, MD, University of
Oklahoma College of Medicine, Oklahoma City, OK,
USA and Eric Treat, MD, Methodist Hospital San
Antonio, San Antonio, TX, USA

7:00 am  Bladder Physiology Before and After
Renal Transplant
John Stoffel, MD
University of Michigan
Ann Arbor, MI, USA

7:15 am  Contemporary Management of Urinary
Tract Infections: Classification,
Work Up, and Therapy. Management
of Reflux in the Renal Allograft
Associated With Infection
Sara Lenherr, MD
University of Utah
Salt Lake City, UT

7:30 am  Understanding and Managing Urinary
Symptoms in the Renal Transplant
Patient
Lindsey Cox, MD
Medical University of South Carolina
Charlston, SC, USA

7:45 am  Endoscopic Management of Ureteral
Structures, Stones, or other ureteral
pathology in the Transplant Ureter
Julie Riley, MD
University of New Mexico
Albuquerque, NM, USA

8:00 am  Management of Bladder Outlet
Obstruction in the Transplant Patient
Mark Wakefield, MD
University of Missouri
Columbia, MO, USA

Joint Plenary Session II
8:30 am — 9:30 am
Veterans Auditorium
Chairs: Kenneth Newell, MD, PhD, Emory University
School of Medicine, Atlanta, GA, USA and Anil
Chandraker, MD, FASN, FRCP, Brigham and
Women's Hospital, Boston, MA, USA

8:30 am  Ledipasvir/Sofosbuvir (LDV/SOF) for
12 or 24 Weeks Is Safe and Effective
in Kidney Transplant Recipients with
Chronic Genotype 1 or 4 HCV Infection.
(Abstract #167)
Stanislas Pol, Alessio Aghemo, Lin Lin,
Robert H. Hyland, Chohee Yun, James
Spellman, Macky Natha, Diana M.
Brainard, John G. McHutchison, Marc
Bourliere, Markus Peck-Radosavljevic,
Manns Michael, Massimo Colombo.
Paris, France; Milan, Italy; Foster City;
Marseilles, France; Hannover, Germany;
Vienna, Austria.

8:45 am  Regulatory T Cell Infusion Can
Enhance Memory T Cell and
Alloantibody Responses in
Lymphodepleted Nonhuman
Primate Heart Allograft Recipients.
(Abstract #168)
Mohamed B. Ezzelarab, Hong Zhang,
Lien Lu, Hao Guo, Alan Zahorchak,
Roger Wiseman, Michael A. Nalesnik, Jay
Bhama, David K. C. Cooper, Angus W.
Thomson. Pittsburgh, PA; Madison, WI.

9:00 am  Impact on Renal Function of Stepwise
Withdrawal of Tacrolimus Combined
with Everolimus and EC-MPS vs
Standard Treatment Combining
Tacrolimus and EC-MPS in De Novo
Liver Transplant Recipients: Results of
the SIMCER Study. (Abstract #169)
Faouzi Saliba, Christophe Duvoux,
Sébastien Dharancy, Jérôme Dumortier,
Yvon Calmus, Fabienne Di Giambattista,
Filomena Conti. Villejuif, France; Créteil,
France; Lille, France; Lyon, France; Paris,
France; Rueil-Malmaison, France.
9:15 am Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy. (Abstract #170)

10:15 am B Cell/Plasma Cell Trafficking in Germinal Centers
Antal Rot, PhD
York University
York, United Kingdom

12:00 pm Analyzing Treg in Vivo
Jonathan Bromberg, MD, PhD
University of Maryland School of Medicine
Baltimore, MD, USA

12:30 pm In Vivo Imaging of Alloreactive T cells
Geoffrey Camirand, PhD
University of Pittsburgh School of Medicine
Pittsburgh, PA, USA

Innate Lymphoid Cells
Room 306
Moderators: Paolo Cravedi, MD, Mount Sinai School of Medicine, New York, NY, USA and Daniel Kreisel, MD, PhD, Washington University in St. Louis, St. Louis, MO, USA

11:30 am Innate Lymphoid Cells – Regulators and Effectors of Immunity
Marco Colonna, MD
Washington University School Medicine
St. Louis, MO, USA

12:00 pm Innate Lymphoid Cells and Mechanisms of Suppression Toward Commensal Bacteria
Arthur Mortha, PhD
Mount Sinai School of Medicine
New York, NY, USA

12:30 pm Innate Lymphoid Cells
Gregory Sonnenberg, PhD
Weill Cornell Medical College
New York, NY, USA

Pancreas Transplantation – How I Do It!
Room 310
Moderators: Steve Bartlett, MD, University of Maryland, Baltimore, MD, USA and Peter Abrams, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA

11:30 am How I Choose the Appropriate Pancreas Donor and Recipient
Jon Odorico, MD
University of Wisconsin
Madison, WI, USA

12:00 pm How I Perform the Complex Pancreatic Transplant Case
Robert Stratta, MD
Wake Forest Baptist Health
Winston-Salem, NC, USA
12:30 pm  How I Manage the Post-Operative Pancreatic Transplant Recipient
Raja Kandaswamy, MBBS
University of Minnesota
Minneapolis, MN, USA

Understanding and Minimizing the Costs of Living Kidney Donation

Ballroom A
Moderators:  David Cohen, MD, Columbia University Medical Center, New York, NY, USA and Amit Mathur, MD, MS, Mayo Clinic Arizona, Phoenix, AZ, USA

11:30 am  Financial Burdens of Living Donation in the Current US System
Rebecca Hays, PhD
University of Wisconsin
Madison, WI, USA

12:00 pm  Reimbursement of Donor Costs Impacts the Opportunity to Be a Living Donor
Robert Merion, MD
University of Michigan
Ann Arbor, MI, USA

12:30 pm  What Approaches Do We Need to Develop to Minimize the Financial Costs Associated with Living Donation that May Preclude Individuals from Exercising Their Wishes?
Alan Langnas, DO
University of Nebraska Medical Center
Omaha, NE, USA

Viral Hepatitis Pre-, Peri- and Post-Liver Transplantation

Room 311
Moderators:  Michael Charlton, MD, Intermountain Medical Center, Murray, UT, USA and Michael Curry, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA

11:30 am  When to Treat Decompensated HCV Patients to Avoid Transplant: The Point of No Return
Rajender Reddy, MD
University of Pennsylvania
Philadelphia, PA, USA

12:00 pm  Perioperative/Prophylactic HCV Treatment: Optimally Timing and Treatment
Norah Terrault, MD, MPH
University of California San Francisco
San Francisco, CA, USA

12:30 pm  Post-operative HCV Therapy
Elizabeth Verna, MD, MS
Columbia University
New York, NY, USA

Heart – Controversies in Immunosuppression

Room 309
Moderators:  Sean Pinney, MD, Mount Sinai School of Medicine, New York, NY, USA and Lori West, MD, D.Phil, University of Alberta, Edmonton, AB, Canada

11:30 am  Debate #1:  The Use of Induction Therapy To Delay The Introduction Of Calcineurins Is Effective In Mitigating Renal Dysfunction Post-Transplant

11:30 am  PRO
Josef Stehlik, MD
University of Utah School of Medicine
Salt Lake City, UT, USA

11:40 am  CON
Allen Anderson, MD, FACC
Northwestern Memorial Hospital
Chicago, IL, USA

11:50 am  REBUTTALS

12:00 pm  Debate #2:  All Patients Who Develop Post-Transplant Renal Dysfunction Should Be Converted To A CNI-Free Regimen

12:00 pm  PRO
Michael Shullo, BS, PharmD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

12:10 pm  CON
David Baran, MD
Barnabas Health
Livingston, NJ, USA

12:20 pm  REBUTTALS

12:30 pm  Debate #3:  All Patients Should Be Converted To A PSI-Based Regimen By 3 Months After Cardiac Transplantation

12:30 pm  PRO
Andreas Zuckerman, MD
Medical University of Vienna
Vienna, Austria

12:40 pm  CON
Jon Kobashigawa, MD
Cedars Sinai Heart Institute
Los Angeles, CA, USA

12:50 pm  REBUTTALS
**Cutting Edge Topics in CMV and Transplant**

**Veterans Auditorium**

Moderators: Raymond Razonable, MD, Mayo Clinic, Rochester, MN, USA and Deepali Kumar, MD, University Health Network, Toronto, ON, Canada

11:30 am  **Savvy Approaches to Prevention**
Emily Blumberg, MD
University Hospital of Pennsylvania
Philadelphia, PA, USA

12:00 pm  **Predicting the Future: Immunodiagnostics and CMV**
Diane Florescu, MD
University of Nebraska Medical Center
Omaha, NE, USA

12:30 pm  **Challenging Clinical CMV Cases**
Daniel Kaul, MD
University of Michigan
Ann Arbor, MI, USA

**Far from the Madding Crowd: Best Practices in OPO and Transplant Center Leadership**

**Room 313**

Moderators: Tim Taber, MD, Indiana University School of Medicine, Indianapolis, IN, USA and Bertram Kasiske, MD, Hennepin County Medical Center, Minneapolis, MN, USA

11:30 am  **Performance Anxiety: When Less Focus on Metrics Leads to More Transplants**
Jeffrey Orlowski, MD
Lifeshare
Oklahoma City, OK, USA

12:00 pm  **Risk Adjustment and Program Specific Reports: Friend or Foe?**
David Axelrod, MD, MBA
Dartmouth-Hitchcock Medical Center
Lebanon, NH, USA

12:30 pm  **Opportunities And Best Practices For Transplant Center And OPO Interaction**
Thomas Pearson, MD, D.Phil.
Emory University Transplant Center
Atlanta, GA, USA

**Technical Challenges in Liver Transplantation**

**Room 312**

Moderators: Goran Klintmalm, MD, PhD, Baylor University Medical Center, Dallas, TX, USA, Seth Karp, MD, Vanderbilt University Medical Center, Nashville, TN, USA and Jean Emond, MD, Columbia University Medical Center, New York, NY, USA

11:30 am  **Preoperative Endovascular Portal Vein Recanalization And TIPS Placement In Transplant Candidates With Complete Portal Vein Thrombosis**
Riad Salam, MD
Northwestern University Feinberg School of Medicine
Chicago, IL, USA

11:45 am  **Discussion**

11:50 am  **Challenging Intraoperative Reconstruction Problems: Cases with Audience Response and Panel Discussion**
John Seal, MD
Ochsner Medical Center
New Orleans, LA, USA

12:25 pm  **Surgical Management Challenges After Liver Transplant: Cases with Audience Response and Panel Discussion**
Sean Kumer, MD, PhD
University of Kansas
Kansas City, KS, USA

**New Avenues for Developing Biomarkers**

**Room 302**

Moderators: Stan Stepkowski, PhD, DVM, University of Toledo, Toledo, OH, USA and Oriol Bestard, MD, PhD, University of California San Francisco, San Francisco, CA, USA

11:30 am  **Aptamer Based Biomarker Discovery**
John Wilkins, PhD
Manitoba Centre for Proteomics and Systems Biology, University of Manitoba
Winnepeg, MB, Canada

12:00 pm  **Monitoring Donor-Derived DNA as a Marker of Graft Injury**
Kiran Khush, MD, MAS
Stanford University
Stanford, CA, USA

12:30 pm  **Discerning Host Alloimmunity by T cell Receptor Sequencing**
Megan Sykes, MD
Columbia University
New York, NY, USA
**Impact of Belatacept in the Clinic**

**Ballroom B**

Moderators: Dixon Kaufman, MD, PhD, University of Wisconsin, Madison, WI, USA and Daniel Brennan, MD, FACP, Barnes Jewish Hospital, St. Louis, MO, USA

11:30 am  A High Level Overview of all the Published Trials using Belatacept with an Emphasis on Factors that May Limit Clinical Application  
Allan Kirk, MD, PhD  
Duke University  
Durham, NC, USA

11:50 am  Use of CNI as Prolonged Induction Therapy to Facilitate a Belatacept-based Maintenance Regimen  
Andrew Adams, MD, PhD  
Emory University  
Atlanta, GA, USA

12:10 pm  Early Conversion to a mTOR Using a Belatacept-based Regimen  
Flavio Vincenti, MD  
University of California San Francisco  
San Francisco, CA, USA

12:30 pm  Planned Conversion from a CNI-based regimen to Belatacept  
Josep Grinyo, MD  
University of Barcelona  
Barcelona, Spain

**Detecting and Dealing with Non-adherence in Transplant Recipients**

**Ballroom C**

Moderators: Samir Patel, PharmD, The Methodist Hospital, Houston, TX, USA and James Rodrigue, PhD, Beth Israel Deaconess Medical Center, Boston, MA, USA

11:30 am  Non-Adherence: How Do You Define That Anyway?  
Marie Chisholm-Burns, PharmD  
University of Tennessee College of Pharmacy  
Memphis, TN, USA

12:00 pm  Determining Non-Adherence Risk Prior To Transplantation  
Emily Fredericks  
University of Michigan  
Ann Arbor, MI, USA

12:30 pm  Methods And Technologies To Improve Adherence In The Transplant Recipients  
Seth Heldenbrand, PharmD  
University of Arkansas for Medical Sciences College of Pharmacy  
Little Rock, AR, USA

**Break**

1:00 — 2:15 pm

**Concurrent Oral Abstract Sessions**

**2:30 pm — 4:00 pm**

**Novel Predictors of Outcome, Big Data and Technology**

**Room 302**

Chairs: Robert Gaston, Univ of Alabama at Birmingham, Birmingham, AL, United States and Daniela Ladner, MD, MPH, Northwestern University, Chicago, IL, United States

2:30 pm  Implementation of Telehealth Is Associated with Improved Timeliness of Kidney Transplant Waitlist Evaluation at a VA Center.  
(Abstract #171)  

2:42 pm  Provider Attitudes Toward Shared Mobile Decision Aid Utilized Among Patients Evaluated for Kidney Transplantation: iChoose Kidney Randomized Trial.  
(Abstract #172)  
Mohua Basu, Stephen Pastan, Sumit Mohan, Michael Wolf, John Friedewald, Daniela Ladner, Kayla Smith, Laura McPherson, Allison Russell, Mariana Chiles, Rachel Patzer. Atlanta, GA; New York, NY; Evanston, IL.
2:54 pm Intervention Development for the Allocation System Changes for Equity in Kidney Transplantation (ASCENT) Study. (Abstract #173)
Kayla Smith, Jennifer Gander, Mohua Basu, Stephen Pastan, Sumit Mohan, Cam Escoffery, Laura Plantinga, Sean Kalloo, Gary Green, Alex Berlin, Gary Renville, Teri Browne, Nicole Turgeon, Sue Caponi, Jenna Krisher, Rachel Patzer. Atlanta, GA; New York, NY; Tampa, FL; Columbia, SC; Lake Success, NY; Raleigh, NC.

3:06 pm Predictors of Patient Uncertainty Regarding Treatment Options Among End Stage Renal Disease Patients Evaluated for Kidney Transplantation. (Abstract #174)
Laura McPherson, Mohua Basu, Stephen O. Pastan, Sumit Mohan, Michael Wolf, Jennifer Gander, Rachel E. Patzer. Atlanta, GA; New York City, NY; Chicago, IL.

3:18 pm Clinical Prediction Tool to Guide Referral of Elderly Dialysis Patients for Kidney Transplant Evaluation. (Abstract #175)
Ling-Xin Chen, Michelle Josephson, Nicole Stankus, Kellie H. Campbell, Donald Hedeker, Mildra R. Saunders. Chicago, IL.

Laura D. Buccini, David A. Goldfarb, Emilio D. Poggio, Stuart M. Flechner, Jesse D. Schold. Cleveland, OH.

3:42 pm Role of Cardiac Evaluation and Management in Kidney and Liver Transplant Candidates. (Abstract #177)
Wade M. Bannister, Charlotte Wu, Mark A. Schnitzler, Anthony F. Bonagura, Bart Laihinen, Frank D. Irwin. Eden Prairie, MN; St Louis, MO.

2:30 pm Prolongation of Graft Survival by Anti-TIM1 Is Specifically Mediated by IL-10+ Bregs and is Not Dependent on IL-35 or Plasma Cell Differentiation. (Abstract #178)
Yu Zhou, Qing Ding, Aravind Cherukuri, David Rothstein. Pittsburgh, PA; Beijing, China.

2:42 pm Fate of Endogenous Alloreactive B Cells in Transplant Tolerance. (Abstract #179)
Jianjun Chen, Jinghui Yang, Ahmed Akl, Qiang Wang, Dengping Yin, Roger Sciammas, Anita S. Chong. Chicago, IL; Houston, TX.

2:54 pm B Lymphocytes Prevent Transplantation Tolerance in NOD Mice by Limiting CD4 Treg Function. (Abstract #180)

3:06 pm Expansion of Regulatory B-Cells and Their Potential Role in Transplantation Tolerance. (Abstract #181)
Beth Amundsen, Hany Deirawan, James Kim, James Markmann. Boston, MA.

3:18 pm Tracking Endogenous B Cells Recognizing Allogeneic MHC Class II in Mice. (Abstract #182)
Jinghui Yang, Jianjun Chen, Ahmed Akl, Roger Sciammas, Anita Chong. Chicago, IL; Shanghai, China; Houston, TX.

3:30 pm Belatacept Does Not Inhibit Plasmablast Formation Supported by Follicular T Helper Cells, but Favors the Development of Transitional Regulatory B Cells in Kidney Transplant Patients. (Abstract #183)
Gretchen N. de Graav, Dennis A. Hesselink, Marjolein Dieterich, Rens Kraaijeveld, Willem Weimar, Carla C. Baan. Rotterdam, South Holland, Netherlands.
3:42 pm Targeting IFN-γ-Expressing TIM-4+ B Effector (Bef) Cells as a Novel Strategy to Prevent Allograft Rejection. (Abstract #184)
Q. Ding, K. Mohib, S. Xiao, V. Kuchroo, David Rothstein. Pittsburgh; Boston.

Clinical Science: Tolerance: Clinical Studies

Room 304
Chairs: John Scandling, MD, Stanford, Palo Alto, CA, United States and Joshua Miller, MD, Northwestern University School of Medicine, Chicago, IL, United States

2:30 pm Early Post-Transplant Immunosuppression (IS) Withdrawal – Final Outcomes of the ITN030ST AWISH Study. (Abstract #185)
A. Shaked, S. Feng, J. Punch, J. Reyes, J. Levitsky, G. Klintmalm, H. Kopetskie, M. DesMarais, A. Priore, N. Bridges, P. Sayre. Philadelphia; San Francisco; Ann Arbor; Seattle; Chicago; Dallas Chapel Hill; Bethesda.

2:42 pm Primary Outcome of iWITH: A Multi-Center Clinical Trial of Complete Immunosuppression Withdrawal (ISW) in Stable Pediatric Liver Transplant (LT) Recipients. (Abstract #185.1)
S. Feng, J. Bucuvalas, A. J. Demetris, K. Spain, S. Kanaparthi, J. Magee, G. Mazariegos, The iWITH Investigators. San Francisco; Cincinnati; Pittsburgh; Chapel Hill; Bethesda; Ann Arbor.

2:54 pm Seven Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients. (Abstract #186)

3:06 pm HLA Identical or Haploidentical Combined Kidney and Bone Marrow Transplantation for Multiple Myeloma with End-Stage Renal Failure. (Abstract #187)

3:18 pm Tolerance Induction with Donor Bone Marrow Transplantation in Kidney Transplantation. (Abstract #188)

3:30 pm Clonal Expansion of Donor-Specific Tregs Following Combined Kidney and Bone Marrow Transplantation. (Abstract #189)
Thomas M. Savage, Susan Dewolf, Aleksandar Obradovic, Sai Ping Lau, Julien Zuber, Laurence Turka, Yufeng Shen, Megan Sykes. New York; Boston.

3:42 pm Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients. (Abstract #190)

3:54 pm Initial Experience with Donor Specific Tregs in Kidney Transplantation. (Abstract #191)
James F. Markmann, Eva C. Guinan, Edward K. Geissler, Geoffrey A. Cole, Sharon K. Germana, James I. Kim, Birgit Sawitzki. Boston, MA; Regensburg, Germany; Berlin, Germany.

Identifying Antibodies - Tools of the Trade

Ballroom B
Chairs: Annette Jackson, PhD, Johns Hopkins University, Baltimore, MD, United States and Vera Hauptfeld-Dolejsek, Ph.D,D(ABHI), University of Alabama at Birmingham, Birmingham, AL, United States

2:30 pm Relationship Between Mean Fluorescence Intensity and C1q/C3d-Fixing Capacities of Anti-HLA Antibodies. (Abstract #192)
Guillaume Claissse, Lena Absi, Eric Alamartine, Nicolas Maillard, Christophe Mariat. Saint-Etienne, France.

2:42 pm Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation. (Abstract #193)
2:54 pm  Blindspots in HLA Antibody Testing: Recognition Is First Step to Nirvana. (Abstract #194)
Ajay Kher, Pranav Dorwal, Vijay Kher.
Gurgaon, Haryana, India.

3:06 pm  An Improved Method for the Evaluation of Microvascular Inflammation in Renal Allograft Biopsies. (Abstract #195)
Michele Rooney, Zhang Ping, Dilip Samarapungavan, Randolph Hennigar.
Spokane Valley, WA; Royal Oak, MI; Little Rock, AR.

3:18 pm  Blocking Fc Receptor in Flow Cytometric Crossmatch: Refining an Old Assay to Improve Patient Management. (Abstract #196)
Nicholas K. Brown, Jinguo Wang, Susana R. Marino.
Chicago, IL.

3:30 pm  Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal. (Abstract #197)
Paris, France; Edmonton, Canada.

3:42 pm  Composite Score to Define the Risk of Allograft Loss After Standard-of-Care Treatment of Antibody-Mediated Rejection in Kidney Transplantation. (Abstract #198)
Paris, France; Pittsburgh.

Innate Immunity in Rejection and Tolerance: Animal Models

Room 313
Chairs: Dianne McKay, UCSD, La Jolla, CA, United States and Anthony Dorling, MB PhD FRCP, King’s College London, London, United Kingdom

2:30 pm  Toll-Like Receptor (TLR) 9-Induced Resistance to Murine Cardiac Allograft Tolerance Is Dependent Upon C3a and C5a Receptor (C3aR/C5aR) Signaling. (Abstract #199)
Joong Hyuk Francis Sheen, Peter S. Heeger.
New York, NY.

2:42 pm  C5a Induces CSF1-Dependent Regulatory Macrophage (Mreg) Development Required for Murine Allograft Tolerance. (Abstract #200)
New York, NY.

2:54 pm  Gsk3β Regulates Macrophage Pro-Inflammatory Immune Activation via AMPK-Mediated Induction of Small Heterodimer Partner (SHP). (Abstract #201)
LA, CA; Nanjing, Jiangsu Province, China; Shanghai, China.

3:06 pm  Macrophage Specific Deletion of RhoA Impedes Macrophage Functions and Abrogates Chronic Rejection of Cardiac Allograft. (Abstract #202)
Yianzhu Liu, Wenhao Chen, Xian Li, Rafik Ghobrial.
Malgorzata Kloc.
Houston, TX.

3:18 pm  Donor-Derived Monocytes Migrate to the Contralateral Lung and Cause Neutrophilia Following Single Lung Transplant. (Abstract #203)
Chicago, IL.

3:30 pm  Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles. (Abstract #204)
Adelaide, Australia; Sydney, Australia.

3:42 pm  Distinct Phenotype and Function of Plasmacytoid Dendritic Cells from Kidney Allografts in Tolerant Recipients. (Abstract #205)
Nicholas Oh, Chao Yang, Makoto Tonsho, Dorothy K. Ndishabandi, Paul S. Russell, Robert B. Colvin, Joren C. Madsen, Alessandro Alessandrinhi.
Boston, MA.
Kidney Immune Monitoring 2

Ballroom C
Chairs: Clifton Kew, MD, Univ of Alabama, Birmingham, AL, United States and Christopher Blosser, MD, Division of Nephrology, Univ of Washington, Seattle, WA, United States

2:30 pm Mining the Human Proteome for Monitoring Renal Transplant Injury. (Abstract #206)

2:42 pm Common Molecular Features of Human Kidney Transplant Rejection Reflect Mechanistic Sharing Between T Cell-Mediated and Antibody-Mediated Rejection. (Abstract #207)
Jeffery M. Venner, Philip F. Halloran. Brisbane, Australia; Edmonton, Canada.

2:54 pm CD57+ CD4 T Cells Persist in the Periphery Following Kidney Transplantation. (Abstract #208)
Jaclyn R. Espinosa, Linda Stempora, Robert Townsend, Allan D. Kirk. Durham; Atlanta; Princeton.

3:06 pm Pre-Transplant Panel of Reactive T Cells (PRT) as an Independent Predictor of 2-Year Kidney Graft Function. (Abstract #209)
I. Gandolfini, E. Crespo, M. Baweja, U. Maggiore, P. Cravedi, P. S. Heeger, O. Bestard. New York, NY; Barcelona, Spain; Parma, Italy.

3:18 pm Human B Cell Cytokines Predict Renal Allograft Rejection and Early Transplant Outcomes. (Abstract #210)

3:30 pm Elevated Intragraft Expression of Innate Immunity and Cell Death-Related Markers Characterizes Deceased Donor Conditions and Is a Risk Factor for Adverse Graft Outcome. (Abstract #211)

3:42 pm IFTA Is Linked to Urinary Microbiome Changes. (Abstract #212)
Brian D. Modena, Rachel Milam, Frank Harrison, Sunil M. Kurian, Daniel R. Salomon, Allan D. Kirk. La Jolla, CA.

Kidney Transplantation: Allocation, Discard, and HCV

Veterans Auditorium
Chairs: Robert Stratta, MD, Wake Forest Baptist Health, Winston Salem, NC, United States and Amy Evenson, MD, MPH, Beth Israel Deaconess Medical Center, Boston, MA, United States

2:30 pm Where Are the KDPI 0-20% Kidneys Going in the New KAS? A Major Allocation Shift. (Abstract #213)
Mark Aeder, Nicole Turgeon, Anna Kucheryavaya, Darren Stewart. Cleveland, OH; Atlanta, GA; Richmond, VA.

2:42 pm Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS. (Abstract #214)
Darren Stewart, Anna Kucheryavaya, Roger Brown, David Klassen, Nicole Turgeon, Mark Aeder. Richmond, VA; Atlanta, GA; Cleveland, OH.

2:54 pm Kidney Donor Profile Index Trend Analyses. (Abstract #215)
Deepak Vikraman, Kadiyala Ravindra, Scott Sanoff, William Irish, Uptal Patel, Debra Sudan. Durham, NC.

3:06 pm Use of Small (<10kg) Kidney Donors in the US. (Abstract #216)
Jodi Smith, J. Snyder, A. Israni, B. Kasiske, R. Perez. Minneapolis; Seattle; Sacramento.

3:18 pm Utilization and Post-Transplant Outcomes Associated with Hepatitis C+ Donor Kidneys in the Advent of Direct-Acting Antivirals. (Abstract #217)
Mary Bowring, Lauren Kucirka, Allan Massie, Xun Luo, Mark Sulkowski, Dorry Segev, Christine Durand. Baltimore.
3:06 pm Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation. (Abstract #223)
Michelle Willicombe, Dawn Goodall, Adam G. McLean, David Taube. London, United Kingdom.

3:18 pm Induction Therapy with Rabbit Anti-thymocyte Globulin (rATG, Thymoglobulin®) vs Basiliximab After Kidney Transplantation: A Health Economic Analysis from a German Perspective. (Abstract #224)
Liana Cremaschi, Regina Thissen, Thomas Benzing, Michael Wiesener, Nikolai Zink, Thomas Paivanas, John F. Reitan, Meghan Gallagher, Friedrich Thaiss. Hamburg, Germany; Colgone, Germany; Erlangen, Germany; Washington, DC; Cambridge, MA.

3:30 pm Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Anti-thymocyte Globulin in Renal Transplantation. (Abstract #225)

3:42 pm B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin. (Abstract #226)
Abigail Benitez, Terry Ann Milford, Karina D. Torralba, Kimberly J. Payne, Michael E. De Vera. Loma Linda, CA.
2:42 pm  Early Hospital Readmission Following Pediatric Kidney Transplantation. (Abstract #228)
Elizabeth King, Lauren Kucirka, Mara McAdams-DeMarco, Sunjae Bae, Dorry Segev. Baltimore, MD.

2:54 pm  Adherence Patterns in Adolescent and Young Adult Kidney Transplant Recipients. (Abstract #229)
Julie Boucquemont, Bethany J. Foster, The TAKE-IT Investigators. Montréal, QC, Canada; Montreal, QC, Canada.

3:06 pm  Angiotensin II Type 1 Receptor Antibodies Are Associated with Allograft Loss in Pediatric Renal Transplantation. (Abstract #230)
Meghan H. Pearl, Qiuheng Zhang, Miguel F. Palma Diaz, Jonathan Grotts, Jenny Brook, David Gjerston, Patricia Weng, Elaine F. Reed, Eileen W. Tsai. Los Angeles, CA.

3:18 pm  Predictors of Early Rejection and Allograft Failure in Pediatric Kidney Transplantation: Impact of Histology and Behavior. (Abstract #231)

3:30 pm  Acute Kidney Injury (AKI) Associated with Chronic Kidney Disease (CKD) in Paediatric Non-Kidney Transplant Recipients. (Abstract #232)
C. Williams, K. Borges, T. Banh, J. Vasilevska-Ristovska, R. Chanchlani, V. Ng, A. I. Dipchand, M. Solomon, D. Hebert, S. J. Kim, B. C. Astor, R. S. Parekh. Toronto, Canada; Madison.

3:42 pm  Graft Outcomes in Pediatric Kidney Transplants Are Better with Laparoscopic Donor Nephrectomy and High Volume Centers. (Abstract #233)

Living Donor Liver Transplantation

Room 210

Chairs: Michael Wachs, MD, Children’s Hospital Colorado, Denver, Aurora, CO, United States and Trevor Nydam, MD, University of Colorado School of Medicine, Aurora, CO, United States

2:30 pm  Live Donor Liver Transplantation for NASH: The Toronto Experience. (Abstract #234)
Andrew S. Barbas, Nicolas Goldaracena, Martin J. Dib, Max Marquez, Gonzalo Sapiochin, David P. Al-Adra, Ian D. McGilvray, Mark S. Cattral, Paul D. Greig, David R. Grant. Toronto, ON, Canada.

2:42 pm  Live Donor Champion Program: Time to Redefine Living Liver Donation. (Abstract #235)
Daniel Maluf, Anita Sites, Melissa Donovan, Jingzhou Wang, Emily Lyster, Curtis Argo. Charlottesville, VA.

2:54 pm  Hepatic Hemodynamics (HD) and Portal Flow Modulation (PM): Tactical Use in Small for Size (SFS) Live Donor Liver Transplantation (LDLT). (Abstract #236)

3:06 pm  Durable Clinical and Immunologic Advantage of Living Donor Liver Transplantation (LDLT) in Children. (Abstract #237)

3:18 pm  Living Donor Liver Transplant Has Similar Outcome to Deceased Donor Liver Transplant for MELD > 25. (Abstract #238)
3:30 pm  Impact of Preoperative Body Composition on Outcomes After Living Donor Liver Transplantation. (Abstract #239)
Yuhei Hamaguchi, Toshimi Kaido, Atsushi Kobayashi, Shinya Okumura, Shintaro Yagi, Hideaki Okajima, Shinji Uemoto. Kyoto, Japan.

3:42 pm  Improving the Efficiency, Safety and Cost of Evaluating Living Donor Liver Candidates Using Single Sequence MRI. (Abstract #240)
Michael Schilsky, Katarzyna Cartiera, Salih Boga, Samantha Schilsky, Sukru Emre, David Mulligan, Jeffrey Weinreb, Gary Israel. New Haven, CT; Silver Springs, MD.

2:30 pm  Molecular and Bio-Markers in Hearts and VADs - A New Hope
Room 102
Chairs: Sean Pinney, MD, Mount Sinai School of Med, New York, NY, United States and Jon Kobashigawa, MD, Cedars Sinai Heart Institute, Los Angeles, CA, United States

2:30 pm  Serial Peripheral Blood Mononuclear Cell Expression Profiling Reveals Inflammatory Genomic Storm Following Mechanical Circulatory Support Surgery. (Abstract #241)
Giovanny Godoy, Galyna Bondar, Azadeh Esmaeili, Eric Arellano, Eleanor Chang, Maral Bakir, Jay Chittoor, Ryan Topashi, Nazera Fazli, Charlotte Starling, Erin Oh, Sherwin Toluie, Zehua Yang, Dan Tran, Martin Cadeiras, Nicholas Wisniewski, Murray H. Kwon, Joanna Schenaen, Yael Korin, Maura Rosetti, Elaine Reed, Mario C. Deng. Los Angeles, CA; Taiyuan, Shanxi, China.

2:42 pm  A P2X7R Mutation with Hypermetabolic T Cells, Th1/Th17 Skewing and Reduced Cardiac Allograft Survival. (Abstract #242)
Francesca D’Addio, Andrea Vergani, Luciano Potena, Anna Maestrini, Sara Tezza, Moufida Ben Nasr, Vera Usueli, Marco Sbolli, Laura Borgese, Attilio Iacovoni, Domenico Corradi, Reza Abdi, Antonio Secchi, Randall C. Starling, Mohamed H. Sayegh, William Harmon, David Briscoe, Peter Heeger, Anil Chandraker, Francesco Grigioni, Paolo Fiorina. Boston, MA; Milan, Italy; Bologna, Italy; Bergamo, Italy; Parma, Italy; Boston; Cleveland; Lebanon; New York.

2:54 pm  Natural Killer CD16/FcR Profiles May Associate with Enhanced Humoral Responsiveness in Heart Transplant Recipients with Cardiac Allograft Vasculopathy. (Abstract #243)

3:06 pm  Primary Graft Failure following Cardiac Transplantation Is Associated with Elevated Pre-Transplant Levels of Pro-Inflammatory Factors. (Abstract #244)

3:18 pm  A New Diagnostic Score for Microvascular Inflammation in Antibody-Mediated Rejection in Heart Transplantation. (Abstract #245)

3:30 pm  Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV). (Abstract #246)

3:42 pm  Elevated Urinary 11-Dehydrothromboxane B2 Is Associated with Increased Bleeding Risk in Left Ventricular Assist Device Patients. (Abstract #247)
Regulatory T Cells: Animal Models

**Room 309**

*Chairs: Qizhi Tang, University of California SF, San Francisco, CA, United States and Wayne Hancock, Childrens Hospital of Philadelphia, Philadelphia, PA, United States*

2:30 pm **Foop3 Controls Oxidative Phosphorylation in Regulatory T Cells.** *(Abstract #248)*


2:42 pm **Direct IL-33 Stimulation of T Regulatory Cells via Suppression of Tumorigenicity 2 (ST2) Is Required for Effective Control of Alloimmune Responses.** *(Abstract #249)*

Xiaoli Zhang, Benjamin M. Matta, Dawn K. Reichenbach, Bruce R. Blazar, Heth R. Turnquist. Pittsburgh, PA; Minneapolis, MN; Changsha, Hunan, China.

2:54 pm **IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.** *(Abstract #250)*


3:06 pm **T-Bet Regulates nTreg Stability and Suppression in an Islet Allograft Model.** *(Abstract #251)*


3:18 pm **DEPTOR Inhibits mTORC1 in CD4+ T Cells and Increases Treg Function by Stabilizing Foxp3 Expression.** *(Abstract #252)*

Johannes Wedel, Sarah Bruneau, David M. Briscoe. Boston, MA.

3:30 pm **Human and Mouse Treg Use Lymphotxin for Migration Across Lymphatic Endothelium.** *(Abstract #253)*

C. Colin Brinkman, Keli L. Hippen, Bruce R. Blazar, Jonathan S. Bromberg. Baltimore, MD; Minneapolis, MN.

3:42 pm **NAD+ Promotes Allograft Survival Independently of CD4+CD25+Foxp3+ Regulatory T Cells.** *(Abstract #254)*

Abdallah Elkhal, Hector Rodriguez Cetina Biefer, Hirofumi Uehara, Markus Quante, Midas Seyda, Jeroen M. Schuitenmaker, Stefan G. Tullius, Abdallah Elkhal. Boston, MA.

Various Viruses, Vaccines, and SOT

**Room 306**

*Chairs: John Baddley, Univ of Alabama at Birmingham, Birmingham, AL, United States and Karen Doucette, MD, MSc, University of Alberta, Edmonton, AB, Canada*

2:30 pm **Evaluation of a Novel Global Immunity Assay to Predict Infections in Organ Transplant Recipients.** *(Abstract #255)*

Muhtashim Mian, Atul Humar, Shanil Keshwani, Shahid Husain, Peter Ashton, Sang Hoon Han, Lianne Singer, Joseph Kim, Eberhard Renner, Mamatha Bhat, Deepali Kumar. Toronto, Canada.

2:42 pm **Diversity of Influenza Antibody Repertoire in Transplant Recipients with Natural Influenza Infection.** *(Abstract #256)*

Victor H. Ferreira, Andrzej Chruscinski, Sang Hoon Han, Atul Humar, Deepali Kumar. Toronto, Canada.

2:54 pm **Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.** *(Abstract #257)*

Hans Hirsch, Johan W. De Fijter, Markus van der Giet, Martin Zeier, Julios Pascual, Yingyos Avihingsanon, Patricia Lopez, Jose Aguilar-Sanchez, Jossy Kochuparampil, Zailong Wang, Hallvard Holdaas, Josep M. Cruzado. Basel, Switzerland; East Hanover.

3:06 pm **Assessment of Chikungunya IgM Prevalence Among Deceased Organ and Tissue Donors Using Two Enzyme Immunoassay (EIA) Kits.** *(Abstract #258)*

Harry Prince, Michelle Altrich, Marek Nowicki. Los Angeles, CA.


Viral Hepatitis

Ballroom A

Chairs: Kimberly Brown, MD, Henry Ford Hospital, Detroit, MI, United States and Dilip Moonka, Henry Ford Hospital, Detroit, MI, United States

2:30 pm  Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy. (Abstract #262) Mary Bowring, Lauren Kucirka, Allan Massie, Xun Luo, Mark Sulkowski, Dorry Segev, Christine Durand. Baltimore.

2:42 pm  Hepatitis E Virus (HEV) Infection Among Kidney Transplant Patients in a Northeast US Center. (Abstract #263) Mary Ann Lim, Saleem Kamili, Tracy Greene, Alexandra Tejada-Strop, Jan Drobeniuc, Mary Vanderveen, Roy D. Bloom. Philadelphia, PA; Atlanta, GA.

2:54 pm  An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study. (Abstract #264) Weiqiang Ju, Anli Yang, Qingqi Ren, Dongping Wang, Zhiyong Guo, Yi Ma, Anbin Hu, Qiang Tai, Xiaofeng Zhu, Xiaoshun He. Guangzhou, Guangdong, China.

3:06 pm  High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials. (Abstract #265) M. Charlton, E. Yoshida, M. Bouliere, S. Fiamm, A. Muir, M. Fried, N. Terrault, S. Arterburn, C. Yun, P. Pang, A. Osinusi, J. Spellman, M. Natha, D. M. Brainard, J. G. Hutchison, M. Manns, N. Afdhal. Salt Lake City; Vancouver, Canada; Marseilles, France; Chicago; Durham; Chapel Hill; SF; Foster City; Hannover, Germany; Boston.

3:18 pm  Time Course of Hepatic Graft Function Improvement After Ledipasvir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR. (Abstract #266) Steve M. Helmke, Jacqueline G. O’Leary, James Burton, Michael Cookson, Shannon Lauriski, James Trotter, John Muczynski, Gregory Everson. Aurora, CO; Dallas, TX; Foster City, CA.


3:42 pm  Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus. (Abstract #268) Joel P. Wedd, Ryan Ford, John Paul Norvell, Samir Parekh, Nicole Cheng, Nikita Young, Anisha Patel, Rahul Maheshwari, Ravi Vora, Okechukwu Mgbemena, James Spivey, Anjana Pillai. Atlanta, GA.
Pediatric/Allied Health Symposium
2:30 pm — 5:30 pm

**Adherence in Transplantation: Applying Findings from the MALT and BRIGHT Studies**

*Room 208*

**Moderators:** Sukru Emre, MD, FACS, Yale New Haven Transplantation Center, New Haven, CT, USA and Heidi Yeh, MD, Massachusetts General Hospital, Boston, MA, USA

2:30 pm  **MALT Study: Methods, Implementation, Primary and Secondary Analysis Results**  
Eyal Shemesh, MD  
Ichan School of Medicine at Mt. Sinai  
New York, NY, USA

3:00 pm  **Insights from MALT: Effects of Barriers to Adherence, Transition of Responsibility for Care, and Psychosocial Variables**  
Estella Alonso, MD  
Ann & Robert H. Lurie Children’s Hospital  
Chicago, IL, USA

3:30 pm  **Putting it All Together: Implications of MALT Results to Clinical Research and to Post Transplant Care**  
George Mazariegos, MD  
Children’s Hospital of Pittsburgh  
Pittsburgh, PA, USA

4:00 pm  **The BRIGHT Study: an Intercontinental Study to Assess Practice Patterns and Behavioral Outcomes in Heart Transplantation: Rationale & Methods**  
Cynthia Russell, PhD, RN  
University of Missouri  
Kansas City, MO, USA

4:30 pm  **YKL-40 Predicts Renal Recovery in Deceased-Donor Transplantation.**  
*Abstract #269*  
Jeremy Puthumana, Isaac E. Hall, Peter P. Reese, Bernd Schröppel, Francis L. Weng, Heather Thiessen-Philbrook, Mona D. Doshi, Veena Rao, Chun G. Lee, Jack A. Elias, Lloyd G. Cantley, Chirag R. Parikh. New Haven, CT; Philadelphia, PA; Ulm, Germany; Livingston, NJ; Detroit, MI; Providence, RI.

4:42 pm  **Deceased Donor Urine C5a Predicts Donor and Recipient Acute Kidney Injury.**  
*Abstract #270*  
Bernd Schroppel, Peter Heeger, Isaac Hall, Mona Doshi, Francis Weng, Peter Reese, Chirag Parikh. Ulm, Germany; New York; New Haven; Detroit; Livingston; Philadelphia.

4:54 pm  **Financial Cost of Cold Ischemia Time in Kidney Transplantation.**  
*Abstract #271*  

5:06 pm  **Many Discarded Kidneys Are Similar to Kidneys Accepted for Transplantation as Judged by Their Histologic Lesions and Molecular AKI Scores.**  
*Abstract #272*  
Konrad S. Famulski, Jeff Reeve, Olivier Aubert, Alexandre Loupy, Silke Niderhaus, Jonathan Bromberg, Philip F. Halloran. Edmonton, Canada; Paris, France; Baltimore.

Coffee Break in the Exhibit Hall
4:00 pm — 4:30 pm

*Halls C&D*
5:18 pm  Delayed Graft Function (DGF) Does Not Accelerate Progression of Fibrosis During the First Year After Deceased Donor Kidney Transplantation.  
(Abtract #273) 
Raymond L. Heilman, Ibrahim Qaqish, Maxwell L. Smith, Hasan Khamash, Bruce Kaplan, Kunam Reddy. Phoenix, AZ.

5:30 pm  Influence of AKIN Stage on the Outcome of Deceased Donor Kidney Transplantation (DDKTx).  
(Abtract #274) 
Ibrahim Qaqish, Danielle Haakinson, Kunam Reddy, Maxwell Smith, Hasan Khamash, Heilman Raymond. Phoenix, AZ.

5:42 pm  Is Prolonged Cold Ischemia a Contraindication to Using Kidneys from Acute Kidney Injury Donors?  
(Abtract #275) 

Antibody Mediated Rejection in Kidney Transplantation: De Novo DSA

Ballroom B  
Chairs: Helio Tedesco Silva, MD, Hospital do Rim-Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil and Irene Kim, MD, Cedars Sinai, Los Angeles, CA, United States

4:30 pm  De Novo Anti-HLA DSA Characteristics and Subclinical Antibody Mediated Kidney Allograft Injuries.  
(Abtract #276) 

4:42 pm  Significant Association of Vitamin-D Receptor (VDR) Gene Polymorphism and Incidence of De Novo DSA in Renal Transplantation.  
(Abtract #277) 

4:54 pm  Phenotype and Outcome of Antibody-Mediated Rejection Due to Pre-Existing and De Novo DSA in Kidney Recipients.  
(Abtract #278) 

5:06 pm  Epitope Load Is Predictive of De Novo Donor Specific Antibodies Occurrence in Renal Transplant Recipients After Conversion from Cyclosporine to Everolimus.  
(Abtract #279) 
Renaud Snaouadj, Caroline Suberbielle, Nassim Kamar, Elisabeth Cassuto, Sophie Caillard, Jean-Luc Taupin, Dany Anglicheau, Christophe Legendre, Alexandre Hertig, Eric Rondeau. Paris, France; Toulouse, France; Nice, France; Strasbourg, France.

5:18 pm  IgM Donor Specific Antibodies Are Frequently Associated with C1q-binding DnDSA in Renal Transplant Recipients.  
(Abtract #280) 
Jamal Bamoulid, Afaf Roodenburg, Oliver Staeck, Constanze Schoenemann, Nils Lachmann, Clemens Budde. Berlin, Germany; Besançon, France; Rotterdam, Netherlands.

5:30 pm  Randomized Controlled Study Evaluating Adherence Monitoring with Electronic Feedback on Reducing Renal Allograft Rejection.  
(Abtract #281) 

5:42 pm  Increased Access to Transplantation of Highly Sensitized Patients Facilitated by the New Kidney Allocation System.  
(Abtract #282) 
Adriana Colovai, Maria Ajaimy, Christina Savchik, Shirley Chan, Peter Masiakos, Juan Rocca, Enver Akalin. Bronx, NY.
Belatacept and Steroid Withdrawal in Kidney Transplantation

**Ballroom A**

**Chairs:** Richard Formica, MD, Yale University, New Haven, CT, United States and Lorenzo Gallon, Northwestern University, Chicago, IL, United States

**4:30 pm** A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation. (Abstract #283)


**4:42 pm** The Optimal Time Point for Steroid Withdrawal After Kidney Transplantation Is One Year After Engraftment. (Abstract #284)

Maria C. Haller, Michael Kammer, Alexander Kainz, Georg Heinze, Rainer Oberbauer. Vienna, Austria.

**4:54 pm** Graft Survival of Steroid-Avoidance Protocols in Pediatric Kidney Transplantation—A Propensity Score Analysis. (Abstract #285)

Edward Nehus, Yu Wang, Bo Lu, Chunyan Liu, Maurizio Macaluso, Mi-Ok Kim. Cincinnati, OH; Columbus, OH.

**5:06 pm** Early Steroid Withdrawal in African American Kidney Transplant Recipients: A Propensity Score Matching Analysis. (Abstract #286)


**5:18 pm** Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study. (Abstract #287)

Steven Chadban, Helen Pilmore, Graeme Russ, John Kanelis, Scott Campbell, Philip O’Connell, Wai Lim, Mark Lutherborrow, Nicol Kurstjens, Rowan Walker. Sydney, Australia; Auckland, New Zealand; Adelaide, Australia; Melbourne, Australia; Queensland, Australia; Perth, Australia.

**5:30 pm** Everolimus/Low Tacrolimus(TAC) Compared to MPA/RegularTAC for Renal Transplantation in the Elderly Recipient – Preliminary Analysis of the nEverOld Trial. (Abstract #288)


**5:42 pm** Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. (Abstract #289)

Xuerong Wen, Michael J. Casey, Alfonso H. Santos, Abraham Hartzema, Karl L. Womer. Gainesville, FL.

**Challenges to Graft Survival and Tolerance: Animal Models**

**Room 306**

**Chairs:** Jonathan Maltzman, Stanford University, Palo Alto, CA, United States and Jeremy Leventhal, Mount Sinai, New York, NY

**4:30 pm** CD4 T Cell Mediated Help Is Required for Intra-Allograft Proliferation of Endogenous Memory CD8 T Cells and Their Ability to Mediate Rejection of Cardiac Allografts Subjected to Prolonged Ischemia. (Abstract #290)

Hidetoshi Tsuda, Toshiaki Tanaka, Charles A. Su, Anna Valujskikh, Robert L. Fairchild. Cleveland, OH.

**4:42 pm** Absence of Receptors for C3a or C5a Prevent Alloreactive CD8 T Effector Cell (Teff) Expansion but Differentially Impact Memory (Tmem) Persistence Posttransplantation. (Abstract #291)


**4:54 pm** Combined CD122 and Costimulation Blockade Prolongs Allograft Survival by Controlling Expansion and Effector Function of Memory CD8 T Cells. (Abstract #292)

David V. Mathews, Ying Dong, Laura Higginbotham, Steven C. Kim, Cynthia Breeden, J. Y. Tso, Andrew B. Adams. Atlanta, GA; Mountain View, CA.
5:06 pm Ageing as a Barrier to Transplant Tolerance. (Abstract #293)
James I. Kim, Ryan T. Stott, Hany Deirawan, Lisa Kojima, Laura A. Washburn, Gaoping Zhao, Heidi Yeh, James F. Markmann. Boston, MA.

4:54 pm Protective Impact of the Kidney in SPK Transplants – Mechanisms for Improved Outcomes Compared with Solitary Transplants. (Abstract #299)
Erik Finger, Ty Dunn, Aleksandra Kukla, Varvara Kirchner, Raja Kandaswamy. Minneapolis, MN.

5:18 pm Enhanced IL-6 Production Impedes Transplant Tolerance Induction in Lupus-Prone Mice. (Abstract #294)
Blair Stocks, Christopher Wilson, Mabel Seto, Andrew Marshall, Daniel J. Moore. Nashville, TN.

5:06 pm The Survival Benefit of Pancreas and/or Kidney Transplantation for Patients with Type 1 Diabetes. (Abstract #300)
Rainer R. W. Gruessner, Vaughn Whittaker, Nuri Ozden, Angelika Gruessner. Syracuse, NY.

5:30 pm Abrogating Donor-Derived Myd88 Signaling Impairs the Recruitment of Recipient Neutrophils and CD8 T Cells into Lung Allografts in Mice. (Abstract #295)
Zhikun Zheng, Jiao-Jing Wang, Xin Yo Yeap, Xin Kang, Yan Xie, Xunrong Luo, Zheng Zhang. Chicago, IL.

5:18 pm Impact of Early Hospital Readmission Following Simultaneous Pancreas Kidney Transplantation. (Abstract #301)
Elizabeth King, Lauren Kucirka, Mara McAdams-DeMarco, Mary Bowring, Allan Massie, Dorry Segev. Baltimore, MD.

5:30 pm Fecal Microbiota Transplant Results in Durable Changes to Host Microbiota That Correlate with Allograft Outcome. (Abstract #296)

4:30 pm Is Facilitated Pancreas Allocation Effective? (Abstract #297)
Robert Carrico, Jonathan Fridell, Jon Odorico, Silke Niederhaus. Richmond, VA; Indianapolis, IN; Madison, WI; Baltimore, MD.

4:42 pm How Did the New Kidney and Pancreas Allocation Systems Effect Pancreas Utilization in the First Six-Months? (Abstract #298)
Robert Carrico, Jonathan Fridell, Jon Odorico, Zoe Stewart. Richmond, VA; Indianapolis, IN; Madison, WI; Iowa City, IA.

4:42 pm Donation After Cardiac Death Dose Not Impact Short and Long Term Graft Outcomes in Simultaneous Pancreas and Kidney Transplantation. (Abstract #303)

CMV: Immune Monitoring & MicroRNA Responses
Room 306
Chairs: Peter Chin-Hong, University of California, San Francisco, San Francisco, CA, United States and Alissa Wright, Vancouver, BC, Canada

4:30 pm CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients. (Abstract #304)
Simon Ball, Alexander Small, Chantelle Waite. Birmingham, United Kingdom.

4:42 pm The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation. (Abstract #305)
Thomas Schachtner, Maik Stein, Petra Reinke. Berlin, Germany.
4:54 pm  An Interventional Study Evaluating Cell Mediated Immunity to Guide Therapy for CMV Viremia. (Abstract #306)
Muhtashim Mian, Atul Humar, Shanil Keshwani, Shahid Husain, Peter Ashton, Sang Hoon Han, Lianne Singer, Joseph Kim, Eberhard Renner, Deepali Kumar. Toronto, ON, Canada.

5:06 pm  Cytometric Deep Profiling of the CD8+ T-Cell Compartment in Transplant Patients with CMV Viremia. (Abstract #307)

5:18 pm  Assessing Return of CMV Specific Cellular Immunity Using the T-SPOT. CMV Soon After Kidney Transplant with Thymoglobulin. (Abstract #308)
Camille Nelson Kotton. Boston, MA.

5:30 pm  Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients. (Abstract #309)

5:42 pm  Levels of VEGF-C, PLGF and Follistatin at 12 Months Post Transplantation Are Associated with Increased Risk for Long Term Progressive Renal Dysfunction. (Abstract #313)
G. J. Dreyer, J. W. de Fijter, D. M. Briscoe, K. P. Daly, M. E. J. Reinders. Leiden, Netherlands; Boston, MA.

4:30 pm  Long-Term Death-Censored Graft Loss in the DeKAF Study. (Abstract #311)

4:42 pm  Post-Transplant Monitoring of Donor-Specific Anti-HLA Antibodies and Their Characteristics Improves Risk Stratification of Kidney Allograft Loss. (Abstract #312)

4:54 pm  Human MicroRNA Responses Are Predictive of CMV Reactivation Following Solid Organ Transplant. (Abstract #310)
Sang Hoon Han, Deepali Kumar, Victor Ferreira, Shahid Husain, Nicolas Mueller, Atul Humar, Muhtashim Mian, Peter Ashton. Toronto, Canada; Zurich, Switzerland.

5:06 pm  Predictors of eGFR Slope at One Year in Kidney Transplants – A Big Data Approach. (Abstract #314)

5:18 pm  Natural History of Response to Wounding in Human Kidney Transplants. (Abstract #315)
Konrad S. Famulski, Jeffery M. Venner, Jeff Reeve, Philip F. Halloran. Edmonton, AB, Canada; Brisbane, Queensland, Australia.

5:30 pm  Impact of Machine Perfusion on Long-Term Kidney Transplant Outcomes. (Abstract #316)
Shaifali Sandal, Xun Luo, Allan Massie, Marcelo Cantarovich, Dorry Segev. Montreal, Canada; Baltimore.
5:42 pm  Optimal Donor/Recipient Pairing for High KDPI Grafts Can Yield Similar Survival to Medium KDPI Grafts. (Abstract #317)
Motaz Selim, Ehab Saad, Michael Zimmerman, Christopher Johnson. Milwaukee.

Kidney: Desensitization

Room 304
Chairs: Martha Pavlakis, MD, Harvard Medical School, Boston, MA, United States and Babak Orandi, MD, PhD, MSc, Johns Hopkins Hospital, Baltimore, MD, United States

4:30 pm  A Prospective Carfilzomib-Based Desensitization Trial: Phase 1 Results. (Abstract #318)

4:42 pm  Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES). (Abstract #319)

4:54 pm  Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES). (Abstract #320)
Ashley A. Vo, Xiaohai Zhang, Summer Williamson, Kate Myers, Nancy Reinsmoen, Jua Choi, Joseph Kahwaji, Alice Peng, Rafael Villicana, Stanley C. Jordan. LA, CA.

5:06 pm  Survival Benefit of Living Donor ABOi Kidney Transplantation. (Abstract #321)
Allan Massie, Bonnie Lonze, Saad Anjum, Xun Luo, Dorry Segev. Baltimore.

5:18 pm  Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES). (Abstract #322)
Ashley A. Vo, Jua Choi, Joseph Kahwaji, James Mirocha, Alice Peng, Rafael Villicana, Stanley C. Jordan. LA, CA.

5:30 pm  RNAseq Transcriptome Analysis of Bone Marrow CD138+ Plasma Cell Responses to Carfilzomib Monotherapy Desensitization. (Abstract #323)

5:42 pm  Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization. (Abstract #324)

Liver Transplantation Peri-Operative Considerations

Room 311
Chairs: Neelhar Parikh, University of Michigan, Ann Arbor, MI, United States, Colleen Jay, MD, MS, University of Texas Health Science Center San Antonio, San Antonio, TX, United States and Peter Abt, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, United States

4:30 pm  Pre-Listing Prescription Narcotic Use: Survival Implications in Liver Transplantation. (Abstract #325)
Henry Randall, Krista L. Lentine, Dorry L. Segev, Hui Yuan, Janet E. Tuttle-Newhall, Mustafa Nazzaal, Chintalapati Varma, Gregory Hess, Bertram L. Kasiske, Mark A. Schnitzler. Minneapolis; Baltimore; Hanover; Greenville; Pittsburgh; St. Louis.

4:42 pm  Non-Invasive Biomarkers for Graft Quality and Outcome Post-Liver Transplantation. (Abstract #326)
Ricardo Gehrau, Valeria Mas, Sai Vineela Bontha, Daniel Maluf. Charlottesville, VA.

4:54 pm  Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Epidemiology, Outcomes, and Costs. (Abstract #327)
5:06 pm  Experience Using a Discharge Calculator for Discharge Planning Post Liver Transplantation (OLT). (Abstract #328)

5:18 pm  Probability, Risk Factors, and Long-Term Outcomes of Biliary Complications After Hepatic Artery Thrombosis in Adult Liver Transplant Recipients: 20 Years Experience from a Single Center. (Abstract #329)
Masato Fujiki, Koji Hashimoto, Teresa Diago, Cristiano Quintini, Federico Aucejo, Dymptna Kelly, Bijan Eghtesad, John Fung. Charles Miller. Cleveland, OH.

5:30 pm  Biliary Epithelial Damage, Regenerative Capacity and Local Immune Response After Cold Storage of DBD Livers Determine Biliary Complications After Liver Transplantation. (Abstract #330)

5:42 pm  When Living Donor Liver Allografts Fail: Exploring the Pitfalls of Retransplantation Using Deceased Donor Organs. (Abstract #331)

4:42 pm  Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic. (Abstract #333)

4:54 pm  High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients. (Abstract #334)

5:06 pm  P-Glycoprotein Function: Association with Race, Gender and Tacrolimus Pharmacokinetics. (Abstract #335)

5:18 pm  Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data. (Abstract #336)
Krista L. Lentine, Abhijit S. Naik, Mark A. Schnitzler, David Axelrod, Jiajing Chen, Daniel C. Brennan, Dorry L. Segev, Bertram L. Kasiske, Henry Randall, Vikas R. Dharnidharka. St. Louis; Detroit; Hanover; Baltimore; Minneapolis.

5:30 pm  Non-adherence is associated with increased risk of rejection and graft loss. (Abstract #337)
Raghavesh Pullalarevu, D. Taber, A. Chokkalingam, R. Browning, M. Kamel, M. Salazar, T. Srinivas, Maria Aurora Posadas Salas. Charleston, SC.

5:42 pm  Does Post-Transplant Adherence Come at a Cost? (Abstract #338)
Kunal Yadav, Thomas Nevins, David Vock, William Thomas, William N. Robiner, Arthur Matas. Minneapolis, MN.
Metabolic Complications in Kidney Transplantation

Room 312
Chairs: Dianne McKay, UCSD, La Jolla, CA, United States and Matthew Weir, MD, University of Maryland School of Medicine, Baltimore, MD, United States

4:30 pm Denosumab Prevents Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: Results from a Randomized Controlled Trial. (Abstract #339)
Marco Bonani, Diana Frey, Jens G. Brockmann, Thomas Fehr, Thomas Müller, Nicole Graf, Rudolf P. Wüthrich. Zurich, Switzerland; Winterthur, Switzerland.

4:42 pm Treatments Against Renin-Angiotensin-Aldosterone System Could Influence FGF23 and Klotho Levels in Renal Transplant Recipients. (Abstract #340)

4:54 pm Effect of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blockade (ARB) Exposure on Intragraft Gene Expression of Kidney Transplant Patients. (Abstract #341)
Christian Suarez-Fuentes, Pilib O Broin, Yi Bao, Enver Akalin. Bronx, NY; Galway, Ireland; Bethesda, MD.

5:06 pm Serum Bicarbonate and Long-Term Outcomes in Kidney Transplant Recipients. (Abstract #342)

5:18 pm Enhanced Activation of Hemostasis During Kidney Transplantation in Patients on Dialysis Compared to Pre-Eemptively Transplanted Patients. (Abstract #343)

5:30 pm Pre-Transplant Bariatric Surgery and One-Year Graft Loss Risk in Kidney Transplants. (Abstract #344)

5:42 pm Smoking Exposure Among Kidney Allograft Recipients and Outcomes After Transplant. (Abstract #345)
Holly Gillott, Sanna Tahir, Francesca Jackson-Spence, Felicity Evison, Jay Nath, Adnan Sharif. Birmingham, United Kingdom.

Pathways of Allograft Rejection: Animal Models

Room 310
Chairs: William Kitchens, MD, PhD, Emory Transplant Center, Atlanta, GA, United States and Gilles Benichou, PhD, Mass Gen Hosp Harvard Med Sch, Boston, MA, United States

4:30 pm The Role of PI3γ and PI3∆ in Alloimmunity. (Abstract #346)

4:42 pm Transfer of Donor-Derived Exosomes to Recipient Ag-Presenting Cells Is Critical for Allograft Recognition. (Abstract #347)
Quan Liu, Darling M. Rojas-Canales, Sherrie J. Divito, William J. Shufesky, Adriana T. Larregina, Adrian E. Morelli. Pittsburgh, PA.

4:54 pm Inhibitory FcgRIIB Functionally Inhibits Donor-Reactive CD8+ Memory T Cell Responses Following Transplantation. (Abstract #348)
David F. Pinelli, Maylene E. Wagener, Danya Liu, Idelberto R. Badell, Mandy L. Ford. Atlanta, GA.

5:06 pm NK-Activating MCMV Strain Is Associated with Increased Murine Renal Transplant Injury. (Abstract #349)
Masako Shimamura, Mao Li, Bo Chen, James F. George, Trenton R. Schoe. Columbus, OH; Birmingham, AL.

5:18 pm The 20S Proteasome, Active within Exosome-Like Vesicles Released by Apoptotic Cells Accelerates Rejection. (Abstract #350)
Mélanie Dieudé, Christina Bell, Julie Turgeon, Deborah Beillevaire, Shijie Qi, Éric Boilard, Pierre Thibault, Marie-Josée Hébert. Montréal, Canada; Montréal, Canada; Québec, Canada; Edmonton, Canada.
5:30 pm  Blocking MHC Class II on Human Endothelium Mitigates Acute Rejection of Vessel Allografts by Effector Memory T Cells. (Abstract #351)  Parwiz Abrahimi, Lingfeng Qin, William G. Chang, Alfred L. M. Bothwell, George Tellides, W. Mark Saltzman, Jordan S. Pober. New Haven, CT.


Pediatric Liver Transplant

Room 206  Chairs: Heung Bae Kim, MD, Boston Children’s Hospital, Boston, MA, United States and Evelyn Hsu, MD, Seattle Children’s Hospital, Seattle, WA, United States


5:06 pm  Long Term Outcome of De-Novo Autoimmune Hepatitis in Pediatric Recipients of Liver Transplantation. (Abstract #357)  Y. Avitzur, P. McKiernan, M. Martinez, S. Lobritto, D. Kelly, V. L. Ng, E. M. Alonso, U. Ekong. Toronto, Canada; Birmingham, United Kingdom; New York; Chicago; New Haven.

5:18 pm  The Medication Level Variability Index (MLVI), a Behavioral Biomarker, Predicts Late Allograft Rejection in Pediatric Liver Transplant Recipients – A Prospective Multisite Study. (Abstract #358)  Eyal Shemesh, John C. Bucuvalas, Ravinder Anand, Robert Venick, Estella M. Alonso, Jeff Mitchell, Rachel A. Annunziato, George V. Mazariagos, Benjamin L. Shneider. New York; Cincinnati; Rockville; Los Angeles; Chicago; Pittsburgh Texas.


Xenotransplantation: Animal Models

Room 102  Chairs: Agnes Azimzadeh, Univ of Maryland Sch of Med, Baltimore, MD, United States and Muhammad Mohiuddin, MD, NHLBI / National Institutes of Health, Bethesda, MD, United States

4:30 pm  The Impact of Sequential Gene Modifications on Cardiac Xenograft Survival. (Abstract #360)  Keith A. Horvath, Avneesh K. Singh, Joshua L. Chan, Marvin L. Thomas, Billeta G. Lewis, David L. Ayares, Philip C. Corcoran, Muhammad M. Mohiuddin. Bethesda, MD; Blacksburg, VA.
4:42 pm  Inclusion of Human Tissue Factor Pathway Inhibitor or Thrombomodulin Transgenes Attenuates Critical Consumptive Thrombocytopenia in Cardiac Xenotransplantation. (Abstract #361)
Joshua L. Chan, Avneesh K. Singh, Philip C. Corcoran, Marvin L. Thomas III, Billeta G. Lewis, David L. Ayares, Keith A. Horvath, Muhammad M. Mohiuddin. Bethesda, MD; Blacksburg, VA.

5:42 pm  Human Leukocyte Antigen-E Expression on Porcine GalTKO.hCD46 Cells Improves Ex-Vivo Xenograft Survival and Attenuates Injury. (Abstract #366)
Christopher T. Laird, Natalia Kubicki, Lars Burdorf, Tianshu Zhang, Xiangfei Chang, Georghe Braileanu, Carol Phelps, David N. Ayares, Agnes N. Azimzadeh, Richard N. Pierson. Baltimore, MD; Blacksburg, VA.

Late Breaking
Room 210
Chairs: Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD, United States and Robert Fairchild, PhD, Cleveland Clinic Foundation, Cleveland, OH, United States

4:30 pm  Pediatric Heart Transplantation Across a Positive Cross-Match Is Associated with High Rates of AMR but No Difference in Short Term Graft Loss, Dysfunction and Death (CTOTC-04 study). (Abstract #572)
Steven Webber, Linda Addonizio, Elizabeth Blume, Anne Dipchand, Robert Shaddy, Brian Feingold, Charles Canter, Daphne Hsu, William Mahle, Adriana Zeevi, Kristen Much, David Ikle, Helena Diop, Jonah Odim, MD, PhD, for CTOTC-04 Investigators. Nashville; NYC; Boston; Toronto, Canada; Philadelphia; Pittsburgh; St. Louis; Atlanta; Chapel Hill; Bethesda.

4:42 pm  Share35 Liver Allocation Is Associated with Increased Early Graft Failure Rate. (Abstract #573)
Tina W. Wong, Naoru Koizumi, Jorge Ortiz. Phoenix, AZ; Arlington, VA; Toledo, OH.

4:54 pm  Development and Validation of a Molecular Microscope Diagnostic System (MMDx) for Heart Transplant Biopsies. (Abstract #574)
Phil Halloran, Daniel Kim, Alex Loupy, Jean-Paul Duong Van-Huyen, Patrick Bruneval, Luciano Potena, Ornella Leone, Jeff Reeve. Edmonton, Canada; Paris, France; Bologna, Italy.
5:06 pm  Banked EBV-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma in Solid Organ Transplantation Recipients. (Abstract #575)
Susan Prockop, Ekatarina Doubrovina, Craig Sauter, Stephanie Suser, Richard O'Reilly. New York, NY.

5:18 pm  Early Proteomic Predictors of Late Chronic Kidney Disease in Liver Transplant Recipients. (Abstract #576)
Josh Levitsky, Sumeet Asrani, Lihui Zhao, Michael Abecassis, Linda Jennings, Goran Klintmalm. Chicago; Dallas.

**Poster Session C**
6:00 pm – 7:00 pm
Poster Viewing: 9:30 am – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm

*Halls C&D*

Poster Session C can be found on pages 154-177.

**AST Town Hall Meeting & Reception**
5:45 pm – 7:00 pm

*Republic Ballroom, Sheraton Boston Hotel*
7:00 am — 8:15 am  Sunrise Symposia

Page 73  Molecular Microscopic Approach to Chronic Allograft Injury
Room 302

Page 73  Fat and Inflammation Basic
Room 306

Page 73  Liver Retransplantation: Who and How
Ballroom A

Page 73  Imminent Death Donation
Room 310

Page 74  Ethical Dilemmas Related to the Internet and Transplant
Room 312

Page 74  Women in Transplant – Networking Breakfast
Room 304

Page 74  BK Virus and the Renal Allograft: A 360 Degree View
Ballroom B

Page 75  The Current Status Of The US Workforce Of Transplant Surgeons And New Paradigms In Transplant Training
Room 311

Page 75  Evaluation of the Medically Complex Living Kidney Donor
Ballroom C

8:30 am — 9:15 am  Plenary

Page 75  Joint Plenary Session III
Veterans Auditorium

9:15 am — 9:30 am  ASTS Awards

Page 75  Veterans Auditorium

9:30 am — 10:00 am  ASTS Presidential Address

Page 75  Veterans Auditorium

10:00 am — 10:30 am  Coffee Break

Halls C&D

10:30 am — 11:15 pm  Controversies in Transplantation

Page 76  Controversies - Reenacting the Civil War – Geographic Disparities in Transplantation
Veterans Auditorium

Page 76  Cellular Therapy Versus Enhancing Endogenous Immunoregulation - To Transfer or to Induce?
Ballroom B

11:15 am — 11:30 am  Break

11:30 am — 1:00 pm  Midday Symposia

Page 76  Autophagy and Immunity
Room 306

Page 76  Innate and Adaptive Immune Memory
Ballroom A

Page 77  Toward Adopting Molecular Diagnostics as Standard of Care in Transplantation
Ballroom C

Page 77  Deal Breakers in VCA -When to Say “Uncle”
Room 313

Page 77  Cross-Disciplinary Understanding of the Risk of Frailty in Transplantation
Room 310

Page 77  Liver Allocation
Room 312

Page 78  ESRD Attributable to Kidney Donation
Ballroom B
Increasing Deceased Donor Organs: Overcoming Barriers to Donor Intervention Research  
Room 302

Updates in Thoracic and Combined Thoracic/Abdominal Organ Allocation  
Room 309

Liver Disease in the Non-Liver Transplant Patient  
Room 311

Novel Solutions to Geographic Disparities in Kidney Transplantation  
Room 304

Subclinical TCMR and ABMR in Kidney Transplantation: Pathogenesis and Management  
Veterans Auditorium

1:00 pm — 2:15 pm Luncheon Workshops

Ticketed Events

2:00 pm — 2:15 pm Break

2:30 pm — 4:00 pm Concurrent Sessions

Concurrent Session: Allograft Tolerance 2: Animal Models  
Room 309

Concurrent Session: Clinical Vascularized Composite Allotransplantation  
Room 102

Concurrent Session: Disparities in Transplant Access and Outcomes  
Room 312

Concurrent Session: Ischemic Injury and Organ Preservation: Animal Models  
Room 313

Concurrent Session: It’s Just Not the Donor: Impact of Recipient Factors on Outcomes  
Ballroom A

Concurrent Session: Kidney AMR: Predicting the Patient at Risk  
Ballroom B

Concurrent Session: Kidney Immunosuppression: Novel Agents  
Veterans Auditorium

Concurrent Session: Kidney Paired Exchange: Outcomes and Issues  
Ballroom C

Concurrent Session: Kidney: Length of Stay/Readmission  
Room 302

Concurrent Session: Kidney: Polyomavirus  
Room 210

Concurrent Session: Liver: MELD, Allocation and Donor Issues (DCD/ECD) 1  
Room 304

Concurrent Session: Living Donation and Transplant: Operational and Economic Factors  
Room 311

Concurrent Session: PTLD and Malignancies  
Room 206

Concurrent Session: T Cell Biology and Alloimmunity: Animal Models  
Room 310

2:30 pm — 5:30 pm Allied Health Symposium

Transplant Pharmacy in the 21st Century: Strengthening an Identity through Optimal Practice  
Room 306

2:30 pm — 5:30 pm Pediatric Symposium

Antibodies: Good, Bad and Customized  
Room 308
Tuesday, June 14

4:00 pm — 4:30 pm  Coffee Break
Halls C&D

4:30 pm — 6:00 pm  Concurrent Sessions

Page 91  Concurrent Session: B cells and Antibody-Mediated Rejection: Animal Models
Room 309

Page 91  Concurrent Session: Bone Marrow Transplantation and Chimerism: Animal Models
Room 313

Page 91  Concurrent Session: Clinical Pancreas Transplantation 2
Room 210

Page 92  Concurrent Session: Diabetes and Obesity in Kidney Transplantation
Room 302

Page 93  Concurrent Session: Ischemia Reperfusion Injury: Clinical Innovation
Room 311

Page 93  Concurrent Session: Kidney Transplant Recipient: Long Term Outcomes Session 2
Ballroom A

Page 94  Concurrent Session: Kidney Waitlist Management and KAS Initial Results
Veterans Auditorium

Page 95  Concurrent Session: Kidney Induction Therapy 2
Room 312

Page 96  Concurrent Session: Liver: MELD, Allocation and Donor Issues (DCD/ECD) 2
Room 304

Page 96  Concurrent Session: Living Kidney Donor Evaluation
Ballroom B

Page 97  Concurrent Session: Novel Approaches and Potential Targets for Promoting Tolerance: Animal Models
Room 310

Page 97  Concurrent Session: Psychosocial and Treatment Adherence
Room 206

Page 98  Concurrent Session: Small Bowel Transplantation
Room 102

Page 98  Concurrent Session: The High KDPI Kidney: Outcomes and Optimal Utilization
Ballroom C

Page 98  Concurrent Session: Small Bowel Transplantation
Room 102

Page 98  Concurrent Session: The High KDPI Kidney: Outcomes and Optimal Utilization
Ballroom C

5:45 pm — 7:00 pm  ASTS Business Meeting

Page 100  Republic Ballroom, Sheraton Boston Hotel

6:00 pm — 7:00 pm  Poster Session D

Presenters in Attendance
Halls C&D

Page 178  Antibody Mediated Rejection: Session #2

Page 180  Chimerism/Stem Cells, Cellular/Islet Transplantation, Innate Immunity, Chronic Rejection

Page 185  Clinical Science: Tolerance: Clinical Studies

Page 185  Fungi, PJP, Mycobacteria, Infection Risk Factors, Vaccination and Donor Derived Infections

Page 187  Ischemia Reperfusion Injury: Clinical Update

Page 188  Kidney Immunosuppression: Novel Agents

Page 190  Kidney-Pediatrics

Page 191  Liver: Immunosuppression and Rejection

Page 192  Organizational and Operational Aspects of Transplantation

Page 193  Pediatric Liver Transplantation

Page 195  Polyomavirus

Page 196  Kidney Complications-Other II
Page 199  Psychosocial and Treatment Adherence

Page 200  Viral Hepatitis

Page 201  Late Breaking

7:30 pm — 11:00 pm  ATC Night Out featuring ATC's Got Talent!

Page 100  Whisky Saigon
### Sunrise Symposia
7:00 am — 8:15 am

#### Molecular Microscopic Approach to Chronic Allograft Injury

**Room 302**
Moderators: Roslyn Mannon, MD, University of Alabama at Birmingham, Birmingham, AL and Jeremy Chapman, MD, FRACP, Westmead Hospital, Westmead, Australia

- **7:00 am** Histopathological and Molecular Features of Chronic Antibody-Mediated Rejection  
  Banu Sis, MD  
  University of Alberta  
  Edmonton, Canada

- **7:25 am** Chronic T-Cell Mediated Rejection: Does it Exist and How to Diagnose by Molecular Microscope?  
  Enver Akalin, MD  
  Albert Einstein College of Medicine, Montefiore Medical Center  
  Bronx, NY, USA

- **7:50 am** Evaluation of Molecular Profiles in Calcineurin Inhibitor Toxicity after Kidney Transplant: Input to Chronic Allograft Dysfunction  
  Valeria Mas, PhD  
  University of Virginia Health System  
  Charlottesville, VA, USA

#### Liver Retransplantation: Who and How

**Ballroom A**
Moderators: Daniel Ganger, MD, Northwestern University, Chicago, IL, USA and Igal Kam, MD, University of Colorado, Aurora, CO, USA

- **7:00 am** Indications and Selection of the Optimal Candidate for Retransplantation  
  Kim Olthoff, MD  
  University of Pennsylvania  
  Philadelphia, PA, USA

- **7:25 am** Surgical Controversies and Obstacles in Liver Re-Transplantation  
  Michael Abecassis, MD, MBA  
  Northwestern University  
  Chicago, IL, USA

- **7:50 am** Making it Work the Second Time Around: Optimizing Outcomes  
  Helen Te, MD  
  University of Chicago  
  Chicago, IL, USA

#### Imminent Death Donation

**Room 310**
Moderators: David Mulligan, MD, Yale-New Haven Hospital, New Haven, CT, USA and Stuart Sweet, MD, PhD, Washington University, St. Louis, MO, USA

- **7:00 am** Imminent Death Donation: An Alternative to DCD  
  Paul Morrissey, MD  
  Rhode Island Hospital  
  Providence, RI, USA

- **7:25 am** Deceased Donor Rule - Is Death Really that Complicated?  
  Sam Shemie, MD  
  Montreal Children’s Hospital, McGill University Health Centre  
  Montreal, QC, Canada

- **7:50 am** Consent and Legal Aspects of Imminent Death Donation  
  Alexandra Glazier, JD  
  New England Organ Bank  
  Waltham, MA, USA
Ethical Dilemmas Related to the Internet and Transplant

Room 312
Moderators: Elmahdi Elkhammas, MD, MBBS, Ohio State University Wexner Medical Center and Elisa Gordon, PhD, MPH, Northwestern University Feinberg School of Medicine

7:00 am Googling your Patients: Helpful or a Headache?
Kristin Kuntz, PhD
Ohio State University Medical Center
Columbus, OH, USA

7:25 am Potential Pitfalls of Seeking Living Donors Online
James Rodrigue, PhD
Beth Israel Deaconess Medical Center
Boston, MA, USA

7:50 am The Effect of Social Media on Public Perception About Transplant
Jody Jones, PhD
University of Iowa Carver College of Medicine
Iowa City, IA, USA

Women in Transplant – Networking Breakfast

Room 304
Moderators: Elaine Reed, PhD, University of California Los Angeles, Los Angeles, CA, USA and Elmi Muller, University of Cape Town, Tyger Valley, Cape Town, South Africa

Co-sponsored by The Transplantation Society (TTS).

7:00 am Career Development Basics for a Successful Career in Transplantation
Nancy Ascher, MD, PhD
University of California San Francisco
San Francisco, CA, USA

7:25 am Negotiation Skills - What you Need to Say to Get What You Want
Lori West, MD, D.Phil.
University of Alberta
Edmonton, AB, Canada

Panel Discussion:

7:50 am Panel Discussion:
Anita Chong, MD, PhD
University of Chicago
Chicago, IL, USA

Rebecca Hays, MSW
University of Wisconsin Hospital
Madison, WI, USA

Michele Morris, MD, FACP
University of Miami
Miami Beach, FL, USA

Elaine Reed, PhD
University of California Los Angeles
Los Angeles, CA, USA

Anat Tambur, DMB, PhD
Northwestern University
Chicago, IL, USA

Adriana Zeevi, PhD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

BK Virus and the Renal Allograft: A 360 Degree View

Ballroom B
Moderators: David Wojciechowski, DO, MGH/ Harvard Medical School, Boston, MA, USA and Vikas Dharnidharka, MD, MPH, Washington University St. Louis, St. Louis, MO, USA

7:00 am Understanding BK Virus Associated Nephropathy from the Virus’s Viewpoint
Hans Hirsch, MD, MSc
University of Basel
Basel, Switzerland

7:25 am The Immune Response to BK Virus after Kidney Transplantation
Joanna Schaanman, MD, PhD
University of California Los Angeles
Los Angeles, CA, USA

7:50 am Pathophysiology of BK Virus Infection in the Kidney: Nephropathy, Rejection, and Malignancy
Cinthia Drachenberg, MD
University of Maryland
Baltimore, MD, USA
Joint Plenary Session III
8:30 am — 9:15 am

Veterans Auditorium

Chairs: Timothy Pruett, MD, University of Minnesota, Minneapolis, MN, USA and Peter Stock, MD, PhD, University of California - San Francisco, San Francisco, CA, USA

8:30 am Would Transplanting Kidneys Currently Being Discarded in the US Place Programs at Risk for Regulatory Review? (Abstract #367)
Jon Snyder, N. Salkowski, B. Thompson, A. Wey, A. Israni, B. Kasiske, S. Leppke. Minneapolis.

8:45 am A Single Histone/protein Acetyltransferase, Tip60, Is Absolutely Essential for Treg Survival and Function, and Its Inhibition Abrogates Induction of Treg-Dependent Allograft Tolerance. (Abstract #368)
Liqing Wang, Aaron Beeler, Satinder Dahiya, Rongxiang Han, Wayne W. Hancock. Philadelphia, PA; Boston, MA.

9:00 am Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant. (Abstract #369)

ASTS Awards
9:15 am — 9:30 am

Veterans Auditorium

ASTS Presidential Address
9:30 am — 10:00 am

Veterans Auditorium

Coffee Break in the Exhibit Hall
10:00 am — 10:30 am

Halls C&D
Controversies in Transplantation
10:30 am — 11:15 am

Controversies - Reenacting the Civil War – Geographic Disparities in Transplantation
Veterans Auditorium
Moderators: Stuart Sweet, MD, PhD, Washington University, St. Louis, MO, USA and Alexander Wiseman, MD, University of Colorado at Denver, Aurora, CO, USA

10:30 am The Argument in Favor of Redistricting and Potential Solutions/Models
Daniela Ladner, MD, MPH
Northwestern University
Chicago, IL, USA

10:40 am Keeping Organs Local Rewards OPO and Transplant Center Performance and is More Cost Effective
Stuart Knechtle, MD
Duke University Medical Center
Durham, NC, USA

10:50 am Should Organ Distribution Models Be Based on Measures Other Than the Transplant Waitlist
Robert Merion, MD
University of Michigan
Ann Arbor, MI, USA

11:00 am Panel Discussion with Audience Participation

Cellular Therapy Versus Enhancing Endogenous Immunoregulation - To Transfer or to Induce?
Ballroom B
Moderators: Anil Chandraker, MD, FRCP, Brigham & Womens Hospital, Boston, MA, USA and Joseph Leventhal, MD, PhD, Northwestern University, Chicago, IL, USA

10:30 am Cellular Therapy
Sandy Feng, MD, PhD
University of California San Francisco
San Francisco, CA, USA

10:40 am Enhance Endogenous Immunoregulation
Robert Fairchild, PhD
Cleveland Clinic Foundation
Cleveland, OH, USA

10:50 am Rebuttal
Sandy Feng, MD, PhD
University of California San Francisco
San Francisco, CA, USA

10:55 am Rebuttal
Robert Fairchild, PhD
Cleveland Clinic Foundation
Cleveland, OH, USA

11:00 am Discussion

Break
11:15 am — 11:30 am

Midday Symposia
11:30 am — 1:00 pm

Autophagy and Immunity
Room 306
Moderators: Bernd Schroppel, MD, University of Ulm, Ulm, Germany and Anthony Dorling, PhD, FRCP, Kings College, London, United Kingdom

11:30 am Autophagy in Immunity and Inflammation
Douglas Green, PhD
St. Jude Children's Research Hospital
Memphis, TN, USA

12:00 pm B Cell Autophagy
Jin Wang, PhD
Baylor College of Medicine
Houston, TX, USA

12:30 pm Autophagy and Bone Marrow Transplantation
Marcel Van den Brink, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Innate and Adaptive Immune Memory
Ballroom A
Moderators: Mandy Ford, PhD, Emory University, Atlanta, GA, USA and Anna Marie Waaga-Gasser, PhD, University of Wuerzburg, Wuerzburg, Germany

11:30 am Innate Memory
Fadi Lakkis, MD
University of Pittsburgh
Pittsburgh, PA, USA

12:00 pm NK Cell Memory
Dan Barouch, MD, PhD
Beth Israel Deaconess Medical Center
Boston, MA, USA

12:30 pm Evolving Status of Long Term T cell Memory to Pathogens
Dirk Homann, MD, MA
Mount Sinai Hospital
New York, NY, USA
Toward Adopting Molecular Diagnostics as Standard of Care in Transplantation

Ballroom C
Moderators: Sophie Brouard, PhD, DVM, University of Nantes, Nantes, France and Barbara Murphy, PhD, Mount Sinai Medical Center, New York, NY, USA
11:30 am From Discovery Science to Standard of Care – A Lesson from Breast Cancer
Philip Bernard, MD
University of Utah
Salt Lake City, UT, USA
12:00 pm Report on Consensus Conference for Transplant Molecular Diagnostics from the BANFF 2015 Meeting
Michael Mengel, MD
University of Alberta
Edmonton, AB, Canada
12:30 pm Adopting a Molecular Test for Transplant Care
Michael Abecassis, MD, MBA
University of California San Francisco
San Francisco, CA, USA

Deal Breakers in VCA -When to Say “Uncle”

Room 313
Moderators: Michael Marvin, MD, University of Louisville, Louisville, KY, USA and Darla Granger, MD, St. John’s Hospital and Medical Center, Detroit, MI, USA
11:30 am Rule-Outs During Evaluation for VCA
Charlotte Brown
University of Pittsburgh Medical Center
Pittsburgh, PA, USA
12:00 pm When to Excise a Vascularized Composite Allograft and Exit Strategies
Emmanuel Morelon, MD, PhD
University Claude Bernard
Lyon, France
12:30 pm Emerging Clinical Applications in VCA: Can We do Them? Vs. Should We do Them?
Arthur Caplan, PhD
NYU School of Medicine
New York, NY, USA

Cross-Disciplinary Understanding of the Risk of Frailty in Transplantation

Room 310
Moderators: Steven Gabardi, PharmD, Brigham and Women’s Hospital, Boston, MA, USA and Joanna Schenaenman, MD, PhD, University of California Los Angeles, Los Angeles, CA, USA
11:30 am Why Does Frailty Matter in Solid Organ Transplantation?
Cassie Kennedy, MD
Mayo Clinic
Rochester, MN, USA
12:00 pm Measures and Methods: How Does One Measure Frailty?
Jennifer Lai, MD, MBA
University of California San Francisco
San Francisco, CA, USA
12:30 pm Fixing Frailty – Is the Goal Feasible or Desirable in Solid Organ Transplantation?
Michael Englesbe, MD
University of Michigan
Ann Arbor, MI, USA

Liver Allocation

Room 312
Moderators: David Foley, MD, FACS, University of Wisconsin School of Medicine, Madison, WI, USA and Sanjay Mehrotra, MD, Northwestern University, Chicago, IL, USA
11:30 am What Have We Learned from Share 35?
Ryutaro Hirose, MD
University of California San Francisco
San Francisco, CA, USA
11:50 am Improving Allocation and Distribution by Defining the Best Metrics?
David Goldberg, MD, MSCE
University of Pennsylvania
Philadelphia, PA, USA
12:10 pm Financial and Logistical Considerations in Redistricting
Richard Gilroy, MD
University of Kansas Medical Center
Lawrence, KS, USA
12:30 pm Panel Discussion
**ESRD Attributable to Kidney Donation**

**Ballroom B**

Moderators: Robert Gaston, MD, University of Alabama, Birmingham, AL, USA and Dorry Segev, MD, PhD, Johns Hopkins University, Baltimore, MD, USA

11:30 am  ESRD in the General Population in Relatives with Those with ESRD
Alexander Wiseman, MD  
University of Colorado  
Aurora, CO, USA

12:00 pm  Known Etiology of ESRD in Kidney Donors
Arthur Matas, MD  
University of Minnesota  
Minneapolis, MN, USA

12:30 pm  Discussing ESRD Risks With Donor Candidates
Peter Reese, MD  
University of Pennsylvania  
Philadelphia, PA, USA

**Increasing Deceased Donor Organs: Overcoming Barriers to Donor Intervention Research**

**Room 302**

Moderators: James Rodrigue, PhD, Beth Israel Deaconess Medical Center, Boston, MA, USA and Sandy Feng, MD, PhD, University of California San Francisco, San Francisco, CA, USA

11:30 am  Deceased Donor Intervention Research: OPO Perspective
Alexandra Glazier, JD  
New England Organ Bank  
Waltham, MA, USA

12:00 pm  Deceased Donor Intervention Research: Researcher’s Perspective
Claus Niemann, MD  
University of California San Francisco  
San Francisco, CA, USA

12:30 pm  Deceased Donor Intervention Research: Where Do We Go From Here? Who Should be Consented: Donor Family, Organ Recipient or Both?
Peter Abt, MD  
Hospital of the University of Pennsylvania  
Philadelphia, PA, USA

**Updates in Thoracic and Combined Thoracic/Abdominal Organ Allocation**

**Room 309**

Moderators: A. Michael Borkon, MD, Mid-America Heart Institute, Kansas City, MO and Martin Zamora, MD, University of Colorado Health Sciences Center, Aurora, CO, USA

11:30 pm  Changes and Updates to the Lung Allocation and Heart/Lung Allocation
Maryam Valapour, MD, MPP  
Cleveland Clinic Foundation  
Cleveland, OH, USA

12:00 pm  Updates and Changes to Heart Allocation
Joseph Rogers, MD  
Duke University  
Durham, NC, USA

12:30 pm  Combined Thoracic and Abdominal Organ Allocation
Yo landa Becker, MD  
University of Chicago  
Chicago, IL, USA

**Liver Disease in the Non-Liver Transplant Patient**

**Room 311**

Moderators: Paul Martin, MD, University of Miami, Miami, FL, USA and Josh Levitsky, MD, MS, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

11:30 am  The Transplant Candidate with Abnormal LFTs?
K. Ram Bhamidimarri, MD, MPH  
University of Miami  
Miami, FL, USA

12:00 pm  The Transplant Recipient With Abnormal Liver Function Tests
Michael Charlton, MD  
Intermountain Medical Center  
Murray, UT, USA

12:30 pm  Treating Viral Hepatitis Pre- And Post-Transplant
Elizabeth Verna, MD, MS  
Columbia University  
New York, NY, USA
Novel Solutions to Geographic Disparities in Kidney Transplantation

Room 304
Moderators: Kenneth Andreoni, MD, University of Florida, Gainesville, FL, USA and John Friedewald, MD, Northwestern University, Chicago, IL, USA

11:30 am An Update on the OPTN Process to Improve Geographic Disparities in Allocation of Kidneys
Mark Aeder, MD
University Hospitals of Cleveland
Cleveland, OH, USA

12:00 pm Novel Methods to Address Geographic Disparity
Daniela Ladner, MD, MPH
Northwestern University
Chicago, IL, USA

12:30 pm Geographic Disparities Reflect Local Practice and Donation Patterns
Stephen Pastan, MD
Emory University
Atlanta, GA, USA

Subclinical TCMR and ABMR in Kidney Transplantation: Pathogenesis and Management

Veterans Auditorium
Moderators: Peter Nickerson, MD, University of Manitoba, Winnipeg, MB, Canada and Flavio Vincenti, MD, University of California San Francisco, San Francisco, CA, USA

11:30 am Subclinical TCMR And ABMR In The Unsensitized Patient: Risk Factors, Pathogenesis, Histological Phenotypes, Surveillance And Evolution
David Rush, MD
University of Manitoba
Winnipeg, MB, Canada

12:00 pm Subclinical TCMR And ABMR In The Sensitized Patient: Risk Factors, Pathogenesis, Histological Phenotypes, Surveillance And Evolution
Mark Stegall, MD
Mayo Clinic
Rochester, MN, USA

12:30 pm Clinical Management Of Sub-Clinical Rejection And Future Studies
Sundaram Hariharan, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

Luncheon Workshops - Ticketed Events
1:00 pm — 2:15 pm

6. Emerging Viruses – Responding to Outbreaks and Impact on Transplantation
Room 102
Moderators: Michael Ison, MD, MS, Northwestern University, Chicago, IL, USA and Michele Morris, MD, FACP, University of Miami, Miami Beach, FL, USA

7. Case-based Approaches to Optimizing Transitions of Care and Patient Education
Room 104
Moderators: Jeong Park, MS, PharmD, BCPS, University of Michigan, Ann Arbor, MI, USA and Rachel Annunziato, PhD, Fordham University, Bronx, NY, USA

8. Total Pancreatectomy and Islet Cell Auto Transplantation
Room 109
Moderators: Srinath Chinnakotla, MD, University of Minnesota, Minneapolis, MN, USA and Chirag Desai, Medstar Georgetown Transplant Institute

9. Strategies and Tactics for Growing a Transplant Program
Room 103
Moderators: Malay B. Shah, MD, FACS, University of Kentucky, Lexington, KY, USA and Rebecca Craft, MBA, MS, University of Kentucky, Lexington, KY, USA

10. Surgical Injuries During Organ Procurement and Putting it Back Together: Reconstruction Options after Injury
Room 108
Moderators: David Foley, MD, FACS, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA and Kelly Wright, Vanderbilt School of Medicine, Nashville, TN, USA

11. Achieving Autonomy
Room 105
Moderators: Vineeta Kumar, MD, University of Alabama at Birmingham, Birmingham, AL, USA and Jonathan Fryer, MD, Northwestern Medical Faculty Foundation, Chicago, IL, USA

12. Getting Your Research Published: A Workshop for New Authors
Room 101
Moderators: Allan D Kirk, MD, PhD; Duke University, Durham, NC, USA; Francisco M Marty, MD; Ron Shapiro, MD, Mount Sinai Hospital, New York, NY, USA; Steven A Webber, MBChB, MRCP, Vanderbilt University, Nashville, TN, USA
Break  
2:00 pm — 2:15 pm

Concurrent Oral Abstract Sessions  
2:30 pm — 4:00 pm

Allograft Tolerance 2: Animal Models  
Room 309  
Chairs: Idelberto Badell, MD, Emory Transplant Center, Atlanta, GA, United States and Ginny Bumgardner, MD PhD, Ohio State University, Columbus, OH, United States

2:30 pm Rapamycin Encapsulated Nanoparticles as Pre-Treatment in Lung Transplantation. (Abstract #370) Grace Bazzle, Suraj Dixit, Kunal Patel, Ann-Marie Broome, Satish Nadig, Carl Atkinson. Charleston, SC.


3:18 pm Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model. (Abstract #374) Cheng-Hung Lin, Madonna Rica Anggelia, Hui-Yun Cheng, Yen-Ling Wang, Wen-Yu Chuang, Chih-Hung Lin, Gerald Brandacher. Taoyuan, Taiwan; Baltimore, MD.


3:42 pm TGFβ in Regulatory B Cells-Dependent Tolerance. (Abstract #376) Hany Deirawan, Lisa Kojima, Laura Washburn, James Markmann, James Kim. Boston, MA.

Clinical Vascularized Composite Allotransplantation  
Room 102  
Chairs: Kadiyala Ravindra, Duke University, Durham, NC, United States and Rolf Barth, MD, University of Maryland School of Medicine, Baltimore, MD, United States


2:42 pm First Clinical Experience with Belatacept in 3 Hand Transplanted Patients. (Abstract #378) Johanna Grahammer, Bernhard Zelger, Bettina Zelger, Marijana Ninkovic, Annelies Muehlbacher, Dietmar Oefner-Velano, Stefan Schneeberger, Annemarie Weissenbacher. Innsbruck, Austria; Oxford, United Kingdom.

3:06 pm  Vascularized Composite Allograft Tolerance with Transient High-Dose Tacrolimus Across a Full MHC Mismatch in a Large Animal Model. (Abstract #380)

3:18 pm  Systematic Pathological Component Scores for Skin-Containing Vascularized Composite Allografts. (Abstract #381)
Ivy Rosales, Matthew DeFazio, Ruth Foreman, David Sachs, Curtis Cetrulo, David Leonard, Robert Colvin. Boston; Chester, United Kingdom.

3:30 pm  Latest VCA Statistics in the U.S. (Abstract #382)
Wida S. Cherikh, Harrison S. McGehee, Christopher Wholley, L. Scott Levin, Sue V. McDiamid. Richmond, VA; Philadelphia, PA; Los Angeles, CA.

3:42 pm  Ex Situ Perfusion of a Human Limb for 24 Hours. (Abstract #383)
Nicole L. Werner, Fares Alghanem, Stephanie L. Rakestraw, Bruce Nicely, Amy Olszewski, Steven M. Rudich, Alvaro Rojas-Pena, John Magee, Kagan Ozer. Ann Arbor, MI.

Disparities in Transplant Access and Outcomes

Room 312
Chairs: Keith Melancon, MD, George Washington University Transplant Institute, Washington, DC, United States and Rachel Patzer, PhD, MPH, Emory University School of Medicine, Atlanta, GA, United States

2:30 pm  Pregnancy Excludes Women from Successful Living Donor Transplantation. (Abstract #390)

2:42 pm  African-American Primary Renal Transplant Recipients Are at a Significantly Higher Risk to Develop De Novo DSA. (Abstract #385)
Matthew Everly, Lorita Rebellato, Carl Haisch, Kimberly Briley, Paul Bolin, Scott Kendrick, Claire Morgan, Angela Maldonado, Anh Nguyen, Paul Terasaki. Los Angeles; Greenville, NC.

2:54 pm  Racial Disparities in Perioperative Complications After Live Kidney Donation. (Abstract #386)
Krista L. Lentine, Ngan Lam, David Axelrod, Mark Schnitzler, Amit X. Garg, Jesse D. Schold, Daniel C. Brennan, Henry Randall, Dorry L. Segev. St. Louis; Edmonton, Canada; Hanover; London; ClevelandBaltimore.

3:06 pm  Investigating Geographic Variation in the Number of Deceased Donor Transplants Performed in the U.S. (Abstract #387)
Robert Carrico, Darren Stewart, Ryan Ehrensberger, Brian Shepard, David Klassen. Richmond, VA.

3:18 pm  Crisis on the Waiting List for Children Listed in Low Volume Solid Organ Transplant Centers. (Abstract #388)
Abbas Rana, Eileen Brewer, Wolfgang Winkelmayer, Christine O’mahony, John Goss. Houston, TX.

3:42 pm  Twenty Years of Evolving Trends in Racial Disparities for Adult Kidney Transplant Recipients. (Abstract #384)

3:30 pm  The Impact of Body Mass Index > 35 on Kidney Transplant Outcomes: A Systematic Review. (Abstract #389)
Debra A. Walczak, Enrico Benedetti. Chicago, IL.
Ischemic Injury and Organ Preservation: Animal Models

**Room 313**

*Chairs: Bernd Schroppel, MD, University of Ulm, Ulm, Germany and Steven Sacks, Guys Hospital, London, United Kingdom*

**2:30 pm** Ischemia Reperfusion Induced Murine Heart Transplant Rejection Is Complement Dependent. (Abstract #391)
N. Chun, M. Zhang, R. Fairchild, P. S. Heeger. NY, NY; Cleveland, OH.

**2:42 pm** HO-1/SIRT1/p53 Axis Regulates Macrophage Activation and Attenuates Liver Ischemia-Reperfusion Injury in Mice. (Abstract #392)
Kojiro Nakamura, Min Zhang, Bibo Ke, Shoichi Kageyama, Ronald W. Busuttil, Jesus A. Araujo, Jerzy W. Kupiec-Weglinski. Los Angeles, CA.

**2:54 pm** Subnormothermic Machine Perfusion (SNMP) Leads to Increased Bile Production and Secretion of Hydrophobic Bile Acids After Liver Transplantation When Compared to Cold Storage (CS). (Abstract #393)

**3:06 pm** Machine Perfusion (MP) at 21°C Simulates Hibernation Metabolic Pathways in a Non-Hibernator Mammal. (Abstract #394)

**3:18 pm** Cold Storage Stabilization of Gap Junctions Reduces Post-Transplant Ischemia Reperfusion Injury. (Abstract #395)

**3:30 pm** Early Alloantibody Responses Against Donor MHC Class I and Class II Molecules Are Differentially Affected by Prolonged Cold Ischemia Storage of Renal Allografts. (Abstract #396)
Victoria Gorbacheva, Ran Fan, William M. Baldwin, Anna Valujskikh. Cleveland, OH.

**3:42 pm** Serelaxin Decreases the Severity of Cold Ischemia-Reperfusion Injury After Liver Transplantation in Mice. (Abstract #397)

It's Just Not the Donor: Impact of Recipient Factors on Outcomes

**Ballroom A**

*Chairs: Scott Sanoff, MD MPH, Duke University, Durham, NC, United States and Richard Fatica, MD, Cleveland Clinic, Cleveland, OH, United States*

**2:30 pm** Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents. (Abstract #398)

**2:42 pm** Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation. (Abstract #399)

**2:54 pm** Insights into the Treatment of Post-Transplant Focal Glomerulosclerosis: Experience Gained from a Concise Diagnostic and Management Protocol. (Abstract #400)
Konstantinos Koutroutsos, Rawya Charif, Linda Moran, Jill Moss, Terence Cook, Candice Roufosse, David Taube, Marina Loucaidou. London, United Kingdom.

**3:06 pm** Recurrence of FSGS Post Kidney Transplantation: Salvage Therapy with ACTHAR® Gel. (Abstract #401)
Pradeep Vaitla, Dilini Daswatta, Antonio Guasch. Atlanta, GA.

**3:18 pm** Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients. (Abstract #402)
Christophe Legendre, Josep Campistol, Thorsten Feldkamp, Jimmy Wang, Giuseppe Remuzzi, Laurent Weckers, Neil Sheerin. Paris, France; Barcelona, Spain; Kiel, Germany; Cheshire, CT; Bergamo, Italy; Liège, Belgium/Newcastle upon Tyne, United Kingdom.
Early Post Renal Transplant aHUS in Patients with Heterozygous CFHR3-CFHR1 Deletion. (Abstract #403)
Salwa Rhazouani, Andrew Malone, Tarek Alhamad, Thin Thin Maw, Daniel Brennan, Rowena Delos Santos. Saint Louis, MO.

Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience. (Abstract #404)

Kidney AMR: Predicting the Patient at Risk

Ballroom B
Chairs: Jayme Locke, MD MPH FACS, University of Alabama at Birmingham, Birmingham, AL, United States and Babak Orandi, MD, PhD, MSc, Johns Hopkins University, Baltimore, MD, United States

Is C3d-fixing Donor Specific HLA Antibody Detection Really Necessary? (Abstract #405)

HLA Antibody in Transplant Recipients During Transition from Paediatrics. (Abstract #406)
Shilpa Kaki, Andrew Lunn, John Goodwin, Tim Key, William McKane. Sheffield, United Kingdom.

DSA After Transplant Increases Risk of Renal Allograft Failure Independent of Concurrent Biopsy Results: The DEKAF Study Data. (Abstract #407)
J. Michael Cecka, Joseph Grande, Fernando Cosio, Robert Leduc, The DeKA F Study Group. Los Angeles, CA; Rochester, MN; Minneapolis, MN.

Immunogenic HLA-DR Eplet Mismatches as Predictors of Transplant Glomerulopathy. (Abstract #408)
Daniel Blum, Kathryn Tinckam, Marilyn Marrari, Joseph Kim, Ruth Sapir-Pichhadze. Montreal, Canada; Toronto, Canada; Pittsburgh.

Association of Ultrastructural Changes in Renal Allograft Biopsies with Antibody-Mediated Rejection (AMR) and Graft Outcomes. (Abstract #409)

Antibody Mediated Rejection and Mixed Acute Rejection: Long Term Results and Predictive Factors for Graft Loss Following Proteasome Inhibitor Therapy. (Abstract #410)

Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection. (Abstract #411)

Polyclonal Treg Adoptive Therapy for Control of Subclinical Kidney Transplant Inflammation (TASK Pilot Trial). (Abstract #412)

A Molecular Biopsy Test for Probability of Non-Adherence. (Abstract #413)
Philip F. Halloran, G. Einecke, J. Reeve. Edmonton, AB, Canada; Hannover, Germany.
2:54 pm  Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial. (Abstract #414)
Jakob Mühbacher, Bernd Jilma, Markus Wahrmann, Lena Marinova, Farsad Eskandary, James C. Gilbert, Sandip Panicker, Georg A. Böhmig. Vienna, Austria; South San Francisco, CA.

3:06 pm  Investigating Posttransplant Allo-Donor Specific CD57+ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen. (Abstract #415)
He Xu, FeiFei Feng, Allan D. Kirk. Durham, NC.

3:18 pm  Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy. (Abstract #416)

3:30 pm  Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation. (Abstract #417)
Pascal Espie, Jacinda Munz, Thierry Flandre, Boerje Haraldsson, Peter Ulrich, James Rush. Basel, Switzerland.

3:42 pm  C1-Inhibitor in Acute Antibody-Mediated Rejection Non-Responsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. (Abstract #418)

Kidney Paired Exchange: Outcomes and Issues

Ballroom C

2:30 pm  A Kidney Paired Donation Standard Acquisition Charge Pilot Program. (Abstract #419)
M. A. Rees, L. J. Reece, S. E. Rees, B. Crandall, A. B. Leichtman. Toledo; Perrysburg; Ann Arbor.

2:42 pm  Removing Geographic and Financial Barriers for Directed Living Kidney Donations: Lessons from Kidney Paired Donation. (Abstract #420)
Mark Aeder, Ruthanne Leishman, Darren Stewart. Cleveland, OH; Richmond, VA.

2:54 pm  Analysis of Broken Chains in Kidney Paired Donation During an 8 Year Period within the National Kidney Registry. (Abstract #421)
Nick G. Cowan, Joe Sinacore, H. Albin Gritsch, Jeffrey L. Veale. Los Angeles, CA; Babylon, NY.

3:06 pm  Characteristics of Compatible Pair Participants in Living Donor Kidney Transplant Exchanges. (Abstract #422)
Francis L. Weng, Tracy Grogan, Anup M. Patel, Shamkant Mulgaonkar, Marie Morgievich. Livingston, NJ.

3:18 pm  Reciprocity for Compatible Pair Participation in Kidney Paired Donation. (Abstract #423)
John Gill, Marie-Chantal Fortin, Caren Rose, Edward Cole, Kathryn Tinckam, Jagbir Gill. Vancouver, BC, Canada; Montreal, QC, Canada; Toronto, ON, Canada.

3:30 pm  Global Kidney Exchange. (Abstract #424)
Tuesday, June 14

3:42 pm Accumulation of Highly Sensitized Patients in a KPD Registry. (Abstract #425) Stanislaw Stepkowski, Beata Mierzejewska, Dulat Bekbolsynow, Michael Rees. Toledo, OH.

Kidney: Length of Stay/Readmission
Room 302
Chairs: G V Ramesh Prasad, MBBS, MSc, MA, St Michael's Hospital, University of Toronto, Toronto, ON, Canada and Heidi Schaefer, MD, Vanderbilt University, Nashville, TN, United States

2:30 pm Early Hospital Readmission Following Kidney Re-Transplantation. (Abstract #430) Elizabeth King, Babak Orandi, Sunjae Bae, Xun Luo, Dorry Segev. Baltimore, MD.


2:54 pm Center-Level Variation in Association Between Early Hospital Readmission and Survival Following Kidney Transplantation. (Abstract #428) Shannon Cramm, Elizabeth King, Dorry Segev. Baltimore.

3:06 pm A Retrospective Study of Simultaneous Bilateral Nephrectomies and Renal Transplantation in Recipients with Polycystic Kidney Disease. (Abstract #432) Elliot I. Grodstein, Dixon B. Kaufman. Madison, WI.


3:30 pm A Nationwide Analysis of Reoperation After kidney Transplant. (Abstract #431) Zhobin Moghadamyeghaneh, Mahmoud Alameddine, George Burke, Gaetano Ciancio, Linda J. Chen. Miami, FL.


Kidney: Polyomavirus
Room 210
Chairs: Daniel Brennan, MD, FACP, Direcotr of Transplant Nephrology, Saint Louis, MO, United States and Parmjeet Randhawa, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States


3:06 pm  Influence of the Tacrolimus Metabolism Rate on BKV Infection After Kidney Transplantation. (Abstract #436)

3:18 pm  BK Nephropathy, but Not Isolated BK Viremia Associated with De Novo DSA Despite Similar Immunosuppression Reduction. (Abstract #437)
Wisit Cheungpasitporn, Donald G. Mitema, Hatem Amer, Fernando G. Cosio, Mark D. Stegall, Carrie A. Schinstock. Rochester, MN.

3:30 pm  Potential Applications of Viral miRNA Assays in the Management of Transplant Patients with Polyomavirus BK Infection. (Abstract #438)
Parmjeet Randhawa, Gang Zeng, Yuchen Huang. Pittsburgh, PA.

3:42 pm  HLA Class II and BK Virus Reactivation in Renal Transplant Recipients. (Abstract #439)
Pratik Shah, Kirsten Anderson, Michael Aubrey, Christina Roark, Brian Freed, Alexander Wiseman. Aurora, CO.

Liver: MELD, Allocation and Donor Issues (DCD/ ECD) 1

2:30 pm  Survival Benefit of DCD Livers. (Abstract #440)
Xun Luo, Allan Massie, Dorry Segev. Baltimore.

2:42 pm  Impact of Proximity MELD/PELD Points on Liver Redistricting Scenarios. (Abstract #441)

2:54 pm  Skipping Comparable Local Waitlist Candidates Under Share 35. (Abstract #442)
Eric K. H. Chow, Allan B. Massie, Xun Luo, Corey E. Wickliffe, Sommer E. Gentry, Andrew M. Cameron, Dorry L. Segev. Baltimore, MD; Annapolis, MD.

3:06 pm  What Are the Charges and Costs of Transplanting High MELD Patients? (Abstract #443)
Kerem Bortecen, Bruce Gelb, Aaron Winnick, Glyn Morgan, Lewis Teperman. New York, NY.

3:18 pm  Impact of Early Allograft Dysfunction (EAD) and Its Components on Patient Survival Following Liver Transplantation (LT): Long-Term Outcomes Up to 10 Years. (Abstract #444)

3:30 pm  Factors Associated with Mortality Among a Large Population of Patients with Cirrhosis and a Low MELD (<15). (Abstract #445)

3:42 pm  The Impact of CMS Policy on Delisting of “Too Sick” Liver Transplant Candidates. (Abstract #446)

Living Donation and Transplant: Operational and Economic Factors

2:30 pm  Financial Burdens and Coping Mechanisms of Living Kidney Donors. (Abstract #447)
2:42 pm Return on Investment for Financial Assistance for Living Kidney Donors in the United States. (Abstract #448)
Amit Mathur, Jiawei Xing, David Dickinson, Patricia Warren, Kimberly Gifford, Barry Hong, Akinololu Ojo, Robert Merion. Phoenix; Ann Arbor; Arlington; St. Louis.


3:06 pm Offering HCV-Positive Kidneys to HCV-Negative Patients on the Kidney Transplant Waitlist is Lifesaving: Results of a Markov Model. (Abstract #450)

3:18 pm The Impact of Readmission following Kidney Transplantation: Is Readmission Becoming More Risky? (Abstract #451)
Elizabeth King, Lauren Kucirka, Mara McAdams-DeMarco, Allan Massie, Dorry Segev. Baltimore, MD.

3:30 pm Functional Status and Comorbidity Are Associated with High Costs After Liver Transplantation. (Abstract #452)
Marina Serper, Michael Rossi, Therese Bitterman, Abraham Shaked, Kim Olthoff. Philadelphia.

3:42 pm Have We Gone Too Far Defining Performance Outliers? One-Third of Kidney Transplant Programs Now Identified for Low Performance within Three Years. (Abstract #453)
Jesse D. Schold, Charles Miller, Mitch Henry, Laura D. Bucchini, Stuart M. Flechner, David A. Goldfarb, Emilio D. Poggio, Ken Andreoni. Cleveland, OH; Columbus, OH; Gainesville, FL.

2:30 pm Identification of MicroRNAs in EBV+ B Cell Lymphomas and Secreted Exosomes. (Abstract #454)

2:42 pm Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig). (Abstract #455)
Bongha Shin, Jua Choi, Joseph Kahwaji, Shili Ge, David Thomas, Ashley Vo, Odette Galera, Rafael Villicana, Alice Peng, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

3:06 pm Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas. (Abstract #457)

3:18 pm Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients. (Abstract #458)
Michael Burke, Lauren Nahum, Nicole Isbel, Robert Carroll, H. Peter Soyer, Ross Francis, Jennifer Bridge, Christine Staatz, James Wells. Brisbane, Australia; Adelaide, Australia; Beersheba, Israel.
3:30 pm Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies. (Abstract #459)
Sergio A. Acuna, Rinku Sutradhar, Joseph Kim, Nancy N. Baxter. Toronto, ON, Canada.


T Cell Biology and Alloimmunity: Animal Models
Room 310
Chairs: Melissa Yeung, Brigham & Women's Hospital, Boston, MA, United States and Mandy Ford, Ph.D., Emory University, Atlanta, GA, United States

2:30 pm Microfluidics to Characterize Leukocyte Trafficking into Allografts and the Resolution of Inflammation. (Abstract #461)
Leo Boneschansker, Daniel Irimia, David Briscoe. Boston.

2:42 pm mTORC2 Negatively Regulates Dendritic Cell (DC) Metabolism and the Allostimulatory Function of Donor DCs in Organ Transplantation. (Abstract #462)

2:54 pm Lymph Node Stromal Laminins Differentially Regulate T Cell Immunity and Tolerance. (Abstract #463)

3:06 pm Sphingosine 1-Phosphate (S1P) Receptors Differentially Regulate Murine and Human CD4 T Cell Migration Across Lymphatic Endothelium. (Abstract #464)

3:18 pm Thymus Is Required for T Cells Reconstitution Following Antibody-Mediated Lymphoablation. (Abstract #465)
Katayoun Ayasoufi, Ran Fan, Anna Valujskikh. Cleveland.

3:30 pm Role of NRP1 in CD4+ T Cell Allo-Activation. (Abstract #466)
Eliza J. Lee, Heung Bae Kim, Gulcin Demirci. Boston, MA.

3:42 pm Profiling Metabolic Differences Between Graft- vs. Pathogen-Elicited CD8+ T Cell Responses. (Abstract #467)
Alana Karp, Maylene Wagener, Jennifer Robertson, Mandy Ford. Atlanta.

Allied Health Symposium 2
2:30 pm — 5:30 pm

Transplant Pharmacy in the 21st Century: Strengthening an Identity through Optimal Practice
Room 306

Fulfilling Responsibilities to the Pharmacy Department
Moderators: Christin Rogers, PharmD, Beth Israel Deaconess Medical Center, Boston, MA, USA and David Taber, PharmD, Medical University of South Carolina, Charleston, SC, USA

2:30 pm Impact of the Transplant Pharmacist on Formulary Management: An administrative and Clinical Perspective
Administrative
James Thielke, PharmD
University of Illinois at Chicago
Chicago, IL, USA

Day to Day
Sabrina Lee, PharmD
Keck Medical Center of USC
Temple City, CA, USA

2:45 pm Balancing Clinical and Operational Responsibilities: Establishing a Role at a New Transplant Program and a Large Established Center
Administrative Perspective/Large Institution
Eric Tichy, PharmD
Yale-New Haven Hospital
New Haven, CT, USA

New Program Perspective
Spencer Martin, PharmD
Hartford Hospital
Hartford, CT, USA
3:00 pm  Optimizing Information Technology in Daily Activities: An Inpatient and Outpatient Perspective

Inpatient Perspective
Demetra Tsapepas, PharmD
Hackensack University Medical Center
Hackensack, NJ, USA

Outpatient Perspective
Jaclyn McKeen, PharmD
New York Presbyterian Hospital
New York, NY, USA

The Pharmacists Role in Individualizing Patient Care
Moderators: Reed Hall, PharmD, University Hospital, San Antonio, TX, USA and Lindsey Pote, PharmD, Johns Hopkins, Baltimore, MD, USA

3:30 pm  Optimizing Medication Therapy Management in the Hospital Setting: Providing Effective Patient Care in Traditional and Nontraditional Roles

Traditional
Timothy Horwedel, PharmD
Barnes-Jewish Hospital
St. Louis, MO, USA

Non-Traditional
Charity Thompson, PharmD, BCPS
The University of Kansas Hospital
Kansas City, KS, USA

3:45 pm  Education Techniques in Patients with Learning Challenges: A Focus on Methods for Those with Poor Health Literacy and Sensory Impairment

Sensory Impaired
Chelsea Sammons, PharmD
New York-Presbyterian Hospital
New York, NY, USA

Poor Health Literacy
Mary Moss, PharmD
University of Maryland Medical Center
Baltimore, MD, USA

4:00 pm  Overcoming Financial Hurdles in the Post-transplant Setting: Optimizing Insurance Coverage and use of Alternative Methods

Optimizing Insurance
Lisa Potter, PharmD
University of Chicago Medical Center
Chicago, IL, USA

Other Mechanisms
Bharath Ravichandran, PharmD
University of Maryland Medical Center
Baltimore, MD, USA

Responsibilities Of The Transplant Pharmacist To The Transplant Center
Moderators: Glenn Pearson, Mazankowski Alberta Heart Institute University of Alberta, Edmonton, AB, Canada and Carl Haisch, MD, East Carolina University School of Medicine, Greenville, NC, USA

4:30 pm  Pharmacist Involvement In QAPI Programming: Providing Oversight And Leadership In QAPI Projects

Pharmacist Led Quality Program
Tiffany Kaiser, PharmD
University of Cincinnati
Cincinnati, OH, USA

Pharmacist Led Quality Projects
Jen Iuppa, PharmD
University of Rochester
Rochester, NY, USA

4:45 pm  Optimizing The Role Of The Pharmacist In The Ambulatory Clinic: Impact On Pre And Post-Transplant Care

Pre-transplant
Steven Gabardi, PharmD
Brigham & Women’s Hospital
Boston, MA, USA

Post-transplant
James Fleming, PharmD
Medical University of South Carolina
Charleston, SC, USA
5:00 pm Successfully Billing For Pharmacist Services In The Ambulatory Setting: Effective Strategies For A Hospital Based And Private Practice Setting
Hospital Based Clinic
Maya Campara, PharmD
University of Illinois at Chicago
Chicago, IL, USA

Private Practice Clinic
Angela Maldonado, PharmD
Vidant Medical Center – Transplant Services
Greenville, NC, USA

Pediatric Symposium 2
2:30 pm — 5:30 pm

Antibodies: Good, Bad and Customized
Room 208

Antibody Mediated Graft Injury in Pediatric Organ Transplantation
Moderators: Robert Venick, MD, Mattel Children’s Hospital at UCLA, Los Angeles, CA, USA and Sharon Bartosh, University of Wisconsin, Madison, WI, USA

2:30 pm Basics of Antibody Mediated Graft Injury
Eileen Tsai Chambers, MD
University of California Los Angeles
Los Angeles, CA, USA

2:50 pm Evolving Role of Antibody Mediated Rejection in Pediatric Liver Transplantation
Laura Wozniak, MD, MS
UCLA Mattel Children’s Hospital
Los Angeles, CA, USA

3:10 pm Prevention and Treatment Strategies for Antibody Mediated Rejection
Jens Goebel, MD
Cincinnati Children’s Hospital
Cincinnati, OH, USA

Coffee Break

Consensus And Controversies In Vaccination In Pediatric SOT - Debate
Moderators: Christian Benden, University Hospital Zurich, Zurich, Switzerland and Lara Danziger-Isakov, MD, MPH, Cincinnati Children’s Hospital, Cincinnati, OH, USA

4:00 pm Vaccinating Our Candidates And Recipients: The Whys And Hows
Tanvi Sharma, MD
Boston Children’s Hospital
Boston, MA, USA

4:10 pm Should Willingness To Vaccinate Be A Precondition For Pediatric SOT? – PRO
Upton Allen, MBBS, MSc
University of Toronto/Hospital for Sick Children
Toronto, ON, Canada

4:20 pm Rebuttal and Discussion

One Size Fits Some - Customization in Pediatric Renal Transplantation
Moderators: William Harmon, MD, Harvard Medical School, Boston, MA, USA and Priya Verghese, MD, MPH, University of Minnesota, Minneapolis, MN, USA

4:30 pm Immunosuppression Tailoring - Costs and Benefits of Individualized Medicine
Paul Grimm, MD
Stanford University Medical Center
Stanford, CA, USA

4:50 pm The Right Donor for the Right Patient: Advising Pediatric Patients in a New Era of Deceased Donor Allocation and Live Donor Risk Tolerance
Sandra Amaral, MD, MHS
Children’s Hospital of Philadelphia
Philadelphia, PA, USA

5:10 pm Recurrent Diseases and Pediatric Kidney Transplantation - Using Limited Data to Devise Rational Treatment Strategies
Robert Ettenger, MD
UCLA Center for Health Science
Los Angeles, CA, USA

Coffee Break in the Exhibit Hall
4:00 pm — 4:30 pm

Halls C&D
Concurrent Oral Abstract Sessions
4:30 pm — 6:00 pm
B cells and Antibody-Mediated Rejection: Animal Models

Room 309
Chairs: Anita Chong, PhD, University of Chicago, Chicago, IL, United States and Emmanuel Zorn, Columbia University Medical Center, New York, NY, United States

4:30 pm Allo-Specific Memory B Cell Recall Responses Are Dependent on B Cell Autophagy. (Abstract #468)
Jeremy S. Leventhal, Miguel Fribourg, Jie Ni, Peter Heeger. NY, NY.

4:42 pm Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies. (Abstract #469)

4:54 pm Selective Deletion of Notch2 on B Cells Abrogates Alloantibody Production in Fully MHC-Mismatched Cardiac and Skin Transplant Models. (Abstract #470)
Naoka Murakami, Ciara Magee, Thiago Borges, Jamil Azzi, Leonardo Riella. Boston, MA.

5:06 pm CTLA4 Negatively Regulates Donor-Reactive CXCR5+PD1+ T Follicular Helper Cell Responses Following Transplantation. (Abstract #471)

5:18 pm Differential Regulation of the Microvascular Endothelial Cell Mediated Allogeneic CD4+ T Cell Response by Anti-HLA-DR and -DQ Alloantibodies in an Inflammatory Context. (Abstract #472)
Nuala Mooney, Amy R. Cross, Julien Lion, Alain Haziot, Denis Glotz. Paris, France.

5:30 pm NK Cells Play a Critical Role in Mediating Inflammation and Graft Failure During Antibody-Mediated Rejection of Kidney Allografts. (Abstract #473)
Toshiaki Tanaka, Naoki Kohei, Nina Dvorina, Anna Valujskikh, William M. Baldwin 3rd, Robert L. Fairchild. Cleveland, OH; Sapporo, Japan.

5:42 pm Metallothionein Accelerates Anti-MHC Induced Small Airway Obliteration and Fibrosis by Negatively Regulating IL-10 and Regulatory Cells. (Abstract #474)
D. Nayak, F. Zhou, N. Benshoff, Thalachallour Mohanakumar. St. Louis, MO; Phoenix, AZ.

Bone Marrow Transplantation and Chimerism: Animal Models

Room 313
Chairs: Alessandro Alessandrini, Massachusetts General Hospital, Boston, MA, United States and Angus Thomson, PhD DSc, University of Pittsburgh, Pittsburgh, PA, United States

4:30 pm Combination of Veto Cell Transfer and inKT Cell Therapy Establishes Complete Hematopoietic Chimerism in Non-Myeloablative BMT Recipients. (Abstract #475)
Rumi Ishii, Toshihito Hirai, Yasuyuki Ishii, Kazunari Tanabe. Tokyo, Japan; Yokohama, Japan.

4:42 pm Post Transplantation High-Dose Cyclophosphamide Treatment Promotes Immune Tolerance After Skin, Solid Organ, and Vascularized Composite Allotransplantation. (Abstract #476)
Georg J. Furtmüller, Byoungchol Oh, Madeline L. Fryer, Paul J. Akre, Sudipto Ganguly, Jeffrey Dodd-o, Damon S. Cooney, Giorgio Raimondi, W. P. Andrew Lee, Leo Luznik, Gerald Brandacher. Baltimore, MD; Boston, MA.

4:54 pm Tolerogenic Interactions Between Host CD8+Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning. (Abstract #477)
David Hongo Apum, Xiangyue Zhang, Edgar Engleman, Samuel Strober. Stanford, CA.
5:06 pm  Delayed Induction of Mixed Chimerism Permits Kidney-Induced Cardiac Allograft Tolerance to be Applied to Recipients of Cadaveric Organs. (Abstract #478)

5:18 pm  Blockade of the ASC Coreceptor Enhances Hematopoietic Stem Cell Engraftment. (Abstract #479)
Reza Elahimehr, Sashi Kasimsetti, Alana Shigeoka, Dianne McKay. San Diego.

5:30 pm  Administration of IL-33 Before Allogeneic Stem Cell Transplantation Expands Recipient Treg That Prevent Graft- vs. Host Disease. (Abstract #480)

5:42 pm  Effect of Adipose Tissue-Derived Mesenchymal Stem Cells in a Rat Model of Chronic Renal Allograft Rejection. (Abstract #481)
Rafael Pepineli, Filipe M. O. Silva, Priscila Q. Gouveia, Giselle L. Tavora, Samirah A. Gomes, Irene L. Noronha. Sao Paulo, Brazil.

Clinical Pancreas Transplantation 2
Room 210
Chairs: Yolanda Becker, MD, University of Chicago, Chicago, IL, United States and Peter Abrams, MD, MedStar Georgetown Transplant Institute, Washington, DC, United States

4:30 pm  Potent Induction Therapy Improves Graft Outcome in Younger Pancreas Transplant Recipients (<30 Years of Age). (Abstract #482)
Angelika C. Gruessner, Vaughn Whittaker, Sriram Narsipur, Vikram Aggarwal, Charlene Hubbel, Rainer Grussner. Syracuse, NY.

4:42 pm  The Impact of One Year Individual or Dual Organ Rejection in Simultaneous Pancreas-Kidney Transplant on Kidney Graft Survival – A UNOS Registry Analysis 2000-2013. (Abstract #483)
Irfan Moinuddin, Tim Taber, Muhammad Yaqub, Oluwafisayo Adebiyi, Muhammad Mujtaba, Jeanne Chen, Michelle Goble, Dennis Mishler, Jonathan Fridell, Asif Sharfuddin. Indianapolis.

4:54 pm  Impact of Early Acute Rejection (AR) on Pancreas Transplant (PT) Outcomes. (Abstract #484)
Varvara Kirchner, Ty Dunn, Aleksandra Kukla, Raja Kandaswamy, Erik Finger. Minneapolis.

5:06 pm  Antibody-Mediated Rejection in Pancreas Transplantation. (Abstract #485)
Oscar K. Serrano, David Vock, Erik B. Finger, Raja Kandaswamy, David E. R. Sutherland, Ty B. Dunn. Minneapolis, MN.

5:18 pm  Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease. (Abstract #486)
Asif Sharfuddin, Jeanne Chen, Muhammad Yaqub, Tim Taber, John Powelson, Dennis Mishler, Michelle Goble, Jonathan Fridell, Oluwafisayo Adebiiy, Muhammad Mujtaba. Indianapolis.

5:30 pm  Incidence and Indications for Pancreatectomy After Late Pancreas Allograft Failure. (Abstract #487)
Sandesh Parajuli, Arjang Djamali, Brad C. Astor, Hans Sollinger, Dixon Kaufman, Robert Redfield, Jon Odorico, Didier Mandelbrot. Madison, WI.

5:42 pm  Pancreas After Islet Transplantation – A Successful Treatment Option After a Failed Islet Transplant. (Abstract #488)
Diabetes and Obesity in Kidney Transplantation

Room 302
Chairs: Antonio di Carlo, MD, Temple University Hospital, Philadelphia, PA, United States and Jayme Locke, MD MPH FACS, University of Alabama at Birmingham, Birmingham, AL, United States

4:30 pm Outcomes of Pediatric en Bloc Kidney (PeB) Grafts After Loss of a Single Kidney. (Abstract #489)
Chandrasekar Santhanakrishnan, Richard Perez, John McVicar, Junichiro Sageshima, Christoph Troppmannn. Sacramento, CA.

4:42 pm Evolution of Body Composition and Associations to Glucose Metabolism During the First Year After Kidney Transplantation. (Abstract #490)

4:54 pm Surgical Site Infection Does Not Fully Explain the Impact of Obesity on Post-Transplant Outcomes. (Abstract #491)
Sunjae Bae, Lauren Kucirka, Allan Massie, Dorry Segev. Baltimore, MD.

5:06 pm Morbid Obesity and Functional Status as Predictors of Surgical Complication After Renal Transplantation. (Abstract #492)

5:18 pm Impact of Morbid Obesity on Breakthrough CMV Infection in Kidney Transplant Recipients. (Abstract #493)

5:30 pm Outcomes Following Inguinal Hernia Repair in Kidney Transplant Recipients. (Abstract #494)
Sandra DiBrito, Israel Olorundare, Claudia Landazabal, Dorry Segev, Nabil Dagher. Baltimore.

5:42 pm Early Post-Transplant Patient, Graft Survival and Rejection Rates Under KAS. (Abstract #495)

Ischemia Reperfusion Injury: Clinical Innovation

Room 311
Chairs: Kenneth Chavin, MD, PhD, Medical University of South Carolina, Charleston, SC, United States and Derek DuBay, MD, University of Alabama at Birmingham, Birmingham, AL, United States

4:30 pm Controlled Oxygenated Rewarming and Subnormothermic Machine Perfusion of Steatotic Livers: First Clinical Results. (Abstract #496)
Dieter P. Hoyer, Anja Gallinat, Juergen Treckmann, Tamás Benköe, Sandra Swoboda, Ursula Rauen, Andreas Paul, Thomas Minor. Essen, Germany.

4:42 pm Hypothermic Machine Perfusion Is Also Beneficial for Deceased Donor Kidneys When Cold Ischemic Time Is Short and a Short Cold Ischemic Time Is Also Beneficial When Kidneys Are Machine Perfused. (Abstract #497)

4:54 pm SLPI in the Perfusion Liquid: A Predictor Marker of Short and Long Term Clinical Outcomes. (Abstract #498)
Ana C. Dotta, Fiorella Caro, Karina Peña Ponce, Nella Ambrosi, Juan F. Salaberry, Xavier García, Elena B. Minué, Luis R. León, Francisco Sánchez, Fernanda Togniolo, Claudio Incardona, Eduardo Chuluyan, Domingo Casadei. Caba, Argentina.

5:06 pm Defective Post-Reperfusion Metabolic Recovery Directly Associates with Incident Delayed Graft Function. (Abstract #499)
Leonie Wijermars, Alexander Schaapherder, Jan Lindeman. Leiden, Netherlands.
5:18 pm  Glycine Is Graft Protective and Improves Kidney Function After Liver Transplantation: Data from HEGPOL-Trial. (Abstract #500)
Arash Nickkholgh, Peter Schemmer, Georgios Polychronidis, Steffen P. Luntz, Ertan Mayatepek, Markus W. Büchler, Ernst Klar. Heidelberg, BW, Germany; Düsseldorf, RP, Germany; Rostock, Germany.

5:30 pm  Matrix Metalloproteinase-9 in Human Orthotopic Liver Transplant Biopsies. (Abstract #501)

5:42 pm  DNA Methylation Patterns and Association with Graft Injury Severity Post Liver Transplantation. (Abstract #502)
Ricardo Gehrau, Sai Vineela Bontha, Valeria Mas, Daniel Maluf. Charlottesville.

4:54 pm  IgG Dilutions, Subclasses, C1q, and IgM: Determining Relevant Testing for De Novo DSA and Outcome Prediction. (Abstract #505)
Matthew Everly, Lorita Rebellato, Carl Haisch, Kimberly Briley, Paul Bolin, Scott Kendrick, Claire Morgan, Angela Maldonado, Anh Nguyen, Paul Terasaki. Los Angeles; Greenville, NC.

5:06 pm  Impact of Delayed Graft Function Varies by Demographic and Clinical Characteristics in Deceased Donor Kidney Transplantation. (Abstract #506)

5:18 pm  Lower Renal Graft Function and Accelerated Fibrosis in HIV-Infected Transplant Recipients with Previous HIVAN Compared to Non HIVAN HIV-Positive Transplant Recipients. (Abstract #507)

5:30 pm  Dynamics of Delayed Graft Function-Associated Risk in Deceased Donor Kidney Transplantation. (Abstract #508)

5:42 pm  Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation. (Abstract #509)
Angela Liu, Nagaraju Sarabu, Augustine Joshua. Cleveland, OH.
Kidney Waitlist Management and KAS Initial Results

Veterans Auditorium
Chairs: Brigitte Sullivan, MBA, New York University, New York, NY, United States and Edward Zavala, MBA, Vanderbilt University Medical Center, Nashville, TN, United States

4:30 pm 99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect. (Abstract #515)
Anna Kucheryavaya, Mark Aeder, Nicole Turgeon, David Klassen, Darren Stewart. Richmond, VA; Cleveland, OH; Atlanta, GA.

4:42 pm Significant Increase in Wait List Removals for Candidates Considered Too Sick from the US Kidney Transplant Waiting List. (Abstract #511)
Emilio D. Poggio, Laura D. Buccini, Stuart M. Flechner, David A. Goldfarb, Jesse D. Schold. Cleveland, OH.

4:54 pm Automated Web-Based Monitoring Identifies Significant Clinical Changes in Patients Awaiting Kidney Transplant. (Abstract #512)

5:06 pm Geographic Differences in Racial Disparity Reduction in Kidney Transplant Rates Before and After the New Kidney Allocation System. (Abstract #513)

5:18 pm Subtype-Compatible (A2/A2B-->B) Transplantation Under KAS Increases Access 3-Fold for Blood Type B Patients, yet Very Few Candidates Are Listed as Eligible. (Abstract #514)
Darren Stewart, Wida Cherikh, Anna Kucheryavaya, Christopher Bryan, Nicole Turgeon, Mark Aeder. Richmond, VA; Westwood, KS; Atlanta, GA; Cleveland, OH.

5:30 pm Wait List Removals and Transplant Rates Are Significantly Associated with Transplant Center Performance Oversight. (Abstract #510)
Jesse D. Schold, Laura D. Buccini, Emilio D. Poggio, Stuart M. Flechner, David A. Goldfarb. Cleveland, OH.

5:42 pm Impact of Cold Ischemia Time on the Outcomes of Kidneys with KDPI >85%: Mate Kidney Analysis. (Abstract #516)
Marcelo Sampaio, Bhavna Chopra, Kalathil K. Sureshkumar. Pittsburgh, PA.

Kidney: Induction Therapy 2

Room 312
Chairs: Daniel Brennan, MD, Washington University School of Medicine in St. Louis, Saint Louis, MO, United States and Jeffrey Rogers, MD, Wake Forest Baptist Medical Center, Winston Salem, NC, United States

4:30 pm The Impact of Ritonavir-Boosted Protease Inhibitors and Non-Depleting Antibody Induction on Outcomes in HIV-Infected Kidney Transplant Recipients. (Abstract #517)

4:42 pm Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin. (Abstract #518)
Nicola Bossini, Silvio Sandrini, Regina Tardanico, Francesca Valerio, Gisella Setti, Chiara Salviani, Stefano Possenti, Paolo Foini, Elisabetta Marta, Giovanni Cancarini. Brescia, Italy.

4:54 pm Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years. (Abstract #519)
Alfonso Santos, Xuerong Wen, Michael Casey, Shehzad Rehman, Karl Womer. Gainesville, FL.
5:06 pm Outcomes of Depleting Antibody Induction in Kidney Transplantation: A Paired Kidney Analysis. (Abstract #520)
Marcelo Sampaio, Bhavna Chopra, Kalathil K. Sureshkumar. Pittsburgh, PA.

5:18 pm Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus. (Abstract #521)
Sunjae Bae, Christine Durand, Lauren Kucirka, Allan Massie, Dorry Segev. Baltimore, MD.

5:30 pm Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation. (Abstract #522)
Namita Singh, Ana Rossi, Marizela Savic, Ronald Rubocki, Mark Parker, John Vella. Portland, ME; Augusta, ME.

5:42 pm Antithymocyte Globulin (ATG) versus Anti-interleukin-2 Receptor (Anti-IL-2R) as Induction Therapy for Kidney Transplantation After a Nonrenal Transplant. (Abstract #523)
Hoa L. Mai, Katy Trébern-Launay, Christophe Legendre, Michèle Kessler, Lionel Rostaing, Valérie Garrigue, Emmanuel Morelon, Sophie Brouard, Magali Giral, Jean-Paul Soulillou. Nantes, France; Paris, France; Nancy, France; Toulouse, France; Montpellier, France; Lyon, France.

Liver: MELD, Allocation and Donor Issues (DCD/ECD) 2

Room 304
Chairs: Jonathan Fryer, MD, MS, MHPE, Northwestern Medical Faculty Foundation, Chicago, IL, United States and Meelie DebRoy, MD, Rutgers Robert Wood Johnson University, New Brunswick, NJ, United States

4:30 pm Modified Normothermic Extracorporeal Liver Perfusion for Discarded Human Livers. (Abstract #524)
Babak Banan, Rao Watson, Min Xu, Yiing Lin, William Chapman. St Louis; Madison.

4:42 pm A Users Guide to Maximizing Utility and Outcome in >70 Year Old Donors. (Abstract #525)
K. J. Halazun, E. Przybyszewski, B. Samstein, E. Verna, A. Fox, R. Brown, J. Emond. NY, NY.

4:54 pm Liver-Intestine Candidates Benefit from National Sharing. (Abstract #526)
Erick Edwards, Ann Harper, Debra Sudan. Richmond, VA; Durham, NC.

5:06 pm Muscle Function, Mass, and Quality in Obese Liver Transplant Candidates: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study. (Abstract #527)

5:18 pm The Impact of Share 35 on Liver Allocation and Utilization: One DSA’s Experience. (Abstract #528)
Jeffrey P. Orlowski, Chad C. Muse, Janice F. Whaley, Ronald A. Squires. Oklahoma City, OK.

5:30 pm Relative Distribution of Livers from HCV+ Donors in the U.S. (Abstract #529)

5:42 pm Geographic Variation in Liver Supply and Demand. (Abstract #530)

Living Kidney Donor Evaluation

Veterans Auditorium
Chairs: Matthew Levine, MD PhD, University of Pennsylvania, Philadelphia, PA, United States and Richard Perez, University California Davis Medical Center, Sacramento, CA, United States

4:30 pm Potential Kidney Donors with Asymptomatic Microscopic Hematuria: Histopathological Findings & Outcomes. (Abstract #531)
Ehab A. Hassan, Hassan A. Aleid, Tariq A. Zulfiquar, Ihab A. Ibrahim, Hadeel M. Almana. Riyadh, Saudi Arabia; Fayoum, Egypt; Cairo, Egypt.

4:42 pm Pre-Donation Weight Loss Postpones Living Kidney Donation without Attaining the Desired Weight Maintenance in the Midterm. (Abstract #532)
Tuesday, June 14

4:54 pm Motivation and Stress Associated with Non-Directed Kidney Donation. (Abstract #533)

4:06 pm The Live Donor Champion Program: A Novel Approach to Identifying Live Kidney Donors. (Abstract #534)
Elizabeth King, Mary Bowring, Komal Kumar, Jaqueline Garonzik Wang, Dorry Segev. Baltimore, MD.

Alex Li, Nellie Foreman, Molly Reissmann, Christine Zuttermeister, Alexander Gilbert, Monica Grafals, Basit Javaid, Seyed Ghasemian, Peter Abrams, Matthew Cooper, Jennifer Verbesey. Washington, DC.

5:30 pm Predonation Prescription Narcotic Use: A Novel Risk Factor for Readmission After Living Donor Nephrectomy. (Abstract #536)
Krista L. Lentine, Dorry L. Segev, David Axelrod, Ngan N. Lam, Amit X. Garg, Gregory Hess, Bertram L. Kasiske, Daniel Brennan, Henry Randall, Mark A. Schnitzler. Minneapolis; Baltimore; Hanover; Alberta, Canada; London, Canada; PittsburghSt. Louis.

5:42 pm Kidney Structural Characteristics as Predictors of Long-Term Kidney Function in Living Kidney Donors. (Abstract #537)
Jerry Mathew, Aleksandar Denic, Mariam P. Alexander, Terri J. Vrtiska, Harini A. Chakkera, Sandra J. Taler, Andrew D. Rule. Rochester, MN; Scottsdale, AZ.

Novel Approaches and Potential Targets for Promoting Tolerance: Animal Models

Room 310
Chairs: Heth Turnquist, Univ of Pittsburgh, T.E. Starzl Transplant Institute, Pittsburgh, PA, United States and Patrick Toby Coates, MD PhD, University of Adelaide, Adelaide, South Australia, Australia

4:30 pm Rapamycin Nanotherapy Delays Heart Transplant Rejection. (Abstract #538)

4:42 pm Mechanistic Insights into How Targeting of HDAC10 Promotes Foxp3+ Treg Cell Suppressive Activity, Gene Expression and Metabolism, and Enhances Allograft Survival. (Abstract #539)
Satinder Dahiya, Liqing Wang, Ulf H. Beier, Alessia Angelin, Rongxiang Han, Douglas C. Wallace, Wayne W. Hancock. Philadelphia.

4:54 pm Aquaporin 4 Blockade Is a Novel Strategy to Prevent T Cell Activation and Effector Functions. (Abstract #540)

5:06 pm Successful Treatment of Established Acute Allograft Rejection with Delayed CTLA-4Ig. (Abstract #541)
James S. Young, Jianjun Chen, Dengping Yin, Roger Sciammas, Vinh Vu, Maria-Luisa Alegre, Anita Chong. Chicago, IL; Houston, TX.

5:18 pm 2B4 Over-Expression Impairs Donor-Reactive CD8+ T Cell Proliferation and Accumulation Following Transplantation. (Abstract #542)
Sonia J. Laurie, Danya Liu, Mandy L. Ford. Atlanta, GA.

5:30 pm Type-I Interferon Induced Cross-Competition of IL-10 Signaling and Its Role in the Abrogation of Transplant Tolerance. (Abstract #543)
5:42 pm  Pre-Transplant Infusion of Extracorporeal Photopheresis Treated Donor Splenocytes Leads to Long-Term Liver Allograft Survival and Donor Specific Tolerance in Rats. (Abstract #544) Xin Kang, Yan Xie, Xinyi Yeap, Jiaojing Wang, Jennifer Schneiderman, Zheng Zhang. Changchun, Jilin, China; Chicago, IL.

Psychosocial and Treatment Adherence

Room 206

Chairs: Zeeshan Butt, Northwestern University Feinberg School of Medicine, Chicago, IL, United States and Cynthia Russell, PhD, University of Missouri-Kansas City, Kansas City, MO, United States


5:06 pm  Transplant Education Increases Wait-Listing Rates in Dialysis Centers with Supportive Administration and Knowledgeable Staff. (Abstract #548) Amy Waterman, John Peipert, Huiling Xiao, Christina Goalby, Krista Lentine. Los Angeles, CA; St. Louis, MO.

5:18 pm  Barriers to Comprehensive Transplant Education at U.S. For-Profit Dialysis Centers and Associations with Waitlist Access. (Abstract #549) Amy Waterman, John Peipert, Huiling Xiao, Christina Goalby, Krista Lentine. Los Angeles, CA; St. Louis, MO.


Small Bowel Transplantation

Room 102

Chairs: Robert Venick, MD, David Geffen School of Medicine UCLA, Los Angeles, CA, United States and Debra Sudan, Duke University, Durham, NC, United States


4:54 pm  IL-17-Producing CCR6+CD4+Th17 Cells Drive Intestinal Allograft Rejection in Humans. (Abstract #554) Jason Kaiser, Christopher Cosentino, Anshi Shukla, Chirag Desai, Raffaele Girlanda, Jason Hawsorth, Cal Matsumoto, Michael Zasloff, Thomas Fishbein, Alexander Kroemer. Washington DC.


The High KDPI Kidney: Outcomes and Optimal Utilization

Ballroom C

Chairs: Jeffrey Halldorson, M.D., University of California, San Diego, San Diego, CA, United States and Hans Gritsch, MD, University of California Los Angeles (Urology), Los Angeles, CA, United States

4:30 pm  Informing Informed Consent for High KDPI Kidneys. (Abstract #559) Angie Nishio Lucar, Douglas S. Keith, Gayle Vranic. Charlottesville, VA.

4:42 pm  The Relationship Between Kidney Donor Profile Index and Six Month eGFR in Deceased Donor Recipients. (Abstract #560) Douglas Keith, Angie Nishio Lucar, Gayle Vranic. Charlottesville, VA.


5:30 pm  High KDPI Kidneys (>85%) Do Not Adversely Affect HRQOL After Kidney Transplantation. (Abstract #564) Rachel C. Forbes, Irene D. Feurer, David LaNeve, Christianna Gamble, David Shaffer. Nashville, TN.

ASTS Business Meeting
5:45 pm — 7:00 pm
Republic Ballroom, Sheraton Boston Hotel

Poster Session D
6:00 pm – 7:00 pm
Poster Viewing: 9:30 am – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm
Halls C&D
Poster Session D program can be found on pages 178-202.

ATC Night Out featuring ATC’s Got Talent!
7:30 pm — 11:00 pm
Whisky Saigon
### AMERICAN TRANSPLANT CONGRESS
Day-at-a-Glance, Wednesday, June 15, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am — 8:15 am</td>
<td><strong>Sunrise Symposia</strong>&lt;br&gt;Page 102&lt;br&gt;Immunoregulation, New Concepts Relevant to Transplantation&lt;br&gt;Ballroom B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Page 102&lt;br&gt;Leveling the Playing Field – How to Minimize Racial and Ethnic Disparities in Access to Transplantation&lt;br&gt;Room 312</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Page 102&lt;br&gt;Advancing Transplant Care Using Pharmacogenomics&lt;br&gt;Ballroom C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Page 102&lt;br&gt;Telemedicine: Excite, Engage, and Enhance Patient Centered Care in Transplantation and Living Donation&lt;br&gt;Room 304</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Page 103&lt;br&gt;The Nuts and Bolts of PHS Increased Risk Donors&lt;br&gt;Ballroom A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Page 103&lt;br&gt;The KPD Plateau: What We Can Do About It&lt;br&gt;Room 302</td>
<td></td>
</tr>
<tr>
<td>8:15 am — 8:30 am</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>8:30 am — 10:00 am</td>
<td><strong>Plenary</strong>&lt;br&gt;Page 103&lt;br&gt;Joint Plenary Session IV&lt;br&gt;Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>10:00 am — 10:30 am</td>
<td><strong>Coffee Break</strong>&lt;br&gt;Level 2 Foyer</td>
<td></td>
</tr>
<tr>
<td>10:30 am — 11:30 am</td>
<td><strong>Innovators in Transplantation</strong>&lt;br&gt;Page 104&lt;br&gt;Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>11:30 am — 11:45 am</td>
<td><strong>Looking Back on Ethical Issues in Transplantation</strong>&lt;br&gt;Page 104&lt;br&gt;Veterans Auditorium</td>
<td></td>
</tr>
<tr>
<td>11:45 am — 12:15 pm</td>
<td><strong>What’s Hot, What’s New</strong>&lt;br&gt;Page 104&lt;br&gt;Veterans Auditorium</td>
<td></td>
</tr>
</tbody>
</table>
Sunrise Symposia  
7:00 am — 8:15 am

**Immunoregulation, New Concepts Relevant to Transplantation**

**Ballroom B**
Moderators: Diana Metes, MD, Thomas Starzl  
Transplant Institute/University of Pittsburgh, Pittsburgh, PA, USA and Madhav Menon, MBBS,  
MD, Mount Sinai School of Medicine, New York, NY, USA

7:00 am Immunoregulatory Effects of Erythropoietin  
Paolo Cravedi, MD, PhD  
Mount Sinai School of Medicine  
New York, NY, USA

7:25 am NOTCH and Treg  
Leonardo Riella, MD, PhD  
Brigham & Women’s Hospital  
Boston, MA, USA

7:50 am The Role of IL-10 in Microbiome Associated Immune Modulation and Disease  
Joaquin Madrenas, MD, PhD  
University of Western Ontario  
London, ON, Canada

**Leveling the Playing Field – How to Minimize Racial and Ethnic Disparities in Access to Transplantation**

**Room 312**
Moderators: Rachel Patzer, MD, MPH, Emory University, Atlanta, GA, USA and Clive Callendar, MD, FACS, Howard University Hospital, Washington, DC, USA

7:00 am Factors Underlying Race Related Differences in Access to Transplantation  
Charles Modlin  
Cleveland Clinic  
Cleveland, OH, USA

7:25 am Race related Differences in Living and Deceased Organ Donation  
Jagbir Gill, MD  
Providence Health Care  
West Vancouver, BC, Canada

7:50 am Educational Strategies to Minimize Race Related Disparities in Access to Transplantation  
Amy Waterman, PhD  
David Geffen School of Medicine at UCLA  
Los Angeles, CA, USA

**Advancing Transplant Care Using Pharmacogenomics**

**Ballroom C**
Moderators: Rita Alloway, PharmD, University of Cincinnati College of Medicine, Cincinnati, OH, USA and Pamela Jacobson, PharmD, University of Minnesota, Minneapolis, MN, USA

7:00 am Pharmacogenomics of Transplant Immunosuppression and Association with Transplant Outcomes  
Ajay Israni, MD, MS  
University of Minnesota  
Minneapolis, MN, USA

7:25 am Implementing Pharmacogenetic Variants in the Transplant Clinic: the Current Evidence  
Kelly Birdwell, MD, MSCI  
Vanderbilt University  
Nashville, TN, USA

7:50 am Understanding Pharmacogenomics Variation: Exploring the Relationship Between Genetic Variation and Gene Expression through GTEx  
Simona Volpi, PharmD, PhD  
National Human Genome Research Institute  
Bethesda, MD, USA

**Telemedicine: Excite, Engage, and Enhance Patient Centered Care in Transplantation and Living Donation**

**Room 304**
Moderators: Tiffany Kaiser, PharmD, University of Cincinnati, Cincinnati, OH, USA and Alexandra Powderly, PharmD, University of Alabama at Birmingham, Birmingham, AL, USA

7:00 am Transplant Evaluation And Technology: Doing More With Less Time  
Deonna Moore, MSN, ACNP  
Vanderbilt University  
Nashville, TN, USA
7:25 am innovative telemedicine education practices in the transplant and donation phase: effective and time-saving strategies
Demetra Tsapepas, PharmD
New York Presbyterian Hospital
New York, NY, USA

7:50 am Telemedicine Post-Transplant: Expanding Where Healthcare Happens
Shimul Shah, MD
University of Cincinnati
Cincinnati, OH, USA

The Nuts and Bolts of PHS Increased Risk Donors

Ballroom A
Moderators: Matthew Kuehnert, MD, FACP, FIDSA, CDC, Atlanta, GA, USA and Jay Fishman, MD, Harvard Medical School, Boston, MA, USA

7:00 am PHS Increased Risk Donors: What’s The Risk? Data Thus Far
Michael Ison, MD, MS
Northwestern University
Chicago, IL, USA

7:25 am “The Devil Is In The Detail”: What Everyone Needs To Know About Using PHS Increased Risk Donors
Emily Blumberg, MD
University Hospital of Pennsylvania
Philadelphia, PA, USA

7:50 am Implementing OPTN-Compliant Programs For Informed Consent & Protocols For Post-Transplant Surveillance
Linda Irwin, RN, MA
Massachusetts General Hospital
Boston, MA, USA

The KPD Plateau: What We Can Do About It

Room 302
Moderators: Marian Charlton, SRN, RN, New York Presbyterian Cornell Weill, New York, NY, USA and David Serur, MD, Rogosin Institute/New York Presbyterian Hospital, New York, NY, USA

7:00 am International Exchange: Could It Offer A Solution To The Stalled Pairs
Michael Rees, MD, PhD
University of Toledo Medical Center
Toledo, OH, USA

7:25 am Quality Markers For Paired Exchange: Is It Equitable And Transparent?
Mark Aeder, MD
University Hospitals Case Medical Center
Cleveland, OH, USA

7:50 am Disparities in KPD: Possible Solutions
Nicole Turgeon, MD
Emory University
Atlanta, GA, USA

Break

8:15 am — 8:30 am

Joint Plenary Session IV

8:30 am — 10:00 am

Veterans Auditorium
Chairs: Randall Sung, MD, University of Michigan, Ann Arbor, MI, USA and Peter Heeger, MD, Mount Sinai School of Medicine, New York, NY, USA

8:30 am Avoidance of CNI and Steroids Using Belatacept – A Preliminary Report of CTOT-16. (Abstract #566)
Roslyn Mannon, Peter Stock, Anesh Mehta, David Ikle, Natasha Watson, Nancy Bridges, Mark Robien, Kenneth Newell. Birmingham; San Francisco; Atlanta; Chapel Hill; Bethesda.

8:45 am Donor-Derived Toll-Like Receptor-Dependent Intravascular Monocytes Cause Primary Lung Graft Dysfunction. (Abstract #567)

9:00 am Novel Function of CD4+ T Cell DEPTOR in Treg Homeostasis and Alloimmunity. (Abstract #568)
Johannes Wedel, Sarah Bruneau, Kaifeng Liu, Nora Kochupurakkal, Mathieu Laplante, David M. Briscoe. Boston, MA; Quebec, Canada.

9:15 am HLA Identical Renal Transplant Tolerance Using Donor Hematopoietic Stems Cells (DHSC): Role of Immunoregulation. (Abstract #569)
9:30 am Outcomes Associated with Carbapenem-Resistant Enterobacteriaceae Infection After Solid Organ Transplantation in a Multicenter Study. (Abstract #570)
Shirish Huprikar, L. Casner, L. Camera Pierrotti, A. Nellore, R. Madan, J. Garcia-Diaz, S. Jacobs, D. Lee, W. Trindade Clemente, G. Alangaden, R. La Hoz, N. Theodoropoulos, M. Miceli, G. Santoro-Lopes, D. Banach, D. Simon, G. Patel. New York; Sao Paulo, Brazil; Birmingham; Bronx; New OrleansPhiladelphia; Belo Horizonte, Brazil; Detroit; Dallas; Columbus; Ann ArborRio de Janeiro, Brazil; New Haven; Chicago.

9:45 am Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11. (Abstract #571)
Anil Chandraker, Jon Kobashigawa, Josef Stehlik, Michael Givertz, Richard Pierson, Sean Pinney, Madsen Joren, Steven Nissen, Indira Guleria, Yvonne Morrison, Brian Armstrong, Nancy Bridges, Mohamed Sayegh, Randall Starling. Boston, MA.

Coffee Break
10:00 am — 10:30 am
Level 2 Foyer

Innovators in Transplantation
10:15 AM — 11:30 AM
Veterans Auditorium
Moderators: Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA and David Mercer, MD, PhD, University of Nebraska Medical Center, Omaha, NE, USA

10:30 am David Sachs, MD
Massachusetts General Hospital

11:00 am Christian Larsen, MD, DPhil
Emory University

Looking Back on Ethical Issues in Transplantation
11:30 am – 11:45 am

Veterans Auditorium
Moderators: Matthew Cooper, MD, Medstar Georgetown Transplant Institute, Washington, DC, USA and David Mercer, MD, PhD, University of Nebraska Medical Center, Omaha, NE, USA

11:30 am 50 Years after the 1966 Ciba Foundation Conference
Lainie Friedman Ross, MD, PhD
Carolyn and Matthew Bucksbaum Professor of Clinical Ethics
University of Chicago
Chicago, IL, USA

What’s Hot, What’s New – Overview of the Top Presented Abstracts
11:45 am — 12:45 pm
Veterans Auditorium
Moderators: Randall Sung, MD, University of Michigan, Ann Arbor, MI, USA and Peter Heeger, Mount Sinai School of Medicine, New York, NY, USA

11:45 am Basic
Ronald Gill, PhD
University of Colorado – Denver
Aurora, CO, USA

12:15 pm Clinical
Josh Levitsky, MD, MS
Northwestern University Feinberg School of Medicine
Chicago, IL, USA
Poster Session A

Poster Viewing: 5:30 pm – 7:30 pm
Presenters in Attendance: 5:30 pm – 7:30 pm
Halls C&D

A# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

B cells & AMR, Alloreactivity, Immune Regulation & Regulatory T Cells, T Cell Biology and Alloreactivity, Immunesuppression

A1 † CD9+ Regulatory B Lymphocytes Control Chronic Lung Inflammation by Inducing Effector T Cell Apoptosis.

A2 † Gene Expression Microarray Analysis of Purified CD16-Stimulated Human NK Cells and Indication Biopsies Supports a CD16-Mediated Role for NK Cells in Antibody-Mediated Kidney Rejection.

Takayuki Hirose, Yuka Tanaka, Hideki Ohdan. Hiroshima, Japan; Sapporo, Hokkaido, Japan.

A4 † Cross-Talk Between TLR and BCR Pathways Induces CNI-Resistance in B-Cells Responding to Blood Group A-Antigens: A Novel Paradigm for Treatment with TLR-Inhibitor for CNI-Resistant AMR.

A5 † Limited Efficacy of Bortezomib on Desensitization via Rapid Humoral Compensation in a Sensitized Rhesus Model.
Jean Kwun, Christopher Burghuber, Neal Iwakoshi, Adriana Gibby, Stuart Knechtle. Durham; Atlanta.

A6 † Late Renal Xenograft Failure Is Antibody-Mediated: Description of the Longest-Reported Survival in Pig-to-Primate Renal Xenotransplantation.
Laura Higginbotham, Steven Kim, Dave Mathews, Allison Stephenson, Cynthia Breeden, Christian Larsen, Mandy Ford, Kenneth Newell, A. Joseph Tector, Andrew Adams. Atlanta, GA; Indianapolis, IN.

A7 † IFN-γ and Contact-Dependent Cytotoxicity Are Rate-Limiting for NK Cells in a Model of Antibody-Mediated Chronic Rejection.
Christine M. Lin, Robert J. Plenter, Ronald G. Gill. Aurora, CO.

A8 † Ibrutinib Suppresses Alloantibody Responses in A Mouse Model of Allosensitization: A Preliminary Report.
Gordon Wu, Irene Kim, Ning-ning Chai, Andrew Klein, Stanley Jordan. Los Angeles, CA.

A9 † Renal Fibroblast Activation and Survival by Anti-MHC Class I Antibody: The Role of mTOR Signaling Pathway.
J. Chen, A. Zmijewska, Roslyn B. Mannon. Birmingham, AL.

A10 † The Role of B Cells in Liver Transplant Tolerance.
Miwa Morita, Gospel Enyindah-Asonye, Neetu Gupta, John J. Fung, Shiguiang Qian, Lina Lu. Cleveland, OH.

Irene Kim, Ning-ning Chai, Andrew S. Klein, Stanley C. Jordan, Gordon Wu. Los Angeles, CA.
A12 † Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with a Moderate Splenic B-Cell Reduction.
Ning-ning Chai, Irene Kim, Stanley Jordan, Andrew Klein, Gordon Wu. Los Angeles, CA.

A13 † The Role of HLA Class II Antibody in Endothelial Cell Activation and Allograft Rejection.

A14 † Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.
Ana Konvalinka, Andrzej Chruscinski, S. Joseph Kim, Kathryn Tinckam, Igor Jurisica, Rohan John. Toronto, ON, Canada.

A15 Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo.
Keisha Bonner, Natalie Moore, Manuel Moreno Gonzales, Mark Stegall. Rochester, MN.

A16 Molecular Diagnosis of Antibody-Mediated Rejection in Routine Formalin-Fixed Paraffin-Embedded Nonhuman Primate Renal Allograft Biopsies.
B. Adam, I. A. Rosales, T. Oura, R. N. Smith, A. B. Cosimi, T. Kawai, R. B. Colvin, M. Mengel. Edmonton, Canada; Boston.

A17 Pathogenic Role of Anti-HLA Antibodies on Endothelial Progenitor Cell Dysfunction of Highly Sensitized Kidney Transplanted Patients.
Vincenzo Cantaluppi, Sergio Dellepiane, Davide Medica, Giuliana Tognarelli, Marco Quaglia, Claudio Musetti, Andrea Airoldi, Luigi Biancone. Novara, Italy; Torino, Italy.

A18 Utilizing HLA Single Antigen Flow Beads Assays to Evaluate Anti-MAMU Antibody in Sensitized Nonhuman Primate Model.
Jean Kwun, Christopher Burghuber, Miriam Manook, Adella Clark, Dongfeng Chen, Stuart Knechtle. Durham; Vienna, Austria.

A19 Sequential Analysis of Donor-Specific Antibodies and Pathological Findings Using Intravenous Immunoglobulin in a Highly Sensitized Rat Kidney Transplant Model.
Yugo Sawada, Kazuya Ooto, Naoki Kohei, Kunio Kawanishi, Masayoshi Okumi, Hideki Ishida, Tanabe Kazunari. Iwaki, Japan; Tokyo, Japan; Shizuoka, Japan.

A20 † IL2 and IL-15 Rescue TEMRA CD8 T Cells from Mitochondrial Dysfunction Associated Senescence through a p38MAPK Dependent Pathway and Foster Their Pathogenic Potential.
Gaelle Tilly, Michelle Yap, Magali Giral, Claire Pecqueur, Sophie Brouard, Nicolas Degauque. Nantes, France.

A21 † Immunologic Basis for Immunocloaking.
Lauren Brasile, Karina Kizjakina, Nicholas Henry, Bart Stubenitsky. Watervliet, NY; Utrecht, Netherlands.

A22 † Autologous BK-Specific T-Cell Lines in Kidney Transplant Recipients.
Caroline Lamarche, Orio Julie, Cedric Carli, Jean-Sébastien Delisle. Montreal, QC, Canada; Edmonton, Canada; Quebec, Canada.

A23 † ASC-Deficient Dendritic Cells Exhibit Activation Defects and a Reduced Ability to Stimulate Allogeneic T Cells.
Andrew T. Scheinok, Alana A. Shigeoka, Sashi G. Kasimsetty, Reza Elahimehr, Dianne B. McKay. La Jolla, CA.

A24 † Single Cell Profiling of Th9 Cells Allows Identification of Functionally Different Subsets.
Katariina Stanko, Julia Schumann, Katrin Vogt, Stephan Schliekeiser, Christine Appelt, Birgit Sawitzki. Berlin, Germany.

A25 † A Unique In Vitro Migration Model for Leukocyte Trans-Lymphatic Endothelial Migration.


A28 CXCL12 as Innovative Immune Isolating Chemokine for Microencapsulated Allo and Xeno-Transplantation in NHPs. Marinko Sremac, Abhinbhen Saraya, Ottavia Clemente, Madeline Penson, Surendra Chavan, Nicolas Chronos, Christian Schuetz, Ji Lei, James Markmann, Timothy A. Brauns, Mark C. Poznansky. Boston, MA; Athens, GA.


A30 Resveratrol Effectively Suppress Th17 Associated Allo-Immune Responses by the Modulation of AMPK/mTOR Pathway. Byung Ha Chung, Kyoung Chan Doh, Ji-Won Min, Kyoung Woon Kim, Bo-Mi Kim, Mi-La Cho, Chul Woo Yang. Seoul, Korea.


A33 Abstract Withdrawn

A34 † Soluble Fibrinogen-Like Protein 2 Regulates Differentiation and Enhances Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Allograft Immunity. Cheng Yang, Lingyan Wang, Ruiming Rong, Tongyu Zhu, Ming Xu. Shanghai, China.


A37 In Vitro Induction of T Regulatory Cells by Multipotent Adult Progenitor Cells. Samantha Stubblefield, Nicholas Williams, Anthony Ting. Cleveland, OH.

A38 CoCl2 Induced ER Stress Protein Mediated Cytotoxicity in FK506 Treated Hepatoma HepG2 Cells. Soo Jin Na Choi, Sang Young Chung. Gwangju, Republic of Korea.

A39 Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epithelial to Mesenchimal Transition. Valeria Tubita, Joan Seguí-Barber, María-José Ramírez-Bajo, Daniel Moya-Rull, Pierluca Piselli, Diana Verdirosi, Federico Oppenheimer, Diego Serraino, Hernando A. Del Portillo, Fritz Diekmann, Josep M. Campistol, Ignacio Revuelta. Barcelona, Spain; Rome, Italy; Madrid, Spain; Aviano, Italy.

A41  Effect of Isolated Intraperitoneal Sirolimus Treatment on the Kidneys of C57BL/6 Mice.

A42  Mechanism of FK506 Induced TNF Related Apoptosis in Jurkat T Cells.
Sang Young Chung, Soo Jin Na Choi. Gwangju, Korea.

A43†  Kidney Allotransplantation Induces the Differentiation of Antigen-Experienced CD8 T Cells with Enhanced Metabolic Profiles.
Gaelle Tilly, Michelle Yap, Magali Giral, Sophie Brouard, Claire Pecqueur, Nicolas Degauque. Nantes, France.

A44  Eliminating Xenoantigen Expression on Swine Red Blood Cells.
Zheng-Yu Wang, Greg Martens, Ross L. Blankenship, Richard A. Sidner, Ping Li, Jose L. Estrada, Mathew Tector, A. Joseph Tector. Indianapolis, IN.

A45  Indirect Allo-Antigen Stimulation Identifies the Presence of Either Regulatory IL-10 or of Effector Cytokines IFN-γ, IL-21, IL-17a Production by Human Blood Allo-Reactive Memory TFH and TCONV CD4+ T Cells.
Camila Macedo, Fadakar Paul, Yamada Masaki, Hadi Kevin, Metes Diana. Pittsburgh, PA.

A46  Adiponectin Is Produced by Leukocytes Infiltrating Renal Transplants.
Sreedevi Goparaju, Ran Fan, Karen Keslar, Nina Dvorina, William Baldwin III. Cleveland, OH.

A47†  HLA Antibody Clonality and Epitopes Dictate Complement Activation.
Kimberly A. Thomas, Nicole M. Valenzuela, Arend Mulder, Elaine F. Reed. Los Angeles, CA; Leiden, Netherlands.

A48  The Role and Mechanism of CD40/CD40L Expression on Different T-Cell Subsets.

A49†  Prospective Long-Term Analysis of B- and Plasma Cell Subsets in Renal Transplant Patients After Combined Treatment with Rituximab and Bortezomib in Antibody Mediated Rejection.
Michael Duerr, Fabian Halleck, Oliver Staeck, Lukas J. Lehner, Dmytro Khadzhynov, Schrezenmeier Eva, Johannes Waiser, Klemens Budde. Berlin, Germany.

A50†  Early De Novo DSA with T Cell Mediated Rejection (TCMR) Is Associated with Allograft Dysfunction with Chronic Injury.

Clinical Pancreas Transplantation and All Islet Cell Transplantation Topics

A51†  Center Volume Is Associated with Outcome Following Pancreas Transplantation within the Eurotransplant Region.
Wouter H. Kopp, Marieke van Meel, Hein Putter, Undine Samuel, Helmut Arbogast, Wolfgang Schareck, Jan Ringers, Andries Braat. Leiden, Netherlands; Munich, Germany; Rostock, Germany.

A52  Long Term Results on Pancreas Transplant Beyond the Standard Indications, at a Single Center.

A53  Use of Integrated National Registry and Pharmacy Claims Data to Identify Diabetes Mellitus After Live Pancreas Donation.
Krista L. Lentine, Ngan N. Lam, Henry Randall, David Axelrod, Dorry L. Segev, Gregory Hess, Amit X. Garg, Daniel C. Brennan, Bertram L. Kasiskie, Mark A. Schnitzler. Minneapolis; Alberta, Canada; Hanover; Baltimore; London, CanadaSt. Louis.

A55 Pancreatic Allograft Failure in Latino Recipients: Diabetes Mellitus Type 2 Conversion? Hoylan Fernandez, Greg McKenna, Nicholas Onaca, Richard Ruiz. Dallas, TX.


A62 Virtual Crossmatch in Simultaneous Pancreas-Kidney Transplant. Erika Bevilaqua Rangel, Adriano Miziara Gonzalez, Claudio Santiago Melaragno, Joao Roberto de Sa, Marcelo Moura Linhares, Alcides Salzedas-Neto, Renato de Marco, Maria Gerbase de Lima, Jose Osmar Medina-Pestana. Sao Paulo, SP, Brazil; Sao Paulo, Brazil.


A67 Plasma Alemtuzumab Levels Show Great Interpatient Variability, but Are Not Associated with Late Acute Rejection in Simultaneous Pancreas-Kidney Recipients.

A68 Outcomes with Steroids Alone for Biopsy-Proven Pancreas Transplant Rejection.
Salahuddin Salahuddin, Brad Astor, Sandesh Parajuli, Arjang Djamali, Jon Odorico, Didier Mandelbrot. Madison, WI.

A69 Utilization of Plasmapheresis and High Dose of Immunoglobulins in the Treatment of the High Level of De Novo Donor Specific Antibodies for the Successful Islet Allotransplantation.
Julia Solomina, Zehra Tekin, Sabrina Matosz, Karolina Golab, Celeste Thomas, Justyna Golebiewska, Sabarinathan Ramachandran, Lindsay Schenck, W. James Chon, Martin Tibudan, Natalia Marek-Trzonkowska, J. Michael Millis, Piotr Witkowski. Chicago, IL; Gdansk, Poland.

A70 Graft Versus Host Disease (GVHD) in Patients with Pancreas Transplant Alone (PTA).
Muhammad Mujtaba, Asif Sharfuddin, Ali Khalil, Tim Taber, Michelle Goble, John Powelson, Jonathan Fridell. Galveston, TX; Indianapolis, IN.

A71 An Analysis of Factors Associated with Pancreas Allograft Thrombosis.
Justin Steggerda, Kathryn Bornhurst, Alagappan Annamalai, Alice Peng, James Mirocha, Donald Dafoe. Los Angeles, CA.

A72 Injurious Procoagulant Pathways During Prolonged Cold Storage of the Donor Pancreas.

A73 Mechanical Thrombectomy for the Treatment of Pancreas Transplant Venous Thrombosis: A Single Center Experience.

A74 Detection of Venous Thrombi by Microdialysis Catheters and Angiographic Guided Thrombus Extraction in Two Solitary Pancreas Transplants.
Gisle Kjosen, Rune Horneland, Einar M. Aandahl, Ole Oyen, Tor I. Tonnessen, Haugaa Hakon. Oslo, Norway.

A75 Duodenal Graft Complications After Pancreas Transplant: Evolving Management.
David P. Al-Adra, Jerome Laurence, Andrea Norgate, Nicholas Goldaracena, Max Marquez, Andrew Barbas, Martin Dib, Markus Selzner, Mark Cattral. Toronto, ON, Canada; Sydney, New South Wales, Australia.

A76 What Is the Decline Rate of Pancreata Attributed to Donation After Cardiac Death When the Accompanied Kidney Is Transplanted?

A77 † Low Risk of Cytomegalovirus (CMV) Transmission in Clinical Islet Transplantation.
Dima Kabbani, Kitty Cheung, Peter Senior, Carlos Cervera, Karen Doucette, Jutta Preiksaitis. Edmonton, AB, Canada.

A78 MicroRNA-375 and -200c Are a Set of Novel Biomarkers That Can Predict Islet Autotransplantation Outcome.
Gumpei Yoshimatsu, Mazhar A. Kanak, Morihiro Takita, S. Prathab Balaji, Charles Chang, Michael C. Lawrence, Marlon F. Levy, Nicholas Onaca, Peter T. Kim, Bashoo Naziruddin. Dallas, TX; Richmond, VA.
A79 † Validation of SUITO Index and C-Peptide/Glucose Creatinine Ratio as Convenient Tools for the Evaluation of the Short and Long-Term Islet Allograft Function.
Justyna Gołębiewska, Julia Solomina, Sabrina Matosz, Celeste Thomas, Lindsay Schenck, Karolina Golab, W. James Chon, Sabarinathan Ramachandran, Martin Tibudan, Alicja Dębka-Śliżień, Bolesław Rutkowski, Piotr Witkowski. Gdańsk, Poland; Chicago, IL.

A80 Total Pancreatectomy with Islet Autotransplantation for Chronic Pancreatitis: Considerations for Early Intervention.

A81 Isolating High Islet Mass Even from Alcoholic Pancreatitis Pancreases Intended for Clinical Islet Autotransplantation: Improved Strategies to Human Islet Isolation Technique.
Appakalai N. Balamurugan, Gopalakrishnan Loganathan, Benjamin Tweed, William Tucker, Sriprakash Mokshagundam, Stuart K. Williams, Michael J. Hughes. Louisville, KY.

A82 Risk Factors for Early Readmission After Total Pancreatectomy with Islet Auto Transplantation.
Rauf Shahbazov, Naziruddin Bashoo, Gumpei Yoshimatsu, Giovanna Saracino, Feredun Azari, Nicholas Onaca, Peter T. Kim, Marlon F. Levy. Charlottesville, VA; Dallas, TX; Richmond, VA.

A83 Comparison of Outcomes from Patients with Completion versus Total Pancreatectomy with Islet Autotransplantation: A Single-Institution Experience with 120 Consecutive Cases.
Gumpei Yoshimatsu, Morihito Takita, Rauf Shahbazov, Michael C. Lawrence, Bashoo Naziruddin, Peter S. Kim, Marlon F. Levy, Nicholas Onaca. Dallas, TX; Charlottesville, VA; Richmond, VA.

A84 Effect of Pylorus Preservation Procedure on Patient and Graft Outcome in Total Pancreatectomy with Islet Autotransplantation.
Rauf Shahbazov, Ali Dabous, Gumpei Yoshimatsu, Hoylan T. Fernandez, Giovanna Saracino, Bashoo Naziruddin, Nicholas Onaca, Peter T. Kim, Marlon F. Levy. Charlottesville, VA; Dallas, TX; Richmond, VA.

A85 Periodical Peer Review of a Pancreas Transplant Programme: Can It Enhance Performance?
Zia Moinuddin, Aneeza Arif, Omar Masood, Afshin Tavakoli, Ravi Pararajasingam, Kay Poulton, Judith Worthington, Bence Forgacs, Titus Augustine, Raman Dhandu. Manchester, Lancashire, United Kingdom.

Clinical Vascularized Composite Allotransplantation

A86 Outcomes of Solid Organ Transplants Following Simultaneous Solid Organ and Vascularized Composite Allograft Procurements.

A87 Planning Genitourinary Vascularized Composite Allograft Transplantation: A Pre-Operative Imaging Protocol.

A88 Vascular Composite Allotransplantation Collaborative Initiative Biobank: Bringing the Power Back to Research.
Jennifer Cheeseman, Mary-Beth Joshi, Francis Leopardi, Robyn Osborne, Debbi Conlon, Linda Stempora, Mingqing Song, Linda Cendales. Durham, NC.

† Radiosensitive Cell Population Prolongs Graft Survival of Vascularized Composite Allografts in Non-Human Primates.

Peritransplant Costimulation Blockade Combined with a Short-Course of Rapamycin Prevents Rejection of Vascularized Composite Allografts.

Assessing the Induction of Tolerance to Vascularized Composite Allotransplantation in Miniature Swine.

Tolerance Induction in Vascularized Composite Allotransplantation with Peri-Transplant Combined Costimulation Blockade.
Byoungchol Oh, Georg J. Furtmüller, Madeline Fryer, Johanna Grahammer, Stefan Schneeberger, Damon Cooney, Giorgio Raimondi, Gerald Brandacher. Baltimore, MD; Innsbruck, Austria.

Rapamycin (RPM) Synergizes with CD154 mAb and DST to Promote Long-Term Vascularized Composite Allograft (VCA) Survival, but Prevents Induction of Donor-Specific Tolerance.

The In Vivo Non-Invasive Long-Term Functional Assessment of Neuronal Regeneration in Vascularized Composite Allotransplantation.
Chih-jen Wen, Cheng-Hung Lin, Shin-lei Peng, Fu-nien Wang, Ling-Yi Huang, Hui-Yun Cheng, Hao-hsiang Hsu, Xiaoting Huang, Chih-Hung Lin, Fu-Chan Wei. Taoyuan, Taiwan; Hsinchu, Taiwan; Taichung, Taiwan.

Subnormothermic Machine Perfusion (SNMP) with a Novel Hemoglobin-Based Oxygen Carrier (HBOC) Solution for Ex Vivo Preservation in Vascularized Composite Allotransplantation (VCA).

Developing a PCR-Based System to Access the Correlation of Local Chimerism and Fate of the Vascularized Composite Allotransplant.
Xiao-Ting Huang, Hui-Yun Cheng, Chih-Fan Lin, Shan-Shan Qiu, Ling-Yi Shih, Fu-Chan Wei. Gueishan, Taoyuan, Taiwan.
Membrane Proteome Profiling Reveals Molecular Changes Associated with Donor-Specific Tolerance to Vascularized Composite Allotransplants.
Hui-Yun Cheng, Chia-Li Han, Feng-Wen Jiang, Ling-Yi Shih, Chih-Fan Lin, Yu-Ju Chen, Fu-Chan Wei. Gueishan, Taoyuan, Taiwan; Taipei, Taiwan.

Kidney Desensitization

Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.

Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
E. S. Woodle, M. J. Pando Rigal, S. Tremblay, A. Girnita. Cincinnati; Scottsdale.

Early Hospital Readmission Among Immunologically Vulnerable Kidney Transplantation Recipients.
Elizabeth King, Babak Orandi, Sunjae Bae, Xun Luo, Dorry Segev. Baltimore, MD.

Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.
Yoshi Wada, Nobuyuki Fukuzawa, Hiroshi Harada. Sapporo, Hokkaido, Japan.

Highly Sensitized Patients Transplanted via the Eurotransplant Acceptable Mismatch Program Have Excellent Long-Term Graft Survival.

The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.

Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.
Stanley C. Jordan, Jua Choi, Bongha Shin, Joseph Kahwaji, Shili Ge, David Thomas, Ashley Vo, Odette Galera, Rafael Villicana, Alice Peng, Mieko Toyoda. Los Angeles, CA.

Survey Results Show Strong Support for Allowing Patients Undergoing Desensitization to Keep Their Pre-Desensitization CPRA Allocation Priority.
Anna Kucheryavaya, Robert Bray, Dolly Tyan. Richmond; Atlanta; Palo Alto.

Kazunari Tanabe, Masayoshi Okumi, Miyuki Furusawa, Kohei Unagami, Toshihito Hirai, Hiroki Shirakawa, Tomokazu Shimizu, Kazuya Omoto, Masashi Inui, Hideki Ishida. Tokyo, Japan; Saitama, Japan.

Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.
Marie Matignon, Caroline Pilon, Morgane Commereuc, Cynthia Grondin, Tomek Kofman, Philippe Lang, Florence Canoui Poitrine, José Cohen, Philippe Grimbert. Créteil, France.

Zero and One Mismatching for HLA DR10,14,16 Produces Increased Kidney Graft Survival.
James C. Cicciarelli, Yong Cho, Michelle Altrich, Noriyuki Kasahara, Nathan Lemp. Los Angeles, CA; Miami, FL.

A2 Kidneys into B Recipients: Is Postoperative Anti-A1 Titer Monitoring Useful?
April DeMers, Rachel Forbes, Deonna Moore, Kristin Smith, David Shaffer. Nashville, TN.
A112  Live Donor Kidney Transplantation of the Most Highly Sensitized Patients in the Era of Kidney Paired Donation.  

A113  Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).  
Amir Nejad, Ashley A. Vo, Jua Choi, Stanley C. Jordan. LA, CA.

Anat R. Tambur, Denis Glotz, Nancy D. Herrera, Erik N. Chatroop, Tal Roitberg, John J. Friedewald, David Gjertson. Chicago; Paris, France; LA.

Kidney Donor Outcomes

A115  Successful Transplantation in ABO- and HLA-Incompatible Kidney-Transplant Patients.  

A116 †  NEAD Chains Do Not Disadvantage Blood Type O, Black, or Highly Sensitized Patients.  
M. Rees, J. Roberts, K. Lentine, A. Roth, A. Leichtman, H. Xiao, S. Rafizadeh, E. Neidich, M. Melcher. Toledo; SF; St Louis; Palo Alto; Ann Arbor.

A117 †  The Prevailing Preference for Left Nephrectomy in Living Donor Transplantation Does Not Adversely Affect Long Term Donor Outcome.  

A118 †  Live Kidney Donors Have Significant Out-of-Pocket Costs Associated with Donation.  

A119 †  Age-Based High GFR Associates with Clinical Risk Among Potential Living Donors, but Only with Increased Nephron Number Among Approved Donors.  

A120 †  Donor-Candidate Mismatch in Age, Sex, HLA, and Body Size Inform a Calculator for Kidney Graft Survival.  
J. D. Kalbfleisch, V. B. Ashby, A. B. Leichtman, M. A. Rees, P. X.-L. Song, A. Sakhija, M. Bray, R. Eikstadt, A. Goulding, W. Wang. Ann Arbor; Ann Arbor, MI; Toledo, OH.

A121 †  Should Renin Angiotensin Blockade Be the Mainstay of Hypertension Treatment in Kidney Donors?  

A122 †  5-Year Follow-Up After Live Donor Nephrectomy – A Prospective Cohort Study.  

A123 †  Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.  
Adarsh Babu, Avgi Androeu, Sunil Daga, Rob Higgins, Dan Mitchell, David Briggs, Natasha Khovanova, Nithya Krishnan. Coventry, West Midlands, United Kingdom; Birmingham, West Midlands, United Kingdom; Coventry, United Kingdom.

A124 †  Outcomes of Donor Nephrectomy in the Elderly.  
A125 † Comparison of Renal Outcomes Between ABO-Incompatible and Kidney Paired Donation Transplantation In Living Donors.
Neda Hashemi, Mehdi Tavakol, Brian K. Lee. San Francisco, CA.

A126 † Clinical Outcome of Elderly Living Kidney Donors: A Single-Center Study in Japan.
Jumpei Hasegawa, Kohei Unagami, Masayoshi Okumi, Kazuya Omoto, Masashi Inui, Hideki Ishida, Kazunari Tanabe. Tokyo, Japan.

A127 † Long Term Follow Up of Kidney Donors with Asymptomatic Renal Stones.

A128 † Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival.

A129 † Gender Differences in Longitudinal eGFR of Living Kidney Donors in a Health Information Exchange.
Macey L. Henderson, Timothy McFarlane, Allan Massie, Dorry Segev, Brian E. Dixon. Indianapolis, IN; Baltimore, MD.

A130 † Poor HLA Matching May Reduce the Beneficial Effect of ABOi Pairs Entering the Paired and Pooled Scheme.
Michelle Willicombe, Christopher Lawrence, Rawya Charif, Adam G. McLean, Jack Galliford, David Taube. London, United Kingdom.

A131 † Young, Caucasian, Better Educated and Less Socially Deprived Patients Are More Likely to Be Transplanted with a Living Donor Kidney in the UK.
Diana Wu, Matthew Robb, Chris Watson, Rommel Ravanam, John Forsythe, Wendy Metcalfe, Chris Dudley, Clare Bradley, Heather Draper, Andrew Bradley, Gabriel Oniscu. Edinburgh, United Kingdom; Bristol, United Kingdom; Cambridge, United Kingdom; London, United Kingdom; Birmingham, United Kingdom.

A132 † Reduced Incidence of Rejection in ABO-incompatible Kidney Transplantation – Five Year Follow-Up in a Single Center.
Alexander Weidemann, Fabian Karpf, Thomas Dienemann, Katharina Birker, Johannes Jacobi, Kai-Uwe Eckardt. Erlangen, Germany.

A133 † Gender Bias and Kidney Transplantation in Nepal.

A134 † No Significant Impact of KAS on Prior Living Kidney Donors’ Access to Timely Transplant of High Quality Kidneys.
J. Wainright, A. Kucheryavaya, M. Aeder, D. Klassen, D. Stewart. Richmond, VA; Cleveland, OH.

A135 † Center Level Analysis of Changes in Living Donor Transplant Rates in the United States.
Douglas Keith, Angie Nishio Lucar, Gayle Vranic. Charlottesville, VA.

A136 † The Effect of Donor-Recipient Relationship on the Immunologic Outcome in Living Kidney Transplantation.
Dmytro Khadzhynov, Fabian Halleck, Lukas J. Lehner, Michael Duerr, Johannes Waiser, Klemens Budde, Oliver Staeck. Berlin, Germany.
A137 † ABO Incompatible Living Related Kidney Transplantation: Results of a Matched-Pair Analysis with ABO Compatible Living Donation. Thorsten Vowinkel, Heiner H. Wolters, Stefan Reuter, Thomas Vogel, Norbert Senninger, Barbara Suwelack. Muenster, Germany; Dortmund, Germany.


A139 Recovery of eGFR in Both Donors and Recipients After Living Donor Kidney Transplantation. Jennifer Verbesey, Alexander Gilbert, Alex Li, Molly Reissmann, Nellie Foreman, Monica Grafals, Basit Javaid, Peter Abrams, Seyed Ghasemian. Washington, DC.


A144 † In Their Own Words: Living Kidney Donors Who Develop Kidney Failure. Lainie Ross, Colin Halverson, Jackie Wang, Michael Poulson, Jennifer Karlin, Megan Crowley-Matoka. Chicago, IL; Washington, DC; San Francisco, CA.


Kidney: Acute Cellular Rejection


A148 Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus. Philippe Gatault, Nassim Kamar, Matthias Buchler, Charlotte Colosio, Dominique Bertrand, Antoine Durrbach, Laetitia Albano, Joseph Rivalan, Marie Essig, Yannick Le Meur, Nicolas Bouvier, Bernard Charpentier, Eric Thervet, Lionel Rostaing, Yvon Lebranchu. Tours, France; Toulouse, France; Reims, France; Rouen, France; Kremlin Bicêtre, France; Nice, France; Rennes, France; Limoges, France; Brest, France; Caen, France; Boulogne-Billancourt, France.

A149 Urinary Exosomal Annexin A1 Is a Predictive Biomarker of Post Kidney Transplant Complications. Hiroshi Harada, Taku Murakami, Cindy M. Yamamoto, Kiyohiko Hotta, Nobuyuki Fukuzawa, Masato Mitsuhashi. Sapporo, Japan; Irvine, CA; Aliso Viejo, CA.
A150  NanoString Detection of Gene Signatures in Urine During Acute Cellular Rejection of Kidney Grafts.

A151  Rapid Emergence of CD28null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.
Miriam Cortes, Sonia J. Laurie, Blayne A. Sayed, Mandy L. Ford. Atlanta, GA.

A152  Recipient Age and KDPI Are Potent Predictors of Early Acute Rejection in the Modern Era of Deceased Donor Kidney Transplantation.
Douglas Keith, Gayle Vranic, Angie Nishio Lucar. Charlottesville, VA.

Vighnesh Walavalkar, Sarah Bowman, Laura Laszik, David Ikle, Sindhu Chandran, Flavio Vincenti, Zoltan Laszik. San Francisco, CA; Chapel Hill, NC.


A155  A Novel Quantitative CD45 Immunofluorescence Assay Can Measure Inflammatory Load in Renal Transplant Biopsies with Excellent Reproducibility and Repeatability.
Zoltan Laszik, Dejan Dobi, Laura Laszik, David Ikle, Sindhu Chandran, Flavio Vincenti. San Francisco, CA; Chapel Hill, NC.

A156  Higher Pre-Transplant Triglyceride Levels Are Associated with Increased Acute Cellular Rejection Risk Following Kidney Transplant.
Jennifer C. Hagopian, Daniel C. Brennan, Krista Lentine, Timothy A. Horwedel. St. Louis, MO.


A158  Clinical Impact of Pre-Transplant Serum 25-Hydroxyvitamin D Levels on the Post-Transplant Immunologic and Non-Immunologic Outcomes in Kidney Transplant Recipients.
Tae Hyun Ban, Jeong Ho Kim, Yoon Seo Lee, Bum Soon Choi, Cheol Whee Park, Chul Woo Yang, Yong-Soo Kim, Byung Ha Chung. Seoul, Korea.

A159  Acute Rejection Profoundly Impacts Graft Survival in Young but Not in Old Kidney Transplant Recipients.
Christian Denecke, Matthias Biebl, Josef Fritz, Andreas Brandl, Sascha Weiss, Tomasz Dziodzio, Felix Aigner, Robert Sucher, Claudia Bösmüller, Johann Pratschke, Robert Öllinger. Innsbruck, Austria; Berlin, Germany.

A160  Natural Language Processing Methods Allow Reliable Extraction of Banff Scores and Grades.

A161  Post-Transplant Reduction of Long Lived Plasma Cells from Peripheral Circulation Is Associated with Acute Rejection in Kidney Transplant Recipients.
Ranjana Walker Minz, Ravi Dhital, Mukut Minz, Ritambhara Nada, Ashish Sharma, Sarbpreet Singh, Deepesh Kenwar. Chandigarh, India.
A162 Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.
Samir J. Patel, Richard J. Knight, Samantha A. Kuten, Joy Nolte, A. Osama Gaber. Houston, TX.

A163 Exposure Analysis for the Composite Efficacy Endpoints in the US92 Phase 3 Kidney Transplantation Trial to Understand Center Effects.
F. Shihab, B. Kaplan, K. McCague, D. Patel, F. Vincenti. Salt Lake City; Phoenix; East Hanover; San Francisco.

A164 Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
Wolfgang Arns, Andrea Huppertz, Thomas Rath, Stefan Ziefle, Lars C. Rump, Anita Hansen, Daniel Baumer, Kiemens Budde, Lukas J. Lehner, Thomas Klein, Peter Schenker. Cologne, Germany; Nuernberg, Germany.

A165 Clinical Outcome in Pure T-Cell Mediated Acute Rejection of the Kidney with No Donor Specific Antibody or C4d Staining.
Parmjeet Randhawa, Gang Huang, Simrath Randhawa, Gang Zeng, Xiaomu Zhao. Pittsburgh, PA; Guangzhou, Guangdong, China; Beijing, China.

A166 Acute Allograft Glomerulopathy: A Distinct Form of Cellular Rejection.
Osamah T. AL-Badri, Mariam P. Alexander, Fernando G. Cosio, Lynn D. Cornell. Rochester, MN.

A167 The Impact of Treating Borderline Cellular Rejections.

A168 Urine-Derived Cell Lines as a Novel Tool for Monitoring Allo-Reactivity in Kidney Transplant Patients.
Constantin Thieme, Benjamin Weist, Michael Schmück, Petra Reinke, Nina Babel. Berlin, Germany; Herne, Germany.

A169 Transcriptome Profiles in Peripheral Blood of Kidney Graft Recipients.

A170 The Impact of Allograft Rejection on DNA Methylation After Kidney Transplantation.

A171 Cytokine Networks in Kidney Transplant Patients.
Robert Sabat, Ellen Witte, Petra Reinke, Kerstin Wolk, Nina Babel. Berlin, Germany; Herne, Germany.

A172 † The Urine Common Rejection Module (uCRM) Is a Sentinel Assay for Graft Rejection.
T. Sigdel, T. Tran, O. Bestard, F. Vincenti, M. Sarwal. San Francisco, CA; Barcelona, Spain.

A173 † Immunological Ageing-Related Expansion of Highly Differentiated CD4+CD28null T Cells Is Associated with a Lower Risk for Early Acute Rejection After Renal Transplantation.

A174 † Plasma Endothelial Microvesicle Counts Indicate Allograft Rejection Following Kidney Transplantation.
Daniel Zecher, Arun Cumpelik, Brigitte Ruhlank, Bernhard Banas, Helmut Hopfer, Michael Dickenmann, Jürg A. Schifferli. Regensburg, Germany; Basel, Switzerland.

A175 † End Stage Renal Disease Patients Have a Skewed T Cell Receptor Vbeta Repertoire.
A176 † Transitional B Cell T1/T2 Ratio Is a Prognostic Marker for Human Renal Allograft Deterioration.
A. Cherukuri, D. Rothstein, Richard Baker. Pittsburgh; Leeds, United Kingdom.

A177 † Urinary Expression of miRNA-155, miRNA-210, miRNA-142 and CXCL-10 Production Predicts the Risk of Acute Rejection and Graft Outcome in Renal Transplant Recipients.

A178 † A Quantitative CD45 Assay May Improve Diagnostic Accuracy of the Diagnosis of Acute Cellular Rejection in Transplant Kidney Biopsies.

A179 Analysis of T Cell Receptor Repertoire in Routine Renal Allograft Biopsy.
Roman Reindl-Schwaighofer, Johannes Weinberger, Raul Jimenez-Heredia, Judith Sunzenauer, Susanne Schaller, Stephan Winkler, Rainer Oberbauer. Vienna, Austria; Hagenberg, Austria.

Liver - Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies

A180 † A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant.

A181 Clinical Significance of Solitary Pulmonary Nodules in Liver Transplant Recipients with Hepatocellular Carcinoma.

A182 Elevated Lung Shunt Fraction as an Independent Predictor of Local Disease Progression and Metastasis in Hepatocellular Carcinoma.
Tyler Sandow, Daniel DeVun, Paul Gulotta, Humberto Bohorquez, David Kirsch. New Orleans, LA.

A183 3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).

A184 Transplantation for Hepatocellular carcinoma Is There a Tumor Size Limit?
Ahmed Daoud, Lary Teeter, Mark Ghobrial, Edward Graviss, Sherif Mogawer, Amany Sholkamy, Mostafa Alshazy, Howard Monsour, A. Osama Gaber. Houston, TX; Cairo, Egypt; Little Rock, AR.

A185 Use of Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma Does Not Increase Recurrence.

A186 Intraoperative Blood Loss Is a Promoter of Early Tumor Recurrence in Liver Transplant Patients with High Risk Hepatocellular Carcinoma.
Arno Kornberg, Ulrike Witt, Jennifer Kornberg, Helmut Friess, Katharina Müller, Katharina Thrum. Munich, Germany; Jena, Germany; Berlin, Germany.
A187 Assessing the Role of Everolimus in Reducing Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation for Patients within UCSF Criteria: Re-Inventing the Role of Mammalian Target of Rapamycine Inhibitors.
Long-Bin Jeng, Ashok Thorat, Horng-Ren Yang, Te-Hung Chen, Shih-Chao Hsu. Taichung, Taiwan.

A188 Occult Multifocal Hepatocellular Carcinoma in Surgical Patients.

A189 Comparative Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma (HCC-CCA) Undergoing Liver Transplantation: A Single Center Matched Cohort Analysis.

A190 Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.
Dong Goo Kim, Gun Hyung Na, Tae Ho Hong, Young Kyung You. Seoul, Korea.

A191 Predictive Value of Preoperation Serum Gamma-Glutamyltranspeptidase for Hepatocellular Carcinoma Prognosis After Liver Transplantation.
Shunjun Fu, Qiang Zhao, Maogen Chen, Linwei Wu, Qingqi Ren, Fei Ji, Zhiyong Guo, Xiaoshun He. Guangzhou, China.

A192 Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.

A193 Which Is the Predictable Value of Post-Transplant HCC Recurrence Between Tumor-Related Factors at the Initial Diagnosis and the Transplantation?

A194 Metabolomic Profiles of Hepatocellular Carcinoma and Cirrhotic Patients Before and After Transplantation.

A195 † Dysfunctional Production of Adipocytokines in Obesity Results in Inferior Oncologic Outcomes from Hepatocellular Carcinoma Following Liver Transplantation.
Abhishek Mathur, Eric Presbyskowski, Dustin Carpenter, Emmanuel Zorn, James Guarrera, Benjamin Samstein, Adam Griesemer, Karim Halazun, Yolanda Veras, Kato Tomoaki, Jean Emond. Ny, NY.

A196 Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?
Seung Hwan Song, Jee Youn Lee, Su-kyung Kwon, Juhan Lee, Jae Geun Lee, Dai Hoon Han, Gi Hong Choi, Myoung Soo Kim, Jin Sub Choi, Soon Il Kim, Dong Jin Joo. Seoul, Korea.

A197 Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation.
Living Donor Liver Transplantation

A198 † Impact of Sarcopenia in Overweight/Obese Recipients on the Outcomes After Adult Living Donor Liver Transplantation.
Ahmed Hammad, Yuhei Hamaguchi, Shinya Okumura, Atsushi Kobayashi, Shintaro Yagi, Shinji Uemoto, Toshimi Kaido. Mansoura, Dakahliya, Egypt; Kyoto, Japan.

A199 † Minimum Graft Size Avoiding Small-for-Size Associated Early Graft Failure in Living Donor Liver Transplantation.
Shigeru Marubashi, Hiroaki Nagano, Hidetoshi Eguchi, Hiroshi Wada, Koji Umesita, Yuichiro Doki, Masaki Mori, Naoya Sato, Takashi Kimura, Akira Kenjyo, Mitsukazu Gotoh. Fukushima, Japan; Suita, Japan.

A200 Laparoscopically Assisted Living Donor Hepatectomy Is Safe and Cost Effective.
Mohamed Akoad, Mary Ann Simpson, Elizabeth Pomfret. Burlington, MA.

A201 † Live Donor Liver Transplantation with Older Donors Only Impacts on a Late HCV Recurrence.

A202 Pretransplant Serum Hyaluronic Acid Can Be a Prognostic Predictor in Adult-to-Adult Living Donor Liver Transplantation.
Shugo Mizuno, Bidhan C. Das, Yusuke Iizawa, Hiroyuki Kato, Yasuhiro Murata, Akihiro Tanemura, Naohisa Kriyama, Yoshinori Azumi, Masashi Kishiwada, Masanobu Usui, Hiroyuki Sakurai, Shuji Isaji. Tsu, Japan; Dhaka, Bangladesh.

A203 Cytokine Storm in Acute Post-Hepatectomy Phase Associates with Liver Injury and Impaired Liver Regeneration.
Yinzhe Xu, Nalu Navarro-Alvarez, Jiahong Dong, James Markmann, Heidi Yeh. Boston, MA; Beijing, China.

A204 Portal Vein Complication After Living Donor Right Hepatectomy.

A205 Opioid-Sparing Pain Management Improves Outcomes and Safety in Living Liver Donors.

A206 Outcomes of Ductoplasty in Right Lobe Living Donor Grafts with More Than One Bile Duct.

A207 Time for the Grown Ups to Split the Difference? Outcomes of Two Adult Split Liver Transplants in the USA.

A208 Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation.

A209 Living Donor Liver Transplantation for Sick Patients with MELD Score ≥ 35.
Ruey-Shyang Soong, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Ching-Song Lee, Wei-Chen Lee. Taoyuan, Taiwan.
A210 Outcomes of Small-for-Size Grafts in Adult Living Donor Liver Transplantation.

A211 Barriers to the Wider Utilization of Living Donor Liver Transplantation (LDLT).
Anna Yegiants, Eric Przybyszewski, Alyson Fox, Jean Emond, Benjamin Samstein. New York, NY.

A212 Impact of Ideal Body Weight vs. Actual Body Weight for the Prediction of Small for Size Syndrome and Graft Loss After Living Donor Liver Transplantation.

A213 Long-Term Outcomes After Splenectomy for Small-for-Size Syndrome in Live Donor Liver Transplantation.

A214 Fatigue, Pain, and Other Physical Symptoms of Living Liver Donors.
Z. Butt, A. DiMartini, Q. Liu, M. A. Simpson, A. Smith, J. Zee, B. Gillespie, S. Abbey, D. Ladner, R. Weinreb, R. Fisher, S. Hafliger, N. Terrault, J. Burton, A. DiMartini. Chicago; Pittsburgh; Ann Arbor; Burlington; Toronto, Canada; Philadelphia; Richmond; New York; San Francisco; Denver.

A215 Longitudinal Psychological Outcomes of Living Liver Donors.
Z. Butt, M. A. Dew, Q. Liu, M. A. Simpson, A. Smith, J. Zee, B. Gillespie, S. Abbey, D. Ladner, R. Weinreb, R. Fisher, S. Hafliger, N. Terrault, J. Burton A. DiMartini. Chicago; Pittsburgh; Ann Arbor; Burlington; Toronto, Canada; Philadelphia; Richmond; New York; San Francisco; Denver.

A216 Personal Relationships and Financial Outcomes in Living Liver Donors.
A. DiMartini, M. A. Dew, Q. Liu, M. A. Simpson, D. Ladner, A. Smith, J. Zee, S. Abbey, B. Gillespie, R. Weinreb, S. Mandell, R. Fisher, J. Emond, C. Freise, Z. Butt. Pittsburgh; Ann Arbor; Burlington; Chicago; Toronto, Canada; Philadelphia; Denver; Richmond; New York; San Francisco.

A217 Technique of “Loop V-Plasty” for Combined Reconstruction of the Middle Hepatic Vein and Multiple Inferior Right Hepatic Veins Using Single Polytetrafluoroethylene Graft in a Right Lobe Living Donor Liver Transplantation.
Te-Hung Chen, Lorena Noriega, Ashok Thorat, Ping-Chun Li, Horng-Ren Yang, Shih-Chao Hsu, Longbin Jeng, Ming-Li Li. Taichung, Taiwan.

A218 A Multi-Center Study of Factors That Increase Cognitive Load in Living Donor Liver Transplants.

A219 Quality of Postoperative Pain Care in Living Liver Donors.
M. S. Mandell, A. Smith, D. Gordon, S. Holtzman, M. A. Dew, T. Howell, A. DiMartini, Z. Butt, M. A. Simpson, C. Freise, S. McCluskey, R. Fisher, J. V. Guarrera, K. Otthoff, E. Pomfret. Denver; Ann Arbor; Seattle; Okanagan, Canada; Pittsburgh; Burlington; Chicago; San Francisco; Toronto, Canada; Richmond; New York; Philadelphia.
A220  Updated Experience of Living Donor Right Hepatectomy Using Mini-Incision Technique.  
Shunji Nagai, Atsushi Yoshida, Michael Rizzari, Kelly Collins, Dean Kim, Marwan S. Abouljoud. Detroit, MI.

A221  Center and Surgeons’ Experience Improves Outcome in Adult-to-Adult Living Donor Liver Transplantation: Validation of the Report of the A2ALL Consortium.  
Shunji Nagai, Atsushi Yoshida, Michael Rizzari, Kelly Collins, Dean Kim, Marwan S. Abouljoud. Detroit, MI.

A227 † Functional Capacity Pre-Transplantation Measured by 6 Minute Walk Test and Clinical Outcomes.  

A228 † Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.  

A229 † Metabolomic Profiling of Individuals with Failing Kidney Allograft.  
Roberto Bassi, Monika A. Niewczas, Luigi Biancone, Stefania Bussolino, Alexander Lin, Anil Chandraker, Paolo Fiorina. Boston; Milan, Italy; Turin, Italy.

A230  Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.  
Lucrezia Furian, Lorenzo Di Maria, Gianni Cappelli, Mario Carmellini, Gionata Spagnoletti, Gian Benedetto Piredda, Paola Todeschini, Stefano Chiaramonte, Giuseppe Tisone. Padova, Italy; Firenze, Italy; Modena, Italy; Siena, Italy; Roma, Italy; Cagliari, ItalyBologna, Italy; Vicenza, Italy.

A231  Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).  
Richard J. Knight, Samir J. Patel, Jennifer Loucks-DeVos, Samantha A. Kuten, A. Osama Gaber. Houston, TX; Kansas City, KS.

A232  Late Outcome Surrogate Score (LOSS) for Kidney Allograft Failure.  
Bing Ho, Lihui Zhao, Samantha Montag, Daniela Ladner, Michael Abecassis, Anton Skaro. Chicago, IL.
A233 Development of Diabetic Glomerulosclerosis (DMGS) After Kidney Transplantation (KTX).
Fernando G. Cosio, Lynn D. Cornell, Mark D. Stegall. Rochester, MN.

A234 A 30% Decrease in Post-kidney Transplant Estimated Glomerular Filtration Rate (eGFR) from 6 Mo-2 Y is a Surrogate for 5 Y eGFR: Results from Clinical Trials in Organ Transplantation- (CTOT)-17.
Geovani Faddoul, Girish Nadkarni, Donald E. Hrick, Peter S. Heeger, CTOT17 Investigators. NY, NY; Cleveland, OH.

A235 Arteriolar Hyalinosis on Renal Transplant Protocol Biopsies Is Not Associated with Tacrolimus Exposure.
S. Yilmaz, D. Shaffer, Y. Qazi, F. Shihab, K. McCague, D. Patel, F. Vincenti. Calgary, AB, Canada; Nashville, TN; Los Angeles, CA; Salt Lake City, UT; East Hanover, NJ; San Francisco, CA.

A236 Renal Graft Survival According to Banff 2013 Diagnostic Categories in Indication Biopsies.
Dolores Redondo-Pachón, Carlos Arias-Cabrales, Maria José Pérez-Sáez, Javier Gimeno, Ignacio Sánchez-Güerri, Sheila Bermejo, Adriana Sierra, Carla Burballa, Marisa Mir, Marta Crespo, Julio Pascual. Barcelona, Spain.

Masayoshi Miura, Hiroshi Higashiyama, Takahiro Tsuji, Yuichiro Fukasawa. Sapporo, Japan.

A238 Cold Ischemia Induced Outcomes in Kidney Transplantation: A Meta-Analysis.
David Bennett, Muhammad Mustafa, Mariana Chiles, Whitney Skilten, Sumit Mohan. New York, NY.

A239 Early Onset Hyperuricemia Is a Prognostic Marker for Kidney Allograft Dysfunction.
Miyeun Han, Seung Hee Yang, In Mok Jung, Su-Kil Park, Young Hoon Kim, Duck Jong Han, Yon Su Kim, Sejoong Kim, Jung Pyo Lee. Seoul, Republic of Korea; Seongnam, Republic of Korea.

A240 Fluctuation of Renal Function During the First Year Is Associated with Negative Impact on Long-Term Kidney Graft Survival: A Retrospective, Propensity Score-Matched Study.
Hoon Young Choi, Dong Jin Joo, Mi Kyung Song, Myoung Soo Kim, Yu Seun Kim, Beom Seok Kim. Seoul, Korea.

A241 Do Highly Sensitized Recipients Benefit from the Immunological Advantages of Zero Mismatched (0MM) Deceased Donors (DD) Kidney Allografts?
Nisreen Elfadawy, Stuart Flechner, Jesse Schold. Cleveland, OH.

A242 Impaired Outcome of Kidney Transplants from Donors with Acute Kidney Injury.
Katharina Schuette-Nuetgen, Gerold Thölking, Hermann Pavenstädt, Sabrina Ehler, Barbara Suwelack, Daniel Palmes, Ralf Bahde, Stefan Reuter. Muenster, Germany.


A244 Impact of Allograft Dysfunction and Early Low Grade Proteinuria on Survival in Expanded Criteria Donor Kidney Transplant Recipients.

A245 The Effect of Everolimus and Tacrolimus Exposure Levels on Renal Histology Parameters 6 Months Post-Transplantation.
S. Yilmaz, D. Shaffer, Y. Qazi, K. McCague, D. Patel, V. R. Peddi, F. Vincenti. Calgary, Canada; Nashville; Los Angeles; East Hanover; San Francisco.

A246 Long-Term Deterioration of Graft Function (DeKAF) Study: Histologic Interpretation of Cross-sectional vs Prospective Cohorts.
Arthur Matas, A. Fieberg, L. Hunsicker, J. Grande, For the DeKAF Group. Mpls, MN; Iowa City, IA; Rochester, MN.
A247 Is Ketorolac Really Safe for Donor Nephrectomy?
Kazuhiro Takahashi, Krishna Putchakayala, Lauren Malinzak, Jason Denny, Marwan Abouljoud, Dean Kim. Detroit, MI.

A248 Serum Albumin Level Has Association with Both Graft Failure and Mortality in Kidney Transplant Recipients.

A249 Cinacalcet Versus Pre-Transplant Parathyroidectomy in Renal Transplant Recipients: Single Centre Experience.

A250 The Effect of Spironolactone on Calcineurininhibitor Induced Nephrotoxicity.
Line Aas Mortensen, Helle Charlotte Thiesson, Claus Bistrup, Finn Thomsen Nielsen, Ulrich Halekoh, Boye Lagerbon Jensen, Niels Marcussen. Odense, Denmark.

A251 Chronic Infection by Hepatitis C Virus and the Development of Transplant Glomerulopathy.
Dabaiba Regidor, Simona Alexandru, Miguel Angel Martinez, Natalia Polanco, Esther González, Antonio Serrano, Jose Maria Morales. Toledo, Spain; Madrid, Spain.

A252 Outcomes of Super Obese Patients Undergoing Kidney Transplantation: A Propensity Match Analysis from the UNOS Dataset.

Kidney Complications-Other III

A253 † Outcomes of Kidney Transplantation in Obese Recipients – Single Center Experience.

A254 † Do Morbidly Obese Patients Have an Increased Risk of Infection Post-Kidney Transplant?

A255 † Should Obese Patients Undergo Renal Transplantation? A Retrospective Analysis to Assess Whether Body Mass Index Can Affect Transplant Outcome.

A256 † Association Between Pretransplant Body Mass Index and Outcomes in Patients Undergoing Living Kidney Transplantation: A Consideration of Gender Differences.
Masayoshi Okumi, Kohei Unagami, Miyuki Furusawa, Toshihito Hirai, Yasuhiro Okabe, Kosuke Masutani, Tomokazu Shimizu, Kazuya Omoto, Hideki Ishida, Takanari Kitazono, Kazunari Tanabe, The Japan Academic Consortium of Kidney Transplantation (JACK). Tokyo, Japan; Fukuoka, Japan; Saitama, Japan.

A257 † Gut Dysbiosis and Metabolic Disorders in Kidney Transplant Recipients.

A258 † Diabetes Mellitus Predicts Outcome in Obesity After Kidney Transplantation.
Thomas Schachtner, Maik Stein, Petra Reinke. Berlin, Germany.

A259 † Impact of Pre-Existing Comorbidities on Long-Term Patient and Graft Survival in Kidney Transplant Recipients.
Fabian Halleck, Dmytro Khadzhynov, Lukas Lehner, Eva V. Schrezenmeier, Michael Duerr, Anna Kleinsteuber, Klemens Budde, Oliver Staeck. Berlin, Germany.
A260 † Can We Predict New-Onset Diabetes After Transplantation Previously?  
Ryoichi Imamura, Koichi Tsutahara, Shigeaki Nakazawa, Yoichi Kakuta, Toyoifumi Abe, Tetsuya Takao, Naotsugu Ichimaru, Seiji Yamaguchi, Shiro Takahara, Norio Nonomura. Suita, Japan; Osaka, Japan.

A261 † Characteristics Independently Associated with Kidney Candidates Having CPRA of 99-100%.  
Anna Kucheryavaya, David Klassen, Darren Stewart. Richmond, VA.

A262 † Complex Constellation of HLA Antibodies Contributes to Decreasing Trend of Transplant Rate in Candidates with 100% CPRA.  
Raja Rajalingam, David Hyon Gae, Dessislava Kopchaliiska, Owen Buenaventura, Kelly Cunniffe, Gil Da Gente, John Roberts. San Francisco, CA.

A263 † Clinical Outcome on Kidney Retransplantation in Comparison with First Kidney Transplantation in Korea – Nationwide Cohort Study.  
Jeong Ho Kim, Tae Hyun Ban, Byung Ha Jung, Bum Soon Choi, Cheol Whee Park, Chul Woo Yang, Yong-Soo Kim. Seoul, Republic of Korea.


A265 † Impact of Preformed Anti-HLA Antibodies in the Outcomes of Kidney Transplantation.  
Sofia Santos, Jorge Malheiro, Marta Costa, Andrea Campos, Sofia Pedroso, Manuela Almeida, La Salete Martins, Leonidio Dias, Castro Henriques, António Cabrita. Porto, Portugal; Viseu, Portugal.

A266 † Bone Allograft: An Unusual Cause of Sensitization.  
Julie Bloch, Vincent Elsermans, Francois Provôt, Arnaud Lionet, Lucie Wajbrot-Houzé, Christian Noel, Marc Hazzan. Lille, France; Béthune, France.

A267 † Early Posttransplant Complications Following Abo-Incompatible Kidney Transplantation.  

A268 † Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation in a Brazilian Center.  

A269 † Differential Characteristics of Kidney Transplant Recipients According to 1-Year Chronic Kidney Disease Stage 3a and Stage 3b Graft Function.  
Chung Hee Baek, Hyosang Kim, Won Seok Yang, Duck Jong Han, Su-Kil Park. Seoul, Republic of Korea.

A270 † United States versus Australia: Is “Percentage Decline in Estimated Glomerular Filtration Rate” Truly a Surrogate Outcome in Graft Survival?  
Karen Parker, Austin Rice, Angel Kirby, Mary Pinion, Karen Parker. Greenville, NC.

A271 † Association Between GFR Decline and Long Term Outcome in Renal Transplantation.  
Agnès Delay, Olivier Moranne, Nicolas Maillard, Eric Alamartine, Christophe Mariat. Saint Etienne, France; Nimes, France.
A272 † Negative Impact of Anticardiolipid Antibodies on 1-Year Renal Allograft Estimated Glomerular Filtration Rate: A Cohort Study.
Marion Gauthier, Florence Canoui Poitrine, Sophie Hue, Dominique Desvaux, Tomek Kofman, Philippe Lang, Philippe Grimbert, Marie Matignon. Créteil, France.

A273 † Serum Inflammatory Biomarkers in Kidney Transplant Recipients and Renal Donors.

A274 † Role of Natural Killer Cells in Kidney Transplant Outcome.
Elisabetta Carta, Roberto Littera, Maria G. Murgia, Maria B. Michitu, Bruno Onano, Gian B. Piredda, Davide Argiolas. Cagliari, Italy.

A275 † Monocytic TNF-α Response to EBV Peptides as a Mean to Identify Over-Immunosuppressed Kidney Transplant Recipients.
Patrice Vallin, Olivier Désy, Stéphanie Béland, Eric Wagner, Sacha A. De Serres. Quebec, QC, Canada.

A276 † Identification of Biomarkers for Progressive Fibrosis in Renal Transplant Patients Using Novel Chemical Imaging Approaches.
Vishal K. Varma, Andre Kajdacsy-Balla, Sanjeev Akkina, Suman Setty, Michael Walsh. Chicago, IL.

A277 † Correlation of the Shear Wave Elastography with Renal Function in Kidney Transplant Recipients: A Proof of Concept Study.

A278 † A Selective Biomarker in Blood Cells Identifies IFTA After Kidney Transplantation.

A279 † Urinary Markers of Proximal Tubular Dysfunction in Kidney Transplant as Predictors for CKD.

A280 † Impact of Social Support on Feelings of Powerlessness and Attitudes Towards the Kidney Transplant in Long-Term Inner City Recipients.
Sylvia Wu, Amarpali Brar, Mariana Markell. Brooklyn, NY.

A281 † Why Do African American Patients Display Disparities in Renal Graft Function Following Renal Transplantation?
Yaw A. Nyame, Valerie Gan, Pedram Aram, Daniel J. Greene, Nitin Yerram, Charles Modlin, Stuart Flechner. Cleveland, OH.

A282 † Evaluating Associations Between Clinical and Psychosocial Risk Factors and Adverse Post-Transplant Events in High Risk Renal Transplant Recipients.
Chelsie Yellman, Daniel Destiche, April DeMers, Irene Feurer, Michael Via, Christianna Gamble, Heidi Schaefer. Nashville, TN.

A283 † Watch Out for the Guy with the Low EPTS Score: Nonadherence and Kidney Allograft Failure.
Angela Liu, Krishna Balabhadrapatruni, Joshua Augustine. Cleveland, OH.

A284 † Kidney Transplant Patient Preferences and Trade-Offs for Outcomes After Transplantation.
Martin Howell, Germaine Wong, John Rose, Allison Tong, Jonathan C. Craig, Kirsten Howard. Westmead, NSW, Australia; Sydney, NSW, Australia; North Sydney, NSW, Australia.

A285 † Outcomes for Kidney Allograft Recipients with Language Barriers Post-Transplantation – A Comparative Analysis.
Sanna Tahir, Francesca Jackson-Spence, Holly Gillott, Felicity Everson, Jay Nath, Adnan Sharif. Birmingham, United Kingdom.
A286 † Predictors of Outcomes After Kidney Transplantation in the Setting of Chronic Opiate Use.
Rickey A. Evans, Nichole R. Neville, Ann M. Fugit, Roberto Gedaly, Timothy M. Clifford. Lexington, KY; Greenville, NC.

A287 † Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.
Rakesh L. Anand, Rachel Hung, Sharon Frame, Kate Bramham, Mary Wain, Antonia J. Cronin. London, United Kingdom.

A288 † The Use of Kidney Donors Older Than 80 Years Does Not Affect Graft Survival in the Medium Term.

A289 † Delayed Graft Function Is an Independent Risk Factor for Renal Allograft Rejection.

Tomohiro Tsuchiya, Hideki Ishida, Taiji Nozaki, Hiroki Shirakawa, Tomokazu Shimizu, Kazuya Omoto, Masayoshi Okumi, Kazunari Tanabe. Tokyo, Japan.

Asif Sharfuddin, Tim Taber, Muhammad Yaqub, Irfan Moiuddin, Ali Khalil, Oluwafisayo Adebiyi, Muhammad Mujtaba. Indianapolis.

A292 Myeloid-Derived Suppressor Cells (MDSC) Accumulate in Intestinal Transplant (IT) Patients.
Shinji Okano, Koji Hashimoto, Kareem Abu-Elmagd, John Fung, Danielle D. Kish, Karen Keslar, Bookie Min, Robert L. Fairchild, Charles Miller. Cleveland, OH.

A293 Number of Bacterial Isolates and Resistance Increases Mortality Risk in Intestinal Transplant Patients.

A294 CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.

A295 Living Related Small Bowel Transplantation in Children, a Single-Center Experience – Growth, Development and Quality of Life 10 Years After Transplant.
Sandra Garcia Aroz, Ivo Tzvetanov, Elizabeth Anne Hetterman, Jeon Hoonbae, Mario Spaggiari, Jose Oberholzer, Giuliano Testa, Eunice John, Enrico Benedetti. Chicago, IL; Chivago, IL; Dallas, TX.

A296 Health Disparities in Pediatric Intestinal Transplantation: Before and After the Implementation of MELD/PELD.
Valeria Cohran, Saeed Mohammed, Joshua Prozialeck, Anusha Gaddam, Juan Carlos Caicedo. Chicago, IL.

A297 Living Related Small Bowel Transplantation in Children – Patient and Graft Survival at 10 Years.
Sandra Garcia Aroz, Ivo Tzvetanov, Elizabeth Anne Hetterman, Jeon Hoonbae, Mario Spaggiari, Jose Oberholzer, Giuliano Testa, Eunice John, Enrico Benedetti. Chicago; Dallas, TX.
A298  Computed Tomography Measures of Nutrition Deficits in Patients with Intestine Failure.  
Indianapolis, IN.

A299  Surgical Techniques in Modified Multiorgan Transplantation.  
Weiqiang Ju, Jianwei Lin, Jian Zhou, Maogen Chen, Anli Yang, Dongping Wang, Yi Ma, Zhiyong Guo, Ming Han, Xiaoping Wang, Xiaofeng Zhu, Xiaoshun He.  
Guangzhou, Guangdong, China.

A300  Influence of Inclusion of the Liver on the Outcome After Intestinal Transplantation.  
Emilio Canovali, Diethard Monbaliu, Ina Jochmans, Mauricio Sainz Barriga, Laurens Ceulemans, Gert De Hertogh, Jacques Pirenne.  
Leuven, Belgium.

A301  The Surgical Preconditioning in Patients with Ultra-Short Gut Using a Native Colonic Conduit for Anticipated Visceral Transplantation.  
Masato Fujiki, Koji Hashimoto, Ajai Khanna, Kareem Abu-Elmagd.  
Cleveland, OH.

A303  Differences in the Prevalence of Food Allergies After Liver and or Bowel Transplantation.  
Khalid M. Khan, Chirag Desai, Stuart Kaufman, Alexander Kroemer, Jason Hawksworth, Raffaele Girlanda, Thomas Fishbein, Cal Matsumoto.  
Washington, DC.

A302  Donor Risk Index for Intestinal & Multi-Visceral Transplantation.  
Gang Zeng, Menghan Chen, Xiaomu Zhao, Douglas Landsittel, Hiroshi Sogawa.  
Pittsburgh, PA; Beijing, China; Valhalla, NY.

Raksha Patel, Megan Keck, Dean Collier, Mary Vacha.  
Omaha, NE.
Poster Session B
Poster Viewing: 9:30 am – 7:00 pm
Presenters in Attendance: 6:00 pm – 7:00 pm
Halls C&D

B# indicates the board location where the poster will be displayed.

† Those posters identified as an ATC Poster of Distinction by this symbol have received review scores that place them in the top 10% of their category. The Planning Committee encourages you to make them a priority when you visit the poster session.

Allograft Rejection, Tolerance, and Xenotransplantation

B1 † High Concentrations of CXCL9 and CXCL10 Chemokines but Not CXCL8 (IL-8), IL-6, TNF-a or IFN-g in Biopsy Tissue Are Associated with Pathological Staging of Rejection After Kidney Transplantation.
Christine S. Falk, Christine Neudörfl, Kerstin Daemen, Jana Keil, Frank Lehner, Hermann Haller, Jessica Schmitz, Cornelia Blume, Jan-Hinrich Bräsen, Hannover, Germany; Hannover, Deutschland, Germany.

B2 † Th17 Development Is Critical for Airway Epithelial Injury After Transplantation.
Jiangnan Xu, Yamei Zhang, Lifeng Wang, Xiaona Li, Rongjuan Chen, Ruochan Zhang, Yaozhong Ding, Beijing, China.

B3 † Activation of Alloreactive T Cells by Allogeneic Exosomes and Cells Cross-Dressed with Allogeneic MHC Molecules.
Mohamed H. Babiker-Mohamed, Jose Marino, Patrick Crosby, Gilles Benichou. Boston, MA.

B4 † Imaging Cell Biology In Vivo with Intravital-Microscopy.

B5 † Donor Sharpin Expression Modulates TNFα Mediated Inflammation and Cardiac Allograft Rejection in Mice.
Rosalind L. Ang, Peter Heeger, Adrian Ting. New York City, NY.

B6 † Exosome-Like Vesicles Released in Association with Tissue Injury Trigger Anti-LG3 Production.
Mélanie Dieudé, Julie Turgeon, Bing Yang, Luc Pomerleau, Katia Hamelin, Shanshan Lan, Shijie Qi, Diane Gingras, Wahiba Dhari, Alain Rivard, Marie-Josée Hébert. Montréal, Canada; Edmonton, Canada.

B7 † Distinct Effects of Chronic Hyperglycemia on Cellular and Humoral Alloresponses In Vivo.
Nicholas H. Bishop, K. Scott Beard, Ronald G. Gill. Aurora, CO.

B8 † Lysosome Activity Regulates LG3 Export by Apoptotic Cells.
Déborah Beillevaire, Julie Turgeon, Éric Boilard, Mélanie Dieudé, Marie-Josée Hébert. Montréal, Canada; Québec, Canada; Edmonton, Canada.

B9 † The Increase of Serum MiR-142-3p Level in Acute Cardiac Rejection as a Reflection of Exosome-Mediated Genetic Exchange Between T Cells and Endothelial Cells.
Ihdina Sukma Dewi, Zsuzsanna Hollander, Bruce McManus, Olof Gidlöf, Jenny Öhman. Lund, Sweden; Vancouver, Canada.

B10 † Heterologous Persistent and Latent Viral Infections Do Not Impact Graft Survival.

B11 † Profiling of T Cell Subsets in a Primate Cardiac Transplant Model.

B12 † Vascular Endothelial Cell Activation by Mitochondria Links Innate and Adaptive Immune Responses to Allograft Injury.
Feifei Feng, He Xu, Liwen Lin, Allan D. Kirk, Todd V. Brennan. Durham, NC.
B13 † Direct Alloimmunity Is Driven by Recipient APCs Displaying Donor MHC Molecules.
Jose Marino, Joshua Paster, Patrick Crosby, Mayuko Uehara, Scott Mordecai, Reza Abdi, Georges Tocco, Gilles Benichou. Boston, MA.

B14 † MHC/HLA-Specific IgE in Allotransplantation.

B15 † Eomesodermin Expression by CD8+ Alloreactive T Cells in Human and Nonhuman Primate Allograft Recipients.
Angelica Perez-Gutierrez, Lien Lu, Alan Zahorchak, Yoshihiro Ono, Angus Thomson, Mohamed Ezzelarab. Pittsburgh, PA.

B16 † Sepsis Prolongs Allograft Survival Compared with Non-Septic Infection in a Murine Model of Skin Transplantation and Pseudomonas aeruginosa Pneumonia.
Lindsay M. Margoles, Sonia J. Laurie, Craig M. Coopersmith, Mandy L. Ford. Atlanta, GA.

B17 † ESAT-6 Inhibits Donor-Specific Memory CD8+ T Cell Generation and Alloimmune Responses.
Zhenhua Dai, Hehua Dai. Guangzhou, China; Pittsburgh.

B18 Heat Shock Protein 90 Inhibitor 17DMAG Is a Potential New Therapeutic Agent Against Acute Allograft Rejection.
Takeshi Maehana, Toshiaki Tanaka, Hiroshi Kitamura, Naoya Masumori. Sapporo, Japan; Toyama, Japan.

B19 Bile Acid Signaling Affects Metabolism and Prolongs Allograft Survival in Obese Recipients.
Markus Quante, Abdallah ElKhal, Midas Seyda, Jeroen Schuitenmaker, Hirofumi Uehara, Stefan G. Tullius. Boston, MA.

B20 Aging Is Critically Impacting the Efficacy of Immunosuppressants.
Jeroen M. Schuitenmaker, Karoline Edtinger, Midas Seyda, Hirofumi Uehara, Marcus Quante, Abdallah ElKhal, Stefan G. Tullius. Boston, MA.

B21 CMV-Accelerated Cardiac Allograft Rejection Is Associated with Dysregulation of Sphingolipid Metabolomics.
Jennifer M. Burg, Takeshi F. Andoh, Nicole N. Haese, Craig N. Kreklywich, Katrina Watters, Thomas O. Metz, Susan L. Orloff, Daniel N. Streblow. Portland, OR; Richland, WA.

B22 Aryl Hydrocarbon Receptor Expression Increases in Skin Graft-infiltrating Th1 and Treg Cells.

B23 † Anti-BTLA Antibody (6B2) Induced Prolongation of Fully MHC-Mismatched Murine Cardiac Allograft and Generation of Foxp3+ Regulatory T Cells.
Masateru Uchiyama, Enzhi Yin, Xiangyuan Jin, Tomoki Shimokawa, Hideo Yagita, Masanori Niimi. Tokyo, Japan; Harbin, China.

B24 † MicroRNA let-7i Regulates Dendritic Cells Maturation Targeting Interleukin-10 via JAK1-STAT3 Signal Pathway Subsequently Induces Prolonged Cardiac Allograft Survival in Rats.
Xiangyuan Jin, Yong Sun, Xianglan Liu, Junfeng Wang, Shidong Xu, Lei Yao, Zheng Zhao, Linlin Jiang, Qiong Wu, Jian Wu. Harbin, China.

B25 † B Lymphocyte-Induced Maturation Protein-1 Promotes Allograft Survival via Modulation of T Cell Development.
B26 † Neonatal Tolerance to Blood Group A-Antigen in a Mouse Model of ABO-Incompatible Heart Transplantation (ABOi HTx).
B. Motyka, B. Lamarche, K. Labonte, S. Wang, J. Pearcey, K. Tao, M. Mengel, B. Sis, P. J. Cowan, Lori J. West. Edmonton, Canada; Melbourne, Australia.

B27 † Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allografts by Combination of Anti-BTLA mAb (6B2) and Anti-PD-1 mAb (PIM-2).
Enzhi Yin, Masateru Uchiyama, Xiangyuan Jin, Tomoki Shimokawa, Hideo Yagita, Masanori Niimi. Tokyo, Japan; Harbin, China.

B28 † Recapitulating Peripheral T Cell Development in Neonatal Mice to Induce Transplant Tolerance.
Roger A. Bascom, KeSheng Tao, Lori J. West. Edmonton, Canada.

B29 † The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.

B30 † Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.
Katayoun Ayasoufi, Victoria Gorbacheva, Fan Ran, Anna Valujskikh. Cleveland.

B31 † Belatacept Immunotherapy Is Not Augmented by Blockade of Activated LFA-1 in a Nonhuman Primate Renal Transplant Model.
Kannan P. Samy, Michael S. Mulvihill, Bradley H. Collins, Denise J. Lo, Mingqing Song, Frank V. Leopardi, Allan D. Kirk. Durham, NC; Atlanta, GA.

B32 † Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells.

B33 † iNKT Cell Activation Under Co-Stimulatory Blockade Establishes Mixed Chimerism Through Thymic Regulatory T Cell Activation.
Toshihiro Hirai, Yasuyuki Ishii, Rumi Ishii, Satoshi Miyairi, Masako Ikemiyagi, Masayoshi Okumi, Kazunari Tanabe. Shinjuku, Tokyo, Japan; Yokohama, Kanagawa, Japan.

B34 † Treg-Rich Organized Lymphoid Structures (TOLS) in Spontaneously Accepted Mouse Kidney Allografts.

B35 † In Vitro Reactivity of CD4+ T Cells Subsets from Hosts with Antigen Specific Transplant Tolerance Mediated by CD4+CD25+ T Cells.
Bruce M. Hall, Catherine M. Robinson, Karren M. Plain, Nirupama D. Verma, Giang T. Tran, Nicole Carter, Masaru Nomura, Rochelle Boyd, Suzanne J. Hodgkinson. Sydney, NSW, Australia.

B36 † Impact of Mixed Xenogeneic Chimerism on Human B Cell Response to Pig Antigens.
Hao Wei Li, Steven Shao, Paresh Vishwasrao, Markus Holzl, Megan Sykes. New York, NY.

B37 † Long Term Heterotopic Cardiac Xenograft Survival from Donor Pigs with Six Gene Modifications.

B38 † Long-Term Islet Xenograft Survival Requires Effective Control of Early Xenogeneic IL-17 Response and Late Xenogeneic IFN-α Response.
Hee Kap Kang, Shusen Wang, Xiaomin Zhang, Amar Singh, Lei Zhang, Wilma Suarez-Pinzon, Stephen Miller, Bernhard Hering, Xunrong Luo. Chicago, IL; Tianjin, China; Minneapolis, MN.
B39 † Successful Human-to-NonHuman Primate Pancreatic Islet Intraportal Xenotransplantation Using a Human Allo-Based Immunosuppression Regimen and Its Potential Pre-Clinical Application.
James J. McGarrigle, Matthew A. Bochenek, Enza Marchese, Arshad Khan, Diana Gutierrez, Augusta Mikalauskaite, Benjamin McCracken, Mick Reedy, Mustafa Omami, Chun-Chieh Yeh, Mario Spaggiari, Mohammad Nourmohammadzadeh, Douglas Isa, Sofia Ghani, Ling-jia Wang, Joshua Mendoza-Elias, Yong Wang, Jose Oberholzer. Chicago.

B40 † Multiplex Profiling of Plasma Proteins After Xenogenic Lung Exposure.
Agnes M. Azimzadeh, Nan Cheng, Xiangfei Cheng, Evan Schwartz, Lars Burdorf, Siamaah Dahi, Natalia Kubicki, Dawn Parsell, Tianshu Zhang, David K. C. Cooper, Carol Phelps, David Ayares, Richard N. Pierson III. Baltimore, MD; Pittsburgh, PN; Blacksburg, VA.

B41 Human PDL1+ SLA-DR- Swine Vascular Endothelial Cells Suppress Pig-Human PBMC Xeno-MLR(Mixed Lymphocyte Reaction) by Inducing Human Regulatory IL-10+Tr1(Type 1 Regulatory T Cells) Subset for Suppression of Xenogeneic Reactions.
Qixiang Shao, Quing Diag. Zhenjiang, Jiangsu Province, China.

B42 A Novel Humanized Mouse Model Incorporating Non-Fetal Tissue.

B43 Porcine Islets Engineered with SA-FasL Protein Induces Robust Tolerance in Mice through CD4+CD25+FoxP3+ Treg Cells.
Kyle B. Woodward, Hong Zhao, Havaal Shirwan, Feng Wang, Melanie Graham, Bernhard Hering, Esma S. Yolcu. Louisville, KY; Minneapolis, MN.

B44 A Novel Inflammation-Targeting Tacrolimus Hydrogel for Liver Transplantation.
Junjun Jia, Jianhui Li, Yanfei Zhou, Li Jiang, Jing Zhang, Haoehao Lu, Haiyang Xie, Lin Zhou, Praveen Kumur, Shusen Zheng. Hangzhou, China; Boston.

B45 Function of Sertoli Cells in Regulating Allogeneic T Cell Differentiation into Treg and Th17 In Vitro.
Lin Xie, Wei Jiang. Wuhan, China; Beijing, China.

B46 † Evaluation of Conformational Diversity of a Single HLA-I Molecule Coated on Single Antigen Beads: Potential Impact on Organ Allocation?
Vadim Jucaud, Mepur H. Ravindranath, Paul Terasaki. Los Angeles, CA.

Disparities in Access and Outcomes

B47 † One-Year Graft Loss Risk in Kidney Transplants – A Big Data Approach.

B48 † Neighborhood Poverty and Gender Disparities in Access to Live Donor Kidney Transplantation.
Tanjala S. Purnell, Xun Luo, Sunjae Bae, Lauren M. Kucirka, Dorry L. Segev. Baltimore.

B49 † Neighborhood Socioeconomic Characteristics Influence Access to Kidney Transplantation Independently of Individual Socioeconomic Status.
Joel T. Adler, James F. Markmann, David C. Chang, Heidi Yeh. Boston, MA.

B50 † African Americans and Organ Donation: Where Do We Go After Moving from the Bottom to the Top?
Clive O. Callender, Naoru Koizumi, Patrice V. Miles, J. Keith Melancon. Washington, DC; Arlington, VA.

B51 Older Patients Reliably Participate in Automated Living Donor Follow Up Rather Than Avoiding This New Technology.
| B52 | African Americans Have Greater Odds of Late Stage Diagnosis of Hepatocellular Carcinoma in Mississippi. Marco Aru, Samantha Seals, Brandon Ingram, Ashley Seawright, Christopher Anderson, Truman Earl. Jackson, MS. |
| B55 | Culture Specific Interventions to Increase Organ Donation Advocacy in a Hispanic Serving Institution. Yasar Tasnif, Suad Ghaddar, Shawn Saladin, Aurora Alaniz. Edinburg, TX. |
| B56 | Why Are Pancreas Transplants Declining in the United States in the Past Decade? Robert J. Stratta, Angelika Gruessner, Jon Odorico, Jonathan A. Fridell, Jeffrey Rogers, Alan C. Farney, Giuseppe Orlando, Rainer W. G. Gruessner. Winston-Salem, NC; Syracuse, NY; Madison, WI; Indianapolis, IN. |
| B57 | Assessment of Transplant Health Literacy of Liver Transplant Candidates and Their Caregivers. Yanik J. Bababekov, Zhi Ven Fong, Joel T. Adler, Heidi Yeh, David C. Chang, James J. Pomposelli. Boston, MA; Burlington, MA. |
| B60 | The Impact of Etiology of Liver Disease and Indication for Transplantation on Access to the Liver Transplant Waiting List in the United States. David S. Goldberg, Benjamin French, Craig Newcomb, Qing Liu, James D. Lewis, Scott D. Halpern. Philadelphia, PA. |
| B61 | Identifying Social Barriers to Health Literacy in ESRD Patients Undergoing Kidney Transplant Evaluation. Katie Leick, Jody Jones, Sue Witte, Lawrence Hunsicker, Zoe Stewart. Iowa City, IA. |
| B64 | Increasing Volume and Improved Survival in Solid Organ Transplantation for Amyloidosis – An Analysis of the UNOS Database. Javier Jaramillo, Josef Stehlik, James Fang, Ragheed Al-Dulaimi, Edward M. Gilbert, Stavros Drakos, Omar Wever-Pinzon, Craig Selzman, Stephen McKellar, Tibor Kovacsovics, Jo Abraham, Mathew Maurer, Jose Nativi-Nicolau. Salt Lake City, UT; New York, NY. |
Michelle Jesse, Eric Goldstein, Nicholas Rebhan, Chuan-Xing Ho, Taylor Macaulay, Mubera Bebanic, Lina Shkokani, Dilip Moonka, Marwan Abouljoud, Atsushi Yoshida. Detroit, MI.


Keren Ladin, Alexis Daniels, Mikala Osani, Raveendhara R. Bannuru. Medford, MA; Boston, MA.

B68  Dynamic Detection of Anti-HLA Antibodies Can Predict aGVHD and OS in HLA-12/12 Matched Unrelated-Donor Allo-HSCT for Hematological Malignancies.  
Jun He, Zhijuan Pan, Xiaoni Yuan, Yang Li, Xiaojin Wu, Wenjuan Zhu, Xiaojin Bao, Qin Qin Zhao. Suzhou, Jiangsu, China.

Vincenzo Cantaluppi, Alessandro D. Quercia, Sergio Dellepiane, Davide Medica, Luigi Biancone. Novara, Italy; Torino, Italy.

B70  Does Pre-Emptive Transplantation Improve Survival Compared to Transplantation After Dialysis Among Deceased Donor Kidney Recipients?  
Jiang Tao, Charlotte Wu, Wade Bannister, Mark A. Schnitzler, Anthony F. Bonagura, Bart Laihinen, Frank D. Irwin. Eden Prairie, MN; St Louis, MO.

B71  Socioeconomic Status and Readmission Following Kidney Transplant.  
Sandra DiBrito, Elizabeth King, Morgan O’Hare, Dorry Segev. Baltimore.


B73  Survival Advantage in the Elderly with Kidney Transplantation.  

B74  Psychiatric Characteristics of Acute Liver Failure Patients: Acetaminophen Overdose versus Other Etiologies.  

B75  Predicting Survival to Listing for Liver Transplantation: Do MELD and Race Interact?  

B76  Post-Transplant Vaccine Initiative Collaboration (VIC) in a Multidisciplinary, Transplant Ambulatory Setting.  
Gregory Malat, Steven DiLollo, Dong Heun Lee, Akskay Sharma, Tiffany Bias, Meera Harhay, Karthik Ranganna, Alden Doyle. Colonia; Philadelphia.

B77  Transplants without Borders – A Project for In Locus Training of New Transplants Centers in Brazil.  
Marcelo Perosa, Juan Branez, Leonardo Mota, Beimar Zeballos, Huda Noujaim, Luiz Esteven Ianhez, Leon Alvim, David Machado, Marcio Moreno, Tercio Genzini, Raja Kandaswamy. Sao Paulo, SP, Brazil; Minneapolis, MN.
Kidney Transplantation Offers a Significant Survival Advantage Compared to Waitlisting, a Single Centre Experience.

Impediments to Timely Listing for HIV+ Patients Being Evaluated for Kidney Transplantation.


Donor Management: All Organs

Pediatric Critical Care Education Impacts Pediatric Organ Donation.
Daniel J. Lebovitz, Thomas A. Nakagawa, Charles Wright. Akron, OH; Wake Forest, NC; Tampa, FL.

Exome Sequencing and HLA-Independent Prediction of Long-Term Kidney Allograft Function.

Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy.
Parissa Tabrizian, Massimo Giacca, Jake Prigoff, Edward Chin, Michael Palese, Daniel Herron, Antonios Arvelakis, Dianne LaPointe Rudow, Sander Florman, Ron Shapiro. New York, NY.

Difficult to Place Livers: Implications for Expanding the Donor Pool.
Erick Edwards, Ann Harper, John Rosendale, James Eason. Richmond, VA; Memphis, TN.

Defining Ischemic Time in Lung Donation After Circulatory Determination of Cardiac Death.
Diana L. Pratt, Zachary N. Kon, Aldo T. Iacono, June Kim, Robert Reed, Irina Timofte, James S. Gammie, Si M. Pham, Bartley P. Griffith, Pablo Sanchez. Baltimore, MD.

Donor Specific Antibody Used to Predict Crossmatch Results: A Clinically Useful Algorithm Derived from the College of American Pathologists Survey.
Sean M. Wrenn, Donna-Sue Hain, Sarah Harm, Susan E. Hillyard, Diti H. Shah, Paullete B. Hammond, Carlos E. Marroquin, Mark Fung. Burlington, VT.

Utility of a Scoring Tool for Living Kidney Donor Volunteers.
Savahanna Lien, Linda Willey, Anne Lecuyer-Koich, Margaret Voges, Ty B. Dunn. Indianapolis, IN; Minneapolis, MN.

Really Old (>84 Years) Deceased Donor Livers Can Save Lives.
Amy L. Friedman, Emmanuel Donor Livers Can Save Lives.
Mary Bowring, Allan Massie, Lauren Kucirka, Eric Chow, Mark Sulkowski, Dorry Segev, Christine Durand. Baltimore.


B93 Deceased Organ Donors Influencing Pancreatic Graft Transplantation and Survival. Mitchell B. Sally, Margaret K. Ellis, Tahnee Groat, Xiang Gao, Salvador De la Cruz, Madhukar Patel, Darren J. Malinoski. Portland, OR.


B95 The Immunologic Profile of Brain Death in Humans: A Whole-Body Analysis. Dustin Carpenter, Nobuhide Matsuoka, Joseph Thome, Tomer Granot, Claire Gordon, Brahna Kumar, Takashi Senda, Michelle Miron, Joshua Weiner, Adam Griesemer, Donna Farber. New York City, NY.

B96 Rapid Withdrawal of Donation After Cardiac Death Donors. Kristin L. Mekeel, Jeff Trageser, Wendy Garrison, Jennifer Berumen, Lisa Stocks, Alan Hemming. La Jolla, CA; San Diego, CA.


B98 Deceased Organ Donors with Zero Organs Transplanted: Why and How Can We Improve? Paul A. Lange, Steven M. Rudich, Nosa Obaseki, Jeffrey Punch. Ann Arbor, MI.

B99 Validation of the Newly Developed North America Islet Donor Scoring System in the Medium Volume Islet Transplant Center. Julia Solomina, Sabrina Matosz, Maciej Sledzinski, Justyna Golebiewska, Omid Savaril, Ling-jia Wang, Tatsuya Kin, Karolina Golab, Sabarinathan Ramachandran, Martin Tibudan, Lindsay Schenck, W. James Chon, Celeste Thomas, Piotr Witkowski. Chicago, IL; Gdansk, Poland; Edmonton, AB, Canada.

B98 Does Location Matter for Withdrawal of Donation After Cardiac Death Donors? Kristin L. Mekeel, Wendy Garrison, Jeff Trageser, Jennifer Berumen, Lisa Stocks, Alan Hemming. La Jolla, CA; San Diego, CA.


B101 Virological Profile of Deceased Organ Donors in the UK. Marcus Lawrance, Katy Davison, Ines Ushiro-Lumb, Sam Lattimore (deceased), Susan Brailsford. London, United Kingdom.

B102 Review of Organ Utilization from Increased Infectious Risk Donors. Arnaud G. L’Huillier, Atul Humar, Clare Payne, Deepali Kumar. Toronto, Canada.

B103 Drug Minimization

B105 † Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.
Sunjae Bae, Allan Massie, Sandra DiBrito, Xun Luo, Lauren Kucirka, Dorry Segev.
Baltimore, MD.

B106 † Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.
Bjorn Nashan, Markus van der Giet, Hallvard Holdaas, Martin Zeier, Julio Pascual, Yingyos Avihingsanon, Patricia Lopez, Jose Aguilar-Sanchez, Jossy Kochuparambil, Zailong Wang, Josep M. Cruzado, Johan W. De Fijter. Hamburg, Germany; Basel, Switzerland; East Hanover.

B107 † Quadruple Induction Regimen with Basiliximub, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.
Masayoshi Miura, Hiroshi Higashiyama. Sapporo, Japan.

B108 † Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.

B109 † A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
Jacek Klepacki, Jost Klawitter, Jelena Klawitter, Anis Karimpour-fard, Erin Anderson, Gordon Ingle, Dharmesh Patel, Kent Johnson, Diane Cibrik, Uwe Christians. Aurora, CO; East Hanover, NJ; Ann Arbor, MI.

B110 † Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.
Aneesha Shetty, Opas Traitanon, M. Javeed Ansari, James Mathew, Joseph Leventhal, Valeria Mas, Lorenzo Gallon. Chicago, IL.

B111 † Stratification of Kidney Transplant Recipients into Those with Low and High Alloreactive T-Cells May Allow Safe Conversion to mTOR-Inhibitor-Based Immunosuppression.
Thomas Schachtner, Maik Stein, Petra Reinke. Berlin, Germany.

B112 † Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.

B113 † Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.

B114 † A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.

B115 † Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.
**B116** How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.
Stavros Papachristos, Anju John John Velvet, Angela Summers, Afshin Tavakoli, Raman Dhanda, Ravi Pararajasingam, Bence Forgacs. Manchester, United Kingdom.

**B117** Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.
Bhavna Chopra, Kalathil K. Sureshkumar. Pittsburgh, PA.

**B118** Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
Hsuan-Ping Chang, Chih-Yuan Lee, Chan-Chan Si, Meng-Kun Tsai, Fe-Lin Lin Wu. Taipei, Taiwan.

**B119** High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.

**B120** Evaluation of an Early Steroid Withdrawal Maintenance Regimen in African American Renal Transplant Recipients.
Steven Gabardi, Miae Kim, Razan Alsheikh, Keri Townsend, Anil Chandraker. Boston, MA.

**B121** Advantages of Computerized Dosing Strategy in Tacrolimus Treatment of Renal Transplant Patients.
Song-Yi Kim, Sungsin Cho, Min-Ji Cho, Chang Hwan Lee, Ahram Han, Chanjoong Choi, Sanghyun Ahn, Sang-il Min, Seung-Kee Min, Myung Hee Park, In Mok Jung, Sang Joon Kim, Jongwon Ha. Seoul, Korea; Goyang-si, Korea.

**B122** A Weighted Approach to Composite Efficacy Analysis in Kidney Transplantation.

**B123** Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.
Enrico Eugenio Minetti, Lorenzo Di Maria, Leonardo Caroti, Elisa Buti, Paolo Carta. Florence, Italy.

**B124** Impact of Ethnicity on Tacrolimus Trough/Dose Ratios Following Solid Organ Transplantation.
Andrew Santeusania, Aniwaa Owusu-Obeng, Janina Jeff. New York.

**B125** Pediatric Patients Benefit from Steroids Free Regimen After Kidney Transplantation: A Meta-Analysis.

**B126** Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.

**B127** Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Kidney Recipients.
Chang-Kwon Oh, Sung-Joo Kim, Kyu Ha Huh, Soo Jin Kim, Hong Rae Cho, Su Hyung Lee. Suwon, Republic of Korea; Seoul, Republic of Korea; Pocheon, Republic of Korea; Ulsan, Republic of Korea.

**B128** The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
E. Steve Woodle, Dixon B. Kaufman, Adele R. Shields, John Leone, Arthur Matas, Alexander Wiseman, Patty Thielke, Rita R. Alloway. Cinci; Madison; Tampa; Minn; Denver; Chic.
B129 TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients—Baseline Characteristics.
Mitchell L. Henry. Columbus, OH.

B130 Elderly Kidney Transplant Recipients Need Optimized Immunosuppression According to Comorbidity and Infection.
Eunjeong Kang, Seokwoo Park, Sehoon Park, Seung Hee Yang, In Mok Jung, Su-Kil Park, Young Hoon Kim, Duck-Jong Han, Yon Su Kim, Jung Pyo Lee. Seoul, Korea.

B131 Steroid Free Immunosuppression and Clinical Outcomes in Recipients of Deceased Donor Kidney Transplant with Positive Flow Cytometry Crossmatch.
Oluwafisayo Adebiyi, Tim Taber, William Goggins, Dennis Mishler, Muhammad Yaqub, Asif Sharfuddin. Indianapolis.

B132 Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.
Shiv Bhutani, Arvind Ponnusamy, Qurat Tak, Siddharth Shah, Judith Worthington, Angela Summers, Kay Pouton, David Van Dellen, Muir Morton, Michael Picton. Manchester, United Kingdom; Preston, United Kingdom.

B133 Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.

B134 Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine versus Tacrolimus Based Immunosuppression Protocol.
Patricia West-Thielke, Alexandra Lasky, James Thielke, Maya Campara, Enrico Benedetti. Chicago.

B135 Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.
F. Shihab, Y. Qazi, S. Mulgaonkar, K. McCague, D. Patel, V. R. Peddi, D. Shaffer. Salt Lake City, UT; Los Angeles, CA; West Orange, NJ; East Hanover, NJ; San Francisco, CA; Nashville, TN.

Hearts and VADs in Depth - The Force Awakens

B136 † Donor-Recipient Race Matching Is Not Associated with Recipient Survival Following Heart Transplantation.
Charles F. Evans, Pablo G. Sanchez, Zachary N. Kon, Erica D. Feller, Bartley P. Griffith, Si M. Pham. Baltimore, MD.

B137 Gender Mismatch in the UNOS Heart Transplant Database: Not a Factor in Younger Heart Transplant Patients.
Jon Kobashigawa, Michelle Kittleson, Lawrence Czer, Tamar Aintablian, Elizabeth Passano, David Chang, Fardad Esmailian, Jignesh Patel. Los Angeles, CA.

B138 Predictors of Donor Heart Utilization in United States.

B139 The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation.
B140  Is Donor Methamphetamine Use a Contraindication in Heart Transplantation?
Michelle Kittleson, Jignesh Patel, Lawrence Czer, Angela Velleca, Tamar Aintablian, David Chang, Fardad Esmailian, Jon Kobashigawa. Los Angeles, CA.

B141  Outcome of the Various Pathology Grades of Antibody-Mediated Rejection After Heart Transplantation.
Jignesh Patel, Michelle Kittleson, David Chang, Tamar Aintablian, Lawrence Czer, Alfredo Trento, Jon Kobashigawa. Los Angeles, CA.

B142†  Assessment of Molecular Mechanisms of Non-Transplant Cardiac Hypertrophy in Cardiac Allograft Hypertrophy – An Exploratory Gene Array Study of Myocardial Biopsy Samples.

B143†  Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and Immuno-Regulatory miRNA Induce Graft Rejection.
M. Sharma, M. Gunasekaran, Z. Xu, N. Steward, W. Liu, N. Benshoff, Thalachallour Mohanakumar. St. Louis, MO; Phoenix, AZ.

B144†  Gene Expression Levels of Advanced Heart Failure Patients in Terms of Coagulation and Its Effect within Multiple Organ Dysfunction Syndrome.
Ryan C. Togashi, Eleanor Chang, Nicholas Wisniewski, Martin Cadeiras, Galyna Bondar, Elaine Reed, Mario C. Deng. Los Angeles, CA.

B145†  Heart and Kidney Transplants in Patients with Mechanical Circulatory Support: Who Needs a Kidney?

B146  The Role of Short-Term Ventricular Assist Device in Patients with Cardiogenic Shock – Is It Really a Solution?

B147  Impact of Transfusion Requirements on Likelihood of Heart Transplantation After Total Artificial Heart.
Jason A. Cook, Le Kang, Maureen P. Flattery, Inna Tchoukina. Richmond, VA.

B148†  Management and Outcomes of Upper Extremity Deep Venous Thrombosis in Heart Transplant Patients.

B149†  Posterior Reversible Encephalopathy Syndrome After Pediatric Heart Transplantation: Increased Risk for Children with Preexisting Glenn/Fontan Physiology.
Mariska Kemna, Braiden Eilers, Erin Albers, Yuk Law. Seattle, WA.

B150  Elucidating Clinical Factors Implicated in Primary Graft Dysfunction After Heart Transplantation.
Raymundo A. Quintana-Quezada, Indranee Rajapreyar, YiChun Yeh, Sangbum Choi, Igor Gregoric, Pranav LoyaIka, Biswajit Kar. Houston, TX.

Jillian P. Casale, Angela T. Logan, Christina T. Doligalski. Tampa, FL.

B152  Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
Arezu Z. Aliabadi, Johannes Goekler, Olivia Salameh, Thomas Haberl, Barbara Steinlechner, Philipp Opfermann, Alexandra Kaider, Keziban Uyanik-Uenal, Guenther Lauffer, Andreas O. Zuckermann. Vienna, Austria.
B153 Treatment for AMR and DSA: A Center Based Review of Pediatric Orthotopic Heart Transplant Recipients.
Diana Droglalis-Kim, Michelle Hickey, Juan Alejos, Elaine Reed, Nancy Halnon. Los Angeles, CA.

B154 Anti-HLA Antibody Composition and Outcomes in Pediatric Heart Transplant Recipients with a Positive Cross-Match.

B155 Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
Maral Bakir, Nicholas Jackson, Eleanor Chang, David Henriquez-Ticas, Chi-hong Tseng, Tam Khuu, Jennifer Zhang, Elaine Reed, Mario Deng, Martin Cadeiras. Los Angeles, CA.

B156 Impact of Donor Specific Antibodies on Cardiac Allograft Vasculopathy.
Anh Vu, Andrew D. Althouse, Adriana Zeevi, Jeffrey J. Teuteberg, Michael A. Shullo. Pittsburgh, PA.

B157 Relationship Between Changes in Brain Natriuretic Peptide Levels and Cardiac Allograft Rejection Early After Heart Transplantation.
Jillian C. Dann, Kimberly M. Deininger, Dominik Reinhold, Robert L. Page II, Amurt V. Ambardekar, JoAnn Lindenfeld, Christina L. Aquilante. Aurora, CO; La Jolla, CA; Salt Lake City, UT; Gainesville, FL; Nashville, TN.

B158 Gene Expression Profiling Score and the Risk of Infection in Heart Transplant Recipients.
Jeffrey J. Teuteberg, Deborah Budge, Michael A. Shullo, Shelley A. Hall, Jon Kobashigawa. Pittsburgh, PA; South Lake City, UT; Dallas, TX; Los Angeles, CA.

B159 Qualitative Assessment of Patient-Perceived Treatment Burden Following Cardiac Transplantation.
Kimberly M. Deininger, Jennifer A. Reich, Jan D. Hirsch, Sarah A. Graveline, Ashley Feist, Joanne LaFleur, Steven M. Smith, Amrut V. Ambardekar, JoAnn Lindenfeld, Christina L. Aquilante. Aurora, CO; La Jolla, CA; Salt Lake City, UT; Gainesville, FL; Nashville, TN.

B160 Clostridium difficile Infection in Patients with a Continuous Flow, Durable Left Ventricular Assist Device.
Jorie Glick Frasiolas, Irene Li, Hyesun (Juliette) Kim, Demetra Tsapepas. New York.

B161 Assessment of Postoperative Glycemic Control in Orthotopic Heart Transplant Recipients.

B162 Prednisone Wean After Dual Heart and Kidney Transplantation: Is There a Risk?
David H. Chang, Jignesh Patel, Michelle Kittleson, Tamar Aintablian, Lawrence Czer, Danny Ramzy, Jon Kobashigawa. Los Angeles, CA.

B163 Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy?
Rajeev C. Mohan, Jignesh Patel, Michelle Kittleson, David Chang, Tamar Aintablian, Lawrence Czer, Fardad Esmailian, Jon Kobashigawa. Los Angeles, CA.

B164 Four-Factor Prothrombin Complex Concentrate as a Strategy to Rapidly Reverse Anticoagulation in Patients Undergoing Cardiac Transplantation: Better Than the Conventional Approach?
Teena Sam, Gonzalo V. Gonzalez-Stawinski, Giovanna Saracino, Aayla Jamil, Shelley Hall, Katy M. Cox, Brian Lima. Dallas, TX.

B165 Comparison of Actual versus Goal Tacrolimus Levels Post Cardiothoracic Transplant.
B166 Using Gastrointestinal Biopsy to Predict Outcome in Patients Evaluated for Cardiac Transplantation for Amyloidosis: A Report from the International Consortium on Cardiac Amyloidosis Transplantation (iCCAT). Yu Li, Karla C. Verkouw, Sara Tabtabai, Roberto Barrios, Ryan Gill, Jamie Koo, Charles Marboe, E. Rene Rodriguez, Carmela D. Tan, Teresa De Marco, Jerry D. Estep, Mazen Hanna, Mathew S. Maurer, Jignesh Patel, Van N. Selby, Marc J. Semigran, James R. Stone. Boston, MA; Houston, TX; San Francisco, CA; Los Angeles, CA; New York, NY; Cleveland, OH.

B167 Medicaid Insurance Is Associated with Shorter Time to Transplant Listing After LVAD Implantation. William M. Schultz, Michael Y. Yin, Yi-An Ko, John D. Vega, Alanna A. Morris. Atlanta, GA.


Kidney Issue in Liver Transplantation


B171 The Importance of KDPI in Simultaneous Liver and Kidney Transplant. Edie Y. Chan, Martin Hertl, James D. Perkins. Chicago, IL; Seattle, WA.


B175 Only 13% of Liver Transplant (LT) Recipients with Moderate to Severe Kidney Disease (KD) Tolerate Conversion to Everolimus and Reduced Tacrolimus (EVR/rTac). Shi-Hui Pan, Irene Kim, Andrew Klein, Alagappan Annamalai, Tsuyoshi Todo, Nicholas Nissen. Los Angeles, CA.

B176 Renal Function Decline Is Higher in the First Year After Liver Transplantation: Final Results from the Italian Observational Study SURF. Alessandro Giacomoni, Matteo Cescon, Giulia Magini, Francesco Paolo Picciotto, Umberto Cillo, Marco Sensolo, Giovanni Vennarecci, Paolo De Simone. Milano, Italy; Bologna, Italy; Bergamo, Italy; Napoli, Italy; Padova, Italy; Roma, Italy; Pisa, Italy.

B177 Hospital Readmissions Following Discharge After Liver Transplantation (LT). Emmanuel Japhet Minja, Srinath Chinnakotla, Kunal Yadav, Amudhan Pugalenth, Oscar Serrano, Raj A Kandaswamy, William Payne, Timothy Pruett, Varvar Kirchner. Minneapolis, MN.
B178 Life-Years Saved After Pediatric Liver Transplantation.
Rainer R. W. Guessner, Angelika C.
Guessner. Syracuse, NY.

B179 Liver Recipient with Renal Dysfunction: Liver Only or Simultaneous Liver-Kidney Transplant?
Kunal Yadav, Timothy L. Pruett, Raja
Kandaswamy, William Payne, Lei Zhang,
Srinath Chinnakotla. Minneapolis, MN.

B180 Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.
J. Clark, T. Sparkes, B. Masters, J.
LaMattina, R. Barth, M. Moss. Baltimore,
MD.

Juhan Lee, Jae Geun Lee, Seung Hwan
Song, Jee Youn Lee, Su-kyung Kwon, Dai
Hoon Han, Man Ki Ju, Gi Hong Choi, Jin
Sub Choi, Myoung Soo Kim, Soon Il Kim,

B182 Kidney Outcomes in Patients with Liver Cirrhosis and Chronic Kidney Disease Receiving an Orthotopic Liver Transplant Alone.
Neeraj Singh, Shahab Ahmadzadeh,
Bakhtiar Amin, Ramesh Marahatta,
Hosein Shokouh-Amiri, Robert McMillan,
Gazi Zibari. Shreveport, LA.

B184 Survival Benefit from Kidney Transplantation Using Kidneys from Deceased Donors Over 75 Years.
Maria José Pérez-Sáez, Emma Arcos,
Jordi Comas, Marta Crespo, Josep
Lloveras, Jaume Tort, Julio Pascual,
Catalan Renal Registry Committee.
Barcelona, Spain.

B185 Impact of Donor AKI on Outcome Following High KDPI Deceased Donor Kidney Transplantation.
D. J. Haakinson, I. Qaqish, M. L. Smith, H.
Phoenix, AZ.

B186 Donor AKI Does Not Adversely Affect the Outcome Following DCD Kidney Transplant.
Ibrahim Qaqish, Danielle Haakinson,
Kunam Reddy, Maxwell Smith, Hasan
Khamash, Raymond Heilman. Phoenix,
AZ.

B187 The Impact of Kidney Donor Profile Index (KDPI) on Rates of Delayed Graft Function (DGF).
Tiffany Zens, Glen LeVerson, Robert
Redfield, Peter Chlebeck, Laura Zitur,
Dixon Kaufman, Luis Fernandez.
Madison, WI.

B188 Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
Tiffany Zens, Glen LeVerson, Robert
Redfield, Peter Chlebeck, Laura Zitur,
Dixon Kaufman, Luis Fernandez.
Madison, WI.

B189 Kidney Donor Profile Index and Recipient BMI Are Potent Predictors of Six Month Deceased Donor eGFR as Opposed to EPTS.
Avinash Agarwal, Winston Ally, Daniel
Maluf, Shawn Pelletier, Kenneth Brayman.
Charlottesville, VA.

B190 High KDPI Is a Predictor of Acute Rejection in Delayed Graft Function.
Brenda L. Muth, Jennifer Turk, Sandesh
Parajuli, Didier A. Mandelbrot, Maha
Mohamed, Robert R. Redfield, Dixon B.
Kaufman, Arjang Djamali. Madison, WI.
| B195 † | Inferior Outcomes in Hepatitis C Virus Positive Donors to Hepatitis C Virus Negative Kidney Recipients: Analysis of National Data. Hasan Fattah, Le Kang, Hitarth Dave, Dhiren Kumar, Anne L. King, Chandra Bhati, Amit Sharma, Gaurav Gupta. Richmond, VA. |
| B201 † | Pediatric En Bloc Kidney Transplants Reduce DGF and Are Misrepresented by the KDPI. Muhammad A. Khan, Hany El-Hennawy, Alan C. Farney, Jeffrey Rogers, Giuseppe Orlando, Amber Reeves-Daniel, Amudha Palanisamy, Michael Gautreaux, Samy Iskandar, William Doares, Scott Kaczmorski, Robert J. Stratta. Winston-Salem, NC. |
| B203 | Young Recipients Receiving Kidneys from Older Donors Have Poorer Allograft Outcomes. Alex Wardle, Michelle Willicombe, Dawn Goodall, Adam G. McLean, David Taube. London, United Kingdom. |

B206 † Dual Kidney Transplants as Policy to Optimize the Allocation of Marginal Donor Kidneys: Analysis of the French Cohort Since 2002. Emilie Savoye, Renaud Sanouдж, Christian Hiesse, Marie-Noelle Peraldi, Antoine Durrbach, Nacéra Ouall, Mathieu Durand, Lionel Badet, Marie-Alice Macher. Saint Denis, France; Paris, France; Suresnes, France; Kremlin Bicetre, France; Nice, France; Lyon, France.


Kidney: Cardiovascular and Metabolic

B209 † Predicting Early Cardiac Death After Kidney Transplantation. Krishna Balabhadrapatruni, Angela Liu, Nagaraju Sarabu, Edmund Sanchez, Joshua Augustine. Cleveland, OH.

B210 † Renal Transplant in Obese Recipients: Consideration of Donor and Recipient Factors Can Improve Outcomes. Paul Stahler, Joshua Mezrich, Glen Leverston, Dixon Kaufman, Hans Sollinger. Madison, WI.

B211 Pre-Transplant Coronary Artery Disease: An Underestimated Risk Factor for Post-Transplant Mortality? Dmytro Khadzhynov, Fabian Halleck, Lukas J. Lehner, Michael Duerr, Anna Kleinstueber, Klemens Budde, Oliver Staeck. Berlin, Germany.


B215 † Pulmonary Hypertension in Renal Transplant Candidates: A Systematic Review and Meta-Analysis of the Available Evidence. Ankush Moza, Abdur Khan, Rohini Prashar, Sobia Khan, Samer Khouri, Sandeep Vetheth, Deepak Malhotra, Michael Rees, George Moukarbel, Jorge Ortiz. Toledo, OH; Louisville, KY; Detroit, MI.

B216 † Pre-Existing Chronic Heart Failure in Kidney Transplantation: An Underestimated Risk Factor for Graft Loss? Fabian Halleck, Dmytro Khadzhynov, Lukas J. Lehner, Eva V. Schrezenmeier, Michael Duerr, Anna Kleinstueber, Klemens Budde, Oliver Staeck. Berlin, Germany.
B217 Regression of Asymptomatic Cardiomyopathy and Clinical Outcome of Renal Transplant Recipients: Long-Term Extension of Two Randomized Controlled Trials.
Ernesto Paoletti, Diego Bellino, Luigina Marsano, Rodolfo Russo, Fabio Masarino, Giacomo Garibotto. Genoa, Italy.

B218 VO2peak Outperforms Troponin T for Risk Prediction of Cardiovascular Disease and All-Cause Mortality in Patients with End Stage Renal Disease Being Evaluated for Kidney Transplant.

B219 Replicative Senescence and Arteriosclerosis After Kidney Transplantation.
Katrien De Vusser, Dries Martens, Evelyne Lerut, Dirk Kuypers, Tim Nawrot, Maarten Naesens. Leuven, Belgium; Hasselt, Belgium.

B220 Muscle Density Is Associated with Mortality Among Kidney Waitlist Candidates.
Rhiannon D. Reed, Sangeeta Nair, Grant D. Smith, Cora E. Lewis, J. Greg Terry, J. Jeffrey Carr, Jayme E. Locke. Birmingham, AL; Nashville, TN.

B221 Alkaline Phosphatase a New Marker for Graft Outcome and High Pulse Wave Velocity in Renal Transplant Recipients.

B222 Soluble ST2 and Cardiovascular (CV) Outcomes and Mortality in Kidney Transplant Candidates.
Mira Keddis, Ziad El-Zoghby, Amber Gray, Jeffrey Meeusen, Leslie Donato, Fernando Cosio, D. Eric Steidley. Phoenix, AZ; Rochester, MN.

B223 The Intrarenal Resistive Index Measured After Transplantation Is Determined by the Upstream Vascular System of the Recipient.
Line Heylen, Maarten Naesens, Ben Sprangers, Sam Heye, Peter Verhamme, Ina Joehmans, Diethard Monbaliu, Jacques Pirenne, Dirk Kuypers, Kathleen Claes. Leuven, Belgium.

B224 Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I Is a Predictive Marker for Graft Loss in Patients Positive for IgA aB2GPI.
Jose Maria Morales, Manuel Serrano, José Angel Martínez-Flores, Dolores Perez, Margarita Sevilla, Oscar Cabrera, Antonio Serrano. Madrid, Spain.

B225 Higher Pre-Transplant HDL Levels Are Associated with Decreased Acute Rejection Following Kidney Transplant.

B226 Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results.

B227 Outcomes of EVAR in Kidney Transplant Recipients: Results form a National Quality Initiative.
Ian C. Bostock, Devin S. Zarkowsky, David S. Stone, Mohammad H. Esliami, Mahmoud B. Malas, Philip P. Goodney. Lebanon, NH; Boston, MA; Baltimore, MD.

B228 Early Use of Statins Associated with Improved Death-Censored Graft Survival Following Kidney Transplant.
Timothy A. Horwedel, Daniel C. Brennam, Krista Lentine, Jennifer C. Hagopian. St. Louis, MO; MO.

B229 Complications of Dual Antiplatelet Therapy Among Recipients of Kidney Transplants.
Francis L. Weng, Anand Athavale, Komal Hussain, Kim Tibaldi, Gary Rogal. Livingston, NJ.
B230 Renal Allograft Outcomes with Renal Artery Angioplasty and/or Stenting in Transplant Renal Artery Stenosis. Ekamol Tantisattamo, Attasit Chokechanachaisakul, Siwadon Pitukweeraukul, Praveen Ratanasrimetha, Aneesha Shetty, Opas Traitanon, Lorenzo Gallon. Royal Oak, MI; Chicago, IL; Evanston, IL; Bangkok, Thailand; Pathumthani, Thailand.

B231 Arterial Hypertension After Renal Transplantation in Pediatric Patients: An Analysis of CERTAIN Registry. Rizky Indrameikha Sugianto, Elke Wühl, Bernhard Magnus Willhelm Schmidt, Kai Krupka, Britta Höcker, Burkhard Tönshoff, Anette Melk. Hanover, Germany; Heidelberg, Germany.


B237 † Pre-Existing Diabetes Mellitus Type 2 and Insufficiently Controlled Post-Transplant HbA1c in Kidney Transplantation. Fabian Halleck, Dmytro Khadzhynov, Lukas J. Lehner, Eva V. Schrezenmeier, Michael Duerr, Anna Kleinsteuber, Klemens Budde, Oliver Staeck. Berlin, Germany.


B239 Infections in De Novo Kidney Transplant Recipients Treated with the RANKL Inhibitor Denosumab: A Post-Hoc Analysis of the POSTOP Clinical Trial (NCT01377467). Marco Bonani, Diana Frey, Jens G. Brockmann, Thomas Fehr, Thomas Müller, Nicole Graf, Rudolf P. Wüthrich. Zurich, Switzerland; Winterthur, Switzerland.


Liver: MELD, Allocation and Donor Issues (DCD/ECD)

B242 † Extreme Hyperoxia During Pre-Implant Normothermic Liver Perfusion (PINLiP) Is Associated with Post-Reperfusion Syndrome and Vasoplegia.
Chris Watson, Vas Kosmoliaptsis, Lucy Randle, Mazin Hamed, John Klinck, Andrew Butler. Cambridge, United Kingdom.

B243 † Trends in Liver Transplant Rates and Waitlist Survival.
Mary Bowring, Allan Massie, Xun Luo, Lauren Kucirka, Eric Chow, Andrew Cameron, Dorry Segev. Baltimore.

B244 † Impact of Left Ventricular Diastolic Dysfunction on Patients Being Evaluated for Liver Transplantation.
Kimberly A. Forde, Rhondalyn C. McLean, William T. O’Donnell, Karen L. Krok, Mamta J. Patel, Grace Lin, Jae K. Oh, Michael J. Krowka, Michael B. Fallon, Steven M. Kawut. Philadelphia, PA; Hershey, PA; Rochester, MN; Houston, TX.

B245 † Does Rising MELD Score Convey Worse Liver Transplant Outcome?

B246 † Fifty Is the New 40? An Argument to Uncap the MELD Score.
Joseph DiNorcia, Yuri Genyk, Kenneth Andreoni, W. Ray Kim, Josh Levitsky, David Mulligan, Randall Sung, Mitra Nadim. Los Angeles, CA; Palo Alto, CA; Gainesville, FL; Chicago, IL; New Haven, CT; Ann Arbor, MI.

B247 † Waitlist versus Population-Based Metrics of Access to Liver Transplantation: Comparing UNOS Waitlist Data and Nationally-Representative Data of Patients with End-Stage Liver Disease.
David S. Goldberg, Benjamin French, James D. Lewis, Scott D. Halpern. Philadelphia, PA.

B248 † Role of Donor Hemodynamic Trajectory in Determining Graft Survival in Liver Transplantation from Donation After Circulatory Death Donors.

B249 † The Impact of Gender Discordance on Graft Survival Among Liver Transplant Recipients.

B250 † Underweight BMI Is Associated with Graft Failure and Increased Mortality in Liver Transplant Recipients.

B251 † Liver Transplantation in Patients Actively Drinking Less Than 6 Months Before Transplant Presenting with Acute Decompensation: A Single-Center Experience.

B252 † Results from 100 Consecutive Donation-After-Circulatory Death (DCD) Liver Transplants Using a Thrombolytic Protocol.
John B. Seal, Humberto Bohorquez, Narendra Battula, Emily Ahmed, David Bruce, Ian Carmody, Reichman Trevor, Gia Tyson, Shoba Joshi, Natalie Bzowej, George Therapondas, Nigel Girgah, Ari Cohen, George Loss. New Orleans, LA.

B253 † Probability of Transplant (POT) Index: A Novel Method to Predict the Likelihood of an Adult Liver Transplant.
Jennifer M. Moffett, Michael L. Kueht, Henrik Petrowsky, Irbaz B. Riaz, Courtney C. Nalty, Saira A. Khaderi, Christine A. O’Mahony, John A. Goss, Abbas Rana. Houston, TX; Zurich, Switzerland; Tucson, AZ; College Station, TX.
B254 Pre-Mortem Cannulation and NECMO Preservation for DCD Liver Transplantation.
Patricia Ruiz, Mikel Gastaca, Andres Valdivieso, Alberto Ventoso, Ibone Palomares, Mikel Prieto, Javier Bustamante, Patricia Salvador, Jorge Ortiz de Urbina. Bilbao, Vizcaya, Spain.

B255 Increased Frequency of Post-Recovery Liver Reallocation: The Law of Unintended Consequences?
Jeffrey P. Orlowski, Chad C. Muse, Janice F. Whaley, Ronald A. Squires. Oklahoma City, OK.

B256 Defining Frailty in Liver Transplant Recipients.
Lisa Louwers, Kareem Eid, Julie Plescia, Naftali Presser, Julia Muntean, Michael Kattan, Kevin Chagrin, Charles Miller, Dympna Kelly. Cleveland, OH.

B257 Factors Associated with Increased Risk of MELD Progression Among a Large Population of Patients with Cirrhosis and an Initial Low MELD Score (<15).

B258 Good Livers with a Bad Reputation: Favorable Outcome with Imported Grafts.
Mohamed Akoad, Mary Ann Simpson, James Pomposelli, Elizabeth Pomfret. Burlington, MA.

B259 The Role of Obesity in Survival Outcomes of Liver Transplant Recipients with High MELD Score.

B260 MELD as a Metric for Survival Benefit of Liver Transplantation.
Xun Luo, Allan Massie, Sunjae Bae, Mary Grace Bowring, Dorry Segev. Baltimore.

B261 Strategies to Prevent Ischemic Cholangiopathy After Donation After Circulatory Death Donor Liver Transplantation.

B262 Outcomes for Liver Transplantation Using Organs from Donation After Cardiac Death Donors: A Single Center Experience.
Jason M. Vanatta, Xu Zhao, Vichin Puri, Ryan A. Helmick, Sahteesh Nair, Sanajaya Satapathy, James D. Eason. Memphis, TN.

B263 Outcomes Following Inguinal Hernia Repair in Patients with End Stage Liver Disease.

B264 Outcomes of Living and Deceased Donor Liver Transplant Recipients According to the MELD Score.

B265 A Call for a New Paradigm of Organ Allocation within the Confines of MELD for Those Who Are Not “the Sickest”.
Talia B. Baker, Alex Siarris, Pascol Accoh, Daniela Ladner. Chicago, IL.

B266 Physical Disability on the Liver Transplant Waitlist: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study.

B267 Resolution of Donor Non-Alcoholic Fatty Liver Disease Following Liver Transplantation.
B268 Use of Elderly Donors in Liver Transplantation: A Paired-Match Analysis at a Single Center.
Davide Ghinolfi, Quirino Lai, Paolo DeSimone, Daniele Pezzati, Giulia Cirillo, Franco Filipponi. Pisa, Italy.

B269 Some DCD Livers Function as Well as DBD Livers: The Implications of Discarding Usable Livers.
Joseph R. Scalea, Robert R. Redfield, David P. Foley. Madison, WI.

B270 Increased Utilization of High Risk Deceased Donors with Share 35 Does Not Affect Outcomes in Liver Transplantation.

B271 Outcomes with the Use of Pediatric Donor Livers in Adult Recipients: Review of the UNOS Database.
Kristopher P. Croome, David Lee, Justin Burns, Justin Nguyen, Dana Perry, C. Burcin Taner. Jacksonville, FL.

B272 Hematopoietic Progenitor Cells and Monocyte Subsets and Hepatic Decompensation in Patients Ref erred for Liver Transplant Evaluation.
Kimberly A. Forde, Karen L. Krok, Mamta J. Patel, Michael J. Krowka, Michael B. Fallon, Steven M. Kawut. Philadelphia, PA; Hershey, PA; Rochester, MN; Houston, TX.

B273 Risk Factors for Short and Long Term Mortality in High MELD Recipients.
Alessandra Bertacco, Manuel Rodriguez-Davalos, Michael Schlisky, Peter Yoo, Sanjay Kulkarni, Brett Fortune, Annmarie Liapakis, Sukru Emre, David Mulligan. New Haven; Padova, Italy.

B274 Thrombolytic Protocol in Organ Procurement from Donation After Circulatory Death Donors Reduces Ischemic Cholangiopathy in Liver Transplantation.
Ji Fan, Gennaro Selvaggi, Werviston De Faria, Seigo Nishida, Akin Tekin, Thiago Beduschi, Yuriy Yushkov, Rodrigo Vianna. Miami.

B275 Liver Graft Steatosis Associates with an Increase of Circulating Immune Response Chemokines.
Ricardo Gehrau, Valeria Mas, Ashish Sharma, Vineela Bontha, Daniel Maluf. Charlottesville.

B276 Systematic Review and Meta-Analysis of the Impact of Computed Tomography Assessed Skeletal Muscle Mass on Outcome in Patients Waiting or Undergoing Liver Transplantation.
Jeroen van Vugt, Stef Levolger, Ron de Bruin, Joost van Rosmalen, Herold Metselaar, Jan IJzermans. Rotterdam, Netherlands.

B277 Long-Term Liver Function of Deceased Liver Transplantation Using Hepatitis B Surface Antigen Positive Grafts.
Wei-Chen Lee, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Chen-Fang Lee, Ruey-Shyang Soong, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Ching-Song Lee. Taoyuan, Taiwan.

B278 Transplanting the Extremely Sensitized Patient: The University of Wisconsin Experience with the New Kidney Allocation System.

Lung Transplantation

B279 Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era.

B280 Abstract Withdrawn

B281 Abstract Withdrawn

B283 † Susceptibility Patterns of Pre-Transplant Pseudomonas and Post-Lung Transplant Outcomes in Patients with Cystic Fibrosis.
Stephanie M. Pouch, Erika D. Lease, Tatiana Bogdanovich, Dora Y. Ho, Rachel Miller, Michele Estabrook, Tara Babu, Camille Kotton, Ciara Shaver, Lora Thomas, Saima Aslam, Todd McCarty, Julia Garcia-Diaz, Karen Doucette, Stephen Kirkby, David van Duin. Columbus, OH; Seattle, WA; Pittsburgh, PA; Stanford, CA; Iowa City, IA; St. Louis, MO; Boston, MA; Nashville, TN; San Diego, CA; Birmingham, AB; New Orleans, LA; Edmonton, AB, Canada; Chapel Hill, NC.

B284 Factors Predicting Tacrolimus Trough Variability After Lung Transplantation.
Kimberly Boyle, M. Moranville, P. Shah. Baltimore, MD.

B285 Effect of Early Tacrolimus Trough Variability on Graft Outcomes in Lung Transplantation.
Kimberly Boyle, Michael Moranville, Pali Shah. Baltimore, MD.

B286 Achieving Timely Therapeutic Mycophenolic Acid Levels in Pediatric Lung Transplant Patients.
Charissa W. Kam, Shelly Kim, Ernestina Melicoff. Houston, TX.

B287 Characteristics and Outcome of Patients Placed on Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation.
Elizabeth Batchelor, Jenna Bland, Debra Douglass, Jessica Mullins, Manish Mohanka, Srinivas Bollineni, Vaidehi Kaza, Michael Wait, Fernando Torres, Amit Banga. Dallas, TX.

B288 † Outcomes in Lung Transplant Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) in the Perioperative Period.
Andreas Habertheuer, Matthew Williams, Samantha Miller, Edward III Cantu, Christian Bermudez, Prashanth Vallabhajosyula. Philadelphia, PA.

Nicole Casciello, Amaris Fuentes, Jill Krisl, Neeraj Sinha, Thomas Kaleekal. Houston, TX.

B290 Comparison of Clinical Outcomes in Lung Transplant Patients with and without Preoperative Pulmonary Hypertension.

B291 The Effect of Body Mass Index on Lung Transplant Outcomes.

B292 Pre-Transplant Prostate Cancer in Lung Transplant Recipients and Impact on Post-Transplant Morbidity and Mortality.
Shahnaz Ajani, Maryam Valapour, Marie Budev. Cleveland, OH.

B293 The Role of Palliative Care in the Thoracic Transplant Multidisciplinary Care Team: Barriers and Benefits.
Amy L. Manfredi, Christine C. Toevs. Maywood, IL; Terre Haute, IN.

B294 Human Leukocyte Antigen (HLA) Mismatch Impact on Lung transplants outcomes.
Godefroy Chery, Laurie Snyder, Michael Durheim, Scott Palmer, Megan Neely. Durham, NC.

B295 Hyponatremia in Early Post Lung Transplantation Predicts Patient and Hospital Outcomes.
Ekamol Tantisattamo, Attasit Chokechanachaisakul, Opas Traitanon, Aneessa A. Shetty, Bing T. Ho, John J. Friedewald, Sangeeta M. Bhorade, Alexander Haynes, Amber Nieland, Lorenzo Gallon. Royal Oak, MI; Chicago, IL; Pathumthani, Thailand.
PTLD/Malignancies: All Topics

B296 6 Minute Walk Test and FVC Analysis: A New Method to Prioritize Organ Allocation for Patients with COPD. Irina Timofte, Michael Terrin, Marniker Wijesinha, Pablo Sanchez, Richard Pierson, Erik Barr, June Kim, Zachary Kon, Si Pham, Aldo Iacono. Baltimore, MD.

B297 EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig). Jua Choi, Bongha Shin, Joseph Kahwaji, Shili Ge, David Thomas, Ashley Vo, Odette Galera, Rafael Villicana, Alice Peng, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.


B299 The First 48 Months of an Australian Renal and Liver Organ Transplant Dermatology Database. Ludi Ge, Patricia Lowe. Sydney, NSW, Australia.


B301 Recipient Outcomes in U.S. Cases of Post-Donation Living Donor Malignancy. Amber R. Wilk, Sarah Taranto, Michael Nalesnik. Richmond, VA; Durham, NC; Pittsburgh, PA.

B302 Rare Presentation of PTLD as Parotitis. Raghavesh Pullalarevu, A. Posadas Salas, G. Mour, T. Srinivas, N. Salazar, Prince Mohan. Charleston, SC.

B303 Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy. Wen Yao Yin. Hualien, Taiwan; Chia-I, Taiwan.

B304 C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains. Christopher Blosser, Yuzhou Zhang, Tejaswini Dhawale, Christopher Johnson, Paul Hendrie, Richard Smith. Seattle, WA; Iowa City, IA.

Antibody Mediated Rejection: Session #1

C1 † Postoperative Rebound of Anti-Blood Type Antibodies and Antibody-Mediated Rejection After ABO-Incompatible Living Related Kidney Transplantation – Is Prophylactic Treatment Necessary?
Hideki Ishida, Tsunenori Kondo, Tomokazu Shimizu, Taiji Nozaki, Kazunari Tanabe. Tokyo, Japan.

C2 † Randomized Controlled Trial of Mixed Acute Rejection Therapy in Renal Allografts: 3 Year Follow Up.

C3 † The Significance of Microvascular Inflammation in Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.
Hiroki Ishihara, Hideki Ishida, Kohei Unagami, Toshii Hiroi, Masayoshi Okumi, Kazuya Omoto, Tomokazu Shimizu, Kazunari Tanabe. Tokyo, Japan.

C4 † Patients Treated with Belatacept Show Low Levels of APRIL and HLA Antibodies.

C5 † Clinical Significance of C3d Binding Donor Specific Anti-HLA Antibodies (DSA) Detected by Single Antigen Beads (SAB) After Kidney Transplantation.
Ronald P. Pelletier, Ivan Balazs, Patrick Adams, Paula Steller, Nicholas DiPaola, Leslie Rankin, Alexandre Diez, Mitchell L. Henry. Columbus, OH; Stamford, CT; Houston, TX.

C6 † Prospective Single Antigen Bead Epitope-Based Clustering for Early Detection of Antibody Mediated Rejection.

C7 † Inconsistent HLA Antibody Reactivity Detected with Different Solid-Phase Assays.
Andrés Jaramillo, Lora J. Nelson, Yvonne M. Desmarteau, Bozena Labuda, Kelly Barrios, John Lunz, Raymond L. Heilman, Marcelo J. Pando. Phoenix, AZ; Itasca, IL.

C8 † Membranoproliferative Glomerulonephritis Pattern without Immunoglobulin and Complement Deposition in Renal Allograft Was Related to the Injury of Antibody-Mediated Rejection.
Jiqiu Wen, Feng Xu, Jisong Chen, Xue Li, Mingchao Zhang, Zhe Zhang, Zhihong Liu. Nanjing, China.

C9 † The Effect of Tocilizumab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
Bong-Ha Shin, Shiili Ge, Jua Choi, Joseph Kahlwaji, Ashley Vo, Anna Petrosyan, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

C10 † Kidney Graft Homing of De Novo Donor Specific HLA Antibodies Is an Early Step within the Antibody-Mediated Graft Damage Process.
Arcangelo Nocera, Michela Cioni, Augusto Tagliamacco, Annalisa Innocente, Iris Fontana, Alberto Magnasco, Angela Nocco, Angela Sementa, Giacomo Garibotto, Gian Marco Ghiggeri, Massimo Cardillo, Patrizia Comoli, Fabrizio Ginevri. Genova, Italy; Milano, Italy; Pavia, Italy.
**C11 † Risk of Acute Rejection Among ABO Incompatible Living Donor Kidney Recipients.**
Paul A. MacLennan, Vineeta Kumar, Rhiannon D. Reed, Darnell Mompoint-Williams, Katherine Stegner, Jayme E. Locke. Birmingham, AL.

**C12 † Tacrolimus as a Tool for Intracellular Assessment of von Willebrand Factor Production by Activated Human Glomerular Endothelial Cells.**
Stéphanie Béland, Patrice Vallin, Olivier Désy, Sacha A. De Serres. Quebec, QC, Canada.

**C13 † Inflammation Amplifier, a Chemokine Inducer in Non-Immune Cells in Kidney Transplantation Graft.**
Haruka Higuchi, Hidenori Bando, Jiang Jing-Jing, Toru Atsumi, Daiki Iwami, Ken Morita, Nobuo Shinohara, Masaaki Murakami. Sapporo, Japan.

**C14 † Prognosis Value of the Presence and Persistence of C1q Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.**
Elodie Bailly, Barbara Proust, Magali Giral, Vincent Vuiblet, Valérie Chatelet, Emmanuel Morelon, Paolo Malvezzi, Sophie Caillard, Benoit Barrou, Lionel Couzi, Johnny Sayegh, Christiane Mousson, Dany Anglicheau, Philippe Grimbert, Marc Hazzan, Georges Mourad, Raj Purgus, Pierre François Westeel, Yvon Lebranchu, Matthias Büchner. Tours, France; Nantes, France; Reims, France; Caen, France; Lyon, FranceGrenoble, France; Strasbourg, France; Paris, France; Bordeaux, France; Angers, France; Dijon, France; Lille, France; Montpellier, France; Marseille, France; Amiens, France.

**C15 † Anti-HLA Antibodies in Allogeneic and Autologous Hematopoietic Stem Cell Transplantation.**
Ana Paula Fernandes Bertocchi, Lucio Roberto Requiao-Moura, Margareth Afonso Torres, Eduardo Jose Tonato, Marcelino de Souza Durao Junior, Ana Cristina Carvalho de Matos, Nelson Hamershclak, Alvaro Pacheco-Silva. Sao Paulo, Brazil.

**C16 † A Novel Study to Determine the Association of Pre-Transplant Donor Specific Antibody and AT1R Antibody with Kidney Transplant Outcomes Prior to Adoption of Solid Phase Antibody Assays.**

**C17 † Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.**
Hilda E. Fernandez, Shefali Patel, Mariana Chiles, Lloyd Ratner, Russell J. Crew. NYC.

**C18 † Comparison of EDTA, DTT and Dilutions to Abrogate the Prozone Effect in Luminex-Based HLA Antibody Assays.**

**C19 † Antibody Titers as Predictors of Kidney Graft Outcomes.**
Alexander Gilbert, Misbah Zaheer, Olga Timofeeva, Sandra Rosen-Bronson, Mariam Awwad, Dong Li, Monica Grafals, Basit Javaid, Peter Abrams, Jennifer Verbesey, Matthew Cooper. Washington, DC.

**C20 † Deceased Donor Kidney Transplantation in the Setting of Positive Donor-Specific Antibodies.**

**C21 † Antibody-Mediated Rejection Can Be Assessed by Histology When DSA Is Unknown or Negative.**
J. Reeve, P. F. Halloran. Edmonton, AB, Canada.

**C22 † Baseline Donor Specific Antibody (DSA) More Predictive of Chronic Antibody Mediated Rejection (CAMR) Than the Change in DSA Over Time.**
Donald G. Mitema, Wisit Cheungpasitporn, Mark Stegall, Fernando G. Cosio, Manish J. Gandhi, Carrie Schinstock. Rochester, MN.
C23 † Preformed Antibodies Against AT1R and EDNRA Correlate with Rejection Post-Transplant.
Alison J. Gareau, Chris Wiebe, Denise Pochinco, Ian W. Gibson, David N. Rush, Peter W. Nickerson. Winnipeg, MB, Canada.

C24 † The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.
Shili Ge, Maggie Chu, Jua Choi, Stanley C. Jordan, Mieko Toyoda. Los Angeles.

C25 † Optimized Flow Cytometry Crossmatch with Increased Sensitivity and Specificity.
Kelly Barrios, John Lunz, Bozena Labuda, Daniel Magas, David J. Freedom, Katarzyna Szewczyk, Martin D. Jendrisak, Andrés Jaramillo. Itasca, IL; Phoenix, AZ.

C26 † Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.

C27 † Early Onset Acute Antibody Mediated Rejection (ABMR) Is More Common in Female Than in Male Recipients of a Living Unrelated Donor (LURD) Renal Transplant and Is Associated with the Presence of Preformed Donor Specific Antibodies (DSA).

C28 † Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.

C29 † Urine IP-10 as the Biomarker for ABMR in Kidney Transplant Recipient with DGF.

C30 † Glomerular Capillary C4d Staining without Evidence of Rejection Is Associated with Worse Graft Function in ABO-Incompatible Kidney Transplantation.
Daisuke Toki, Masashi Inui, Masayoshi Okumi, Hideki Ishida, Kiyoshi Setoguchi, Tomokazu Shimizu, Kohei Unagami, Kazunari Tanabe. Chiba, Japan; Tokyo, Japan.

C31 † Association of Genetic Polymorphisms in Complement Independent Pathways with Donor Specific Antibodies in Kidney Allograft Recipients.
Youngil Chang, Tariq Shah, David Min. Pomona, CA; Los Angeles, CA.

C32 † The Coefficient of Variability of Tacrolimus Levels Can Predict Antibody-Mediated Rejection After Renal Transplantation.

C33 † IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.
Kasia A. Sablik, Caspar W. N. Looman, Marian C. Claesen-van Groningen, Jeffrey Damman, Dave L. Roelen, Madelon van Agteren, Michael G. H. Betjes. Rotterdam, Netherlands; Leiden, Netherlands.

C34 † Breadth of HLA-Specific B Cell Reactivity and Frequency Assessed by a Novel Multiplex Bead Based Assay Predicts and Correlates with Rejection in Kidney Transplant Recipients.
Clinical Science - Kidney
Immunosuppression: Induction Therapy

C35  Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer.
Neel Koyawala, Jeffrey Silber, Paul Rosenbaum, Roy Bloom, Wei Wang, Alex Hill, Susanna Nazarian, Deirdre Sawinski, Jennifer Trofe, Maryann Lim, Jesse Schold, Peter Reese. Philadelphia; Cleveland.

C36  Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
Sunjae Bae, Allan Massie, Sandra DiBrito, Xun Luo, Lauren Kucirka, Fawaz Al Ammary, Dorry Segev. Baltimore, MD.

C37  Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.
Irina Gutman, Michael L. Misel, Dianne B. McKay, Alan W. Hemming, Janice Kerr, Kristin L. Mekeel. San Diego, CA.

C38  Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.

C39  Pharmacokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Kohei Unagami, Masayoshi Okumi, Miyuki Furusawa, Toshihito Hirai, Tomokazu Shimizu, Kazuya Omoto, Masashi Inui, Hideki Ishida, Kosaku Nitta, Kazunari Tanabe. Tokyo, Japan.

C40  After Alemtuzumab Induction, Tac+MMF Is Superior to CsA+MMF in Pediatric Kidney Transplantation.
Michael Kaabak, Nadeen Babenko, Allan Zokoyev, Ron Shapiro. Moscow, Russian Federation; New York, NY.

C41  Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.

C42  Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.

C43  Comparison of De Novo Donor Specific Antibody Formation for Kidney Transplant Recipients Induced with Thymoglobulin or Basiliximab.
Alexander Gong, Kristina Lee, Shruti Patel, Michael Brande, Rahul Dhawan, Chong Parke, Mirek Smogorzewski, Lorena Aguirre, Bich Duong, Sophoclis Alexopolus, Yasir Qazi. Los Angeles, CA.

C44  Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.

C45  Quality Assessment and Process Improvement of Thymoglobulin Dosing.

C46  Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.

C48 Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations. Mara McAdams-DeMarco, Qiong Huang, Xun Luo, Babak Orandi, Segev Dorry. Baltimore.

C49 Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation. Ilja Striz, Eva Cecrdlova, Alena Sekerkova, Janka Slatinska, Veronika Svachova, Ondrej Viklicky. Prague, Czech Republic.

C50 Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections. Vishwanath Siddagangaiah, Hemant Sharma, Nikhil Lal, Jason Rai, Matthew Howse, Daniel Ridgway, Ajay Kumar Sharma, Abdul Hammad, Sanjay Mehra. Liverpool, United Kingdom; Manchester, United Kingdom.


C55 A Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/Kg vs. 6mg/Kg in Kidney Transplant Patients Under Minimization Maintenance Immunosuppressive Regimen. Tainá V. Sandes-Freitas, Jerônimo Junqueira Junior, Maria Luiza M. B. Oliveira, Celi M. Girão, Ronaldo M. Esmeraldo. Fortaleza, Brazil.


C57 Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients. Qiong Huang, Xun Luo, Mara McAdams-DeMarco, Dorry Segev. Baltimore, MD.

C58 A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial. Hideki Ishida, Kazunari Tanabe, Shiro Takahara, Noritoshi Amada, Kota Takahashi, Hiroshi Toma. Tokyo, Japan; Osaka, Japan; Sendai, Japan; Niigata, Japan; Toda, Saitama, Japan.
Economics, Public Policy, Allocation, Ethics

C59 † National Trends in Liver Discards: The Weekend Effect.
Dustin Carpenter, Sumit Mohan, Karim Halazun, Elizabeth Verna, Mariana Chiles, Gregory Charak, Lloyd Ratner. New York City, NY.

C60 Age and Education Level Are Predictors of Patient Preferences for Educational Formats in ESRD Patients Undergoing Transplant Education.
Katie Leick, Jody Jones, Sue Witte, Lawrence Hunsicker, Zoe Stewart. Iowa City, IA.

C61 Racial Differences Amongst Infants Undergoing Intestine Transplants.
Khalid M. Khan, Chirag Desai, Stuart Kaufman, Rafaeele Girlanda, Jason Hawksworth, Alexander Kroemer, Thomas Fishbein, Cal Matsumoto. Washington, DC.

C62 Is It Worth Risking Lives of Multiple Procurement Surgeons to Save One Life in Extreme Weather Conditions?

C63 † KDPI Outcomes and Discard Rates – The Contradiction of the U.S. and European Approach.
Lukas J. Lehner, Anna Kleinsteuber, Fabian Halleck, Dmytro Khadzhynov, Michael Duerr, Klemens Budde, Oliver Staeck. Berlin, Germany.

C64 † Simulating Alternative Bayesian Criteria to Identify Transplant Center Performance Outliers.
Jesse D. Schold, Charles Miller, Mitchell Henry, Laura D. Buccini, Stuart M. Flechner, David A. Goldfarb, Emilio D. Poggio, Ken Andreoni. Cleveland, OH; Columbus, OH; Gainesville, FL.

C65 † Understanding the Dynamics of a Suddenly Plateauing Kidney Waiting List.
Amber R. Wilk, Darren E. Stewart, Erick Edwards. Richmond, VA.

C66 † Acute-on-Chronic Liver Failure Admissions Cost 3 Times More Than Non-ACLF Related Admissions.
Sara G. Leffingwell, Jacqueline G. O’Leary, Sumeet Asrani. Dallas, TX.

C67 † Do All cPRA 100% Candidates Have Equal Access to Organ Allocation?
Howard M. Gebel, S. Gustafson, D. Segev, B. Kasiske, A. Israni. Minneapolis; Atlanta; Baltimore.

C68 Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.
Robert A. Bray, Ronald F. Parsons, Nicole A. Turgeon, Howard M. Gebel. Atlanta, GA.

Adela Mattiazzi, Warren Kupin, David Roth, Linda Chen, George W. Burke, Gaetano Ciancio, Philip Ruiz, Rodrigo Vianna, Giselle Guerra. Miami, FL.

C70 Early Changes to Kidney Distribution Under the New Kidney Allocation System.
Allan Massie, Xun Luo, Bonnie Lonze, Niraj Desai, Adam Bingaman, Matthew Cooper, Dorry Segev. Baltimore; San Antonio; Washington.

C71 Thoracic Simulated Allocation Modeling (TSAM) of Broader Sharing.
Monica Colvin, M. Skeans, L. Robbins Callahan, L. Edwards, J. Zeglin, S. Silvestry, R. Davies, M. Farr, A. Israni, J. Rogers. Minneapolis, MN; Richmond, VA; Orlando, FL; Wilmington, DE; New York, NY; Durham, NC.

C72 Projection versus Reality: KPSAM and KAS.
Sally Gustafson, Ajay Israni, Joshua Pyke, Nicholas Salkowski, Jon Snyder, Bertram Kasiske. Minneapolis, MN.
C73 Prospective Randomized Controlled Study Evaluating the Relationship Between Electronic Adherence Data and Tacrolimus Concentration Data. Brenna Kane, Mark Lockwood, Lisa Potter, Laura Lourenco, Adam Bodzin, Diane Covington, Kimberly H. Mayer, J. Michael Millis. Chicago, IL; Tucson, AZ; Madison, WI.


C74 The Environmental Impact of Dialysis vs Transplantation. Monica Grafals, Ramon Sanchez. Washington, DC; Boston, MA.


C75 LACE Index Risk Assessment Tool Predicts Liver Transplant Readmissions. Anahita Masoumi, Rolf N. Barth, John C. LaMattina, David A. Bruno, Laci Hebert, Nicholas Schluterman, Steven I. Hanish. Baltimore, MD.

C82 Fatty Liver in Non-Hepatic Organ Transplantation. Nyingi Kemmer, Angel Alsina. Tampa, FL.

C76 Development of an Integrated Transplant Data Mart for Customized Data Reporting. Rachel Patzer, Kendra Little, Jake Kirsch, Jeff Weaver, Andrew Adams. Atlanta.


Ischemia Reperfusion Injury and Organ Preservation


C88 † Alterations in Central Carbohydrate Metabolism in Porcine Liver Allografts Preserved with a Subnormothermic Machine Perfusion (SNMP) System.

C89 † Liver Graft Rejuvenation Prior to Transplantation: A Bench-to-Bedside Approach.
Ali Zarrinpar, Bibo Ke, Haofeng Ji, Elaine Reed, Ronald Busuttil, Jerzy Kupiec-Weglinski. Los Angeles, CA.

C90 † Mesenchymal Stem Cells Reprogram Macrophage Polarization and Attenuate Liver Ischemia and Reperfusion Injury by Regulating Notch/Cox2/PGE2 Signaling Pathway.
Changyong Li, Shi Yue, Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski, Bibo Ke. Los Angeles, CA; Wuhan, China.

C91 † Anti-Inflammatory Effects of AAV-Mediated TIMP-1 Gene Transfer in Hepatic Ischemia-Reperfusion Injury.

C92 † Immunosuppressive Actions of CLI95 and CORM401 on TLR4 in Renal Ischemia Reperfusion Injury.

C93 † Metabolic Dysregulation and Mitochondrial Dysfunction Are Key Features of Injury Profiles of Donor Kidneys After Brain Death.
Maria Letizia Lo Faro, Mohammed Z. Akhtar, Honglei Huang, Maria Kaisar, Rolando Robolledo, Karl Morten, Lisa C. Heather, Anthony Dona, Henri G. Leuvenink, Susan V. Fuggle, Benedikt M. Kessler, Christopher W. Pugh, Rutger J. Ploeg. Oxford, United Kingdom; Groningen, Netherlands; Sydney, Australia.

C94 † The Fine-Tuning of CXCL8 Protects Kidney Against Ischemia-Reperfusion Injury in Mice Lacking MicroRNA-146a.
Lucile Amrouche, Geoffroy Desbullois, Marion Rabant, Christophe Legendre, Fabiola Terzi, Dany Anglicheau. Paris, France, Metropolitan.

C95 † Liver Ischemia Induces Kupffer Cell Necroptosis to Facilitate Liver Inflammatory Immune Activation.
Shi Yue, Haoming Zhou, Ronald Busuttil, Jerzy Kupiec-Weglinski, Xuehai Wang, Yuan Zhai. Los Angeles, CA; Nanjing, Jiangsu Province, China.

C96 † Recombinant TSGL-Ig Protects Liver Endothelial Cells Against Prolonged Cold Preservation Injury in Mouse Liver Transplantation.

C97 † Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Protects Against Loss of Hepatic Integrity After Ischemia-Reperfusion Injury.
Takehiro Fujii, Sergio Duarte, Ronald W. Busuttil, Ana J. Coito. Los Angeles, CA.

C98 † Protective Effects of Nrf2 Over-Activation in Myeloid Cells During Hepatic Ischemia Reperfusion Correlates with Stat3 Signaling in Hepatocytes.
Calvin Harberg, Lung-Yi Lee, Sabine Werner, Delinda A. Johnson, Jeffrey A. Johnson, David Foley. Madison, WI; Zurich, Switzerland.
Ivonne Palma, Sandra Kabagambe, Yulia Smolin, Tristan Boyer, Ivan Palma, Oliver Fiehn, Yue-Julia Chen, Junichiro Sageshima, Chandrasekar Santhanakrishnan, Christoph Troppmann, Richard V. Perez. Sacramento, CA; Davis, CA.

C100 † Reciprocal Effects of HDAC1 and HDAC2 Deletion on Renal Cold Ischemia Survival and Nuclear Co-Repressor Complex Expression.

C101 † Activating Transcription Factor 5 (ATF5) Regulates Liver Ischemia/Reperfusion Injury.
Gong-Qing Shen, Miwa Morita, John J. Fung, Lina Lu, Shiguang Qian. Cleveland, OH.

C102 † Persufflation Improves Viability and Function of Porcine Kidneys Relative to Static Cold Storage.
Catherine Min, Leah Steyn, Abhishek Pandey, Robert Harland, Jean-Philippe Galons, Klearchos K. Papas. Tucson, AZ.

C103 † Bioinformatic Analysis of Pathways Mediating Clusterin Functions in Kidney Cells Under Normoxia and Hypoxia.
Ghida Dairi, Qiuonong Guan, Colin Collins, Chris Ong, Martin Gleave, Chris Nguan, Caigan Du. Vancouver, BC, Canada.

C104 † Stem Cell-Mediated Regeneration of Ischemically Damaged Renal Allografts During Ex Vivo Warm Perfusion.
Lauren Brasile, Nicholas Henry, Bart Stubenitsky. Watervliet, NY; Utrecht, Netherlands.

C105 † Ex Vivo Perfusion of Porcine Forelimbs to Prolong Allowable Ischemia Time.

C106 † Creation of a Small Animal Model of Ex-Vivo Normothermic Perfusion (EVNP) for Treatment of Kidney Ischemia-Reperfusion (I/R) Injury.

C107 † Histone Deacetylase-2 Gene Deletion in Mice Mitigates Liver Ischemia/Reperfusion Injury.

C108 † Replacing Cold Storage with Normothermic Ex Vivo Kidney Perfusion Improves Function of Grafts Retrieved After Circulatory Death (DCD).

C109 † NecroX-7 Attenuates Ischemia-Reperfusion Renal Injury.

C110 † Subnormothermic Machine Perfusion (SNMP) with a Hemoglobin Based Oxygen Carrier (HBOC) Solution Reprograms Dynamic Inflammation Networks When Compared to Cold Storage (CS) in a Porcine Liver Allograft Model.
C111 † Allograft TLR4 Receptor Signaling Induces Specific Early Inflammatory Events in Promotes Allografts Subjected to Prolonged Cold Ischemic Storage.
Takafumi Yagisawa, Naoki Kohei, Danielle D. Kish, Robert L. Fairchild. Cleveland, OH.

C112 Distinctive Roles of Gsk3 Inhibitory Phosphorylation in Liver Inflammatory Immune Response and Hepatocellular Injury Against Ischemia Reperfusion.
Haoming Zhou, Jianjun Zhu, Shi Yue, Ronald W. Busuttil, Jerzy W. Kupiecweglinski, Ling Lu, Yuan Zhai. Los Angeles, CA; Nanjing, Jiangsu Province, China.

C113 ER Stress and Loss of GRP78 Expression Provides a Link Between Renal Ischemia/Reperfusion Injury and the Urinary Metabolome.
Cees van Kooten, Tiziana Pacchiarotta, Pieter van der Pol, Johan W. de Fijter, Nicole Schlagwein, Danielle J. van Gijlswijk, Oleg A. Mayboroda. Leiden, Netherlands.

C114 Local Infusion of MyD88 Inhibitor Inhibits Ischemia-Reperfusion Kidney Injury.
Hong R. Cho, Jong Soo Lee, Hye J. Kim, Yong K. Han, Byungsuk Kwon, Sang J. Park, Kyung S. Park. Ulsan, Republic of Korea.

C115 The mTORC2 Activation Is Critical for Hepato-Cytoprotection Against Ischemia and Reperfusion Injury.
Haoming Zhou, Jianjun Zhu, Shi Yue, Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski, Xuehao Wang, Yuan Zhai. LA, CA; Nanjing, Jiangsu Province, China; Shanghai, China.

C116 Heparanase: A New Factor Involved in the Pro-Fibrotic Renal Biological Machinery Activated by the Ischemia/Reperfusion (I/R) Injury.
Gianluigi Zaza, Valentina Masola, Giovanni Gambero, Maurizio Onisto, Gloria Bellin, Israel Vlodavsky, Zaid Abassi, Antonio Lupo. Verona, Italy; Rome, Italy; Padova, Italy; Israel, Italy.

C117 Adding Anti-Inflammatory Agents During Normothermic Ex-Vivo Liver Perfusion Improves the Preservation of Pig Liver Grafts Before Transplantation.
Nicolas Golдарacena, Echeverri Juan, Kath Moritz, Vincent Spetzler, Andrew Barbas, David Grant, Markus Selzner. Toronto, Canada.

C118 Role of TGF-Δ in Ischemia and Reperfusion Injury Induced Renal Fibrosis in Human Proximal Tubular Epithelial Cells.

C119 Subnormothermic Machine Perfusion (SNMP) of Liver Allografts with a Novel Hemoglobin-Based Oxygen Carrier (HBOC) Increases Δ-Oxidation of Fatty Acids and Decreases Lipid Peroxidation (LP).

C120 Sphingosine-1 Phosphate Receptor 1 Agonist SEW2871 Ameliorates Hepatocellular Injury on Ischemic Reperfusion in Mice: A New Therapeutic Target.
Takahiro Ito, Naohisa Kuriyama, Akitoshi Matsuda, Hiroyuki Kato, Yusuake Iizawa, Yasuhiro Murata, Akihiro Tanemura, Yoshinori Azumi, Masashi Kishiwada, Shugo Mizuno, Masanobu Usui, Hiroyuki Sakurai, Shuji Isaji. Tsu City, Mie, Japan.

C121 Short-Term Starvation Attenuates Liver Ischemia Reperfusion Injury by SIRT1-Autophagy Signaling in Mice.

C122 Short, Cool and Well Oxygenated – HOPE for DCD Kidneys.
Philipp Kron, Andrea Schlegel, Olivier de Rougemont, Christian Eugen Oberkofler, Pierre- Alain Clavien, Philipp Dutkowski. Zurich, Switzerland.

C123 Hydrogen Sulfide Treatment Mitigates Donor Tissue Necrosis During Prolonged Cold Storage and Improves Survival Following Allogeneic Renal Transplantation.
Ian Lobb, Weihua Liu, Jifu Jiang, Dameng Lian, Alp Sener. London, ON, Canada.
C124  Activation of Innate Immunity During Human OLT-IRI Triggers Adaptive Immunity and Correlates with the Degree of IRI Injury.
Ali Zarrinpar, Rebecca Sosa, Ping Rao, Charles Lassman, Ronald Busuttil, David Gjertson, Jerzy Kupiec-Weglinski, Elaine Reed. Los Angeles, CA.


C126  Mitochondrial Membrane Potential Correlates with Ischemic Injury and Kidney Graft Function in Rats.

C127  Normothermic Perfusion of Livers Donated After Circulatory Death: A New Clinically Relevant Experimental Model.
Yiming Cao, Hong C. Chew, Karen Fernandez, Ling Gao, Jeanette Villanueva, Mark Hicks, Peter Macdonald, Kumud Dhital, Henry Pleass. Sydney, NSW, Australia.

C128  Signs of a Dying Organ: Beyond Resistance in Subnormothermic Kidney Perfusion.
Matthew F. Blum, Daniel Urcuyo, Qiang Liu, Basem Soliman, Toshihiro Okamoto, David A. Goldfarb, Cristiano Quintini. Cleveland, OH.

C129  Prolonged Cold Ischemia Time Negatively Impacts Graft and Recipient Survival in a Murine Orthotopic Hindlimb Transplant Model.
Neha Datta, Sean G. Devaney, Antoinette Allen, Ronald W. Busuttil, Kodi Azari, Jerzy Kupiec-Weglinski. Los Angeles, CA.

C130  Re-Examining the Role of B-1 Cells in a Murine Model of Renal Ischemia Reperfusion Injury.
Daniel J. Firl, Abhishek Das, John J. Fung, Michael C. Carroll. Boston; Cleveland; Chevy Chase.

C131  An Improved Flow Cytometry Based Platelet Counting in Xeno Perfusion Models.

C132  The Effects of Brain Death and Ischemia on Tolerance Induction Are Organ-Specific.
Sebastian G. Michel, Maria Lucia L. Madariaga, Glenn M. LaMuraglia II, Robert B. Colvin, Evan A. Farkash, James S. Allan, David H. Sachs, Kazuhiro Yamada, Joren C. Madsen. Boston, MA; Munich, Germany.

C133  C1-Inhibitor Abrogated Ischemia/Reperfusion (I/R) Induced Inflammaging by Inhibiting Senescence-Associated Secretory Phenotype (SASP) in Tubular Epithelial Cells (TEC).

C134  Anti-LG3 Antibodies Enhance Renal Microvascular Rarefaction, Fibrosis and Dysfunction Associated with Ischemia-Reperfusion Injury.
Bing Yang, Katia Hamelin, Méllisa Hénault-Rondeau, Natalie Patey, Julie Turgeon, Shan Shan Lan, Luc Pomerleau, Junzheng Peng, Johanne Tremblay, Mélanie Dieudé, Marie-Josée Hébert, Héloïse Cardinal. Montreal, QC, Canada; CNTRP, Canada.

C135  Attenuation of Warm Hepatic Ischemia-Reperfusion Injury by Bruton’s Tyrosine Kinase Inhibition.
Kidney Donor Evaluation and Donor Nephrectomy

**C136** † Amino Acid (AA) Metabolism During Liver Allograft Preservation Comparing Subnormothermic Machine Perfusion (MP) Against Cold Storage (CS).

**C137** † Evolution of Donor Nephrectomy: Long-Term Outcomes with Four Different Techniques Between 1963 and 2014 at a Single Institution.

**C138** † Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies.
Francis Tinney Jr, Lenar Yessayan, Marwan Abouljoud, Anita Patel. Detroit, MI.

**C139** † Health Insurance Trends in United States Living Kidney Donors.
James R. Rodrigue, Aaron Fleishman. Boston, MA.

**C140** † The Impact of Pre-Donation eGFR on Recipient Outcomes, as a Function of Donor Age.

**C141** † Clinical Outcomes of Kidney Allograft Recipients with Apolipoprotein L1 (APOL1) Risk Alleles from Living Kidney Donors.

**C142** † Effect of Baseline Co-Morbidity on Mortality in Living Kidney Donors – 10 Year UK Cohort Study.
Nithya Krishnan, Lisa Bradbury, Neil Raymond. Coventry, United Kingdom; Bristol, United Kingdom.

**C143** † Robotic-Assisted Laparoscopic Donor Nephrectomy with Transvaginal Extraction of the Kidney.

**C144** † Improving Donor Comfort: Perioperative Dexamethasone Decreases Nausea, Vomiting, and Pain After Laparoscopic Donor Nephrectomy.

**C145** † Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance.

**C146** † Altruistic Kidney Donation: A Single US Transplant Center Experience.
A. Aguire-Alarcon, M. Lubetzky, M. McKinney, L. Kayler. Bronx, NY; Buffalo, NY.

**C147** † Post-Donation eGFR and Hypertension in Living Kidney Donors.
Allan Massie, Abimereki Muzaale, Saad Anjum, Joseph Leanza, Jennifer Alejo, Jayme Locke, Dorry Segev. Baltimore; Birmingham.

**C148** † Renal Efficiency: A New Metric for Evaluating Kidneys in Living Donors.
Alejandro Diez, Kang Rima, Jon Von Visger, Uday Nori, Todd Pesavento, Amer Rajab, Mitchell Henry, Ronald Pelletier. Columbus, OH.

**C149** † What Are the Benefits of Transvaginal Route for Kidney Extraction in Laparoscopic Living Donor Nephrectomy?
Ineligible: Attitudes and Follow-Up of Individuals Ruled Out of Living Kidney Donation.

Measured Glomerular Filtration Rate of the Remaining Kidney Divided by Its Volume Prior to Donation Is a Predictor of the Long-Term Gain of Function in Living Kidney Donors.
Marie Courbebaisse, François Gaillard, Alexis Le Nestour, Jean-Michel Correas, Hind Slimani-Thevenet, Carine Leon, Dominique Eladari, Marc-Olivier Timsit, Philippe Otal, Gérard Friedlander, Pascal Houillier, Nassim Kamar, Christophe Legendre. Paris, France; Otago, New Zealand; Toulouse, France.

Peri-Operative Events and Complications in Minimally-Invasive Live Donor Nephrectomy: What Should We Tell Potential Donors?
Kirsten Kortram, Jan N. M. Ijzermans, Frank J. M. F. Dor. Rotterdam, Netherlands.

The Effect of Families on Organ Donation Among Native Americans.
Tasce Bongiovanni, James Rawlings, Joyce A. Trompeta. San Francisco, CA; New Haven, CT.

Text Messaging Facilitates Follow-Up Communication with Live Donors.

A Pilot Study of Donor: A Smart Phone Application for Identifying Live Kidney and Liver Donors.
Komal Kumar, Elizabeth A. King, Abimereki D. Muzaale, Jonathan M. Konel, Greg Segal, Jenna Arnold, Katrina A. Bramstedt, Dorry L. Segev, Andrew M. Cameron. Baltimore, MD; New York, NY; Gold Coast, QLD, Australia.

Can Qrisk Be Useful to Predict Future Cardiovascular Co-Morbidities and Type II Diabetes in Living Kidney Donors Prior to Donation?
Shiv Bhutani, Rajkumar Chinnadurai, Gabriel Bernal-Blanco, Bavik Patel, Angela Summers, David Van Dellen, Muir Morton, Picton Michael. Manchester, United Kingdom.


The Safety and Efficacy of Suspended Gasless Laparoscopy Living-Donor Nephrectomy in Renal Transplantation.
Jun Tian. Jinan, China.

Pre-Emptive Kidney Transplantation with Living-Donor and Concomitant Unilateral Nephrectomy in Patients with Autosomal-Dominant Polycystic Kidney Disease: A Safe Strategy?
Constance Michel, François Audenet, Mehdi Ariane, Christophe Legendre, Dominique Joly, Arnaud Méjean, Marc-Olivier Timsit. Paris, France.

Prospective Investigation of the Reliability and Validity of the Live Donor Assessment Tool (LDAT).

Low-Pressure Pneumoperitoneum in Living Kidney Donors: An Age-Dependent Analysis of Recipient Outcomes.
Sanjay Kulkarni, Smith Douglas, Elizabeth Cohen, Sarah Swift, Isaac Hall. New Haven, CT.

Altruistic Kidney Donation: From the Donor’s Perspective.
Rachel E. Burge, Stephen Potts, Sarah Lundie. Edinburgh, United Kingdom.
C163 † Hand-Assisted Laparoscopic Donor Nephrectomy: Experience with Over 2400 Cases at a Single Center.
Han Li, Mark D. Stegall, George Chow, Patrick Dean, Julie Heimbach, Timucin Taner, Mikel Prieto. Rochester, MN; Charleston, SC.

C164 † Living Donor Kidney Transplantation: How Do Recipients Benefit Psychologically?

C165 † Living Kidney Donor Priorities for Outcomes: A Nominal Group Technique Study.
Camilla S. Hanson, John Kanellis, Germaine Wong, Jule Pinter, Steve J. Chadban, Jeremy R. Chapman, Jonathan C. Craig, John S. Gill, Amit X. Garg, Joshua R. Lewis, Allison Tong. Sydney, Australia; Melbourne, Australia; Vancouver, Canada; London, Canada.

C166 † Effect of Baseline Proteinuria on Long- and Short-Term Outcomes in Live Kidney Donors – 10 Year U.K Cohort Study.
Nithya Krishnan, Lisa Bradbury, Neil Raymond. Coventry, United Kingdom; Bristol, United Kingdom.

C167 † End Stage Renal Disease (ESRD) Patients’ Willingness to Accept Risks to Living Kidney Donors.

C168 † Do We Need Radioisotope Renography in Evaluation of Split Renal Function in Living Kidney Donors?

C169 † Protocol for Health Information Exchange Living Donor Cohort Discovery.
Macey L. Henderson, Anna Roberts, Allan Massie, Dorry Segev, William Goggins, Cynthia Stone, Brian E. Dixon. Indianapolis, IN; Baltimore, MD.

C170 † Kidney Transplantation from Thin Basement Membrane Nephropathy Donor.
Chanjoong Choi, Ahram Han, Song-Yi Kim, Sungsin Cho, Min-Ji Cho, Chang Hwan Lee, Sanghyun Ahn, Seung-Kee Min, Jongwon Ha, Myung Hee Park, Sang Joon Kim, In Mok Jung, Sang-il Min. Seoul, Republic of Korea; Goyang, Gyeonggi-do, Republic of Korea.

C171 † An Assurance of Insurance: Should Living Kidney Donors Be Required to Have Health Insurance?
Jordan R. Siegel, Abhinav Humar, Peter J. Gianaros, Jennifer L. Steel. Pittsburgh, PA.

C172 † Urinary Neutrophil Gelatinase-Associated Lipocalin in Living Kidney Donor Nephrectomy.

Kidney Transplantation: AKI/Preservation/DCD

C173 † Ex-Vivo Normothermic Perfusion for Assessment of High Risk Deceased Donor Kidneys for Transplantation.

C174 † Predicting Delayed Kidney Graft Function with Gene Expression in Preimplantation Biopsies.
Tuíla B. Mourão, Karina L. Mine, Erika F. Campos, Jose O. Medina-Pestana, Helio Tedesco-Silva, Maria Gerbase-De Lima. São Paulo, SP, Brazil.

C175 † Predictive Model of Delayed Graft Function in Machine Perfused Kidney Transplantation: Model Validation Using Decision Curve Analysis.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>C176 †</td>
<td>The Use of Kidneys with Acute Kidney Injury: The Good, the Bad and the Ugly.</td>
<td>Catherine Boffa, Fenna van de Leemkolk, Elinor Curnow, James Gilbert, Edward Sharples, Rutger Ploeg.</td>
<td>Oxford, United Kingdom; Bristol, United Kingdom.</td>
</tr>
<tr>
<td>C178 †</td>
<td>Markers of Activation of Microvascular Endothelial Cells Predict a Poor Long-Term Graft Outcome in Early Renal Graft Biopsies Displaying Acute Tubular Necrosis.</td>
<td>Yi-chun Dubois-Xu, Pedram Ahmadpoor, Anthony Corchia, David Buob, Pierre Galichon, Isabelle Brochériou, Caroline Suberbielle, Alexandre Hertig, Eric Rondeau.</td>
<td>Paris, France.</td>
</tr>
<tr>
<td>C180 †</td>
<td>Hypothermic Machine Perfusion Ameliorates Vasospasm and Edema of Podocytes and Renal Tubular Epithelial Cells Through Upregulating Expression of Krüppel-Like Factors 2.</td>
<td>Zibiao Zhong, Dicken Shiu-Chung Ko, Yanfeng Wang, Qifa Ye.</td>
<td>Wuhan, MA.</td>
</tr>
<tr>
<td>C183</td>
<td>Influence of Cold Ischemia Time in Kidney Transplants from Small Pediatric Donors.</td>
<td>Liise Kayler, Michelle Lubetzky, Patricia Friedman.</td>
<td>Buffalo; Bronx.</td>
</tr>
<tr>
<td>C184</td>
<td>The Impact of Total Ischaemic Time, Donor Age and the Pathway of Donor Death on Graft Outcomes After Deceased Donor Kidney Transplantation.</td>
<td>Germaine Wong, Armando Teixeira-Pinto, Chapman R. Jeremy, Craig C. Jonathan, McDonald Stephen, Lim H. Wai.</td>
<td>Sydney, Australia; Adelaide, Australia; Perth, Australia.</td>
</tr>
</tbody>
</table>
C187 Associations of Perfusate Biomarkers and Pump Parameters with Delayed Graft Function and Deceased-Donor Kidney Allograft Function.
Chirag R. Parikh, Isaac E. Hall, Ronik S. Bhangoo, Joseph Ficek, Peter L. Abt, Heather Thiessen-Philbrook, Haiqun Lin, Milan Bimali, Patrick T. Murray, Veena Rao, Bernd Schröppel, Mona D. Doshi, Francis L. Weng, Peter P. Reese. New Haven, CT; Phoenix, AZ; Philadelphia, PA; Dublin, Ireland; New York, NY; Detroit, MI; Livingston, NJ.

C188 Controlled Cardiac Death Donor Program for Kidney Transplantation – Spanish Multicenter Experience with Two Years of Follow-Up.

C189 Association Between Delayed Graft Function and Long-Term Outcomes After Kidney Transplantation from Donors After Circulatory Death.

C190 Factors Associated with Prolonged Warm Ischemia Time Among Deceased Donor Kidney Transplant Recipients.

C191 Delayed Graft Function (DGF) Doesn’t Affect Adversely the Long-Term Survival of Renal Transplantations (RT) from Uncontrolled Donation After Cardiac Death (UDCD) as Compared with RT from Standard Criteria Donor (SCD).

C192 Comparison of Outcomes of Kidney Transplantation from DBD, DCD or DBCD Donors: A Single Center Experience from China.

C193 † Imminent Death Donation: Potential Effects on Organ Donation Numbers and Clinical Outcomes.
Vishnu Potluri, Susanna Nazarian, Matthew Levine, Peter Reese. Wynnewood; Philadelphia.

C194 † Improving Kidney Allocation System with Higher Resolution.
M. Cusick, J. Friedewald, K. Haarberg, J. Leventhal, A. Tambrur. Chicago, IL.

C195 † Pre-Transplant Anti-A Titers in Waitlisted A2 to B Kidney Transplant Candidates.
Deonna Moore, Irene Feurer, Rachel Forbes, April DeMers, David Shaffer. Nashville, TN.

C196 † Optimizing CPRAs for Sensitized Kidney Waitlist Candidates: The Devil Is in the KAS Details.

C197 Impact of New Kidney Allocation System on Transplant Rates for Highly Sensitized Patients-Center Specific Study.
Xiaohai Zhang, Mehrnoush R. Naim, Ashley Vo, Stanley Jordan, Nancy L. Reinsmoen. Los Angeles, CA.

C198 Kidney Transplant Outcomes in Patients with CPRA Values >98% After Implementation of the New OPTN/UNOS Kidney Allocation System (KAS): A Single Center Study Update.
170

C199 Deceased Donor ABO-Incompatible Kidney Transplantation Has the Potential to Reduce Blood Group Disparity.
Miriam Manook, Lisa Bradbury, Daniel Osei-Bordom, Bynvant Sandhu, Tim Maggs, Olivia Shaw, Nicos Kessaris, Sapna Shah, Anthony Dorling, Nizam Mamode. London, United Kingdom; Bristol, United Kingdom.

C200 Donor Interstitial Fibrosis and Tubular Atrophy (IFTA) Are Not Independent Risk Factors for a Lower GFR at One Year.

C201 Preimplant Donor Histology Does Not Improve Discrimination of 5 Year Kidney Allograft Outcomes.
Carol Traynor, Tony Dorman, Declan de Freitus, Peter J. Conlon, Conall O’Searghlda. Durham, NC; Dublin, Ireland.

Camila Mazeti, Heloisa Caldas, Ida Maria Fernandes-Charpiot, Maria Alice Baptista, Mario Abbud-Filho. Sao Jose do Rio Preto, SP, Brazil.

Liver Transplantation Complications and Other Considerations

C203 Don't Judge a Book by Its Cover: Normal Liver Enzymes After Transplantation Can Be Associated with Pathologies Requiring Intervention.
Czarina Mae Sanchez, Sean Kumer, Shelbi Olson, Richard Gilroy, Timothy Schmitt, Bartholomew Kane, Ryan Taylor. Kansas City, KS.

C204 Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.
Ravish Parekh, Maria Segovia, Nirmal Kaur. Detroit, MI.

C205 Outcomes Following Appendectomy in Liver Transplant Recipients.

C206 Utilization of Parenteral Nutrition in Patients Undergoing Liver Transplantation.

C207 Multifactorial Prediction of Biliary Stricture After Liver Transplantation: The Impact of Platelet Counts.
Kazuhiro Takahashi, Krishna Putchakayala, Michael Rizzari, Kelly Collins, Shunji Nagai, Atsushi Yoshida, Marwan Abouljoud, Gabriel Schnickel. Detroit, MI.

C208 Bariatric Surgery and Increased Risk of Death After Listing for Liver Transplantation.
Sumeet K. Asrani, Fatima Khan, Giovanna Saracino, Gregory McKenna, Jeanette Hasse, Goran Klintmalm, James Trotter. Dallas, TX.

C209 Cholangioscopy in Liver Transplant Recipients.

C210 Telemedicine to Reduce Readmissions Post Liver Transplant: Compliance and Feasibility Results.

C211 Reducing Non-Anastomotic Biliary Strictures After Donation After Circulatory Death Liver Transplantation, a Matter of Time?


C221  The Use of Perioperative Lactate Values as Markers for Adverse Outcomes in Liver Transplantation. Bharat Rao, Atsushi Yoshida, Mostafa Ibrahim, Syed-Mohammed Jafri. Detroit, MI.


C223  Stress Cardiomyopathy in the Peri-Operative Period After Liver Transplant. Naftali Presser, Benico Barzilai. Cleveland, OH.

C224  Predictive Factors of Early Hospital Readmission in Liver Transplant Recipients. Amy Hilliard, Marissa Brokhof, Jennifer Geyston, Josh DeMott, Edie Chan, Martin Hertl, Nicole Alvey. Chicago, IL.


Outcomes of Aorto-Hepatic Conduit During Liver Transplantation – A 31-Year, Single Center Experience. Amar Gupta, Tiffany Anthony, Robert Goldstein, Greg McKenna, Nicholas Onaca, Richard Ruiz, Giuliano Testa, Goran Klintmalm, Peter Kim. Dallas, TX.

Caval Replacement versus Piggyback Liver Transplantation: The Toronto Experience. Andrew S. Barbas, Martin J. Dib, Nicolas Goldaracena, Max Marquez, Gonzalo Sapisochin, David P. Al-Adra, Stuart A. McCluskey, Ian D. McGilvray. Toronto, ON, Canada.

Transcatheter Aortic Valve Replacement (TAVR) for Severe Aortic Stenosis as a Bridge to Liver Transplantation. Rashid Z. Syed, Pedro Cox-Alomar, Humberto Bohorquez, George Therapondos, Nigel Girgrah, Shobha Joshi, Gia Tyson, Trevor Reichman, Ian Carmody, George Loss, Ari Cohen, David Bruce, Emily Ahmed, John Seal, Patrick E. Parrino, Stephen Ramee, Natalie Bzowej. New Orleans, LA.


Kidney Complications-Other I

Single Center Experience with Robotic Kidney Transplantation for Recipients with BMI >40 kg/m2: A Comparison with the UNOS Registry. Ivo Tvetanov, Sandra Garcia Aroz, Mario Spaggiari, Jeon Hoonbae, Jose Oberholzer, Enrico Benedetti. Chicago, IL.

Robotic Kidney Transplantation in Obese Recipients Can Lead to Superior Outcomes in Terms of Wound Infection and Graft Survival – 48 Months of Follow-up. Ivo Tvetanov, Sandra Garcia Aroz, Mario Spaggiari, Jeon Hoonbae, Jose Oberholzer, Enrico Benedetti. Chicago, IL.


C244 † Outcomes Following Appendectomy in Kidney Transplant Recipients. Sandra DiBrito, Israel Olorundare, Claudia Landazabal, Dorry Segev, Nabil Dagher. Baltimore.


C252 † Predictors of Urologic Complications After Pediatric En-Bloc Donor Kidney Transplantation.
Sandra Kabagambe, Angelo De Mattos, Richard Perez, Chandrasekar Santhanakrishnan, Junichiro Sageshima, Christoph Troppmann, John McVicar.
Sacramento, CA.

C253 † Universal Stenting of Renal Transplants Associated with a Low Complication Rate When Quality Assurance Program Ensures Stent Removal.
Carrie E. Yeast, Julie M. Riley, Catherine Ashbaugh, Gilbert Ross, Mark Wakefield.
Columbia, MO.

C254 † Ureteroenterostomy in Kidney Transplant: Retrospective Analysis of 30 Consecutive Cases.
São Paulo, Brazil.

C255 † Common Iliac Artery Stenosis: An Often Overlooked Cause of Graft Dysfunction.
Emily Christie, Patricia Campbell, Kevin Wen.
Edmonton, AB, Canada.

C256 † Use of Preoperative Embolization Prior to Transplant Nephrectomy.
Carrie E. Yeast, Julie M. Riley, Joshua Holyoak, Stephen Weinstein, Gilbert Ross, Mark Wakefield.
Columbia, MO.

C257 † Early Hospital Readmisson Among Older Kidney Transplant Recipients.
Elizabeth King, Lauren Kucirka, Mara McAdams-DeMarco, Fawaz Al-Ammary, Dorry Segev.
Baltimore, MD.

C258 † Hospital Readmissions in the First Year Post Transplant Over a 12-Year Span at a Single Center.
Columbus, OH.

C259 † Resource Utilization and Cost Analysis of Early Hospital Readmissions Following Kidney Transplantation.
Magdalene Au, Olusegun Famure, Yanhong Li, Joseph Kim.
Toronto, ON, Canada.

C260 † Early Hospital Readmission After Kidney Transplantation: Seasonality, Causes and Prognosis.
Melissa Gaspar Tavares, Marina Pontello Cristelli, Laila Almeida Viana, Mayara Ivani de Paula, Helio Tedesco Silva Junior, José Osmar Medina Pestana.
Sao Paulo, Brazil.

C261 † Effect of Telehealth Monitoring on Early Hospital Readmission After Renal Transplantation.
Kelly Noon, Nagaraju Sarabu, Joshua J. Augustine, Donald E. Hricik, Barbara Deleva, Kenneth J. Woodside, Mark Aeder, Joel Foote, Alison Bruno, Kevin Walsh, Melissa Johnston, Vanessa R. Humphreville, Edmund Sanchez.
Cleveland, OH; Ann Arbor, MI.

C262 † Impact of Early Hospital Readmissions After Kidney Transplantation on Graft Function.
Im-Kyung Kim, Man Ki Ju, Sunyoung Son.
Seoul, Korea.

C263 † Never Events and Hospital Acquired Conditions After Kidney Transplant.
Zobin Moghadamyeghaneh, Mahmoud Alameddine, George Burke, Gaetano Ciancio, Linda J. Chen.
Miami, FL.

C264 † Utilization of Subacute Rehabilitation Facility Early After Kidney Transplantation.
Fu L. Luan, Marie Ben-Israel, Shamkant Mulgaonkar.
Livingston, NJ.

C265 † Factors Affecting Mortality During Waiting Time for Kidney Transplantation: A Nationwide Population-Based Cohort Study Using the Korean Network for Organ Sharing (KONOS) Database.
Sunhwa Lee, Kyung Don Yoo, Jung Nam An, Yun Kyu Oh, Chun Soo Lim, Yun Su Kim, Jung Pyo Lee.
Seoul, Republic of Korea; Gyeongju, Republic of Korea.
C266 † Relationship Between Dialysis Duration and Prevalence of Cardiovascular Diseases in Kidney Transplantation Recipients.

C267 † Changes in Fatigue After Kidney Transplantation.
Hao Ying, Israel Olorundare, Nabil Dagher, Bonnie Lonze, Robert Montgomery, Mara McAdams-Demarco, Dorry Segev. Baltimore, MD.

C268 † The Effect of Immunosuppression Regimen on Iga Nephropathy Recurrence Post Kidney Transplantation.
Konstantinos Koutroutsos, Andreas Kousios, Laura Leighton, Rawya Charif, Dawn Goodall, Terence Cook, Jack Galliford, David Taube, Marina Loucaidou. London, United Kingdom.

C269 † Outcome After Kidney Transplant (KTx) in Patients with Chronic Hypotension on Haemodialysis (HD).

C270 † Which Post-Transplant Complications Are More Common in Elderly Renal Recipients?

C271 † Age Adapted Immunosuppression for Elderly Kidney Allograft Recipients: Balancing Risks for Cancer versus Rejection.
Francesca Jackson-Spence, Holly Gillott, Sanna Tahir, Felicity Evison, Jay Nath, Adnan Sharif. Birmingham, United Kingdom.

C272 † Evaluation of T Cell Immunity in Elderly Solid Organ Transplant Recipients.

C273 † Patients with ESRD Due to Diabetes Have Higher Variability of Their Tacrolimus Levels and Worse Outcomes.
Dawn Goodall, Michelle Willicombe, Adam McLean, David Taube. London, United Kingdom.

Viruses and SOT

C274 † Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.

C275 † Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.
Catherine Burton, Yupin Tong, Jutta Preiksaitis. Edmonton, Canada.

C276 † An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
Jeanne M. Chen, Rachel Hoffman, Maggie R. Thomas, Jane Gervasio. Indianapolis, IN.

C277 † Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.
Ali Alghamdi, Atul Humar, Yoichiro Natori, Shahid Husain, Lianne Singer, Eberhard Renner, Coleman Rotstein, Deepali Kumar. Toronto, ON, Canada.

C278 † Polyfunctionality of CD8 T Cell Responses to Cytomegalovirus in Transplant Patients.
Outcomes of Transplant Recipients Treated with Cidofovir for Resistant or Refractory Cytomegalovirus Infection.
Seema Mehta, Mona Alfares, Alex Valsamakis, Shmuel Shoham, Ravit Boger, Laura Lees, Darin Ostrander, Robin Avery. Baltimore.

Cytomegalovirus Infection After Cardiac Transplantation.

Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
Gionata Spagnoletti, Maria Paola Salerno, Valentina Bianchi, Nicola Silvestrini, Francesca Apponi, Jacopo Romagnoli. Rome, Italy.

Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.

Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVig) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Samir J. Patel, Samantha A. Kuten, Jordan J. Snyder, Richard J. Knight, A. Osama Gaber. Houston, TX.

Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.
Carlos A. Q. Santos, Mohammed J. Saeed, Daniel C. Brennan, Margaret A. Olsen. Saint Louis, MO.

Down-Regulated of Circulating miR-29b, miR-185 and NR_073415.2 in Post-Transplanted Patients with Cytomegalovirus Infection May Serve as Novel Biomarkers for Early Diagnosis.

James Thielke, Natalia M. Jasiak, Niveen Hilal, Salma Salah, Enrico Benedetti, Patricia M. West-Thielke. Chicago, IL.


Development of a Sequencing-Based Cytomegalovirus UL55 Glycoprotein B (gB) Genotyping Assay.
Scott Cowden, Kevin Grantham, Ingrid Caton, Jeff Hester, Michelle Altrich, Steve Kleiboeker. Lee’s Summit, MO.

Alexander Gilbert, Matthew Cooper, Jennifer Verbesey, Reza Ghasemian, Peter Abrams, Jack Moore, Monica Grafals, Jeffrey Chahine, Stacey Punnett, Ellen Hall, Isa Anzak, Basit Javaid. Washington, DC.

Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.
Arnoldo Adrian Gonzalez, Farid Forouton, Atul Humar, Shahid Husain. Toronto, ON, Canada.


C293 Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen. MacKenzie A. McRae, Tam How, Allan D. Kirk, He Xu. Durham, NC.


C296 Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(−) and HBcAb(+) After Kidney Transplantation? Guodong Chen, Chang Wang, Lizhong Chen, Jiang Qiu, Changxi Wang. Guangzhou, Guangdong, China.


C298 Predictors of Post Transplant Lymphoproliferative Disorder Among Adult Kidney Transplant Recipients. Maha Mohamed, Sandesh Parajuli, Brenda Muth, Arjang Djamali, Brad Astor. Madison, WI.


C303 Direct Detection of T and B Memory Lymphocytes Reveals HCMV Exposure That Serum Antibodies Fail to Identify. Srividya Sundararaman, Fredrik Terlutter, Tobias M. Nowacki, Richard Caspell, Paul V. Lehmann. Shaker Hts, OH.
Antibody Mediated Rejection: Session #2

D1  † Assessment of mRNA Gene Profiles in Plasma Exosome to Predict Risk for Antibody-Mediated Rejection (ABMR) of Renal Allografts.
Hao Zhang, Joseph Kahwaji, Ping Li, Shili Ge, David Thomas, Cynthia C. Nast, Ashley A. Vo, Mark Haas, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

D2  † Predicting the Ability of Anti-HLA Antibodies to Activate Complement.
Dulat Bekbolsynov, Caitlin Baum, Beata Mierzejewska, Afnan Malebari, Michael Rees, Stanislaw Stepkowski. Toledo.

Caiyun Liao, Allan Massie, Sunjae Bae, Dorry Segev. Baltimore.

D4  The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.
Farsad Eskandary, Jeff Reeve, Heinz Regele, Luis Hidalgo, Daniel Yoo, Nicolas Kozakowski, Konrad Famulski, Georg A. Böhmig, Philip F. Halloran. Edmonton, AB, Canada; Vienna, Austria.

D5  The Combined Effect of Acute Rejection and De Novo Donor-Specific Antibodies on Kidney Allograft Survival.
Scott W. Davis, Jane Gralla, Alexander C. Wiseman, James E. Cooper. Aurora, CO.

Jessica Schmitz, Abdelrazag Khalifa, Hermann Haller, Hans Heinrich Kreipe, Friedrich Feuerhake, Jan Hinrich Bräsen. Hannover, Germany.

D7  Enhanced Natural Killer Responsiveness Is a Potent Cytotoxic Mechanism Associating to Kidney Allograft Dysfunction and Pathogenic Effects of Donor-Specific Antibodies (DSA).

Carrie Schinstock, Wisit Cheungpasitporn, Fernando Cosio, Donald Mitema, Manish Gandhi, Mikel Prieto, Patrick Dean, Mark Stegall. Rochester, MN.

D9  Posttransplant AT1Rabs Precede De Novo HLA-DSA Development.
Jose Manuel Arreola-Guerra, Eric Cuevas, Eric Fernandez-Mendez, Mario Vilatoba, Alan Contreras, Julia Ramirez, David de Rongs, Julio Granados, Luis Eduardo Morales-Buenrostro, Josefina Alberu. Mexico City, Mexico; Aguascalientes, Mexico.

D10 Detection of Endothelial Cell Specific Molecule-1 According to Allograft Status After Kidney Transplantation.

D11 C1q Donor Specific Antibody Associates with Post Transplant Biopsy Findings in Highly Sensitized Kidney Transplant Recipients.
Sarat Kuppachi, Dannielle Holanda, Sara Gallegos, Elizabeth H. Field. Iowa City, IA.
**D12** Focal C4d Staining in Biopsies of Kidney Transplant Recipients Is Not Associated with Antibody Mediated Rejection and Does Not Correlate with Graft Survival.
Rohini Prashar, Michael I. Goggins, Lenar Yessayan, Anita Patel, Mariella Goggins. Detroit, MI.

**D13** Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.
Lucio Requião-Moura, Margareth Afonso, Araci Sakashita, Maurício Fregonesi Silva, Ana Cristina Carvalho Matos, Alvaro Pacheco-Silva. São Paulo, Brazil.

**D14** Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
Ashley A. Vo, Christina Boutsicaris, Xiaohai Zhang, Nancy Reinsmoen, Jua Choi, Stanley C. Jordan. LA, CA.

**D15** C1q Assays Are Not Associated with Clinical or Serologic Endpoints.
Alexander Gilbert, Misbah Zaheer, Olga Timofeeva, Mariam Awwad, Dong Li, Sandra Rosen-Bronson, Basit Javaid, Monica Grafals, Jennifer Verbesey, Peter Abrams, Matthew Cooper. Washington, DC.

**D16** Impact of C3d and C1q-Binding DSA Detected Long-Term After Kidney Transplantation.

**D17** Outcomes of Second Kidney Transplantation Compared Primary Transplantation According to Donor Specific Antibody.

**D18** Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.
Avgi Andreou, Adarsh Babu, Tom Barber, Rob Higgins, David Briggs, Dan Mitchell, Natasha Khovanova, Torgyn Shaikhina, Sunil Daga. Coventry, United Kingdom.

**D19** Type of Sensitization Does Not Impact Kidney Graft Outcome in Weakly Sensitized Patients.
Alexander H. Morrison, Deirdre Sawinski, Mary Ann Lim, Matthew H. Levine, Malek Kamoun, Paige M. Porrett. Philadelphia, PA.

**D20** Diffuse Extent of Peritubular Capillaritis in Late Antibody Mediated Rejection Is Associated with More Severe Chronic Allograft Damage.

**D21** The Impact of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx) Is Independent of Time Post-Transplant.
Robert S. Gaston, Joseph P. Grande, Robert Leduc, The DeKAF Study Group. Birmingham, AL; Rochester, MN; Minneapolis, MN.

**D22** Presence of Highly Immunogenic Mismatch Eplets Is Associated with Development of Chronic Active Antibody-Mediated Rejection: A First Report from Japan.

**D23** Factors Mediating Kidney Rejection in Patients of Simultaneous Liver-Kidney Transplants.
Ruizhi Dong, Anat R. Tambur, Lorenzo Gallon, Josh Levitsky. Chicago, IL.

**D24** Kidney Transplantation with Strong Preformed Donor-Specific Antibodies: Impact of C1q-Binding Ability.
D25 The Prediction of Molecular ABMR by Anti-HLA Donor-Specific Antibody Properties.
Farsad Eskandary, Jeff Reeve, Daniel Yoo, Heinz Regele, Luis Hidalgo, Georg A. Böhmig, Philip F. Halloran. Edmonton, AB, Canada; Vienna, Austria.

D26 Expansion of Anti-HLA Antibodies After Renal Transplantation and Prognosis in Those Which Fix C1q.

D27 The Effect of Tocilizumab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.
Bong-Ha Shin, Shili Ge, Jua Choi, Joseph Kahwaji, Ashley Vo, Anna Petrosyan, Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA.

D28 The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.

D29 Graft Survival in Sensitized and Non-Sensitized Patients: Role of the Combination of Donor-Specific Antibodies and Acute Rejection.
Patricia Souza, Anna Rita Aguirre, Gislene Bezerra, Helcio Rodrigues, Fabiana Agena, Daisa David, Flavio de Paula, Elias David-Neto, Maria Cristina Castro. Sao Paulo, Brazil.

D30 Alloimmunity Through Non-HLA Epitopes in Kidney Transplantation.
Roman Reindl-Schwaighofer, Alexander Kainz, Brian Cole, Jessica van Setten, Kira Jelencsics, Brendan Keating, Rainer Oberbauer. Vienna, Austria; Philadelphia, PA.

D31 Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.

D32 Elevation of Peripheral IL-6 in Kidney Transplant Recipients with Antibody Mediated Rejection.

Chimerism/Stem Cells, Cellular/Islet Transplantation, Innate Immunity, Chronic Rejection

D33 † The Function of CD8+TCR- Facilitating Cells and Regulatory T Cells Is Impaired in Flt3-Ligand Knockout Mice.
Yiming Huang, Hong Xu, Thomas O. Miller, Yujie Wen, Suzanne T. Ildstad. Louisville, KY.

D34 † c-Kit+ Cells Are Kidney-Specific Progenitor/Stem Cells with Regenerative Potential.
Samirah Abreu Gomes, Garett Goss, Bradley Goldstein, Barbara Seidler, Dieter Saur, Joshua Hare, Erika Bevilaqua Rangel. Sao Paulo, SP, Brazil; Miami; Munich, Germany.

D35 † CD8+TCR- Facilitating Cells in Mobilized Peripheral Blood Mononuclear Cells Are Enriched with IL-10 Producing B Cells.
Yujie Wen, Esma S. Yolcu, Yiming Huang, Larry E. Kahn, Suzanne T. Ildstad. Louisville, KY.

D36 † iNKT Cell Ligands Administered with Bone Marrow Cells Expand Allo-Specific Regulatory T Cells In Vivo and Establish Transplant Tolerance.
Satoshi Miyairi, Toshihito Hirai, Masayoshi Okumi, Yasuyuki Ishii, Kenji Yamazaki, Kazunari Tanabe. Tokyo, Japan; Yokohama, Japan.
D37  † Improved Regeneration of the Remnant Liver After Extended Hepatectomy or Partial Liver Transplantation by Pharmacologic Mobilization of Endogenous Stem Cells in Rats. Melissa Chen, Rujun Zhai, Le Qi, Andrew Cameron, Benjamin Philosophe, Zhaoli Sun. Baltimore, MD.


D41  † Contrasting Effects of Tacrolimus and Everolimus on Regulatory T Cell Activation and Mixed Hematopoietic Chimerism Induced by Natural Killer T Cell Stimulation. Satoshi Miyairi, Toshihito Hirai, Rumi IShii, Masayoshi Okumi, Yasuyuki Ishii, Shinichi Nunoda, Kenji Yamazaki, Kazunari Tanabe. Tokyo, Japan; Yokohama, Japan.

D42  † In Vitro and In Vivo Characterization of Human Hematopoietic Chimeric Cells – A Novel Approach for Tolerance Induction in Transplantation. Maria Siemionow, Ewa Bryndza Tfaily, Malgorzata Cyran, Rafał Gendek, Marcin Strojny, Erzsebet Szilagyi, Joanna Cwykiel. Chicago, IL.

D43  † Inflammatory Conditions Switch the Effect of MSC on B Cells from Pro-Tolerogenic to Anti-Proliferative. Marcella Franquesa, Franka Luk, Sander S. Korevaar, Louis Boon, Francesc E. Borras, Michiel G. H. Betjes, Carla C. Baan, Martin J. Hoogduijn. Rotterdam, Netherlands; Badalona, Spain; Utrecht, Netherlands.


D46  † FGF and Wnt Signaling in Pancreatic Progenitor and Beta-Cell Growth. Solomon Afelik, Nicholas Yonan, Brandon Pool, Jan Jensen, Jose Oberholzer. Chicago, IL; Cleveland, OH.

D47  † Optimizing the Immunogenicity and Immunomodulatory Properties of MSC for Cellular Therapy. Samantha de Witte, M. Franquesa, T. Strini, S. Korevaar, F. Luk, S. Elliman, P. Newsome, M. Gargesha, D. Roy, A. Merino, C. Baan, Martin Hoogduijn. Rotterdam, Netherlands; Galway, Ireland; Birmingham, United Kingdom; Mayfield Village.

D48  † Mechanisms of Cellular Repopulation within Healthy or Intrinsically Scarred Kidney Extracellular Matrix Scaffolds. Joseph S. Uzarski, Carol A. Deaton, Heather H. Ward, Angela Wandinger-Ness, William M. Miller, Jason A. Wertheim. Chicago, IL; Albuquerque, NM; Evanston, IL.
D49 † The IFN-Gamma-Inducible Protein (IP-10/CXCL10) Is a Promising Target to Improve Endocrine Function Following Islet Transplantation. Gumpei Yoshimatsu, Mazhar A. Kanak, Prathab Balaji S, Charles Chang, Carly Darden, Morihito Takita, Michael C. Lawrence, Bashoo Naziruddin. Dallas, TX; Richmond, VA.

D50 † Human Epineural Allograft Conduits Supported with Mesenchymal Stem Cells Enhance Peripheral Nerve Regeneration: A Preliminary Report. Maria Siemionow, Marcin Strojny, Wojciech Malewski, Joanna Cwykiel, Malgorzata Cyran. Chicago, IL.

D51 † NFκB Inhibitor Withaferin A Blocks IBMIR In Vitro: miRNA 375 Analysis. Mazhar A. Kanak, Morihito Takita, Gumpei Yoshimatsu, Michael C. Lawrence, Marlon F. Levy, Bashoo Naziruddin. Richmond, VA; Dallas, TX.

D52 † A Novel Microfluidic Device for Purification of Pancreatic Islet Preparations. Walter Varhue, Linda Langman, Daniel Bowers, Shayn Peirce-Cottler, Nathan Swami, Kenneth Brayman. Charlottesville, VA.

D53 † Citrate-Based Thermoresponsive Hydrogel as a Versatile Platform for Extrahepatic Islet Transplantation. Yunxiaozhu, Xiaomin Zhang, Amer Guillermo, Xunrong Luo. Chicago, IL.

D54 † IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression. Kisha N. Sivanathan, Darling Rojas-Canales, Stan Gronthos, Shane T. Grey, Patrick T. Coates. Adelaide, South Australia, Australia; Sydney, New South Wales, Australia.

D55 † A Novel, Non-Viral mRNA Delivery System for Targeted Protein Translation in Human Islets. José Oberholzer, Diana Gutierrez, Enza Marchese, Mohammad Nourmohammadzadeh, Yong Wang. Chicago, IL.

D56 † A Non-Hematopoietic Erythropoietin Analogue, ARA 290, Prolonged Allogeneic Pancreatic Islet Graft Survival in a Mouse Model. Masaaki Watanabe, Ming Han Yao, Dennis Andersson, Michael Brines, Torbjörn Lundgren, Makiko Kumagai-Braesch. Stockholm, Sweden; Tarrytown, NY.


D59 † High Resolution Detection of Human Pancreatic Islet Damage During and After Isolation Procedure Using MicroRNAs. S. Prathab Balaji, Mazhar A. Kanak, Gumpei Yoshimatsu, Charles Chang, Marlon F. Levy, Michael C. Lawrence, Peter T. Kim, Nicholas Onaca, Bashoo Naziruddin. Dallas, TX; Richmond, VA.

D60 † IgM Treatment Successfully Prevents Type 1 Diabetes by Dysregulation of Pancreatic MicroRNAs with Immunomodulatory Roles. Preeti Chhabra, Ricardo Gehrau, Valeria Mas, Daniel Bower, Daniel Maluf, Kenneth Brayman. Charlottesville.
**D61 † Tacrolimus (Tac), Rather Than Cyclosporine (CsA), Interacts with Insulin Resistance (IR) to Alter Key Transcription Factors for Δ-Cell Identity & Function without Altering NFAT Localization.**

**D62 † Delaying the Induction of Mixed Chimerism Until Two Months After NHP Heart and Kidney Cotransplantation Results in Long Term Survival.**
Kyu Ha Huh, Makoto Tonsho, Philip J. Spencer, Joshua Thomas Paster, Ximing Wu, Isabel M. Hanekamp, Tatsuaki Kawai, Rex Neal Smith, A. Benedict Cosimi, Abbas Dehnadi, Gilles Benichou, Robert B. Colvin, Joren C. Madsen. Boston, MA.

**D63 † Tissue Priming of Plasmacytoid Dendritic Cells Enhances Their Phagocytosis and Lowers the Threshold for Subsequent Toll-Like Receptor 7/9 Activation.**

**D64 † Monocyte Recruitment to HLA Class I Antibody-Activated Endothelial Cells Is Dependent Upon mTOR.**
Sahar Salehi, Elaine F. Reed. Los Angeles, CA.

**D65 † Complement Receptor C5aR2 Deletion in Kidney Transplantation in Mice Attenuates Renal Damage.**

**D66 † Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.**
Joshua D. Budihardjo, Marcos Iglesias, Jeffrey Walch, Xiomara Calderon-Colon, W. P. Andrew Lee, Gerald Brandacher, Julia Patrone, Giorgio Raimondi. Baltimore, MD; Laurel, MD.

**D67 † Dendritic Cells and Damage-Associated Molecular Patterns in Aging.**
Midas Seyda, Hong M. Li, Guangxiang Liu, Markus Quante, Hirofumi Uehara, Jeroen M. Schuitemaker, Abdala Elkhal, Stefan G. Tullius. Boston.

**D68 † Thrombalexin: Detection & Efficacy of a Membrane-Bound Anti-Thrombin Agent.**

**D69 † Resveratrol Attenuates Liver IRI by Regulating Macrophage Activation Through SIRT1/p19/p53 Pathway.**
Kojiro Nakamura, Min Zhang, Bibo Ke, Shoichi Kageyama, Ronald W. Busuttil, Jesus A. Araujo, Jerzy W. Kupiec-Weginski. Los Angeles, CA.

**D70 † TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.**
Markus Wahrmann, Jakob Mühlbacher, Heinz Regele, Farsad Eskandary, James C. Gilbert, Sandip Panicker, Georg A. Böhmg. Vienna, Austria; South San Francisco, CA.

**D71 † NKG2A-Expressing Natural Killer Cells Dominate the Response to Latent Epstein-Barr Virus Infection.**
Olivia L. Hatton, Dara Strauss-Albee, Sheri M. Krams, Catherine Blish, Olivia M. Martinez. Stanford, CA.

**D72 † Natural Killer Cells Display Functional and Receptor Diversity in Response to Alloantigen.**
Olivia Hatton, Todd Shawler, Catherine Blish, Olivia M. Martinez, Sheri M. Krams. Stanford.

**D73 † HCK Is a Potential Mediator of Renal Fibrosis.**
Chengguo Wei, Madhav C. Menon, Li Li, Zhengzi Yi, Karen L. Keung, Christopher Woytovich, Ilana Greene, Weijia Zhang, John Cijiang He, Barbara Murphy. New York, NY; New South Wales, Australia.
<table>
<thead>
<tr>
<th>D74</th>
<th>Necroptosis Is Involved in CD4+ T-Cell Mediated Microvascular Endothelial Cell Death and Chronic Cardiac Allograft Rejection.</th>
<th>D81</th>
<th>The Apoptosis of the Tracheal Epithelia Increase the Recipient's MSCs Derived Myofibroblasts in Allografts to Exacerbate Obliterative Bronchiolitis After Tracheal Transplantation in Mice.</th>
</tr>
</thead>
<tbody>
<tr>
<td>D75</td>
<td>Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.</td>
<td>D82</td>
<td>Novel Nuclear Factor-ΔB Activation Inhibitor, Dehydroxymethylepoxyquinomicin, Prevents the Development of Chronic Cyclosporine Nephropathy in Rats.</td>
</tr>
<tr>
<td>D76</td>
<td>Chemokine Receptor CXCR4 Antagonist, a Novel Pathway to Prevent Chronic Allograft Nephropathy.</td>
<td>D83</td>
<td>Transplantation of Islet Preconditioned with Hydrogen Sulfide Enhances the Graft Function in Diabetic Mice.</td>
</tr>
<tr>
<td>Yue Xu, Qiang Zhang, XiaoPeng Hu. Beijing, China.</td>
<td>Dan Wang, Ming Xiao Ding, Jun Wu Xue, Jin Zheng, Shun Xin Feng, Hui Xiao Tian, Yang Li. Xi'an, China.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D77</td>
<td>aPC Pretreatment of hEPCR-Expressing PAECs Attenuates Endothelial Cell Damage and Thrombosis.</td>
<td>D84</td>
<td>In Vivo and In Vitro Characterization of 1.5 mm Ba2+-Alginate Macro-Encapsulated Cynomolgus Monkey Islets.</td>
</tr>
<tr>
<td>Christopher T. Laird, Beth French, Donald Harris, Xiangfei Chang, David L. Ayares, Richard N. Pierson, Agnes M. Azimzadeh. Baltimore, MD; Blacksburg, VA.</td>
<td>Matthew A. Bochenek, James J. McGarrigle, Joshua Mendoza-Elias, Enza Marchese, Mohammad Nourmohamadzadeh, Yong Wang, Arshad Khan, Mustafa Omami, Chun-Chieh Yeh, Igor Lacik, Berit Strand, Jose Oberholzer. Chicago, IL; Bratislava, Slovakia (Slovak Republic); Trondheim, Norway.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D78</td>
<td>MiRNA-200b Inhibits Epithelial-Mesenchymal Transition in TGF-b1 Induced Human Bronchial Epithelial Cells.</td>
<td>D85</td>
<td>Establishment of SCID Pigs Cell Lines to Prevent Immunodeficiency Using RGEN System.</td>
</tr>
<tr>
<td>D79</td>
<td>Hydrogen Sulphide Is an Important Regulator of Erythropoietin Synthesis in Patients with Anemia of Chronic Kidney Disease.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical Science: Tolerance: Clinical Studies

D86 † Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation. Lorenzo Gallon, Joseph Leventhal, Catherine Dumur, James Mathew, Lakshmi Nadimpalli, Aneesha Shetty, Suzanne Ildstad, Valeria Mas. Chicago, IL; Charlottesville, VA; Louisville, KT.


D89 IL-10 Expression of In Vitro Activated B Cells as A Biomarker for B Cell Tolerance. Tetsu Oura, Kiyohiko Hotta, Kerry Crisalli, Benedict A. Cosimi, Tatsuo Kawai. Boston, MA.


D91 Three-Year Outcome After HSCT with Subsequent KT from the Same Haploidentical Donor without Immunosuppression. Christoph Schwarz, Anita Lawitschka, Georg A. Böhmg, Eva M. Dauber, Hildegard Greinix, Nicolas Kozakowski, Ferdinand Mühlbacher, Gabriela A. Berlakovich, Thomas Wekerle. Vienna, Austria; Graz, Austria.


D93 Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome. Mindy Tseng, Shill Ge, Robert Roberts, Caroline Kuo, Jua Choi, Nicholas Nissen, Maggie Chu, Irene Kim, Bonga Shin, Mieko Toyoda, Stanley Jordan. Los Angeles, CA.

Fungi, PJP, Mycobacteria, Infection Risk Factors, Vaccination and Donor Derived Infections


D95 Circulating miR-215, miR-let-7c miR-154, miR-193a, NR_036506.1 and NR_027669.1 as Biomarkers Predict Fungal Infection in Post-Transplanted Recipients. Anli Yang, Zhiyong Guo, WeiQiang Ju, Chuanzhao Zhang, Zhuohui Li, Xiaopeng Yuan, Qiang Zhao, Haidan Ye, Yuan Liao, Xiaofeng Zhu, Xiaoshun He. Guangzhou, Guangdong, China.


D100 Diagnosis of Pulmonary Nocardiosis: A Single Center Study. Dannah Wray, Soe Win, Marc Heincelman, Lisa Steed, Joseph Cantey. Charleston, SC; Salinas, CA.

D101 Shifts of Etiology in Patients with in Bacteremic Liver Transplant Recipients. Sang Il Kim, Youn Jeong Kim, Jong Young Choi, Seung Kyu Yoon, Gun Hyung Na, Ji Il Kim, In Sung Moon, Yung Kyung Yoo, Dong Goo Kim. Seoul, Republic of Korea.


D103 Vaccination Compliance in Listed Kidney Transplant Candidates: A Retrospective Chart Review. Ibrahim Tawhari, Catherine Staffeld-Coit, Julia Garcia-Diaz. New Orleans, LA.

D104 Descriptive Epidemiology and Trends of Community Parenteral Antimicrobial Therapy Utilization Among Solid Organ Transplant Recipients at a High Volume Transplant Center 2008 to 2014. Steven D. Mawhorter, Nabin K. Shrestha. Cleveland, OH.

D113 Increased Incidence of Clostridium difficile Infections with Proton Pump Inhibitor Use Post-Kidney Transplant. Michael L. Spinner, Kajal S. Patel, Elizabeth A. Neuner, Brian R. Stephany. Cleveland, OH.


D116 The Preventive and Therapeutic Effect of Immunoglobulin on Infectious Complications in Donation After Cardiac Death Liver Transplant Recipients: A Prospective Randomized Controlled Study. Anli Yang, Zhiyong Guo, Weiqiang Ju, Yinghua Chen, Ming Han, Xiaoping Wang, Dongping Wang, Yi Ma, Anbin Hu, Xiaofeng Zhu, Xiaoshun He. Guangzhou, Guangdong, China.


D122 In Situ Aortic Flush with Lactated Ringer’s (LR) Solution During Donation After Brain Death (DBD) Organ Procurement Provides Similar Outcomes and Significantly Decreases Costs in Kidney and Liver Transplantation Compared to Standard Preservation Solutions. Steven M. Rudich, Paul A. Lange. Ann Arbor, MI.


D125 **Differential Effect of Delayed Graft Function (DGF) on Kidney Transplant Outcomes: When Does DGF Not Make a Difference?**

D126 **Kidney Transplants from Anuric Deceased Donors on Renal Replacement Therapy.**

D127 **Significance of Preservation Fluid Cultures in Solid Organ Transplantation.**
Hannah Nam, Niharika Perni, Kelly Galen, Maya Campara, Raquel Roca-Garcia, Vijay Yeldandi. Chicago.

D128 **Storage Kidneys Prior to Transplantation Using First Polish Preservation Solution “Biolasol” – Preliminary Report.**
Agnieszka Jozwik, Piotr Domagala, Rafał Kieszek, Michał Wszola, Monika Bieniasz, Marta Serwanska-Swietek, Magdalena Durlik, Florian Ryszka, Andrzej Chmura, Artur Kwiatkowski. Warsaw, Poland; Sosnowiec, Poland.

**Kidney Immunosuppression: Novel Agents**

D129 † **Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.**

D130 † **First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.**
Jua Choi, Stanley C. Jordan, Ashley A. Vo. Los Angeles, CA.

D131 † **Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Tacrolimus with CsA for Two Years Result by a Japanese Multicenter Study.**

D132 † **Post-Trial Experience with Belatacept: A Large Single Center Experience.**

D133 † **Acute Rejection by Belatacept (Bela) Dosing Frequency: Results from a Phase II Study of Kidney Transplant Recipients.**
F. Vincenti, G. Blancho, A. Durrbach, G. Grannas, J. Grinyó, U. Meier-Kriesche, M. Polinsky, H. Zhao, C. P. Larsen. San Francisco, CA; Nantes, France; Le Kremlin-Bicêtre, France; Hannover, Germany; Bellvitge, Spain; Lawrenceville, NJ; Atlanta, GA.

D134 † **Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.**
S. Florman, A. Durrbach, V. Duro Garcia, K. Calderon, U. Meier-Kriesche, M. Polinsky, H. Zhao, J. Medina Pestana. New York; Le Kremlin-Bicêtre, France; Porto Alegre, Brazil; Lawrenceville; Sao Paulo, Brazil.

D135 **Successful Prophylactic Use of Eculizumab in aHUS Kidney Transplant Patients: A Report of 9 Cases.**
D136 Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients. Erika T. Rhone, Ricardo Gehrau, Sai Vineela Bontha, Patrick D. Walker, Catherine Dumur, Daniel Maluf, Valeria Mas. Charlottesville, VA; Little Rock, AR; Richmond, VA.

D137 Reduced Incidence and Level of De Novo Donor-Specific Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results from BENEFIT. R. Bray, H. Gebel, R. Townsend, M. Polinsky, L. Yang, U. Meier-Kriesche, C. P. Larsen. Atlanta, GA; Lawrenceville, NJ.

D138 Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT. S. Florman, J. Medina Pestana, M. del C Rial, L. Rostaing, D. Kuypers, A. Matas, T. Wekerle, J. Grinyó, U. Meier-Kriesche, M. Polinsky, H. Zhao, A. Durbach. New York; Sao Paulo, Brazil; Buenos Aires, Argentina; Toulouse, France; Leuven, Belgium; MinneapoliisVienna, Austria; Barcelona, Spain; Lawrenceville; Le Kremlin-Bicêtre, France.

D139 Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT. F. Vincenti, J. Medina Pestana, M. Abouljoud, B. Bresnahan, V. Duro Garcia, L. Mulloy, K. Rice, L. Rostaing, C. Zayas, K. Calderon, U. Meier-Kriesche, M. Polinsky, H. Zhao, C. P. Larsen. San Francisco; Sao Paulo, Brazil; Detroit; Milwaukee; Porto Alegre, Brazil; AugustaDallas; Toulouse, France; Atlanta; Lawrenceville.


D143 Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study. Steven M. Steinberg, Roberto Gedaly, Laurence Chan, Anthony Langone. San Diego; Lexington; Aurora; Nashville.

D144 Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients. Eva Schrezenmeier, Thomas Doerner, Oliver Staeck, Klemens Budde, Fabian Halleck. Berin, Germany; Berlin, Germany.

D145 Schisandra Sphenanthera Extract Facilitates Anti-Tuberculosis Treatment Post Renal Transplantation Through Increasing Bioavailability of Tacrolimus. Ronghai Deng, Ling Zhang, Longshan Liu, Hongmei Fu, Jun Li, Qian Fu, Changxi Wang. Guangzhou, China.

D146 Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort. Marizela Savic, Margaret R. Cruz, Ana P. Rossi, John P. Vella. Portland, ME; Storrs, CT.
Kidney-Pediatrics

D147 † Impact of Everolimus and Low-Dose Ciclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.

D148 † Vaccination Status and Titers Before and After Pediatric Renal Transplantation: An Analysis of the CERTAIN Registry.

D149 † Incidence of Post-Transplant Malignancy (PTM) After Pediatric Kidney Transplantation (PKTx).

D150 † The Impact of Donor Procurement Characteristics in Contemporary Live Donor Pediatric Renal Transplantation Outcomes: An Analysis of 282 Cases.

D151 † Should HLA DR and DQ Eplet Mismatching Replace Traditional DR and DQ Mismatching for Deceased Donor Offers in Pediatric Renal Transplantation?
Christopher F. Bryan, Vimal Chadha, Bradley A. Warady. Kansas City, KS; Kansas City, MO.

D152 Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.
Irene K. Kim, Jua Choi, Ashley Vo, Alexis Kang, Mieko Toyoda, James Mirocha, Elaine Kamil, Sabrina Louie, Odette Galera, Stanley Jordan, Dechu Puliyanda. Los Angeles, CA.

D153 Factors Predicting Risk for Antibody-Mediated Rejection in Highly Sensitized Pediatric Renal Transplants.
Irene Kim, Jua Choi, Ashley Vo, Sabrina Louie, James Mirocha, Stanley Jordan, Elaine Kamil, Dechu Puliyanda. Los Angeles, CA.

D154 Renal Outcomes of Pediatric Kidney Transplant Recipients Following a Previous Solid Organ Transplantation.
Gilad Hamdani, Bin Zhang, Jens Goebel, Edward Nehus. Cincinnati, OH; Aurora, CO.

D155 † Acute Rejection, New-Onset Diabetes After Transplant and Transplant Outcomes in Pediatric Kidney Recipients: Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) Database.
Alireza Mehrnia, Thuy X. Le, Tamer R. Tamer, Suphamai Bunnapradist. Los Angeles, CA.

D156 Using 3D Printing in Complex Pediatric Renal Transplantation.

D157 Unexpected Early Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
Megan V. Yanik, Roslyn B. Mannon, Michael E. Seifert. Birmingham, AL.

D158 Pediatric Kidney Transplantation and Mortality: Distance to Transplant Center Matters.
Joel T. Adler, Yanik J. Bababekov, James F. Markmann, David C. Chang, Heidi Yeh. Boston, MA.
D159 Low Pretransplant BMI/Weight and Changes in Posttransplant T Cell Exhaustion Levels Are Associated with Viremia/Viral Infection in Pediatric Kidney Transplantation in the First Post-Transplant Year – A Report from the IMPACT Study Consortium. Robert B. Ettenger, Hyunsook Chin, Paul Grimm, Karen Kesler, Elaine Reed, Minnie Sarwal, Barry Warshaw, Eileen W. Tsai, Allan Kirk. LA, CA; Chappel Hill, NC; Palo Alto, CA; SF, CA; Atlanta, GADurham, NC.

D160 The Effect of Bortezomib on DSA Reduction During the Treatment of AMR in Pediatric Kidney Transplant Patients. Omar Moussa, Sally Self, Katherine Twombley. Charleston, SC.

D161 Differences in Reported Barriers to Immunosuppression Adherence Among a Cohort of Pediatric Renal Transplant Recipients from the United States and Canada. Orville N. R. Bignall II, Ahna L. Pai, Sandra Amaral, Susan L. Furth, Noelle E. Bergman, Jens Goebel. The TAKE-IT Study Investigators, Bethany J. Foster. Cincinnati, OH; Philadelphia, PA; Aurora, CO; Montreal, QC, Canada.


Liver: Immunosuppression and Rejection


D170 Pre-Transplant Risk Factors: Predicting Nonadherence and Rejection in Adult Liver Transplant Recipients. Sarah R. Lieber, Jacqueline Helcer, Emily Leven, Christopher S. Knight, Catherine Wlodarkiewicz, Akhil Shenoy, Eyal Shemesh, Sander S. Florman, Thomas D. Schiano, Rachel Annunziato. NY.

D171 Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation. Aos Karim, Diane Conway, Glen Leverson, Joshua Mezrich, Luis Fernandez, Anthony D’Alessandro, David Foley. Madison, WI.
D172  Preoperative Cytokine Storm in High MELD Patients Accentuates Incidence of Rejection Following Liver Transplantation.
Abhishek Mathur, Eric Presbyskowski, Emmanuel Zorn, Kortney Rogers, James Guerrera, Benjamin Samstein, Adam Griesemer, Karim Halazun, Tomoaki Kato, Jean Emond. NY, NY.

D173  Early Tacrolimus Exposure in Patients Treated De Novo with Once-Daily Tacrolimus After Liver Transplantation: Relationship with Acute Rejection and Long-Term Outcome.

D174  Sublingual Tacrolimus in Liver Transplantation: A Valid Option?
Manuel A. Moreno Gonzales, Laura J. Myhre, Timucin Taner. Rochester, MN.

D175  Deceased Non-A2 Donor ABO-Incompatible Liver Transplantation – Promising Results with Anti-A/B Antibody Reduction Both Pre- and Post-Transplant.

D176  Association of Smoking Habits with Comorbidity 15 Years After Liver Transplantation.

D177  Experience of Short-Term Preemptive Treatment for Cytomegalovirus Infection in Seropositive Patients After Liver Transplantation – Ten Years Result of a Single Institution.
Ting-Jung Wu, Yu-Chao Wang, Chih-Hsien Cheng, Tsung-Han Wu, Ruey-Shyang Soong, Chen-Fang Lee, Hong-Shiue Chou, Kun-Ming Chan, Wei-Chen Lee. Taoyuan, Taiwan.

D178  A Retrospective Analysis of Rabbit Antithymocyte Globulin Dosing, MELD, Race, and Weight on Infection and Rejection Rates in Liver Transplantation.
Reid Imai, Uerica Wang. Stanford, CA.

D179  † Compensating Live Kidney Donors: The Views of United States Voters.
Jonathan S. Fisher, Thomas G. Peters, Robert G. Gish, Richard J. Howard. La Jolla, CA; Jacksonville, FL; Stanford, CA; Gainesville, FL.

D180  Efficacy of Nine National Policies Reimbursing and Incentivizing Live Organ Donation.
Vandana Apte, Sigrid Fry-Revere. Lovettsville, VA.

D181  What Living Organ Donors See as Their Unmet Needs in the United States.
Sigrid Fry-Revere, Michael Middelman. Lovettsville, VA.

D182  A Visualization Software Platform for Managing a Kidney Paired-Donation Program.
Mathieu Bray, Wen Wang, Michael A. Rees, Peter X.-K. Song, Alan B. Leichtman, Valarie B. Ashby, John D. Kalbfleisch. Ann Arbor, MI; Toledo, OH.

D183  † Optimal Integration of Kidney Exchange Programs with Antibody Reduction Therapy to Increase Successful Transplant in Difficult to Match Recipients.
Keith J. Melancon, Naoru Koizumi, Monica Gentili, Clive O. Callender. Washington, DC; Arlington, VA; Louisville, KY.

D184  Here Comes the Sun: Industry’s Payments to Transplant Physicians.
Rizwan Ahmed, Eric Chow, Sunjae Bae, Allan Massie, Elizabeth King, Babak Orandi, Joseph Lopez, Bonnie Lonez, Dorry Segev. Durham, NC; Baltimore, MD.
D185  A Web-Based Survey of Academic Transplant Nephrologists in the U.S. on Relative Value Unit (RVU)-Based Productivity Assessment and Financial Compensation.
W. James Chon, Martha Pavlakis, Piotr Witkowski, Ling-Xin Chen, Pradeep V. Kadambi. Chicago, IL; Tucson, AZ; Boston, MA.

D186  Quality Improvement Initiative to Provide Comprehensive Pharmacy Services to Kidney Transplant Patients at a Small Transplant Center.

D187  Novel Approaches to Medication Teaching in Solid Organ Transplantation.
Demetra Tsapepas, Nick Jandovitz, Shyreen Dulanya, Dave Salerno, Sara Hammad, Patrick Jordan. New York.

D188  A Model to Explore the Potential Budget Impact of a Novel Screening Tool for the Detection of Subclinical Rejection Among Kidney Transplant Patients.
Kevin E. Jaglinski, Hiroshi Uchida, Timothy J. Inocencio, Kathleen E. Hughes. Waukesha, WI; Washington, DC.

D189  Cost-Effectiveness of Machine Perfusion Use After Long Cold Ischemic Time in a Kidney Transplantation Program.
Ana Cristina Matos, Daniel Malheiros, Silvia Morgado, Lucio Requiao-Moura, Milton Borrelli, Mario Nogueira, Marcelino Durao, Eduardo Tonato, Álvaro Pacheco-Silva. Sao Paulo, Brazil.

D190  Economic Analysis of Survival for Patients Undergoing Kidney Transplant in a Philanthropic Hospital of Sao Paulo, Brazil.
Ana Cristina Matos, Daniel Malheiros, Silvia Morgado, Lucio Requiao-Moura, Alberto Kanamura, Miguel Cendoroglo, Oscar Pavao Santos, Álvaro Pacheco-Silva. Sao Paulo, Brazil.

D191  When Liver Transplants and Procurement Occur at One Location – A National Study of Graft Survivals.
Jorge Ortiz, Naoru Koizumi, Chang Kwon, Yanjia Zhang, Christopher Ortiz. Toledo, OH; Fairfax, VA; Lewisburg, PA.

Boris I. Yaremmin, Alexey A. Mironov, Alexander V. Kolsanov, Albert S. Navasardyan, Ravil B. Akhmetshin, Anna A. Starostina. Samara, Russian Federation; Moscow, Russian Federation.

D193  Transplant Specialized Community Pharmacists’ Role in Care Transitions for Transplant Patients.
Darlene Nguyen, Nathanial Rickles, Christin Rogers, Katelyn Richards, Justin Thomas, Allison Loring, Heather Kirkham, Meen Kang, Karen Poliskey. Boston, MA.

Pediatric Liver Transplantation

D194 † Ideal Outcome After Liver Transplantation: An Exploratory Study Using Machine Learning Analyses to Leverage Long-Term Registry Data from Studies in Pediatric Liver Transplantation (SPLIT).
Evelyn K. Hsu, Michele L. Shaffer, Ravinder Anand, Vicky L. Ng, John C. Bucuvalas. Seattle, WA; Rockville, MD; Toronto, ON, Canada; Cincinnati, OH.

D195 † The Heterogenous Genomic Landscape of Unresectable Hepatoblastoma Requiring Liver Transplantation: Prognostic Implications.
Mylarappa Ningappa, Brandon W. Higgs, Sarangarajan Ranganathan, Chethan Ashokkumar, Rakesh Sindhi. Pittsburgh, PA.

D196 † Pediatric Liver Transplant Exception Request Narratives – How Do We Justify Requests?
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>D197</td>
<td>Airway Inflammation and Symptoms in Children Following Liver and Heart Transplantation.</td>
<td>Andrew Redmann, J. Bucuvalas, R. Wood, C. Chin, C. Hart. Cincinnati, OH; Cincinnati, OH.</td>
</tr>
<tr>
<td>D200</td>
<td>Children Listed as Status 1B for Liver Transplantation Are Disenfranchised by MARS Therapy.</td>
<td>Ankur Bakshi, Michael Kueht, Abbas Rana, Ayse Akcan Arikan, John Goss. Houston, TX.</td>
</tr>
<tr>
<td>D201</td>
<td>Effect of Conversion to mTOR Inhibition on Allograft Fibrosis in Pediatric Liver Transplantation.</td>
<td>Ryan T. Fischer, Sierra Foster, Alexander Kats, Walter S. Andrews, Richard J. Hendrickson, James F. Daniel. Kansas City, MO; Kansas City, KS.</td>
</tr>
<tr>
<td>D208</td>
<td>Living Donor Liver Transplantation for Children With Biliary Atresia in the Pediatric End-Stage Liver Disease Era: The Role of Age and Insurance Status.</td>
<td>Jaime Chu, Rachel Annunziato, Rebecca Aviles, Ronen Arnon. NY, NY; Bronx, NY.</td>
</tr>
<tr>
<td>D209</td>
<td>Use of the Psychosocial Assessment Tool to Identify Risk in Families of Pediatric Liver Transplant Recipients.</td>
<td>Emily M. Fredericks, Tanya Smith, Jessica Sevecke, Sally Eder, Christina Limke, Caitlin Shneider, M. James Lopez. Ann Arbor, MI.</td>
</tr>
</tbody>
</table>
D211 The Effect of Maternal Graft in Early Acute Cellular Rejection After Pediatric Living Donor Liver Transplantation.

D212 Outcome of Partial Reconstruction of Multiple Hepatic Arteries in Pediatric Living Donor Liver Transplantation Using Left Lateral Section Grafts.

D213 The Impact of Thromboelastography on Resuscitation in Pediatric Liver Transplantation.

D214 Conversion from Tacrolimus (TAC) to Sirolimus (SLR)-Based Immunosuppression in Pediatric Patients Who Underwent Liver Transplantation for Unresectable Hepatoblastoma – 2 Year Follow-Up.

D215 Mass Cytometry Reveals NK Cell and T Cell Subsets in Pediatric Liver Transplant Patients with Acute Rejection.

D216 Growth of Liver Allografts in Pediatric Transplant Recipients.
Sulemon Chaudhry, Jeffrey Stern, Steven Lobritto, Mercedes Martinez, Jennifer Vitorrio, Jean Emond, Tomaoki Kato, Benjamin Samstein, Stuart Bentley-Hibbert, Adam Griesemer. New York, NY.

D217 Factors in a Successful Transfer of Pediatric Liver Transplant Recipients to Adult-Based Care.

D218 Pediatric Split Liver Transplantation: Single Center Experience.

D219 Combined Liver-Kidney Transplantation in Children: Long-Term Follow-Up in 27 Children.
Markus J. Kemper, Björn Nashan, Lutz Fischer, Florian Brinkert. Hamburg, Germany.

D220 Biopsy-Proven Rejection in Children After Liver Transplantation Is Associated by an IL-12p40-Mediated Innate Immune Response Followed by Th1 T Cell Activation.
Christine S. Falk, Imeke Goldschmidt, Frauke Mutschler, Eva Pfister, Frank Lehner, Jana Keil, Christine Neudörfl, Andre Karch, Rafael Mikolajczyk, Ulrich Baumann. Hannover, Bitte Wählen, Germany; Braunschweig, Germany.

Polyomavirus

D221 † Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients.

D222 Identification of Donor HLA-Specific Antibodies as a Risk Factor for Graft Dysfunction and Failure Following BK Virus Associated Nephropathy.

D223 Slipping Through the Cracks: Late Onset BK Viremia.
Jinal Gandhi, Matthew Mackenzie, David DeWolfe, Francesca Cardarelli, Martha Pavlakis, Chen S. Tan. Boston, MA.

D225 Impact of BKV Subtype Distribution on BKV Nephropathy, Viremia, and Renal Outcome in Patients After Renal Transplantation.

D226 Increased Gene Expression of TGF-α in Peripheral Blood Mononuclear Cells from Renal Transplant Patients with Polyomavirus BK Viremi.
Wen Yao Yin, Ming Chi Lu. Chia-I, Dalin, Taiwan.

D227 Simultaneous Pancreas/Kidney Transplantation Increases the Risk of Late-Onset BKV-Associated Nephropathy.
Thomas Schachtner, Marina Zaks, Andreas Kahl, Petra Reinke. Berlin, Germany.

D228 Urinary CXCL9 Protein as Biomarker for BK Polyoma Viremia.
Nagaraju Sarabu, Rasha El-Rifai, Joshua J. Augustine, Aparna Padiyar, Anne M. Huml, Tricia Young, Victoria Rodriguez, Donald E. Hricik. Cleveland, OH; Chicago, IL.


D230 Results of a Biopsy Based, Early Intervention Treatment Protocols for BK Viraemia and BK Virus Associated Nephropathy.

D231 Evaluation of Polyomavirus (BK) Treatment and Clinical Outcomes in Pediatric Kidney Transplant Recipients: A >10 Year Single Center Retrospective Experience.
Rochelle Liverman, Emily Kraus, Rouba Garro, Barry Warshaw, Pamela Winterberg, Roshan George. Atlanta, GA.

D232 Incidence of Polyoma Virus Associated Nephropathy in a Single Transplant Center Employing a Reduction of Immunosuppression at a Lower Threshold of BK Viremia.
Marwan M. Azar, Aziz K. Valika, David D. Banach, Isaac E. Hall, Maricar F. Malinis. New Haven, CT.

D233 BK Viremia Surveillance and Management in Simultaneous Pancreas-Kidney Transplants.
Scott G. Westphal, Clifford D. Miles. Omaha, NE.

Kidney Complications-Other II

D234 † De Novo Proliferative Glomerulonephritis with Monoclonal IgG Deposits of the IgG1α Subtype in a Kidney Allograft: Protocol Biopsy Findings.
Takahiro Tsuji, Masayoshi Miura, Mitsuuru Yanai, Hiroe Itami, Yasushi Ishii, Mayuko Akimoto, Yuichiro Fukasawa. Sapporo, Japan.

D235 Nuclear Factor of Activated T-Cells Post-Renal Transplant.

D236 † Factors Associated with Response to Plasmapheresis in Patients with Recurrent FSGS.
Jun Shoji, Vasishta Tatapudi, Zoltan Laszik, Antwan Jones, Joshua H. Wolf, Deborah Adey, Flavio Vincenti. California, CA; New York, NY; Washington, DC; Atlanta, GA.

D237 † Graft Loss Due to Recurrence of Focal Segmental Glomerulosclerosis in Second Renal Transplant.
Vikram Aggarwal, Angelika Gruessner, Rainer Gruessner, Vaughn Whittaker, SriRam Narsipur. Syracuse, NY.

**D239 †** The Clinical Differences Between First and Second Kidney Transplant in IgA Nephropathy: A Multicenter Retrospective Study.
Chung Hee Baek, Jae Geun Lee, Ji Hyeon Park, Hyosang Kim, Yu Seun Kim, Woo Seong Huh, Jaeseok Yang, Duck Jong Han, Su-Kil Park. Seoul, Republic of Korea.

**D240 †** Comparison of Efficacy of Different Regimens for Treating Recurrent IgA Nephropathy After Kidney Transplantation.
Guodong Chen, Chang Wang, Lizhong Chen, Jiang Qiu, Changxi Wang, Jiguang Fei, Suxiong Deng, Jun Li, Gang Huang, Qian Fu. Guangzhou, Guangdong, China.

**D241 †** Management of Recurrent aHUS After Adult Kidney transplantation Despite Eculizumab Prophylaxis.
Muir Morton, Rajkumar Chinnadurai, Shahed Ahmed, Asheesh Sharma, Tina Dutt, Shiv Bhutani, Helen Denley, Titus Augustine, Tim Goodship, Neil Sheerin, Michael Picton. Manchester, United Kingdom; Liverpool, United Kingdom; Newcastle, United Kingdom.

**D242 †** Thrombotic Microangiopathy After Kidney Transplantation: A Rare but Serious Complication.


**D244 †** Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.
Yihung Huang, Jeong Park, Abhijit Naik, Daniel Kaul. Ann Arbor, MI.

**D245 †** Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.
Kristeen Barker, Natasha Cook, Polkinghorne Kevan, Ierino Frank. Melbourne, Victoria, Australia.

**D246 †** Is CMV Prophylaxis Effective in CMV-Seropositive Patients Receiving Thymoglobulin as Induction Therapy?
Emanoela B. Feitosa, Fabiana Agena, José O. Reusing Jr, Francine B. C. Lemos, Elias David-Neto. Sao Paulo, Brazil.


**D248 †** Urinary Tract Infections During the First Year After Renal Transplantation: Risk Factors and Nomograms.

**D249 †** Risk Factors for Single and Recurrent Symptomatic Urinary Tract Infections within the First Year After Kidney Transplantation.
Kassem Bourgi, Woo Jeong Choi, Asaad Nakhle, Zaid Abdel-Rahman, Odaliz Abreu-Lanfranco, Mayur Ramesh, Anita Patel, Ramon Del Busto, George Alangaden. Detroit, MI.

**D250 †** Urinary Virome in Human Kidney Transplants Reveals Multiple Virus Subtypes with Distinct Genome Polymorphisms.
Ravi Ranjan, Asha Rani, Halvor S. McGee, Daniel C. Brennan, Patricia W. Finn, David L. Perkins. Chicago, IL; St. Louis, MO.
D251 † Pneumocystis jirovecii Pneumonia: Late and Serious Complication Among Kidney Transplant Recipients. Laila Viana, Taina Sandes, Marina Cristelli, Anderson Oliveira, Daniel Santos, Helio Tedesco-Silva, Jose Osmar Medina-Pestana. São Paulo, Brazil.


D255 † Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study. Caroline Pettenati, Anne-Sophie Jannot, Virginie Verkarre, Sophie Hurel, Henri Kreis, Martin Housset, Christophe Legendre, Arnaud Méjean, Marc-Olivier Timsit. Paris, France.

D256 † Long-Term Renal Allograft Outcome After Parathyroidectomy. Margret Patecki, Irina Scheffner, Hermann Haller, Wilfried Gwinner. Hannover, Germany.


D260 † Post-Transplantation Hypomagnesemia as a Predictor of Survival Among the Kidney Transplant Population. Tammy Hod, Bhanu K. Patibandla, Anil Chandraker. Boston, MA.

D261 † The Burden and Outcomes of Fractures in Kidney Transplant Recipients. Norman Atagu, Tania Nguyen, Nicholas Phan, Olusegun Famure, Yanhong Li, Joseph Kim. Toronto, ON, Canada.


D263 † Association of Genetic Polymorphisms of Angiopoietin-Like 4 with Proteinuria in Kidney Allograft Recipients. Youngil Chang, Tariq Shah, Ya-Ting Chuang, David Min. Los Angeles, CA; Taipei, Taiwan; Pomona.

D265 † What if Mycophenolic Acid Product Is Discontinued Less Than 6 Weeks Before Pregnancy?

D266 † Pregnancy in the Renal Transplant Recipient: Pregnancy Viability and Effects on Graft Function.
André Lima, Marina Cristelli, Cinthia Teixeira, Igor Pietrobon, Geovana Basso, Laila Viana, Mayara de Paula, Cristina Cândido, Hélio Tedesco-Silva, José Medina Pestana. São Paulo, Brazil.

D267 † Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.

D268 † Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
Kajal Patel, Brian Stephany, Julie Barnes, Seth Bauer, Michael Spinner. Cleveland, OH.

D269 † Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.

D270 † Do Powerful Induction Antibodies Increase Post Renal Transplant Infections?
Mira M. John, Isabelle Dortonne, Benjamin Kim, Chao Li, Mary Killackey, Anil Paramesh, Belinda Lee, Rubin Zhang, Geoff Parker, Joseph F. Buell. New Orleans, LA.

D271 † Anti-Thymocyte Globulin Induced Thrombocytopenia and Bleeding After Kidney Transplantation.

D272 † Diabetes Mellitus and Kidney Transplant Outcomes.
Alireza Mehrnia, Amy L. Wang, Wikrom Chaiwatcharyut, Edmund Huang, Suphamai Bunnapradist. Los Angeles, CA; Bronx, NY.

D273 † The Incidence of Symptomatic Pericardial Effusion with Long-Term Sirolimus Therapy.
Nikolaos Chandolias, Stephanie Wang, Amy Hahn, Radmilta Lyubarova, Reynold Lopez-Soler, David Conti. Albany, NY.

D274 † Outcomes from De Novo Tacrolimus Weight-Based Dosing Compared to Conservative Dosing in Kidney Transplant Recipients.
Bryant Summers, Kristen Szempluch, Matt Harris, April Miller Quidley, Carl Haisch, Angela Maldono. Greenville, NC; Durham, NC.

D275 † Effect of Inflammation on Concentration of Intracellular Tacrolimus.
Eunjin Bae, Seung Hee Yang, Seung Seok Han, Jae-Yoon Park, Hajeong Lee, Yon Su Kim. Seoul, Republic of Korea.

D276 † Evaluation of the Utilization of Filgrastim in Kidney Transplant Recipients.
Teresa Poon, Christina Guerra. Brooklyn, NY.

Psychosocial and Treatment Adherence

D277 † Social Support Does Not Predict Medication Adherence Post-Transplantation: A Systematic Review and Meta-Analysis.
Keren Ladin, Alexis Daniels, Raveendhara R. Bannuru, Mikala Osani. Medford, MA; Boston, MA.

D278 † Incidence of Anxiety Following Live Kidney Donation.
D279 Psychosocial Factors Associated with Medication Adherence Based on Self Reports in Kidney Allograft Recipients: Baseline Findings from the PRIMA (ImPROving Adherence to Immunosuppressive Therapy by Mobile Internet Application) Study. Ahram Han, Chan Joong Choi, Song-Yi Kim, Sungshin Cho, Min-Ji Cho, Chang Hwan Lee, Sanghyun Ahn, Sang-il Min, Seung-Kee Min, In Mok Jung, Sang Joon Kim, Myung Hee Park, Jongwon Ha. Seoul, Republic of Korea; Goyang-si, Gyeonggi-do, Republic of Korea.

D280 Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels. Dawn Goodall, Michelle Willicombe, Adam McLean, David Taube. London, United Kingdom.

D281 Introducing a Mobile Phone Application to Transplant Patients to Encourage Medication Compliance and Education in This At-Risk Cohort. Alana Zanetti Yabur, Amanda Rizzo, Jay Graham, Juan Rocca. Bronx, NY.


D284 American and European Transplant Surgeons: Research, Teaching, and Burnout. Michelle Jesse, Marwan Aboujoud, Anne Eshelman, Chantal DeReyck, Jan Lerut. Detroit, MI; Saint-Luc, Bruxelles, Belgium.

D285† Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1, Hepatitis C Infection Post Liver Transplant. DeAnn Jones, Sarah Baggett, Mohamed Shoreibah, Omar Massoud. Birmingham, AL.


D288 Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin? Apurva A. Modi, John Hermann, Hector Nazario, Stevan G. Gonzalez, Janet Ginshover, Manjushree Gautam, Jeffrey Weinstein, Darryn Potosky, Maisha Barnes, Adil Habib, Parvez Mantry, James F. Trotter. Dallas-Fort Worth, TX; Dallas, TX; Baltimore, MD.

D289 Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies. Shelbi Olson, Adam McCann, Sean Kumer, Timothy Schmitt, Beth Floyd, Ryan Taylor, Richard Gilroy. Kansas City, KS.

D291 Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.
Joshua J. Wiegel, Timothy M. Egbuka. Portland, OR.

D292 Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.
Amilcar L. Morales, Manish Singla, Holly Greenwald, Suzanne Robertazzi, Colleen Rodigas, Valeria Washington, Rohit Sotoskar, Coleman Smith. Washington, DC; Bethesda, MD.

D293 Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.
Tyson Sievers, Julie Thompson, John Lake. Minneapolis, MN.

D294 Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.
Teresamari Pastrana-Camacho, Michelle Bradley, Holli Winters, Sylvester Black, Kyle Porter, Khalid Mumtaz. Columbus, OH.

D295 Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.

D296 Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.
Alexander Weick, Omar Sadiq, Syed-Mohammed Jafri, Dilip Moonka. Detroit, MI.

D297 Safety and Efficacy of Ledipasvir/ Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.
Kristofe Gutierrez, Jennifer Scheuermann, Inna Goldvarg, Shobha Joshi, Gia Tyson, Natalie Bzowej, Nigel Girgrah, Stephanie Anders, George Loss, George Therapondos. New Orleans, LA.

Late Breaking

D298 An In-Situ Treatment of Donor Skin Induces MARCH1 and Decreases MHC II Expression on Donor Dendritic Cells, Promoting Skin Allograft Acceptance.
Thiago J. Borges, Felipe D. Machado, Cristina Bonorino, Leonardo Riella. Porto Alegre, RS, Brazil; Boston, MA.

D299 Genetic TIM-4 Deletion Promotes Immunoregulatory Tissue-Resident Macrophage Survival and Lowers the Barrier to Cardiac Allograft Tolerance.
Thomas B. Thornley, Periklis Kyriazis, Krishna A. Agarwal, Zemin Fang, Lingzhi Ma, Vaja Chipashvili, Maria Koulmanda, Terry B. Strom. Boston, MA.

D300 Liver Transplantation (LT) Using Liver Allografts from Deceased After Cardiac Death (DCD) Donors: Opinions, Practices and Reality.
Linda Sher, Peter Abt, Yuri Genyk, Mary Lo, Pui Yan, Lingyun Ji, Christopher Marsh. Los Angeles; Philadelphia; San Diego.

D301 Potential Biomarkers and Treatment for BK Virus Associated Nephropathy.
Minal Borkar, Vikas Srivastava, Ryan Cunnington, Tejeswin Sharma, Lee Anne Tibbles. Calgary, AB, Canada; Lucknow, Uttar Pradesh, India.

D302 Ischemia-Reperfusion Injury Following Transplantation: Implications for the Modulation of CXCL8 Chemokine Function.
Beatriz Martinez Burgio, Simi Ali, John Kirby, Neil Sheerin, Steven Cobb, Dmitry Kashanin. Newcastle-upon-Tyne, United Kingdom; Durham, United Kingdom; Dublin, Ireland.


D305  Real Time Assessment of Kidney Transplant Indication Biopsies by Microarrays: First Results of the INTERCOMEX Study. P. Halloran, J. Reeve. INTERCOMEX Study Group. Edmonton, Canada.

D306  Kidney Transplant Recipient Adherence Measured by Proportion of Days Covered Is Associated with Late Biopsy Proven Acute Rejection. Brooke Hofmeyer, Kevin Look, Jillian Fose, Andy Pulvermacher, Arjang Djamali, David Hager. Madison, WI.

D307  Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients. Stanley C. Jordan, Jua Choi, Xiaohai Zhang, Mark Haas, Alice Peng, Joe Kahwaji, Rafael Villicana, Ashley Vo. Los Angeles, CA.

D308  Pulse Wave Velocity Amongst African-American Kidney Transplant Recipients Randomized to Once-Daily MeltDose Tacrolimus Tablets (Envarsus XR) vs. Traditional Twice-Daily Tacrolimus Capsules: Exploratory Results from a Phase III Trial. Jennifer Trofe-Clark, Raymond Townsend, Robin Neubauer, Mary Ann Lim, Leslie A. Callahan, Roy D. Bloom. Philadelphia, PA; Edison, NJ.

